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Abstract 
Estimates of the cost-effectiveness of chlamydia control interventions are highly 
sensitive to the risk of progression from genital chlamydia infection to pelvic inflammatory 
disease (PID).  There is no consensus for the risk of PID following asymptomatic chlamydia 
infections detected through population-based testing.  The aim of this thesis is to generate 
improved estimates of this risk of PID that can be used to parameterise mathematical models 
and inform chlamydia control policy.  
We have determined the risk of PID following a positive chlamydia test in three 
cohorts: a small historic prospective clinical cohort of sex workers (Praed Street Project (PSP)); 
a large population-based retrospective cohort from Manitoba, Canada established for this 
research; and a large nationally representative retrospective cohort from Denmark.    
The risk of PID was higher in women with a positive chlamydia test compared to 
women who tested negative (PSP: adjusted hazard ratio (AHR) 2.03 (95%CI 0.75-5.49); 
Manitoba: 1.55 (95%CI 1.43-1.70); Denmark: 1.42 (95%CI 1.32-1.53)).  There was 
heterogeneity in this risk: 13-23% higher following a repeat infection; up to four-fold higher in 
younger women (Manitoba: AHR 4.55 (95%CI 3.59-5.78) in 12-15 compared to 30-40 years); 
two-fold higher following previous gonorrhoea (PSP: 2.28 (95%CI 1.14-4.56)).  The increased 
risk following a positive test lasted considerably longer than the likely duration of infection and 
fewer than 10% of PID diagnoses within 12 months of a test could be attributed to a positive 
result.  This suggests that there are other important causes of PID. 
Individual-based risks of progression that capture this heterogeneity may improve the 
accuracy of estimates from mathematical models and therefore their utility to policy makers.  
Further research is needed to fully characterise the aetiology of PID to inform the design of 
chlamydia control interventions.  In the meantime, interventions should focus on young 
women and those at risk of repeat chlamydia infection.    
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1.1 Overview 
In this chapter I describe how, in high-income settings, asymptomatic genital infection with 
Chlamydia trachomatis (chlamydia) became a major public health priority of the last few decades.  I 
demonstrate that despite over thirty years of research effort we know very little about the natural 
history of infection or its resultant burden of morbidity.  I start with a description of the early clinical 
studies that identified chlamydia as a cause of pelvic inflammatory disease (PID) and other adverse 
reproductive complications and discuss the initial ecological evidence that suggested enhanced 
chlamydia control could reduce morbidity.  I look at evidence from cohort studies of the magnitude 
of the association between chlamydia and PID and evidence from randomised controlled trials 
(RCTs) for the benefit of chlamydia testing in preventing PID.  I contrast this with more recent 
ecological evidence that has cast doubt on the impact that can be attributed to systematic chlamydia 
control.  
To underpin this review I summarise the evidence for the biological mechanisms that lead to 
PID following chlamydia and consider how changes to chlamydia test methods and testing practices, 
antibiotic treatment and the epidemiology of other sexually transmitted infections (STIs) may have 
influenced the underlying association between a diagnosis of chlamydia and PID.  I then review the 
role that transmission dynamic mathematical modelling played in estimating the population benefit 
of chlamydia control interventions and their cost-effectiveness.  I unpick the evidence-base 
supporting the parameters used in models and describe why the risk of progression from chlamydia 
to PID is vital to accurate model predictions. Finally I consider the current uncertainty in the 
contemporary risk of PID following chlamydia and explain that this parameter must be urgently 
determined in order to inform international chlamydia control policy and resource allocation 
decisions.  
In this chapter I refer to a peer-reviewed publication that I co-authored with Sarah-Jane 
Anderson, Dr Katy Turner and Professor Helen Ward (Davies et al., 2014).  These co-authors have 
also provided comments on this chapter.     
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1.2 History of chlamydia control 
Chlamydia trachomatis was identified as a cause of non-gonococcal urethritis in 1976 and 
treatment of chlamydia infection in women was linked to a reduction in PID in the mid-1980s. 
(Schachter et al., 1976, Stamm et al., 1984, Rahm et al., 1986).  Growing evidence about the 
consequences of asymptomatic chlamydia infection, including PID, ectopic pregnancy and infertility, 
and the availability of practical testing methods meant that chlamydia control became an aspiration.  
The basic aim of chlamydia testing strategies was to identify and treat asymptomatic infections so 
they resolve earlier than they would spontaneously. It is thought that shortening the duration of 
infection will reduce transmission and therefore incident infections and will also reduce the 
probability of infection progressing to upper reproductive tract damage (Gottlieb et al., 2010b).  Set 
against the backdrop of newly emerging HIV, several countries became early adopters of chlamydia 
control including the USA (Wisconsin Chlamydia Prevention Program, 1986 (Addiss et al., 1994, Hillis 
et al., 1995); Region X Infertility Prevention Project, 1988 (Fine et al., 2008)), Canada (Manitoba’s 
chlamydia control programme, 1987 (Blanchard et al., 1998, Orr et al., 1994); British Colombia  
(Brunham et al., 2005, Rekart et al., 2013)) and Sweden (Kamwendo et al., 1998). In general in these 
settings chlamydia became a notifiable infection and funds were set aside for the testing and 
treatment of asymptomatic young women and other risk groups.   
Ecological studies that reported on the performance of these chlamydia control efforts 
(Blanchard et al., 1998, Egger et al., 1998, Hillis et al., 1995, Kamwendo et al., 1998, Orr et al., 1994) 
observed a decrease either in the rate of chlamydia diagnosis or the proportion of tests that were 
positive and a decline in hospitalisation rates of PID (Hillis et al., 1995, Kamwendo et al., 1998) and 
ectopic pregnancy (Egger et al., 1998, Hillis et al., 1995).  This was put forward as potential evidence 
for the effectiveness of enhanced chlamydia control on chlamydia prevalence or incidence although 
the potential impact of changing test patterns was acknowledged (Hillis et al., 1995, Orr et al., 1994).  
The trend in PID was interpreted more cautiously as it was accompanied by a decline in gonorrhoea 
and a shift towards out-patient care however the declining ectopic pregnancy rate was taken as 
firmer evidence of the benefit of chlamydia control (Egger et al., 1998, Kamwendo et al., 1998).  
This initial optimism about chlamydia control was encouraged by findings from RCTs that 
demonstrated a reduction in PID at one year in women offered a chlamydia screen (Ostergaard et 
al., 2000, Scholes et al., 1996).  However in the mid-1990s countries with mandatory notification 
systems began to observe an increase in chlamydia diagnosis rates or test positivity accompanied by 
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a continual decline in PID and stable rates of ectopic pregnancy (Bender et al., 2011, Fine et al., 
2008, Rekart et al., 2013, Scholes et al., 2012).  This created confusion and led to speculation that 
this was evidence both for and against the provision of widespread control.  Several explanations 
have been suggested for these patterns, including a reduction in PID from the successful detection 
and treatment of infections; policy change leading to fewer cases of PID being identified; improved 
reporting of chlamydia test data; decline in gonorrhoea leading to decline in PID; artefact due to the 
increase in sensitivity of the novel nucleic acid amplification tests (NAATs) used to diagnose 
chlamydia.  Two interesting theories emerged to explain these patterns in terms of the effect that 
chlamydia control had on the relationship between chlamydia and PID: a change in the immune 
response to infection that reduced the risk of PID after a repeat infection (Brunham et al., 2005) and 
a reduction in average pathogenicity of a diagnosed infection (Hadgu and Sternberg, 2009).  But 
neither of these has been proved.  In recent years a RCT that would have been able to address 
whether screening with modern NAATs in the absence of high rates of gonorrhoea can reduce PID 
was underpowered (Oakeshott et al., 2010).  
Therefore despite over thirty years of research, equipoise remains around the benefit of 
enhanced chlamydia control at the level of the population (Gottlieb et al., 2013).  Testing at-risk 
population groups for asymptomatic chlamydia infections is recommended by a number of leading 
health organisations including the US Centers for Disease Control and Prevention (CDC), the Public 
Health Association of Canada (PHAC) and the UK Department of Health (DH).  These and many other 
high income countries are investing heavily in chlamydia control.  England has a controversial 
national screening programme for young adults and it is estimated that over £100 million was spent 
on chlamydia screening between 2002 and 2009 without demonstrating value for money (National 
Audit Office, 2009).  
It is clear that policy makers and healthcare commissioners urgently need guidance about 
the potential impact of chlamydia control interventions in order to inform their resource allocation 
decisions.  Transmission dynamic mathematical modelling has become a popular tool for providing 
timely information to plug such gaps in the literature.  However due to the different underlying 
assumptions used by models, including those about the natural history of chlamydia, this field has 
failed to deliver a consensus opinion (Kretzschmar et al., 2009). Estimates of the cost-effectiveness 
of chlamydia control interventions have been shown to be highly sensitive to the risk of progression 
from chlamydia to PID (Adams et al., 2007).  There is no consensus for this parameter and models 
predominantly use a single risk of progression of approximately 22% similar to historical clinical 
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studies that is much higher than estimates from RCTs or population-based cohorts (Herzog et al., 
2012b).  The uncertainty in this parameter calls into question all current estimates of the clinical and 
cost-effectiveness of control interventions obtained from mathematical models.  Improved 
estimates of this risk are urgently needed to inform regional, national and international policy 
decisions.   
In the following sections I will expand on these issues to introduce the rationale for the 
following chapters of this thesis exploring the association between chlamydia and PID.  This thesis 
will focus on chlamydia in women because the high societal cost of adverse reproductive 
complications in women is the driving force behind widespread population-based chlamydia testing 
interventions for asymptomatic people.  
 
1.3 Epidemiology of chlamydia  
1.3.1 Overview 
There is a large body of research that characterises the epidemiology of chlamydia.  In this 
section I outline what is known about the organism, the natural history of infection and patterns in 
its incidence and prevalence in women.  In women the predominant site of infection is the 
endocervix and most infections are asymptomatic but can progress to cause adverse reproductive 
complications (PID, ectopic pregnancy and tubal factor infertility).  There are widespread 
uncertainties in several fundamental areas of the natural history of infection, including the duration 
of infection and the risk of complications.  The interpretation of trends in the incidence and 
prevalence of the infection is further complicated by secular changes following the introduction of 
widespread control and improvements in the performance of diagnostic tests.  In general, the 
number of diagnosed cases of chlamydia is increasing while prevalence appears to remain stable and 
chlamydia-induced morbidity may be declining.  
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1.3.2 Chlamydia trachomatis  
Chlamydia trachomatis is an obligate intracellular gram-negative bacteria (Everett et al., 
1999) that exists in two physiological states: the elementary body (EB) which is found outside cells 
and the reticular body (RB) which is found inside human cells.  Chlamydia trachomatis is divided into 
three biologically distinct groups, called biovars.  Infection with each biovar leads to a different 
clinical condition; trachoma (infection of the conjunctiva epithelium of the eye); chlamydia (non-
invasive predominantly urogenital infection) or lymphogranuloma venereum (LGV) (invasive 
infection of lymphatics and lymph nodes draining the genitals, rectum or pharynx).  Chlamydia 
trachomatis is further classified into serovars based on monoclonal antibody reactions to the major 
outer membrane proteins (MOMP) (Millman et al., 2004).  Chlamydia, the subject of this thesis, is 
caused by serotypes D-K (D, Da, E, F, G, H, I, Ia, J, Ja, and K).   
Chlamydia is transmitted through sexual contact or vertically from an infected mother to her 
infant during childbirth.  Chlamydia is not able to invade or progress beyond the epithelial surface 
and infection at different epithelial sites leads to different clinical presentations: eye causing 
conjunctivitis; urethra and lower reproductive tract causing urethritis or cervicitis in women and 
urethritis and epididymitis in men; female upper reproductive tract (uterus and fallopian tubes) 
causing PID, ectopic pregnancy and tubal factor infertility; and lung causing neonatal pneumonia.  
Chlamydia is also a cause of reactive arthritis which can present as the clinical triad of arthritis, 
conjunctivitis or uveitis and urethritis or cervicitis.   
 
1.3.3 Natural history of infection 
Chlamydial EBs can infect non-ciliated columnar epithelial cells using a ligand-receptor 
interaction that triggers their phagocytosis (Wyrick, 2010).  Once inside the phagosome, EBs can 
escape destruction by preventing the host lysosomes from binding to the phagosome (Wyrick, 
2010).  Over the next 8 to 12 hours the EB transforms into a non-infectious RB within the inclusion 
body.  The RB then replicates using binary fission over 18 to 30 hours until all the intracellular 
resource has been consumed (Wyrick, 2010).  This triggers the transformation of RBs back to EBs 
which are then released from the cell (around 48-72 hours after the initial infection) and go on to 
infect neighbouring epithelial cells (Wyrick, 2010).  
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There are three possible and non-mutually exclusive events following infection with 
chlamydia: (1) persistence; (2) clearance (either spontaneous or with treatment); (3) progression to 
the upper genital tract with accompanying inflammation and tissue damage (Geisler, 2010).  
Chlamydia can cause inflammation of the endometrium or PID by direct ascension through the cervix 
into the upper genital tract1.  Beyond this overview, there is marked uncertainty in the natural 
history of infection.  The factors that influence the outcome of infection, including chlamydia 
virulence factors and host immune response and the timing of spontaneous clearance or ascension 
to the upper genital tract have not yet been fully characterised (Batteiger et al., 2010, Darville and 
Hiltke, 2010, Geisler, 2010).  This is an important focus of research because these answers are 
needed to identify the most appropriate structure for chlamydia control interventions (Gottlieb et 
al., 2010b).  Chlamydia testing has been introduced for asymptomatic women on the assumption 
that shortening the duration of infection with antibiotics will benefit long-term reproductive health; 
an assumption that may not hold if the natural immune response to infection protects against 
reproductive tract damage and if this benefit outweighs the risk following a single infection (Gottlieb 
et al., 2010b).  
Chlamydia persists until it is cleared by the immune system or by antibiotic treatment.  The 
proportion of infections that are spontaneously cleared increases with time since diagnosis which 
suggests that an appropriate immune response may take time to develop (Geisler, 2010).  A 
systematic review found that 11%-44% of infections in women resolved in the relatively short 
interval between chlamydia testing and treatment and by a year 43%-54% of infections had resolved 
(Geisler, 2010).  However the authors of the systematic review described three important 
methodological limitations which may bias these estimates of duration (Geisler, 2010).  Firstly, the 
observed duration of infection starts at the date of the chlamydia test rather than the date of 
infection therefore this observed duration will underestimate the true duration by an unknown 
amount.  Secondly, most studies do not attempt to differentiate persistent from repeat infection, 
and those that do cannot discriminate between persistence and reinfection with the same strain.  
Thirdly, the majority of studies were performed in settings with a high prevalence of chlamydia so 
                                                          
1
 Paavonen et al. report that “an estimated 10% of C.trachomatis cervical infections ascend to cause PID” (Paavonen, 
2008). 
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the findings may not be generalisable to a general population setting.  However this evidence base is 
unlikely to be improved because it is unethical to leave infections untreated.       
Women mount an innate immune response to infection but this is probably not able to clear 
infection because chlamydial EBs can evade it by preventing lysosome fusion to the intracellular 
phagosome they occupy (Linhares and Witkin, 2010). However the exact nature of the adaptive 
immune response that can clear infection has not yet been determined.  Cell-mediated immunity 
(macrophages, CD8 cytotoxic T cells and cytokines) is likely to play a central role in women in part 
because there is no evidence that the concentration of B cells2 change from the uninfected state 
(Geisler, 2010).  In vitro studies suggest that antibodies (from mature B cells) may be able to 
contribute to clearance as they can opsonise or neutralise extracellular EBs to enhance their 
phagocytosis or prevent their transformation into RBs (Rank and Whittum-Hudson, 2010).  
Chlamydia may also be able to persist as “morphologically enlarged, aberrant and non-
dividing RBs” that have been demonstrated in vitro (Wyrick, 2010).  They cannot be cultured but 
they can transform back into infectious EBs when tryptophan is depleted from the host cell (Wyrick, 
2010). If they exist, abnormal RBs could lead to reproductive tract damage by stimulating a chronic 
inflammatory response from the host immune system (Wyrick, 2010). It is important to explore this 
hypothesis because penicillin, an antibiotic that was widely used to treat gonorrhoea, can induce 
transformation into abnormal RBs and that when they return to EBs they are more refractory to the 
effects of azithromycin, the main antibiotic used to treat chlamydia infection (Wyrick, 2010).    
Clinical studies have demonstrated that chlamydia can cause endometritis or PID, either 
alone or in the presence of other microorganisms (Paavonen and Lehtinen, 1996), epidemiological 
and clinical studies have demonstrated an association between chlamydia and ectopic pregnancy, 
infertility and tubal factor infertility (Cates et al., 1990, Westrom et al., 1992, Wiesenfeld et al., 
2012).  There are two competing hypotheses for how reproductive tract damage occurs: the cellular 
paradigm and the immunological paradigm.  The cellular paradigm states that epithelial cells are a 
“central player of pathogenesis” and in this model, infected epithelial cells secrete inflammatory 
mediators which stimulate an immune response and cause tissue damage (Darville and Hiltke, 2010).  
Therefore infection must be present in the epithelial cells of the fallopian tube for tubal damage to 
                                                          
2
 B cells mature into plasma cells which secrete antibodies; this response is known as humoral immunity.  
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occur.  This theory is supported by reports of damage to the reproductive tract in the absence of T 
cells (Darville and Hiltke, 2010).  The immunological paradigm postulates that tissue damage is the 
result of antigen dependent delayed-type hypersensitivity or autoimmunity due to molecular 
mimicry (Brunham and Rey-Ladino, 2005). In this case, it is assumed that ascension of the organism 
from the lower to the upper genital tract is not instantaneous and therefore may occur once the 
adaptive immune response has already been primed so the T cell response in the upper genital tract 
is activated by very small quantities of antigen reaching the fallopian tube on re-infection leading to 
inflammation (Darville and Hitke 2010). This is similar to the pathology in trachoma where repeat 
infections, even of very low antigen quantities, can induce marked pathology through a delayed-type 
hypersensitivity reaction (Grassly et al., 2008, Rank and Whittum-Hudson, 2010).  For this hypothesis 
to be true women would need to develop protective immunity and this has yet to be conclusively 
proved.  Epidemiological studies have suggested that women may develop a partial protective 
immunity to reinfection as organism load has been shown to be non-significantly lower in women 
with a repeat infection  (Geisler, 2010).   
Under the cellular paradigm, the risk of reproductive tract damage would be highest 
following a primary infection or similar in all infections and the benefit of treatment will be related 
to the timing of ascension of chlamydia relative to treatment (the longer the interval, the greater the 
potential benefit).  By contrast under the immunological paradigm repeat infections would have a 
greater risk of damage.  There is need for further characterisation of the immune mechanisms 
responsible for reproductive tract damage following a chlamydia infection.  But it is unlikely that 
there will be any further empirical studies as it is unethical to withhold treatment from infected 
women because infection can lead to irreversible reproductive tract damage.  Animal models are not 
an appropriate alternative: they require the use of a different species of Chlamydia or species from 
the genus Chlamydophila as humans are the only natural host of C.trachomatis; animals often have 
different routes of infection, for example gut infections (Rank and Whittum-Hudson, 2010); there 
are unknown differences in immune response across species which affect the generalisabilty of any 
research findings.   
Epidemiological studies in human populations can be used to investigate the risk of 
complications and explore the role of repeat infection to provide information that will allow policy 
makers to design chlamydia control programmes that balance the potential benefit of preventing 
primary infections and the associated reduction in the risk of adverse complications with the 
potential risk of increasing re-infections with their attendant risk of complications (Geisler, 2010).   
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1.3.4 Diagnostic tests  
Chlamydia trachomatis was first identified in the 1900s but it was not until 1957 that it was 
first grown in embryonated eggs and shortly after in 1963 it was grown in cell culture (Black, 2013).   
Since this time there have been several advances to the method used to diagnose chlamydia from 
samples obtained from infected people.  Table 1.1 is a summary of the main chlamydia diagnostic 
tests and additional details are provided in Appendix 1.  Briefly, the two key features of a diagnostic 
test are accuracy and technical requirement.  If a perfect test existed, everyone with the infection 
would have a positive result (100% sensitivity) and everyone without the infection would have a 
negative result (100% specificity).  However such a test does not exist for chlamydia and people can 
be incorrectly classified as infected when they are not (false positive) and uninfected when they are 
(false negative).    
With chlamydia culture, people without the infection always have a negative result (100% 
specificity) but a negative result can also be seen in up to 25% of people with the infection (75% 
sensitivity) (Schachter, 1986). Novel antigen detection techniques (direct immunofluorescence (DFA 
or DIA) and enzyme immunoassay (EIA)) were introduced in the 1980s because they were less 
technically demanding but they had a lower specificity (over diagnosis of infection could occur).  
These tests have been gradually replaced  by nucleic acid methods of diagnosis (NAATs) that have 
higher sensitivity and are more acceptable to patients (allow urine samples to be used) but the 
specificity remains poorer than culture.  
  These step-wise changes to the performance of chlamydia diagnostic tests (increase in 
sensitivity with fluctuations in specificity) make it difficult to fully interpret the trends in chlamydia 
diagnosis rates seen in surveillance data.  One would expect to see an increase in diagnosed cases in 
proportion to the increase in sensitivity of the test.  But quantifying this proportion is complex, as 
demonstrated by Westh and Kolmos who estimated that changing from an EIA to a NAAT in 
Copenhagen would lead to an increase in detected cases of 18.75% if overall figures were used, or 
4% if age-specific testing rates and prevalence were used (Westh and Kolmos, 2003).    
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Table 1.1: Summary of diagnostic tests used for chlamydia 
 
 Culture Direct 
immunofluorescence 
(DFA or DIA) 
Enzyme 
immunoassay     
(EIA) 
Nucleic acid 
amplification 
techniques (NAATs) 
Description Grow viable 
chlamydia 
organisms 
 
Detect presence of 
chlamydia antigen 
Detect presence of 
chlamydia antigen 
Detects presence of 
chlamydia DNA or 
RNA 
Date  Early 1980s 
 
Mid 1980s Mid 1980s Mid 1990s 
Strengths 100% specificity Good sensitivity 
compared to culture 
Technically easier 
than DIF and 
culture; good 
sensitivity 
compared to 
culture 
Very good for high 
volume and urine 
testing; highest 
sensitivity 
 
Limitations Low sensitivity Low specificity 
compared to culture; 
not suitable for high 
volume testing 
Need a 
confirmatory test 
due to low 
specificity 
Need a 
confirmatory test 
due to low 
specificity 
 
1.3.5 Incidence 
Chlamydia is the most common bacterial STI diagnosed in high-income settings including 
England (Public Health England, 2014), Europe (European Centre for Disease Control and Prevention, 
2013), the US (Centers for Disease Control and Prevention, 2014) and Canada (Public Health Agency 
of Canada, 2012). It is predominantly a disease of young adults and rates of infection can reach over 
3,000 per 100,000 in the at-risk populations (Centers for Disease Control and Prevention, 2010).  
There were 208,755 documented cases of chlamydia in the UK in 2013 (Public Health England, 2014), 
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87,210 cases in Canada in 2009 (Public Health Agency of Canada, 2011) and 1.2 million cases in the 
US in 2009 (Centers for Disease Control and Prevention, 2010).  
There are broadly consistent patterns in the incidence of chlamydia across high-income 
settings with implemented control strategies and compulsory notification for cases.  There was an 
initial increase in the diagnosis rate after the introduction of widespread testing followed by a 
gradual decline until the mid-1990s followed by a steady increase in diagnosis rates or test positivity 
that continues (Brunham and Rekart, 2008, Elliott et al., 2002, Fine et al., 2008, Gotz et al., 2002, 
Scholes et al., 2012).   
 For example3, in Sweden the diagnosed incidence of chlamydia in women was around 500 
per 100,000 at the start of widespread testing in the mid-1980s, it increased immediately after the 
introduction of statutory notification in 1988 then declined between 1991 and 1994 by 36% (20,980 
cases in 1991 to 13,600 cases in 1994, p<0.001) and increased by 20% between 1997 and 1999 (Gotz 
et al., 2002).  This increase was accompanied by an increase in the proportion of tests that were 
positive, from 4.1% in 1994 to 5.4% in 1999 (Gotz et al., 2002).   
However as an unknown proportion of predominantly asymptomatic infections will go 
undiagnosed there is a complicated relationship between diagnosed incidence and the true 
incidence of infection in the underlying population that may have been affected by secular changes 
including the increase in the sensitivity of diagnostic tests, the introduction of widespread chlamydia 
testing and an increase in laboratory reporting of infections.  Therefore there are a number of 
possible explanations, which may act alone or in combination, for these observed trends in the 
absence of a true rise in incident cases (Low, 2008, Miller, 2008, Rekart and Brunham, 2008, Navarro 
et al., 2002):    
 
                                                          
3
 The early decline in diagnosed incidence was observed in Wisconsin where rates of chlamydia increased in young women, 
from around 500 per 100,000 in 1985 to over 2,000 per 100,000 in 1991 accompanied by a 30% decline in test positivity 
(Hillis et al., 1995). In British Colombia, the rate of chlamydia declined from 216 per 100,000 when enhanced control was 
introduced to 104 per 100,000 in 1997 and then increased after 1998 to reach 192.6 per 100,000 in 2003 (Brunham et al., 
2005). There were similar findings from US Public Health Service Region X that introduced enhanced chlamydia control as 
part of their Infertility Prevention Project in 1988 (Fine et al., 2008).  They reported a decline in chlamydia positivity from 
1988 to 1996 (10.36% to 4.0%) followed by an increase in positivity from 1997 to 2004 (3.9-5.7%) accompanied by a 38% 
increase in testing volume and an increase in self-reported past infection in the last year (2.6% in 1988 and 3.7% in 2004).   
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 Increase notification of diagnosed cases: The introduction of statutory notification has been 
shown to be temporally associated with an increase in the number of cases reported in 
surveillance datasets (Brunham and Rekart, 2008, Gotz et al., 2002).  However this is a short 
term event and it is unlikely to explain an ongoing trend.   
 
 
 Increase in sensitivity of diagnostic test(s): The introduction of NAATs will have increased 
the proportion of infections that were detected (see Appendix 1).  However this is unlikely to 
account for most of the observed effect.  Westh and Kolmos predicted only a 4% increase in 
diagnosed incidence on switching to NAATs (Westh and Kolmos, 2003).  Furthermore in 
Sweden the increase in diagnosis rates was observed in laboratories that had yet to 
introduce nucleic methods of diagnosis (Gotz et al., 2002).  In the US the greatest increase in 
chlamydia diagnosis rate was seen during the shift to NAATs in 2005-2007 but this was 
accompanied by an increase in testing rates, 25% of women enrolled with Medicaid or a 
commercial healthcare plan were screened annually in 2000, this increased to over 40% by 
2007 (Scholes et al., 2012).   
 
 Increase in test coverage: In the absence of a true increase in incidence, testing more people 
will lead to more cases being detected (assuming a random increase in testing) (Rekart and 
Brunham, 2008).  Miller demonstrated a clear linear relationship between coverage and 
diagnosed incidence using insurance company data from the US between 1999 and 2005 
(Miller, 2008). But if incidence is stable and case mix is unchanged, then an increase in 
coverage should be accompanied by stable positivity which was not the case in Sweden 
(Gotz et al., 2002).  
 
 Change in case mix:  An appropriate change in case-mix (i.e. an increase in the incidence of 
chlamydia in the population attending for testing changes) would increase the diagnosed 
incidence rate with an associated increase in positivity in the presence of a stable incidence 
in the population.  But testing appears to have become more widespread and less focussed 
within traditional core groups.   
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 True increase in incidence: All of these factors need to be carefully considered in a specific 
setting before attributing the observed increase in cases to a true increase in incidence (Low, 
2008).  Most authors have concluded the increase in incidence from the mid-1990s cannot 
be completely explained by the introduction of more sensitive testing methods or an 
expansion of the population participating with testing (Brunham et al., 2005, Elliott et al., 
2002, Fine et al., 2008, Gotz et al., 2002) and that the increase in diagnosed incidence rate 
represented a true increase in chlamydia incidence or prevalence (Gotz et al., 2002) or test 
positivity (Fine et al., 2008) or a true increase in prevalence that was caused by the 
interaction of the control programme with a woman’s natural immune response (Brunham 
et al., 2005).   
 
This “altered immunity hypothesis4” centres on the role of repeat infection.  In British 
Colombia the increase in diagnosis rate started at the same time that notification became 
compulsory (1994) and it was associated with a 4.6% per year increase in repeat infection5 although 
one of the recommendations that accompanied the control programme was to retest women.  They 
suggest that identifying and treating asymptomatic chlamydia infections led to a reduction in the 
average duration of infection which reduced the development of a protective immune response 
against future infections (Brunham et al., 2005) although there is no empirical evidence of protective 
immunity in women (Batteiger et al., 2010).  
Settings that were later to introduce widespread testing, including England and Australia, did 
not observe a decline in rates after control measures but experienced an immediate increase in rates 
from the mid-1990s6 (Brunham and Rekart, 2008).  Brunham and Rekart have suggested that the 
altered immunity hypothesis acted quicker as higher proportions of the population were screened 
                                                          
4
 Brunham and Rekart demonstrated the plausibility of this theory with a mathematical model that assumed women 
progressed through 3 distinct infected groups during the course of an untreated infection and these determined their level 
of immunity and likelihood of reinfection on return to the susceptible group. However this model has been criticized for 
over representing the proportion who participated with testing (Low, 2008).  The authors also draw on evidence from 
Finland of a fall in chlamydia antibody seroprevalence accompanied by increasing reinfections although they do not 
address the limitations of serology as a marker of previous infection in women (cross-reactivity with antibodies to 
Chalmydophilla pneumonia) (Brunham and Rekart, 2008, Lyytikainen et al., 2008b, Rekart and Brunham, 2008, Lyytikainen 
et al., 2008a, Baud et al., 2010, Low, 2008).    
5
Defined as a positive test >30 days after a previous positive test. 
6
 In UK the number of cases diagnosed in genito-urinary medicine clinics increased from 32,288 in 1995 to 104,155 in 2004.  
This was explained by changes in sexual risk behaviour, increased testing and more sensitive tests (Health Protection 
Agency, 2006, Brunham and Rekart, 2008).  
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more quickly and Bender et al. suggested that patterns could represent countries in different phases 
of their epidemics (Bender et al., 2011, Brunham and Rekart, 2008).  However Low has suggested 
that the initial declines in diagnosis rates in settings that implemented control in the 1980s may have 
been a consequence of sexual behaviour change in response to the HIV epidemic (Low, 2008).    
A lack of unbiased prevalence estimates and accurate information about the duration of 
untreated infection has hampered a full understanding of these patterns (European Centre for 
Disease Control and Prevention, 2014, Geisler et al., 2008) and if the duration of infection is 
shortened then an increase in incidence can occur in the absence of a change in prevalence (Miller, 
2008).  
 
1.3.6 Prevalence 
Chlamydia infection is mainly asymptomatic so prevalence is an attractive option for 
quantifying the number of infected people but there are many challenges to obtaining an accurate 
measure of the population prevalence of chlamydia.  It requires sampling of a large proportion or 
representative sample of a whole population in a short space of time which has considerable 
organisational difficulties and resource costs and it can introduce complex ethical issues if the results 
are not returned to the participants.  A recent systematic review pooled the findings from the 
limited number of nationally representative cross-sectional surveys from Europe and the USA to 
obtain an estimate of prevalence in sexually experienced adults (18-26 years) of 3.6% (95% 
confidence interval (CI) 2.4%-4.8%) in women and 3.5% (95% CI 1.9%-5.2%) in men (European Centre 
for Disease Control and Prevention, 2014).  Prevalence estimates varied by age, geographic 
coverage, sexual experience and response rate; for example, the prevalence of asymptomatic 
infection in unscreened women in Europe was between 1.7-17[.0]% “depending on the setting, 
context and country” (Wilson et al., 2002) but the prevalence of infection in UK general practice  
surgeries was not significantly higher than in population-based studies, 8.1% (95% CI 6.5-9.9) 
compared to 5.0% (95% CI 3.2-7.6) (Adams et al., 2004).   
The most interesting recent evidence on the prevalence of chlamydia comes from the UK, 
where two cross-sectional measurements of population prevalence were obtained in 2000 and 2010 
using a stratified probability sample of 18-44 year olds, the National Survey of Sexual Attitudes and 
Lifestyles (NATSAL) survey. Despite a population based screening programme aimed at young adults 
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that covered the majority of the population from 2008 onwards, there has been no change in the 
underlying prevalence of chlamydia.  Prevalence in women was estimated as 1·5% (95% CI 1·1–2·1) 
in 2000 and 1·5% (95% CI 1·1-2·0) in 2010 (Sonnenberg et al., 2013, Fenton et al., 2001).  But further 
information is needed before any conclusion can be made about the impact of chlamydia control 
because it was introduced towards the end of the interval between the surveys and figures were 
based on different NAATs and it is important to remember that incidence can change with a stable 
prevalence as duration of infection changes.  
 
1.3.7 Risk factors  
Infection with chlamydia can only occur following unprotected sexual intercourse (or 
contact) with an infected partner.  However the probability of this event and the risk of contact 
progressing to infection are influenced by a number of behavioural and biological factors that act at 
the level of the individual and society.  They are summarised in Table 1.2. 
 
1.3.8 Treatment  
Chlamydia can be effectively treated with antibiotics.  The original mainstay of treatment 
was a short course of doxycycline but in most settings this was replaced by a single dose of 
azithromycin in the mid-1990s.  Azithromycin was favoured because it has a shorter course and 
milder side effect profile which can improve compliance.  People have called into question whether 
it has an equivalent effectiveness to doxycycline but a recent meta-analysis reported that the pooled 
difference in the efficacy of azithromycin and doxycycline was 1.5% (95% CI −0.1%-3.1%) in favour of 
doxycycline for a microbiological cure7 of urogenital chlamydia at 3 months (Handsfield, 2011, Kong 
et al., 2014).  Several mechanisms have been suggested for azithromycin treatment failure (Horner, 
2012) and this could contribute to the increasing rate of chlamydia diagnosis, i.e. persistent rather 
than repeat infections.  However doxycycline has also be implicated in treatment failure, particularly 
in chronic infection (Horner, 2012) and a case series of people with possible persistent infection had 
been equally treated with both drugs (Pitt et al., 2013).      
                                                          
7
 It is unclear if a “microbiological cure” excludes the presence of persistent morphologically abnormal RBs.  
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Table 1.2: Summary of risk factors for chlamydia infection  
 
Risk factor 
 
Description  
Age Highest rates in 15-24 year olds: 63% of all chlamydia cases diagnosed in 
Genito-Urinary Medicine (GUM) clinics in England in 2010 (Health Protection 
Agency, 2011), and rates of infection over 3,000 cases per 100,000 in 
women in US in 2009 (Centers for Disease Control and Prevention, 2010).  It 
is likely to represent a combination of biological, behavioural and societal 
factors.   
 
Sex Case rate in women was 2.7 times higher than men in the US in 2009 (592.2 
compared to 219.3 cases per 100,000) (Centers for Disease Control and 
Prevention, 2010, Centers for Disease Control and Prevention, 2011) 
although prevalence in the UK in 2010 was the same in both sexes (1·5% 
(95% CI 1·1-2·0) in women and 1·1% (0·7-1·6) in men (Sonnenberg et al., 
2013)). This may reflect a true difference in incidence or testing bias.   
 
Ethnicity Inconsistent evidence for racial or ethnic patterns in risk. It is postulated that 
the reported associations may be a proxy for healthcare seeking behaviour 
(Navarro et al., 2002).  In 2009 in the US the rates of reported infection were 
8.7 times higher in African Americans than whites (Centers for Disease 
Control and Prevention, 2011).   
 
Cervical ectopy The protrusion of columnar epithelium through the cervical os is more 
common in young women (Lee et al., 2006) and is postulated to increase the 
available target cells for chlamydia EBs.   
 
Hormonal 
contraception 
Evidence is poor quality but there is likely to be a positive association 
between hormonal contraception and chlamydia and the evidence is 
stronger for depot medroxyprogesterone acetate than for combined oral 
contraceptive (COC) (Mohllajee et al., 2006).  It may be mediated through 
cervical ectopy (Mohllajee et al., 2006). This relationship may be 
confounded by use of barrier methods of contraception but a meta-analysis 
reported a three-fold increased unadjusted risk of chlamydia in women 
using the COC compared to barrier methods (Pooled odds ratio (OR) 2.91 
(95% CI 1.86–4.55)) (Cottingham and Hunter, 1992).   
 
Geography North-South gradient in England (North East: 2,600 per 100,000 compared 
to South East Coast 1,600 per 100,000 (Health Protection Agency, 2007)) 
and in the US (South: 452.4 per 100,000 and Northeast: 363.9 per 100 000) 
(Centers for Disease Control and Prevention, 2010).  It is not clear how these 
overlap with socio-economic trends.  They may be a proxy for sexual 
network risk factors or an individual’s risk environment (Wylie and Jolly, 
2001).  
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1.4 Epidemiology of pelvic inflammatory disease 
1.4.1 Overview 
PID is defined as “infections of the upper genital tract caused by microorganisms that ascend 
from the cervix or vagina” and it is often used interchangeably with salpingitis (Paavonen, 2008). It is 
predominantly associated with STIs but it has multiple infectious aetiologies and a range of clinical 
presentations.  The diagnosis is usually made using clinical criteria that are non-specific and there is 
no non-invasive gold-standard diagnostic test.  In addition, marked variation in the diagnosis of PID 
with respect to symptoms, signs and infections has been shown across clinician groups and the 
diagnosis has been shown to provide a challenge to the most experienced clinicians (Morris et al., 
2014). Therefore there is uncertainty surrounding the accuracy of the diagnosis.  Rates of PID 
hospitalisations have been declining since the 1960s as a result of a variety of factors including a 
change in the aetiology of PID, gonorrhoea control, or possibly enhanced coverage of chlamydia 
testing. The tissue damage that accompanies the inflammation can lead to serious adverse 
reproductive outcomes in women, including ectopic pregnancy and tubal factor infertility.   
 
1.4.2 Aetiology 
PID is caused by STIs or vaginal floras that ascend through the cervix. Trans-cervical medical 
intervention (e.g. intra-uterine contraceptive device (IUCD) insertion) can cause ascension and 
sexual intercourse may increase the risk while hormonal contraception may be protective 
(Paavonen, 2008).  It can be difficult to determine the causative organism(s) in a case of PID because 
multiple organisms are often identified and the presence of a pathogen in the lower genital tract 
does not necessarily mean it is the cause of upper tract inflammation (Paavonen, 2008).  A poly-
microbial aetiology is likely because broad-spectrum antibiotics have been shown to be more 
effective than treatment aimed at gonorrhoea or chlamydia (Kamwendo et al., 1998).    
Microorganisms associated with bacterial vaginosis (BV) have frequently been identified in 
the upper tract of women with PID but they have not been directly associated with an increased risk 
of PID (adjusted hazard ratio (AHR) 0.89 (95% CI 0.55-1.45)) (Ness et al., 2004, Paavonen, 2008).  
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New potential pathogens keep being identified (Haggerty et al., 2004, Hebb et al., 2004) and the 
PHAC list the following as causative organisms for PID (Public Health Agency of Canada, 2010):  
 
 Chlamydia trachomatis 
 Neisseria gonorrhoea 
 Trichomoniasis vaginalis 
 Herpes Simplex Virus 
 Mycoplasma genitalium 
 Mycoplasma hominis 
 Ureaplasma urealyticum 
 Bacteroides spp. 
 Peptostreptococcus spp.  
 Prevotella spp. 
 Escherichia coli 
 Gardnerella vaginalis 
 Haemophilus influenzae 
 Streptococcus spp. 
 
 
In the context of this thesis, the critical parameters are the proportion of cases of PID that 
are caused by chlamydia and the probability that a chlamydia infection will progress to PID.  There 
are marked uncertainties in these estimates and they are likely to have changed over time.  The risk 
of PID following chlamydia is described in section 1.5.  Historical studies found that the prevalence of 
chlamydia in women with PID was between 5% and 77% (Cates and Wasserheit, 1991, Paavonen and 
Lehtinen, 1996) and a further study found that 38.4% of cases of PID were associated with chlamydia 
between 1977 and 1984 (Westrom et al., 1992). The widely quoted figure is that 30% of PID is 
caused by chlamydia (Paavonen et al., 2008).   
The relative contribution of chlamydia will have increased as the proportion of cases caused 
by gonorrhoea has steadily declined.  In the late 1960s in Sweden, 45% of women with PID had 
gonorrhoea but by the mid-1970s it had fallen to below 20% and it continued to decline (Kamwendo 
et al., 1996).  Gonorrhoea is now the causes of fewer than 2% of PID cases in the UK (Ross and 
Hughes, 2014), and therefore early estimates of this proportion are probably no longer relevant and 
modern estimates may not be generalisable between settings.   
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1.4.3 Natural history 
PID can cause severe adverse reproductive complications including ectopic pregnancy and 
infertility (Paavonen, 2008). The strongest evidence for this was from a retrospective cohort of 
women with PID diagnosed between 1960 and 1984 (Westrom et al., 1992). Women with abnormal 
findings on laparoscopy were six times more likely to have infertility or an ectopic pregnancy as the 
outcome of their first pregnancy compared to women with normal findings (16.0% compared to 
2.7% and 9.1% compared to 1.4% respectively).  In a more recent prospective cohort of women with 
PID, 18% reported infertility and 0.5% had had an ectopic pregnancy three years after diagnosis 
(Ness et al., 2002).  
In addition to this, subclinical PID can also lead to ectopic pregnancy and tubal factor 
infertility: a strong association between anti-chlamydia antibodies and adverse reproductive 
outcomes has been demonstrated in women without a history of clinical PID (Cates and Wasserheit, 
1991). However there are concerns over the validity of chlamydia serology as a marker of previous 
genital infection predominantly due to cross-reactivity with antibodies against other Chlamydia 
species (Patel et al., 1995).   A recent prospective clinical study has provided additional evidence of 
this relationship:  after treatment for STIs (chlamydia, gonorrhoea and BV) women with subclinical 
PID (diagnosed using endometrial biopsy) were 40% less likely to experience a pregnancy during 
follow-up than women without subclinical PID (HR 0.6 (95% CI 0.4-0.8)) (Wiesenfeld et al., 2012).   
 
1.4.4 Clinical presentation, diagnosis and management 
PID is a clinical diagnosis.  There are three minimum diagnostic criteria for symptomatic PID 
in Canada (Public Health Agency of Canada, 2010): lower abdominal tenderness; cervical motion 
tenderness and adnexal tenderness.  Other diagnostic features that may assist in the diagnosis 
include evidence of inflammation8 or chlamydia or gonorrhoea infection at the cervix.  There are 
                                                          
8
 Temperature >38.2°C; blood tests including an elevated C-reactive protein or erythrocyte sedimentation rate; white blood 
cells in vaginal secretions.  
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three definitive diagnostic criteria: histological evidence of endometritis on an endometrial biopsy; 
abnormal imaging with thickened and fluid filled fallopian tubes; laparoscopic evidence of PID.   
 Women with PID can present with a range of symptoms and the clinical severity of the 
condition can vary from mild abdominal pain to frank peritonitis (Paavonen and Lehtinen, 1996).  
The only gold standard diagnostic test is a laparoscopy but due to its invasive nature, this is not 
widely performed.  In Sweden, 60-65% of cases were confirmed with laparoscopy in the 1970s-1980s 
but by the 1980s they were only performed if the diagnosis was in question (Kamwendo et al., 
1998).   
In women with a clinical diagnosis of PID, the individual signs and symptoms have poor 
sensitivity and specificity for predicting the presence of a laparoscopic diagnosis, with exception of 
tenderness on bimanual examination which has a sensitivity of  99%  (95% CI 97.7-99.7)  but a 
specificity of <1%  (95% CI <0.1-2.8) and proctitis which had a specificity of 92% (95% CI 86.2-96.2) 
but a sensitivity of 10%  (95% CI 7.4-12.9) (Simms et al., 2003).  The CDC minimum diagnostic criteria 
for PID9 have a sensitivity of 83.3% (95% CI 78.7-87.3) and a specificity of 21.8% (95% CI 17.5-26.5) 
for the presence of histological endometritis in women with clinically suspected PID10 (Peipert et al., 
2001).  In addition to this, a study of the practice of clinicians grouped by their level of experience 
has demonstrated a marked variability in the application of the diagnosis with respect to clinical 
criteria (Morris et al., 2014).  This differentiation in performance was interpreted as the appropriate 
application of diagnostic acumen by experienced practitioners. But this only acts to highlight the 
challenges faced when making a clinical diagnosis of PID.   
One key factor that is likely to play a role in clinical decision making is past medical history.  
This is not a formal diagnostic criterion for PID but it is standard practice for clinicians to adopt a 
Bayesian11 approach and direct their differential diagnosis based on the events leading up to the 
current presentation (Ward et al., 2012). In this particular situation, there is likely to be an 
appropriate diagnostic bias towards PID in women with a past history of chlamydia (at any point 
before the current presentation) (Haggerty et al., 2010).  The advantage of this is that the sensitivity 
                                                          
9
 CDC minimal diagnostic criteria defined as lower abdominal tenderness, adnexal tenderness, and cervical motion 
tenderness. 
10
 Women in this study went on to be randomised into different treatment arms for PID.  
11
 Bayesian statistics use prior knowledge about the probability of an event to interpret the probability in the light of new 
evidence.   
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of the diagnosis may be increased and fewer women will have an untreated episode of pelvic 
inflammation that can lead to adverse reproductive complications.  But this diagnostic bias has not 
been quantified.  Taking all these factors into consideration, there is marked uncertainty about the 
validity of the clinical diagnosis of PID.    
Subclinical or asymptomatic PID, which can only be diagnosed through the presence of 
endometritis on histology, clearly does not appear in administrative health records but is probably a 
common event.  Endometrial biopsies are not performed in the investigation of PID12 therefore 
information on subclinical PID has been obtained in the setting of clinical trials (Gordon, 2009).  It is 
widely quoted that 60% of PID may be subclinical (Paavonen et al., 1998) and a recent clinical study 
found that 25% of women with asymptomatic chlamydia or gonorrhoea may have had subclinical 
PID (Wiesenfeld et al., 2012).    
In general, the treatment of PID is broad-spectrum antibiotics for 14 days as an out-patient 
in milder uncomplicated cases or otherwise as an in-patient, at least initially, with intravenous 
antibiotics.  The PHAC has the following criteria for admitting a woman to hospital for the 
management of suspected PID (Public Health Agency of Canada, 2010): 
 
 Pregnancy; 
 Cannot exclude a surgical emergency; 
 Clinical severity of illness;  
 Tubo-ovarian abscess; 
 Unable to follow out-patient oral treatment; 
 No response to out-patient oral treatment; 
 HIV infection; 
 Youths or adolescents (especially if there are concerns over treatment compliance). 
 
                                                          
12
 Endometrial biopsy is clinically indicated in cases of abnormal uterine bleeding, post-menopausal bleeding, 
amenorrhoea, endometrial dating, evaluation of infertility, evaluation of uterine response, atypical glandular cells, follow-
up of endometrial hyperplasia (Gordon, 2009).  
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There is evidence to suggest that the clinical presentation (or lack of in the case of subclinical 
disease) of PID can differ depending on the causative organism and that chlamydia-associated PID 
may be less severe than that associated with gonorrhoea (Short et al., 2009).  In two early clinical 
studies the risk of progression to PID following chlamydia was much higher in the cohort with co-
exposure to gonorrhoea compared to the cohort without (Rahm et al., 1986, Stamm et al., 1984).  
More recently, the rate of hospitalisation for PID following a diagnosis of gonorrhoea was found to 
be three times higher than that seen following chlamydia (adjusted13 incidence rate ratio 3.48 (95% 
CI 2.51-4.82)) (Reekie et al., 2014). 
 
1.4.5 Administrative health data 
Authors have used administrative health data (predominantly hospital admissions or out-
patient appointments) to study aspects of the epidemiology of PID.  These data are routinely 
collected as part of the usual function of health services and relies on an accurate transcription of 
the clinical record into an appropriate International Classification of Diseases (ICD) code14.  However 
there is no standard ICD definition for PID in the literature (Andersen et al., 2010, Bakken and 
Ghaderi, 2009, Low et al., 2006).  The reason for this is apparent on review of the ICD-9 and ICD-10 
codes, as they refer to anatomical locations and/or causes of inflammation rather than the 
overarching clinical diagnosis of PID.  Several studies of US insurance records have looked at the 
accuracy of ICD definitions for PID.  One used a broad definition for an episode of acute PID15 but 
found that 55.78% of cases used ICD-9 614.9 (Bohm et al., 2010). This 614.9 code has been shown to 
have a positive predictive value (PPV) of 18.1% for representing a case of PID meeting the CDC 
diagnostic criteria (Ratelle et al., 2003).  While a study using a broader definition of PID, the 
physician stating that the patient had PID in the medical notes, found that the PPV of a broader 
range of ICD-916 codes was 79% (Satterwhite et al., 2011).   
                                                          
13
 Adjusted for age, year, socio-economic status, region, parity.  
14
 The ICD system is an international standard for classifying diseases that is maintained by the World Health Organisation 
(World Health Organisation, 2014).  
15
 ICD-9-CM codes: O98.10; O98.16; O98.17; O98.19; O98.86; O99.56; 614.0; 614.2; 614.3; 614.5; 614.8; 614.9; 615.0; 
615.9 (Bohm et al., 2010). 
16
 ICD-9 codes 098.10; 098.16; 098.17; 098.19; 098.86; 099.56; 614.0; 614.5; 614.8; 614.2; 614.3; 614.9; 615.0; 615.9  
(Satterwhite et al., 2011). 
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1.4.6 Incidence 
Administrative health datasets have been used to perform ecological analyses of hospital 
admissions with PID to report trends in the incidence of PID.  Hospitalisation rates have shown a 
consistent decline in PID in high-income settings since reporting began (often coinciding with the 
introduction of chlamydia control interventions) (Bender et al., 2011, Owusu-Edusei et al., 2010, 
Rekart et al., 2013, Scholes et al., 2012). For example in Wisconsin, the incidence of hospitalisation 
declined from almost 140 per 100,000 in 1982 to under 100 per 100,000 in 1987 and 60 per 100,000 
in 1991 (Hillis et al., 1995).  These observed declines were cautiously attributed to chlamydia control, 
but hospitalisation rates have continued to decline in the presence of increasing rates of chlamydia. 
For example, in the US, the rate of PID diagnosis fell by 50% from 1997 to 2007 (823 per 100,000 to 
473 per 100,000 (p<0.01)) (Scholes et al., 2012). This has led authors to speculate about other causes 
for the observed patterns (Simms and Stephenson, 2000):  
 Reduced case ascertainment: A shift from in-patient to out-patient treatment would lead to 
a decline in the observed hospitalisation rate without a decrease in the true incidence of PID 
(Hillis et al., 1995).  This could occur following a change in the spectrum of clinical severity, a 
healthcare policy decision or a change in healthcare seeking behaviour.  However data on 
healthcare presentations in British Colombia found no evidence of a shift from hospital to 
community care (Rekart et al., 2013).  The proportion of women not referred to secondary 
care for PID was 82.5% in 1992 and 87.6% in 2009 and PID hospitalisation rates declined by 
80% (150.1 to 30.1 per 100,000) and community treatment rates declined by 70% (771.0 to 
245.7 per 100,000).  In fact in the UK, Ross and Hughes suggest that care has shifted from 
primary care to hospitals as attendance rates in primary care have fallen (400 per 100,000 in 
2003 to 180 per 100,000 in 2011) while at the same time GUM clinics have seen a 27% 
increase (Ross and Hughes, 2014).  
 
 Change in aetiology of PID: It is possible that different aetiological agents may lead to a 
reduction in the severity of PID and a shift from in-patient to out-patient care (see above) or 
a shift to subclinical disease.  Evidence for a reduction in the severity of PID comes from an 
analysis of UK primary care data that demonstrated a decline in the rates of definite or 
probable PID with an increase in the rates of possible PID which suggests that the clinical 
features of the diagnosis may have become less pronounced (French et al., 2011) and the 
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clinical criteria used to make a diagnosis have not changed (Ross and Hughes, 2014).  Scholes 
et al. have questioned how much of the PID in the US is caused by chlamydia as an 
uncoupling of these two conditions could explain the observed patterns (Scholes et al., 
2012).  
 
 Wider behavioural change: Authors suggest that the initial observed declines in PID from 
the early to mid-1980s that occurred against the backdrop the HIV/AIDS epidemic may have 
been the result of behavioural change in the heterosexual population (Coutinho et al., 1992, 
Kamwendo et al., 1998, Low, 2008). This is supported by evidence of declines in PID in 
settings without organised chlamydia control (Hillis et al., 1995, Low, 2008).  However this 
effect would have been mediated through the incidence of STIs therefore can only have 
plausibly occurred as STI incidence was in decline.   
 
 Chlamydia control: Identifying and treating cases of chlamydia could reduce the observed 
incidence of PID, either through a true reduction in PID overall or through a shift from 
clinical to sub-clinical inflammation.  In Wisconsin the observed rate of decline in PID 
hospitalisations was the same pre-1987 as post-1987 which makes chlamydia control a less 
likely explanation (Hillis et al., 1995).  In addition, this decline in the rate of PID was seen in 
other areas of the US that had not introduced widespread chlamydia control.   
 
1.4.7 Risk factors 
The risk factors for PID are similar to those for STIs as most PID is caused by STIs but there is 
also a mechanical role from trans-cervical instrumentation and sexual intercourse (Paavonen, 2008).  
In general practice in the UK, a diagnosis of PID has been shown to be more likely in younger age 
groups, women who smoke and women with a lower socio-economic status (Simms et al., 1999). 
Women with an IUCD have been shown to have a 3-fold increased risk of PID (relative risk (RR) 3.3 
(95% CI 2.1-5.3)) (Gareen et al., 2000).  In Sweden where there was a spike in the number of cases of 
PID association with increased prescribing of IUCDs in young sexually active women (due to 
ascension of the vaginal flora) and when clinical practice was changed rates of PID returned to 
baseline (Kamwendo et al., 1998).  Use of oral contraceptives has been shown to reduce PID by 50% 
and douching may increase the risk (Simms and Stephenson, 2000). 
  Chapter 1 
43 
 
 
1.5 Estimates of the association between chlamydia and PID  
1.5.1 Overview 
Chlamydia-associated PID is an important cause of morbidity.  PID is commonly studied as a 
“surrogate or intermediary outcome” of chlamydia because it has a pathological relationship with 
ectopic pregnancy and tubal factor infertility but occurs over a more convenient, shorter time 
interval following acute infection (Haggerty et al., 2010). In this section I review the evidence for an 
association between chlamydia and PID that has been used to support the implementation of 
widespread control interventions and consider the outstanding uncertainty in this relationship.  
 
1.5.2 Clinical studies 
Early clinical studies in high risk women demonstrated that some women with untreated 
chlamydia developed subsequent PID.  However this risk varied between women with and without 
gonorrhoea infection or exposure.  A third of women with treated gonorrhoea and an untreated 
chlamydia infection17 developed PID within 7 weeks (30% (6/20) in chlamydia infected compared to 
0% (0/37) in chlamydia uninfected, p=0.01) (Stamm et al., 1984). In another study, 3.8% (4/106) of 
asymptomatic women with untreated chlamydia developed PID by three months (Rahm et al., 1986).  
There have been three further cohort studies that measured the risk of PID following 
untreated chlamydia in women attending STI clinics (Bachmann et al., 1999, Geisler et al., 2008, 
Hook et al., 1994).  A systematic review reported their combined findings as evidence that 2-5% of 
untreated infections progressed to PID within two weeks of diagnosis in high risk settings (Haggerty 
et al., 2010).  This review identified a further cohort, this time of asymptomatic women from a 
                                                          
17
 The study was a prospective cohort of women with gonorrhoea or a partner with gonorrhoea who were treated with one 
of three antibiotic regimes known to be effective against gonorrhoea.  The incidence of cervicitis or PID in women treated 
with a regime ineffective against chlamydia (penicillin-probenecid) was compared between women with baseline positive 
endocervical chlamydia cultures and women who were negative for chlamydia at the start of the study.  
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general population setting (pre-employment health check) who were tested using NAATs and they 
had a risk of progression of 0.0% (95% CI 0.0-9.5%) over 1 year (Haggerty et al., 2010, Morre et al., 
2002).  The final estimate of this risk comes from an RCT of chlamydia screening (the Prevention Of 
Pelvic Infection (POPI) trial) where 9.5% (95% CI 4.7-18.3%) of untreated women progressed to PID 
at one year (Oakeshott et al., 2010) but it has been suggested that this risk of progression may be 
conservative as a proportion of women may have sought treatment at some point during follow up 
(Gottlieb et al., 2013).   
The highest risk of progression from diagnosis to hospitalisation with PID seems to occur in 
the first seven days (Reekie et al., 2014) therefore it is difficult to directly compare the risk of 
progression over different durations of follow-up.  But if we assume that the rate of progression 
from diagnosis to PID is constant (as seen in (Haggerty et al., 2010)), then the risk of PID over 7 
weeks in the above studies is between 0-35% (Table 1.3).  
 
Table 1.3: Estimates of progression of untreated chlamydia to PID over 7 weeks  
  
Study Estimate Description 
Stamm et al. (Stamm et al., 1984)   30% Treated for gonorrhoea 
Rahm et al. (Rahm et al., 1986) 0.29% Asymptomatic 
Haggerty et al. (Haggerty et al., 2010) 10-35% Asymptomatic or 
symptomatic 
Morré et al. (Morre et al., 2002) 0.0-1.28% Asymptomatic 
Oakenshott et al. (Oakeshott et al., 
2010) 
1.4% Asymptomatic 
 
It is important to apply a cautious interpretation to these findings because of the 
methodological limitations to studies of the duration of untreated infection (discussed in section 
1.3.3).  However the general pattern suggests that infections in asymptomatic women 
representative of the general population (Morre et al., 2002, Oakeshott et al., 2010, Rahm et al., 
1986) may have a lower risk of progression than infections in women recruited from clinical settings 
(Haggerty et al., 2010, Stamm et al., 1984).  Chlamydia control is now well-established in many 
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settings and leaving infections untreated is clearly unethical, which means it is very unlikely that any 
further evidence on the risk of PID following chlamydia will be obtained from untreated women.  
Therefore I will look to the insights that have been provided from different study designs.   
 
1.5.3 Randomised controlled trials 
There have been four RCTs of chlamydia testing in asymptomatic general population settings 
that have reported the incidence of PID at 12 months as an outcome (Table 1.4) (Andersen et al., 
2010, Oakeshott et al., 2010, Ostergaard et al., 2000, Scholes et al., 1996).  However, with the 
exception of the POPI trial discussed in section 1.5.2, they do not provide direct estimates of the risk 
of PID following untreated or treated infection.  Instead they report on the benefit of screening to 
the incidence of PID.   
 Low et al. pooled the findings from these four RCTs and reported that the risk of PID was 
around 40% lower at one year in women offered a chlamydia test compared to women with usual 
care (pooled risk ratio 0.64 (95%CI 0.45-0.90)) (European Centre for Disease Control and Prevention, 
2014).  Authors have compared this estimate to evidence about the proportion of PID cases that are 
attributed to chlamydia (commonly quoted as 30%) and have suggested that screening and 
treatment may clear a wider range of PID-causing organisms than just chlamydia (European Centre 
for Disease Control and Prevention, 2014).  However it could also reflect a difference in the 
proportion of cases of PID that are caused by chlamydia between the earlier clinical studies and 
these general population based RCTs (see section 1.4.2).  This raises a further question about how 
comparable historical cohorts may be to the modern setting.  
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Table 1.4: Summary of RCTs of the effect of chlamydia screening on PID  
 Scholes et al. (Scholes et al., 
1996)   
Ostergaard et al. (Ostergaard 
et al., 2000) 
Andersen et al. (Andersen et 
al., 2010, Andersen et al., 2002) 
Oakeshott et al. (Oakeshott 
et al., 2010) 
Location   Seattle, USA Aarhus, Denmark Aarhus, Denmark London, UK 
Date 1990-1992 1997-1998 1997 2004-2007 
Population High risk 18 to 34 year old 
women registered with a 
health maintenance 
organisation 
High school students 
randomised at level of school 
21-23 year olds Women under 27 at 
educational institutions 
Intervention  Offer of a chlamydia screen 
from a healthcare provider 
Offer of home collected screen Home test kit through post Immediate chlamydia test 
Control No chlamydia screen Offer of usual care in a clinic Usual care Deferred chlamydia test at 
12 months 
Outcome PID at 12 months identified 
from medical records 
Self-reported PID at 12 months Doxycycline prescription or 
hospitalisation for PID at 12 
months 
PID at 12 months identified 
from medical records 
Result Intervention group had a 
significantly lower risk of PID 
(RR  0.44 (95% CI 0.20–0.88)) 
Intervention group had a 
significantly lower risk of PID 
(4.2% compared to 2.1%, 
p=0.045) 
No difference in PID risk (HR 
1.12 (95% CI 0.70-1.79)) 
Intervention group had a 
non-significantly lower risk 
of PID (RR 0.65 (95% CI 0.34-
1.22)). Risk of PID in 
chlamydia positive control 
women was 9.5% (95% CI 
4.7-18.3%) 
Comment 
(Gottlieb et 
al., 2013) 
7% of randomised women 
were enrolled; selection bias 
from differential contact with 
two arms of study 
Uptake of screening in the 
control arm was very low 
compared to intervention (8% 
versus 93%); 50% loss to follow-
up; non-blinded outcome 
assessment 
Uncertain accuracy of definition 
of outpatient PID; low uptake of 
screening (9% outside 
intervention) 
Underpowered 
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These four RCTs in combination have been interpreted as “direct evidence that chlamydia 
screening and treatment can reduce the risk of PID at 1 year for individual women” although the 
authors caution this statement with an acknowledgement that the most methodologically robust 
study was underpowered and failed to show an effect, so earlier studies may overestimate the true 
benefit of screening (Gottlieb et al., 2013).  Therefore it is unlikely that there will be any further RCTs 
of chlamydia screening in which to nest a study of the risk of PID following untreated infection to 
test hypotheses about the magnitude of benefit from chlamydia control. 
 
1.5.4 Population-based cohort studies 
An alternative method for advancing the evidence base for the relationship between 
chlamydia and PID is to measure the risk of PID following a diagnosed and treated chlamydia 
infection.  The POPI study reported that the risk of PID by one year in women in the intervention arm 
who were chlamydia positive at baseline was 1.6% (1/63) (Oakeshott et al., 2010).  This is much 
lower than the risk observed in a prospective cohort of sex workers in Nairobi where 30% (44/146) 
of women who were tested for chlamydia and appropriately treated went on to developed PID over 
an average of 17 months (Kimani et al., 1996).  This comparison is further support for the hypothesis 
that progression is more common in high risk women rather than the general population. 
The risk of PID following treated chlamydia can be further studied using retrospective 
population-based cohorts constructed from administrative health records (Chow, 2013). There are 
two published cohorts that have measured the risk of PID following diagnosed and treated 
chlamydia (summarised in Table 1.5 and fully described in Appendix 2) (Bakken and Ghaderi, 2009, 
Low et al., 2006).   
The first of these cohorts based in Uppsala, Sweden found that 5.6% (95% CI 4.7-6.7) of 
women who were diagnosed and treated for chlamydia had a hospital presentation for PID by the 
age of 35 which was around 30% higher than women who only had negative tests (AHR 1.27 (95% CI 
1.04-1.55)) (Low et al., 2006).  This was much higher than the absolute risk reported in Sør-
Trøndelag, Norway where only 1.09% (95% CI 0.82-1.44) of women diagnosed and treated for 
chlamydia had developed PID after fifteen years (Bakken and Ghaderi, 2009).  But the increased risk 
of PID in women who tested positive compared to women who tested negative was comparable 
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between the cohorts (adjusted hazard 1.69 (95% CI 1.21-2.36)) (Bakken and Ghaderi, 2009).  These 
studies suggest that the risk of PID following a treated chlamydia infection is low but the difference 
between them suggests that more evidence is needed to determine whether they can be 
generalised to other settings.  
There are some important limitations to these studies that resulted from the available data 
and affect the validity of their findings.  Firstly, they used hospital discharge information to identify 
cases of PID which means that there was under ascertainment of cases of PID treated in the 
community.  Secondly, they were not able to control for potential confounding from gonorrhoea, 
contraception use or incidental antibiotic treatment.  Thirdly, the rates of repeat testing were too 
low for the authors to estimate a risk following repeat infections although the preliminary findings in 
Uppsala were suggestive of a “slightly” increased risk of any complication in women with more than 
one infection (Low et al., 2006). Finally, these studies provide a single risk of PID following chlamydia 
over a fifteen year time period but there is evidence to suggest that the nature of the relationship 
between chlamydia and PID may have changed since the introduction of widespread control 
interventions (Bender et al., 2011, Darville and Hiltke, 2010, Hadgu and Sternberg, 2009, Rekart et 
al., 2013).   
 
1.6 Temporal patterns in the relationship between chlamydia and PID 
Ecological analyses from settings with widespread chlamydia control interventions (see 
section 1.3.5 and 1.4.5) have demonstrated a change in the relationship between trends of 
chlamydia and PID over time.  Following an initial decline in the rate of chlamydia diagnosis and a 
decline in the rate of hospitalisation for PID after the introduction of control interventions there has 
been a continual decline in PID hospitalisation rates with an increase in rates of chlamydia diagnosis 
(Bender et al., 2011, Owusu-Edusei et al., 2010, Rekart et al., 2013, Scholes et al., 2012). In this 
section I consider the potential causes of this observed event and the impact that the control 
interventions may have had on this relationship. 
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Table 1.5: Summary of retrospective population based cohorts of the association between 
chlamydia and PID 
 
 Low  (Low et al., 2006) Bakken (Bakken and Ghaderi, 2009) 
Location   Uppsala, Sweden Sør-Trøndelag, Norway 
 
Date 1985-1999 1990-2005 
 
Population Women aged 15-24 between 1985-
1989 
Women aged 20-35 between 1990-2005 
 
Chlamydia 
test 
method 
 
Culture until 1995; PCR in 1996 EIA until 1992; Non-nucleic acid based 
assay until 1999; PCR until 2005 
Chlamydia 
exposure 
definition  
Women classified as never tested until 
date of first test, negative following 
first negative test and positive 
following first positive test 
Women classified as positive or 
negative based on the result of their 
first chlamydia test, switch to positive 
on date of first positive test 
 
PID In-patient and out-patient 
presentations with ICD-10 N70-74 
In-patient and out-patient 
presentations with ICD-9 614 or ICD-10 
N70 
 
Covariates age, education, income and housing age at first test 
 
Adjusted 
hazard 
ratio of PID 
  
1.27 (95% CI 1.04-1.55) in positive 
women compared to negative women 
1.69 (95% CI 1.21-2.36) in positive 
women compared to negative women 
Comment  No community managed PID; most 
chlamydia tests were low sensitivity; 
never tested are a heterogeneous 
group before their first test and never 
tested across lifetime 
No community managed PID; findings 
not generalizable to population 
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The general consensus is that the observed trend in chlamydia diagnosis rates and test 
positivity represent a true increase in the incidence of infection and that the true number of cases of 
clinical PID has been falling.  The cause of this inverse association is likely to be multifactorial; 
Bender et al. could not identify a consistent relationship between rates of chlamydia diagnosis and 
PID hospitalisations in six high income countries between 1998 and 2008 (Bender et al., 2011).  
There are several potential explanations for this observed relationship:  
 Change in the aetiology of PID: There has been a decline in the diagnosed incidence rate of 
gonorrhoea over the last thirty years in many settings (Jolly et al., 2005, Kamwendo et al., 
1996, Miller and Zenilman, 2005) which will have contributed to the decline in the incidence 
rate of PID.  However this cannot explain the continual decline in PID as rates of gonorrhoea 
have plateaued since the late 1990s, although certain population groups remain at high risk 
of infection (Jolly et al., 2005, Kamwendo et al., 1996, Miller and Zenilman, 2005).  An 
additional explanation is that as gonorrhoea incidence has declined, the proportion of cases 
of PID associated with chlamydia is likely to have increased (section 1.4.2) and these 
chlamydia-associated cases are likely to have a milder clinical presentation, on average, and 
therefore are less likely to appear in hospital datasets (Short et al., 2009, Reekie et al., 2014). 
But again, this does not fully explain the continual decline in PID in the face of rising 
chlamydia.   
 
 Repeat infections have a different rate of progression:  Rekart et al. argue that repeat 
chlamydia infections contribute a high proportion of the increase in diagnosed cases but 
carry a lower risk of PID (Rekart et al., 2013) (see section 1.3.5).  There was evidence that the 
risk of PID increased with number of infections in a prospective cohort of sex workers in 
Kenya (OR 1.8 (95% CI 1.3-2.4)) but the risk following each infection was similar (Kimani et 
al., 1996). Women with repeat infections had a higher risk of PID in a retrospective 
population-based cohort of women in Wisconsin, USA18 (Hillis et al., 1997). Compared to 
women with one positive test, women with 3 or more positive tests were six times as likely 
to be hospitalised with PID between 1989-1994 (AOR 6.4 (95% CI 2.2-18.4)) and women with 
two or more positive tests were four times as likely to be hospitalised (AOR 4.0 (95% CI 1.6-
                                                          
18
 Women resident in Wisconsin, aged 10-44 and tested for chlamydia between 1985-1992.  
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9.9)).  This study controlled for confounding from age, gonorrhoea, ethnicity, place of 
residence, type of healthcare setting and date, but the available data meant that there was 
under ascertainment of PID in the early part of the study and it was possible that a temporal 
relationship between chlamydia and PID could be violated.  On balance, the current 
evidence suggests that repeat infections may increase the risk of PID and therefore cannot 
explain the observed relationship between chlamydia and PID.  However this risk needs to 
be further characterised as current studies suggest that the effect is cumulative i.e. related 
to duration of exposure to chlamydia but an increased pathology due to repeat infection 
cannot be excluded and clarification is needed to inform control strategies (Gottlieb et al., 
2010b, Haggerty et al., 2010).   
 
 Reduced case ascertainment of PID:  see section 1.4.5 
 
 Increase in false positive chlamydia results: Hadgu and Sternberg  argue that the true 
specificity of NAATs is between 94.0% and 97.6% which means that in a population with a 
chlamydia prevalence of 3%, over 50% of infections will be false positive, compared to 25% if 
specificity is 99% (see Appendix 1) (Hadgu and Sternberg, 2009). They suggests that the 
reduction in PID may be at least partially explained by the low specificity of NAATs leading to 
an increase in the proportion of diagnosed cases with no risk factor for progression to PID.   
 
 Decrease in pathogenicity of a true positive test:  The pathogenicity of a positive test may 
have changed since the introduction of NAATs.  Culture, by definition detects the presence 
of viable organisms so a positive culture reflects the presence of organisms with the 
potential to establish infection.  In contrast NAATs detect the presence of genetic material, 
which may or may not have derived from a viable organism and a positive result could 
plausibly result from “contamination” with genetic material rather than the presence of an 
organism that is able to ascend and infect the upper genital tract (Hadgu et al., 2005).  There 
is evidence to suggest that resolution rates were higher in people diagnosed using NAAT 
tests compared to EIA or culture (Geisler et al., 2008). There is no evidence to suggest that 
circulating serotypes may have changed in virulence (Byrne, 2010).   
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 Direct effect of chlamydia control: A time-series analysis of the trend in chlamydia, 
gonorrhoea and PID diagnosis in the US between 2001 and 2006 demonstrated that with a 
four-month time lag between an STI test and PID, a 10% increase in the diagnosis rate of 
chlamydia was associated with a 3.6% decline in PID (with similar findings for gonorrhoea) 
(Owusu-Edusei et al., 2010).  This does not exclude gonorrhoea treatment as the cause of 
the association.  For this conclusion to be true, chlamydia must be able to progress to PID 
throughout the entire untreated duration of infection but as with almost all chlamydia 
natural history parameters, there is marked uncertainty in the timing of this progression 
(Herzog et al., 2012a, Herzog et al., 2012b). 
 
In summary, we know that chlamydia screening can reduce the risk of PID in an individual.  
But there is uncertainty in an individual’s risk of PID following an untreated infection.  The very high 
rates of progression reported from clinical studies in high risk populations in the 1980s and 1990s 
were not replicated by studies in the general population and studies of diagnosed and treated 
chlamydia report considerably lower, but non-negligible risks of PID.  Further studies are needed to 
quantify the comparative risk of PID following a first and a repeat infection, adjusted for the 
presence of gonorrhoea and including PID managed outside a hospital.  
 
1.7 The role of dynamic transmission modelling in chlamydia control 
Due to the urgent need for information to guide chlamydia control policy and the absence of 
definitive answers from empirical, clinical and epidemiological studies, transmission dynamic 
mathematical models have been used to estimate the population level impact and cost-
effectiveness19 of chlamydia screening strategies.  Dynamic models can provide estimates of the 
                                                          
19
 Cost-effectiveness is a relative concept and describes the situation where the monetary cost of providing an intervention 
is balanced against the costs (financial and human) saved from the averted events with an acceptable overspend based on 
the society’s ethical framework.  Consideration of the cost-effectiveness of interventions is necessary because healthcare 
systems operate under resource constraints, ultimately due to limited budget, and any money spent on one intervention is 
an implicit decision not to spend the money on an alternative.  This concept is known as the “opportunity cost” of the 
intervention.  The field of economic analysis has developed to allow health policy makers to compare anticipated health 
benefits and costs across interventions to assist them in making relative decisions about which services to provide.  
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incidence and prevalence of chlamydia in a simulated population which are allowed to change over 
time in response to the modelled intervention (Mishra et al., 2011, Welte et al., 2005, Low et al., 
2007).  These estimates are then fed into a decision analytic cost-effectiveness model. 
The three main chlamydia transmission dynamic mathematical models have failed to deliver 
a consensus on the impact of screening interventions, due to their different underlying assumptions, 
parameter values and model structures (Kretzschmar et al., 2009, Kretzschmar et al., 1996, Low et 
al., 2007, Turner et al., 2006b, Althaus et al., 2012).  The implication of this is that policy 
recommendations based on model output would be different depending on which model was used 
(Kretzschmar et al., 2009).  By extension, cost-effectiveness analyses based on these three models 
also came to different conclusions, but in general they all found that screening could be cost-
effective in certain circumstances (Adams et al., 2007, Low et al., 2007, Welte et al., 2000):  
 RIVM (Dutch National Institute of Public Health and the Environment) model (Kretzschmar 
et al., 1996, Welte et al., 2000): Reported that opportunistic screening of heterosexual 15-24 
year olds in general practice in the Netherlands would be “cost-saving after about 5 years if 
over 90% of eligible individuals were screened annually” and would remain cost saving if the 
risk of PID was reduced to 20% but they did not explore a risk of progression lower than this. 
 
 ClaSS (Chlamydia Screening Studies) model (Low et al., 2007): Compared a call and recall 
screening intervention with a home posted test kit to opportunistic screening and was 
parameterised with data from a real-life pilot of this intervention.  It concluded that 
screening was only cost-effective if uptake rates and rate of progression to PID were high.   
 
 HPA (Health Protection Agency) model (Turner et al., 2006b, Turner et al., 2006a, Adams et 
al., 2007): Investigated different screening strategies but found that the threshold for cost-
effectiveness for opportunistic screening of under 25 year olds within the National Health 
Service (NHS) in England is a 10% risk of progression to PID.  
 
We completed a systematic review of transmission dynamic models that were linked to cost-
effectiveness analyses of chlamydia control interventions to explore the evidence-base for the 
fundamental assumptions that govern the transmission dynamics of the infection: the proportion of 
infections that are asymptomatic, the duration of infection and the probability of transmission 
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(Davies et al., 2014) (Appendix 3).  We found a concerning variation in the range of values used for 
each parameter.  Specifically the proportion of asymptomatic infections varied by 25% in women 
and 75% in men, the duration of asymptomatic infection varied six-fold and the per act transmission 
probability varied four fold.  We thought that much of this uncertainty was likely to come from the 
lack of consensus in the empirical literature.  Mathematical models have recently been used to test 
these natural history assumptions and estimate the true value of the parameters as further empirical 
studies are unlikely (Althaus et al., 2010, Price et al., 2013).  Almost all of the studies in our 
systematic review performed a sensitivity analysis of their model assumptions, but none of them 
explored the parameters included in our review.   
Such sensitivity analyses have identified that one of the critical parameters for predicting the 
cost-effectiveness of intervention is the probability of progression to PID following an infection 
(Adams et al., 2007, Low et al., 2007, Hu et al., 2006).  Hertzog et al. conducted a systematic review 
to look at how the progression from chlamydia to PID has been described in mathematical models 
(Herzog et al., 2012b).  They found that in the 28 static models included in their review, the average 
risk of progression to PID following a chlamydia infection was 22%.  The 9 dynamic models presented 
a range of assumptions about the timing and risk of progression: progression was uniform during the 
infectious period; more likely in the first 6 months; more likely in the second 6 months or most likely 
at some other interval between 1 and 12 months and the risk of progression was included as a 
probability of 20.2-30%, an annual rate of 2.8 to 10% or a daily rate of 0.0008 based on a 20% 
probability.  Most of these estimates of the risk of progression are much higher than the 10% 
reported by the POPI trial and are more similar to the estimates from early clinical studies of high 
risk women (Stamm et al., 1984, Oakeshott et al., 2010).   
Policy makers are increasingly using individual-based dynamic mathematical models of 
chlamydia transmission linked to economic analyses to inform resource allocation decisions.  There 
is clear evidence that further modelling studies are needed to improve the accuracy of estimates of 
the cost-effectiveness of chlamydia control interventions and this work must follow improved 
estimates of chlamydia natural history parameters including the risk of progression to adverse 
reproductive consequences (Haggerty et al., 2010, National Audit Office, 2009, Risser and Risser, 
2007, Wallace et al., 2008). 
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1.8 Study designs that can measure association between chlamydia 
and PID 
The progression from chlamydia to PID can be modelled within a transmission dynamic 
model, or it can be included as a static proportion in the cost-effectiveness decision tree (Herzog et 
al., 2012b).  Both methods require an estimate of the proportion of cases that progress to PID 
(together with an assumption about the timing of this progression in a dynamic model).  However 
models can be difficult to understand and interpret for non-specialists so there is also a need for a 
straightforward estimate of how many cases of PID could be prevented by chlamydia control 
interventions.  The most extreme measure of this benefit is called the population attributable 
fraction (PAF) defined as “the proportion of disease in the population that should be prevented if the 
risk factor is removed” (Ward et al., 2012).  In this context, undiagnosed infections are likely to be 
present across the population, therefore the PAF will describe the proportion of PID that could be 
prevented in a given time period if the incidence of chlamydia in women who test positive was 
reduced to the level in women who do not have a positive test.  Therefore the PAF will be affected 
by the level of testing in the population.  Despite the widespread appeal of a PAF in public health 
there are no published estimates of the PAF of chlamydia on PID.  
The PAF makes three assumptions: there is a causal relationship between the exposure and 
the outcome; once the exposure is eliminated all exposed people return to the risk of an unexposed 
individual; and all other risk factors remain unchanged (Rockhill et al., 1998). It is commonly 
calculated using the following equation (Kirkwood, 2006): 
 
𝑃𝐴𝐹 =
𝑝𝑒(𝑅𝑅−1)
1+𝑝𝑒(𝑅𝑅−1)
 
 
Where RR is the relative risk (the risk of PID in women with chlamydia divided by the risk of 
PID in women without chlamydia) and pe is the proportion of the population who have chlamydia.  
The following equation may be more appropriate if confounding is present and adjusted measures of 
the RR are used, pd where is the proportion of women with PID who have been diagnosed with 
chlamydia (Rockhill et al., 1998):     
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𝑃𝐴𝐹 = 𝑝𝑑 
(𝑅𝑅−1)
𝑅𝑅
 
 
Therefore the parameters needed to better quantify the benefit of chlamydia testing on PID at 
the level of the population are: 
 Prevalence of chlamydia in the population 
 Proportion of women with PID who have had chlamydia 
 Risk of PID in women with chlamydia 
 Risk of PID in women without chlamydia 
 
 I briefly consider the study designs that can be used to generate these statistics.  Interventional 
studies are recognised as having the highest quality design for an individual study in the hierarchy of 
clinical evidence (Ward et al., 2012).    Their major strength is that they can provide evidence of a 
causal relationship between an intervention and a subsequent outcome.  There have been four RCTs 
of the effect of testing and treating asymptomatic people for chlamydia (Table 1.4).  Authors agree 
that the pooled estimates from these RCTs have provided clear evidence of the benefit of screening 
to the individual (Chow, 2013, European Centre for Disease Control and Prevention, 2014, Gottlieb 
et al., 2013).  However equipoise remains about the benefit of widespread population based 
screening and Chow proposes that observational studies using electronic health records in setting 
with chlamydia screening are an appropriate approach for filling this gap in the evidence (Chow, 
2013).    
Ecological studies with repeated cross-sectional measures on the same population are not 
able to measure the association at the level of the individual level therefore are not an appropriate 
design.  Therefore the two observational study designs that can provide an estimate of the 
association between a chlamydia and PID are a case-control study or a cohort study.  A case-control 
study selects participants on the basis of whether or not they experienced the outcome of interest 
and they are most appropriate for studying a single, rare outcome.  Cohort studies select 
participants on the basis of a common characteristic and they are appropriate for looking at rare 
exposures or multiple outcomes.  Therefore the choice between a case-control study and a cohort is 
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guided by the research question and the rarity of the exposure or outcome in the population.  As 
neither chlamydia nor PID are rare20 events, at the population level, a cohort would appear to be the 
more appropriate design for measuring the association between chlamydia and PID.  If the 
population size was large enough, a cohort study can also be used to generate a nested case-control 
study so that rare outcomes could be explored.  The major strength of a cohort study is that the 
proportion of people that are exposed to the risk factor can be obtained if the cohort population is 
representative of the underlying population.  This estimate is needed to calculate the PAF in the 
absence of confounding.  On the other hand, a case-control design can reduce the size of the 
required study population as you can specifically include people with the outcome of interest.   
Prospective observational studies require ongoing data collection throughout the period 
when PID may occur as a result of chlamydia.  Cohorts have indicated that a chlamydia infection can 
elevate the risk of PID throughout the reproductive lifetime therefore a prospective study may 
necessitate a long period of follow-up (Bakken and Ghaderi, 2009, Low et al., 2006).  However 
measurement of chlamydia and PID events can be designed to minimise bias and error.  The 
alternative, retrospective design (pre-existing records are used and all events have occurred prior to 
the start of the study) can produce faster results with less resource requirement although the main 
limitation is the potential for misclassification bias in chlamydia and PID status.  It is possible to 
collect ad-hoc health information from medical records or individuals, but the most efficient source 
of the individual-level information needed to determine the association between chlamydia and PID 
are administrative healthcare datasets.  These datasets are by definition, routinely maintained as 
part of the “ordinary” function of the healthcare system or its monitoring organisation.   
 
1.9 Research question and aim of thesis 
Mathematical models that have been used to estimate the population impact of chlamydia 
screening interventions have used a risk of progression from chlamydia to PID that is similar to the 
risk observed in studies conducted in clinical settings.  We wish to determine whether the 
                                                          
20
 Defined as a lifetime prevalence of <1%. 
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predominantly asymptomatic chlamydia infections detected through population-based control 
interventions have a similar risk of subsequent PID.  
The aim of this thesis is to advance the evidence-base for chlamydia control by using 
observational studies to improve estimates of the risk of PID following chlamydia that can be used to 
parameterise mathematical and economic models.    
 
1.10 Outline of thesis 
In this thesis I have used observational studies in three different population groups to 
advance the evidence-base of the risk of PID following a positive chlamydia test.  In chapter 2 I 
describe the analysis of a historic prospective clinical cohort of sex workers to estimate the risk of 
PID following chlamydia, adjusted for chlamydia infection and exposure to gonorrhoea.  This analysis 
was also an opportunity to develop appropriate methodology for the subsequent chapters.  The 
work presented in this chapter forms the basis of a peer-reviewed publication (Davies et al., 2013).   
Chapter 3 describes the design and construction of a large representative population-based 
cohort from administrative health data in Manitoba, Canada that is analysed in chapter 4. This 
cohort enabled us to develop estimates of the risk of PID in women who participated with chlamydia 
testing and explore heterogeneity in this risk by age and repeat infection.  Findings from this analysis 
form the basis of an article that is currently under review and have been presented at the Wellcome 
Trust Theoretical Frameworks for STI Epidemiology Workshop in January 2014.     
In chapter 5 I performed a comparable analysis to chapter 4 using an existing large national 
population-based study constructed from administrative health data in Denmark.  This study 
enabled us to explore the generalizability of estimates of the risk of PID following chlamydia and 
explore the risk following repeat infection. 
The findings from the analysis of the observational datasets described in chapters 2, 4 and 5 
are drawn together in chapter 6 where I consider the potential mechanisms that may underlie the 
observed associations between chlamydia and PID and outline the potential implications of these 
findings.
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2  2 
Chapter 2 
Praed Street Project Cohort: risk of pelvic 
inflammatory disease following chlamydia in 
sex workers 
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2.1 Overview 
 
In chapter 1 I outlined the need to improve estimates of the risk of PID following chlamydia 
to increase the utility of estimates of the cost-effectiveness of population-based chlamydia testing 
for policy makers.  In this chapter I present novel estimates of the risk of PID following chlamydia in a 
small historic prospective clinical cohort of sex workers, the Praed Street Project Cohort.  In this 
analysis we were able to adjust the risk of PID following chlamydia for the presence of gonorrhoea 
co-infection and previous infections with chlamydia and gonorrhoea.  This analysis was also an 
opportunity to develop the survival analysis methodology used in later chapters of this thesis to 
analyse large population-based datasets.  I will describe the rationale for this study, the design and 
construction of the dataset and the secondary statistical analysis I performed.  The work presented 
here has been published in a peer-reviewed journal (Davies et al., 2013).    
The analysis in this chapter was carried out on an existing dataset from the Praed Street 
Project.  The design, construction and original research was performed by Professor Helen Ward and 
Professor Sophie Day and funded by the Medical Research Council.  Professor Helen Ward identified 
the dataset as suitable for use in this thesis and assisted with the development of the research 
question.  I was responsible for designing and performing the analysis described in the chapter.  I 
received advice on the statistical analysis from Dr Marie-Claude Boily, Dr Simon Cauchemez, Dr Idé 
Cremin, Dr Jeffrey Eaton and Dr Margaret May.  Dr Katy Turner and Professor Helen Ward 
contributed to the interpretation of the study findings and have commented on this chapter. 
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2.2 Introduction  
2.2.1 Risk of PID following a chlamydia infection 
In chapter 1 I argued that one of the most influential parameters in cost-effectiveness 
analyses of chlamydia screening interventions is the risk of progression to PID following a chlamydia 
infection (Adams et al., 2007, Hu et al., 2006, Low et al., 2007) and showed that there is no 
consensus for the value of this parameter (Haggerty et al., 2010, Risser and Risser, 2007, Shaw et al., 
2010, Wallace et al., 2008, Herzog et al., 2012b).  Current evidence suggests that the risk of 
progression seen in modern population-based chlamydia testing programmes may be much lower 
than those seen in historic clinical cohorts (Haggerty et al., 2010, Oakeshott et al., 2010).  Yet a high 
proportion of the published mathematical models of chlamydia screening strategies have used 
estimates of progression that are more similar to those seen in historical clinical cohorts (Herzog et 
al., 2012a).  It is clear that this uncertainty will jeopardise the validity of estimates of the cost-
effectiveness of chlamydia screening interventions.  
There are two additional factors that contribute to this uncertainty in the risk of PID that 
have not been extensively studied: repeat infection and co-infection with other STIs.  Repeat 
chlamydia infections are becoming increasingly common, in part because women are participating 
more regularly with testing (Rekart et al., 2013).  Authors have suggested that the pathogenesis of a 
repeat infection may differ from that of a first infection and if this is proven it will have important 
implications for the structure of control interventions (Gottlieb et al., 2010a, Rekart et al., 2013).  
Empirical studies of the pathogenesis of chlamydia have not been able to resolve this question 
(Darville and Hiltke, 2010) and the two published epidemiological studies suggest that the risk of PID 
does increases with reinfection but it is unclear whether the risk after each infection remains 
constant and repeat infections increase risk in a cumulative fashion or whether the risk after each 
subsequent infection is different (Haggerty et al., 2010, Hillis et al., 1997, Kimani et al., 1996). 
PID has a multifactorial aetiology.  Historically gonorrhoea was an important cause of PID 
but it has been declining since the 1970s in many settings and it has been suggested that this may 
have been associated with a decline in the severity of PID (Kamwendo et al., 1996).  The two 
published retrospective cohort studies of the risk of PID following chlamydia were not able to 
control for potential confounding from co-infection with gonorrhoea due to limitations in the 
available data (Bakken and Ghaderi, 2009, Low et al., 2006) and there were potential methodological 
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limitations to the cohort study that did adjust for gonorrhoea (Hillis et al., 1997) so this relationship 
warrants further exploration.  In addition, studies have not considered the role of BV and 
trichomoniasis which have both been associated with PID (although not proven to be causal) 
(Haggerty et al., 2004, Ness et al., 2004, Swygard et al., 2004).  
There is a need for better estimates of the risk of PID following a diagnosed chlamydia 
infection controlled for the presence of co-infection and repeat infections to strengthen current 
knowledge.  This information can be used to improve estimates of the cost-effectiveness of 
chlamydia screening interventions and to develop hypotheses about how to target testing 
interventions (e.g. relative importance of first versus repeat infection) and how to structure sexual 
health services (e.g. multiple platform testing).  
 
2.2.2 Praed Street Project  
The Praed Street Project (PSP) was established in the 1980s and remains in service today 
providing free and confidential sexual health and support services for women who work in or are 
associated with the sex industry in London.  It is based at the department of GUM, St Mary's 
Hospital, Paddington, London (Imperial College Healthcare NHS Trust, 2014). The research 
component of this service is known as the “Praed Street Project cohort”.  The PSP cohort is a 
prospective cohort of 598 sex workers recruited through the PSP clinic and referrals from a drop-in 
centre run by PSP, St Mary’s walk-in sexual health clinic and outreach services to local streets and 
sex work venues at any point during the study period, from 3rd January 1985 until 14th November 
1993.  The aim of this cohort was to study the incidence and prevalence of STIs and HIV in women 
working as prostitutes21 [sex workers].  During the study repeat cross-sectional measurements of 
sexual behaviour, occupational factors, previous medical history, current symptoms and STI 
diagnostic test results were collected.  
This cohort has been extensively studied looking at STI and HIV risk and more widely at the 
experience of sex workers at this time (Day and Ward, 1997, Day and Ward, 2001, Day et al., 1988, 
                                                          
21
 In the mid-1980s when the original research cohort was established, prostitute was the accepted term.  
However this was felt to be stigmatising and it was replaced by sex worker in the late 1980s.  I use the term sex 
worker throughout the remainder of the chapter (Day, 2007, Ward, 2010).   
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Ward and Day, 2006, Ward et al., 2004, Ward et al., 1993, Ward et al., 1999). The PSP cohort dataset 
is a research resource within the School of Public Health at Imperial College London and has suitable 
ethical approval for further study and was available immediately.    
 
2.2.3 Research Question 
We wish to determine the risk of PID following a diagnosed case of chlamydia in this 
population with access to STI care and to explore whether this risk differs in women without a 
diagnosed case of chlamydia, following a repeat chlamydia diagnosis or in the presence of co-
infection with gonorrhoea, BV, trichomoniasis or candida.  
 
2.2.4 Aims and objectives 
 To describe the prevalence, incidence and rate of chlamydia, gonorrhoea, BV, trichomoniasis 
and candida in sex workers in London between 1986 and 1993. 
 To compare the distribution of STIs in women who develop PID to the distribution in women 
who do not. 
 To use survival analysis techniques to explore the association between a diagnosed case of 
chlamydia and PID, considering the role of previous chlamydia, co-infection and age.  
 To develop an appropriate analysis plan for longitudinal time-to-event data to be used in the 
subsequent chapters of this thesis (chapters 4 and 5). 
 
2.3 Methods  
2.3.1 Data source  
The PSP cohort was a prospective clinical cohort that collected repeat cross-sectional 
measurements from participants each time they visited the study clinic.  To be recruited to the 
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cohort women had to be at least 16 years old, define themselves as sex workers and to have worked 
in the 3 months before their first visit to the clinic (full details of the cohort have been published 
previously (Ward et al., 2004, Ward et al., 1999, Day and Ward, 1997)).  A detailed sexual history 
interview was conducted at the baseline clinic visit.  This covered basic demographics, sexual 
behaviour, previous medical history (including self-reported diagnoses of chlamydia and 
gonorrhoea) and current symptoms.  Following this all women were offered tests for chlamydia, 
gonorrhoea, BV, trichomoniasis and candida.  Other investigations were offered if they were 
considered clinically appropriate.  PID was diagnosed according to consistent standard clinical 
criteria by one of the three clinicians who worked at the PSP clinic.  Women were freely able to 
attend the clinic and this protocol was repeated at all subsequent visits during the study period.  The 
variables included in the dataset are summarised in Table 2.1.  I was provided with a copy of the 
dataset in STATA (StataCorp LP, TX, USA) format and a Microsoft Excel spreadsheet of women’s past 
history of chlamydia and gonorrhoea.    
2.3.2 Data checking  
A participant was defined as all the records with a unique study identification number.  The 
dataset was ordered by identification number and date of clinic visit.  Duplicate records were 
removed in two stages.  First any record that was a complete match for an earlier row was removed.  
Secondly it was assumed that an individual would only have attended the clinic a maximum of once 
per day, therefore duplicate records with the same identification number and date of clinic visit 
were flagged and compared.  If they contained identical STI results the second entry was manually 
removed, if only one entry had missing STI results then this entry was manually removed and if 
differences could not be resolved, the participant was removed from the dataset.   
Participants with a clinic visit date that was outside the study period were removed from the 
dataset as it was not possible to determine where this event would have occurred in the sequence of 
clinic visits.  Information about self-reported past history of chlamydia and gonorrhoea (yes, no or 
missing) was manually entered into the dataset.  For participants where age was recorded in a 
subset of visits, this information was used together with clinic visits dates to assign an appropriate 
age to the visit with a missing entry.  All variables that were used in the analysis were checked for 
potential errors and recoded so that “0” = negative and “1” = positive and missing values were 
changed to “.” to reflect STATA nomenclature.  
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Table 2.1: Summary of variables in the PSP cohort dataset   
 
Demographic Behavioural Medical history Current health Investigations Diagnosis Treatment 
ID number Location of sex work Past history of Symptoms Chlamydia Microtrak Chlamydia Hepatitis B 
Age at visit Number of clients    chlamydia Days since last Chlamydiazyme Gonorrhoea   vaccine 
Date of visit Number of new clients Past history of    sexual Gonorrhoea TV  
Year of visit Number of clients seen   gonorrhoea   intercourse Trichomoniasis Candida  
Visit number    more than once   Candida PID  
 Type of intercourse with   Vaginal slide for clue cells Syphilis  
   clients   Pregnancy test Pregnancy  
 Number of non-paying   HIV test Other  
   partners   Hepatitis B status   
 Condom use  HTLV   
   Cervical Pap Smear   
  Syphilis serology   
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2.3.3 Definition and coding of variables  
2.3.3.1 Visit number 
With the dataset ordered by identification number and time, the visit number variable was 
re-coded to start with 1 and to be consecutive within participants.   
 
2.3.3.2 Age 
Age was recorded at each clinic visit as a whole integer and date of birth had been removed 
as part of the anonymisation process.  For the descriptive analysis I categorised age in three different 
ways at the date of the most recent clinic visit:  
 a continuous integer variable;  
 a categorical variable: 16-19 years, 20-24 years, 25-29 years and ≥30 years;  
 a binary categorical variable, under 25 years and 25 years and over.  
Age was not normally distributed.  Therefore I attempted three transformations of the 
variable to improve the fit of the survival analysis model: (1) age squared; (2) age centred on mean 
age at recruitment; (3) age centred on median age at recruitment.  However these categories made 
interpretation of the model outcome complex.   
 
2.3.3.3 Chlamydia  
Past history of chlamydia was defined as yes, no or missing based on self-reported 
information collected at the baseline clinic visit.  At each chlamydia test episode in the cohort 
women could be tested with a Syva Microtrak® DIF test (Syva Co., San Jose, CA), a Chlamydiazyme® 
Abbott EIA test (Abbott Laboratories, Chicago, IL) or both.  The DIF test was 12.6% more sensitive 
than the EIA test (p<0.001) and had a higher sensitivity when both tests were compared to culture 
(DFA 74.5% (95% CI 67.6-80.5); EIA 61.9% (95% CI 55.6-68.7)) (Newhall et al., 1999).  Therefore we 
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used a positive DIF result to define chlamydia cases in preference to the EIA result.  A woman was 
considered to have had a diagnosis of chlamydia if her DIF test was positive, or if her EIA test was 
positive if a DIF test was not performed.   
Chlamydia cases diagnosed at the first clinic visit were defined as “prevalent” and infections 
diagnosed at subsequent visits were defined as “incident”.  Collectively, prevalent and incident 
infections were called “cases during the cohort”.  The dataset contained information on chlamydia 
exposure from multiple time points and chlamydia exposure was coded as a time-varying variable 
(Low et al., 2006): 
 
 Ever: negative or missing chlamydia test results (that occur before the first positive 
test) were recorded as “no”; first positive chlamydia test was labelled “yes” and this 
was applied to all future records;   
 Cumulative:  the number of chlamydia cases (during the cohort) a woman had up to 
and including the date of that clinic visit; 
 Lifetime:  coded as “yes”, “no” or “missing” using self-reported past history of 
chlamydia; in women without a past history, it changed to “no” at the date of the 
first negative test during the cohort and “yes” at the date of the first positive test; 
women could not leave the “yes” group.   
 
Initially I used the “ever” (exposure during the cohort) and “past history” (to identify if a 
case in the cohort was a repeat infection) variables to describe exposure to chlamydia.  But this was 
an oversimplification as it ignores what is known about the temporal association between a 
diagnosed case of chlamydia and PID22.  Therefore I assumed that a woman’s risk of PID related to 
her chlamydia diagnosis differed based on the time since diagnosis and generated variables to 
explore this:  
                                                          
22
 To cause PID, chlamydia has to ascend through the cervix before the infection is cleared ((Geisler, 2010, Paavonen, 
1998)) 
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 Recent:  women who had been exposed to chlamydia within the previous 6 
months23.  The variable flags clinic visits that occurred within 6 months (0-186.5 
days) of a chlamydia infection diagnosed in the cohort; 
 Previous:  binary variable that identifies women who have a past history of 
chlamydia, or an infection diagnosed during the study but more than 6 months ago.  
If a case diagnosed during follow-up was a woman’s first known exposure to 
chlamydia, then the previous diagnosis field remained negative until the first clinic 
visit that was 6 months after the diagnosis date. 
 
2.3.3.4 Co-infection 
The methods used to diagnose gonorrhoea (gram stain with culture confirmation), 
trichomoniasis (direct microscopy) and candida (direct microscopy) were consistent during the 
study.  Therefore a diagnosis in the dataset was used as proof of a diagnosis.  BV was a clinical 
diagnosis based on modified Amsel’s criteria and I restricted the diagnosis to the presence clue cells 
(epithelial cells coated with bacteria) in a vaginal specimen together with a recorded clinical 
diagnosis of BV.   
Gonorrhoea exposure was classified in the same way as chlamydia, and the following 
variables were generated: ever, cumulative, recent, previous and lifetime (see section 2.3.3.3).  I 
defined exposure to BV, trichomoniasis and candida as “missing” until the date of the first test 
during the study, “negative” from the date of the first negative test and “positive” from the date of 
the first positive test.  Women were able to move from the negative to the positive category.  The 
“ever” variable was also generated for these infections (see section 2.3.3.3).     
 
                                                          
23
 Evidence suggests that the average untreated duration if infection is around a year to 18 months (Geisler, 2010, Price et 
al., 2013). However as women in this cohort were diagnosed and most likely treated and I reduced the duration to 6 
months.  
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2.3.3.5 PID 
PID was diagnosed using consistent standard clinical criteria. Therefore a recorded case in 
the dataset was considered adequate proof of a diagnosis.  I generated the “ever” variable for PID 
(see section 2.3.3.3).     
 
2.3.4 Eligibility criteria  
Women within the PSP cohort were eligible for this analysis if they: 
 had a complete set of key variables (clinic date; age); 
 had at least one chlamydia test result recorded; 
 attended the clinic more than once during the study period; 
 were not diagnosed with PID at their first visit.   
 
2.3.5 Follow-up 
The original dataset contained all recorded visits between the date a woman entered the 
cohort and her last visit before the end of the study on 14th November 1993.  A woman’s period of 
follow-up was calculated from the date of her first visit to the date of her final clinic visit. We 
censored follow-up at the first diagnosis of PID.  For simplicity, records of clinic visits occurring after 
this time were removed from the study dataset.   
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2.3.6 Generation of dataset for survival analysis24  
I converted the dataset from longitudinal snapshot data into time-span data suitable for 
survival analysis in STATA using the “snapspan” command.  A woman’s multiple records were linked 
using her unique identification number and the time variable was the date of the clinic visit.  Using 
this “snapspan” command, the variables in the dataset are assumed to be constant from the start of 
the period of observation (the clinic visit) until the start of the next period of observation (the next 
clinic visit).  Except for “event” variables which are defined as those that “happen at an instant” and 
are assumed to apply from the end of the time span i.e. the clinic visit at the end of the period 
(StataCorp, 2009). I specified a diagnosis of PID as the only event variable in this dataset.   
I then declared this “snapspan” dataset to be survival-time date using the “stset” command.  
Multiple records per women were identified using the unique identification number, the time 
variable was specified as the date of the clinic visit, women were defined as entering the cohort and 
being at risk of the outcome from the date of the first clinic visit and because records occurring after 
a diagnosis of PID had been removed, exit from the cohort was defined as the date of the last clinic 
visit.  The failure event varied depending on the specific analysis performed and is stated below.  
2.3.7 Statistical analysis  
All statistical analysis was performed using STATA SE 11.1 software for windows (StataCorp 
LP, TX, USA).  Two-sided tests at the 95% level of significance are used to interpret the results of 
statistical tests.     
                                                          
24
 After the publication of the paper that accompanied this chapter (Davies et al., 2013), I revisited this analysis 
and repeated the process for generating the dataset for the survival analysis with two additional steps 
informed by methods developed for the later chapters.  Firstly I moved the date of a chlamydia or gonorrhoea 
case diagnosed during  the cohort backwards by one day if it was diagnosed on the same date as an episode of 
PID.  The aim of this was to increase the data included in the survival analysis (see section 4.3).  Secondly I 
generated an additional row in the dataset that was exactly 6 months after the date of a chlamydia or 
gonorrhoea diagnosis (excluding those diagnoses where the end of the 6 month period fell during the 6 month 
period following a subsequent case of the same infection or after the end of a woman’s period of follow-up). 
The aim of this was to ensure that “current exposure” terminated at exactly 6 months. This resulted in changes 
to the descriptive analysis and a marginal change to the data presented in Table 1 of the paper.  Of note, in the 
final adjusted model the AHR for age became non-significant (p=0.072) and the AHR for recent chlamydia 
became significant (p=0.047). This revised version of Table 1 is presented in Appendix 5. The analysis 
presented in this chapter uses the same dataset and assumptions as reported in the paper.  
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2.3.7.1 Descriptive analysis 
For the overall cohort and separately for women with and without a diagnosis of PID I 
described attendance at the study clinic (total number of visits; mean; median and standard 
deviation (sd) per woman), age at enrolment and exit (mean and sd) and exposure to STIs.  For 
chlamydia and gonorrhoea, I presented the proportion of women with a self-reported past history, 
prevalence at the initial visit, incidence at subsequent visits and proportion of women who were 
diagnosed with a case during the cohort, overall and by past history status.  The relative contribution 
of the two chlamydia testing methods to diagnosed chlamydia cases was also considered.  For BV, 
trichomoniasis and candida I calculated the incidence and prevalence of infection and the proportion 
of women who were diagnosed with a case during follow-up.  
  I compared the above findings for women with and without an episode of PID during 
follow-up to test the null hypothesis that they were drawn from the same overall population and do 
not differ with respect to exposure to STIs.  I used the Wilcoxon rank sum test for age and number of 
clinic visits as these continuous variables graphically did not conform to the normal distribution.  I 
used the difference between two proportions for the remaining variables as an assumption was 
made that they conformed to the binomial distribution. 
The dataset was interrogated to determine the number of women with an exposure to an 
STI at the time of their PID diagnosis and to identify women who had their first known exposure to 
chlamydia or gonorrhoea during the study.  
 
2.3.7.2 Rationale for use of survival analysis 
The outcome under consideration in this analysis, PID, is a binary variable.  However logistic 
regression was not the most appropriate method for analysing this dataset of time-to-event data 
(Kirkwood, 2006).  The dataset contained information about the time interval between chlamydia 
and PID and women had variable periods of follow-up as they could enter and exit the study dataset 
at any point.  Logistic regression analysis would ignore the time-to-event data and bias the estimate 
of the association (odds ratio) towards women who were in the cohort for longer and therefore had 
a longer time period in which to experience the outcome.   
  Chapter 2 
72 
 
Poisson regression techniques can be used to analyse longitudinal data where the measure 
of interest is the rate of the outcome.  But this method was also rejected because it requires an 
assumption that the rate of PID is independent and constant over time periods (Kirkwood, 2006). I 
considered that this assumption would be violated in this cohort for the following reasons:  
 the majority of cases of PID that develop as a direct result of chlamydia are likely to 
occur before spontaneous resolution of the infection so the rate of PID will be higher 
during the period of active infection preceding treatment rather than randomly 
distributed across follow-up; 
 it is likely that at least some of the sex workers in this cohort will be part of a 
common sexual network as they are geographically related, therefore the incidence 
of STIs and by extension PID caused by STIs cannot be considered to be 
independent.  
Survival analysis does not require an assumptions about the about the rate of the outcome 
over time (Kirkwood, 2006). It can be used to compare the survival pattern (or time-to-event) in 
groups with different exposures and these groups can also have different lengths of follow-up before 
experiencing the event.  Kaplan-Meier plots are a method for graphically representing the risk of the 
outcome event in different exposure groups across time.  Cox proportional hazards regression is the 
commonest survival analysis method used to estimate the association between exposure and 
outcome variables whilst controlling for the presence of confounding variables.  In this method, each 
time an outcome event occurs, the instantaneous hazard25 of experiencing the outcome is 
determined.  The risk sets of all individuals in one exposure group are compared to the risk sets of 
individuals in the comparator group(s) to determine the ratio between the hazards in each group.  
This ratio is assumed to be constant over time therefore a single value can describe the difference in 
risk between exposure groups at any point in time.  The output of the analysis, the hazard ratio (HR), 
is an approximation of the relative risk (RR). 
                                                          
25
 The instantaneous hazard is the number of people who experience the outcome divided by the number of people at risk. 
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2.3.7.3 Survival analysis 
With the data in a suitable format for survival analysis, I determined the total number of 
person years (py) of follow-up and the median duration of follow-up per woman and repeated these 
measures for women with and without PID.  I then calculated the crude incidence rate for each STI 
(multiple diagnoses were allowed per woman).   
Kaplan-Meier survival curves of time to PID by chlamydia exposure status are not reported 
as women could cross from one chlamydia exposure group to the other.  I calculated the crude rate 
of PID overall and by infection status.  I then used Cox proportional hazards regression to explore the 
association between a “recent” diagnosed case of chlamydia and PID.  I constructed univariate 
models using age (both as a continuous and a categorical variable), recent chlamydia, previous 
chlamydia, recent gonorrhoea, previous gonorrhoea, ever BV, ever trichomoniasis and ever candida.  
The assumption of proportion hazards was tested in the univariate model using Schoenfeld residuals 
(“estat phtest”).  The null hypothesis is that the log-hazard ratio is constant over time and rejection 
of this hypothesis suggests that proportional hazards cannot be assumed.  
I constructed a multivariable model using significant (p<0.05) or borderline significant 
(p<0.20) variables from the univariate analysis and other variables known to be risk factors.  I used 
the log likelihood26 of the univariate models for age as a continuous variable and a categorical 
variable to determine how best to categorise age in the final model.  I compared the final model to a 
model containing all explanatory variables in the dataset using the likelihood ratio test to determine 
whether the larger model provided a better fit for the data.  I tested for interactions27 between 
variables in the final model.  Where there was a significant interaction term, the model including the 
interaction term was compared to the model without the interaction term using the likelihood ratio 
test to determine which provided the better fit for the data.  I then tested the assumption of 
proportional hazards in the final model firstly, by looking for the presence of a significant interaction 
between the variables and time by including time varying covariates in the model and secondly, by 
                                                          
26
 Likelihood ratio = -2ln (likelihood for null model/likelihood for alternative model).  Null hypothesis is that the alternative 
model fits at least as well; alternative hypothesis is that alternative model fits the data better.  
27
 Interaction describes the situation where there is a non-additive effect of two variables on a third. 
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using Schoenfeld residuals28 to estimate whether the log hazard function in the final model is 
constant over time.  
 
2.3.8 Ethical and institutional permissions 
Ethical approval was not specifically sort for this study.  We conducted a secondary analysis 
of an existing dataset and analysis of this dataset was covered by earlier ethical permissions.  The 
study received approval from Parkside Health Authority Research Ethics Committee (1089); 
Kensington, Chelsea and Westminster Local Research Ethics Committee (3279); and St Mary’s 
Hospital Local Research Ethics Committee (reference no. 97/Bi/158E).  The use of this dataset did 
not require the collection of any additional information or contact with the participants or original 
study team, with the exception of Helen Ward.   
 
2.4 Results  
The PSP dataset contained 598 unique identification numbers and 2980 records and the 
study cohort contained 307 women (51.35%) and 1973 visits to the study clinic (66.21%).  The 
process of forming the study dataset is described in Figure 2.1.  The mean age of women at their first 
visit was 26.18 years (sd 6.43; range 16-52) and the mean number of clinic visits per person was 6.43 
(sd 6.64; median 4; range 2-44).  The median duration of follow-up was 9.9 months (range 1 week to 
6 years 8 months; mean 15.7 months).  Most variables contained missing data: 30.29% (n=93) of 
women were missing a self-reported past history of chlamydia29 and 18.89% (n=58) were missing a 
self-reported past history of gonorrhoea.  At the majority of clinic visits STI diagnostic tests were 
performed.  But either they were not carried out or the results were not available, for chlamydia at 
                                                          
28
 Schoenfeld residuals are calculated by comparing the parameter value of the person who failed at time (t) to 
the weighted average of the parameter values of all other individuals remaining under observation at time (t).  
To test the hypothesis that the log hazard function is constant over time these residuals are plotted against 
time and best-fitting regression line is estimated.  The null hypothesis is that there is no relationship between 
the value of the residuals and time (i.e. the correlation coefficient of the regression line (r) = 0). This is 
achieved in STATA using the estat phtest command.  
29
 In the mid-1980s when this cohort was established gonorrhoea testing was widespread but chlamydia testing was not a 
routine part of clinical practice (Ward, 2010).  
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30.06% (n=593) of visits, gonorrhoea at 0.30% (n=6), BV and trichomoniasis at 28.03% (n=553) and 
candida at 27.88% (n=550).  
Figure 2.1: Generating the study dataset from the original dataset (adapted from (Davies et al., 
2013)) 
Original cohort 
 
598 women 
2980 records 
 Removed 
 
108 records that were considered duplicates 
1 woman (with 36 records) with conflicting PID result in a 
duplicate record 
4 women (with 81 records) with an invalid clinic date 
264 women with a single clinic visit 
2 women (with 33 records) with missing age 
8 women (with 40 records) who had PID at their first visit 
12 women (with 27 records) who had no chlamydia test  
418 records that occurred after first diagnosis of PID 
 
 
  
Study dataset 
 
307 women  
1973 records 
censored at first PID  
  
 
Of the 1380 clinic visits where a diagnostic test for chlamydia was carried out, 88.48% 
(n=1221) had at least a DIF test, 63.19% (n=872) had a DIF and an EIA test and 11.52% (n=159) only 
had an EIA test.  Seventeen (10.69%) of the isolated EIA tests were positive and changed the “recent 
chlamydia” status 14 times in 13 women.  At the first clinic visit, 38.79% (83/214) of women 
reported a past history of chlamydia and 46.18% (115/249) reported a past history of gonorrhoea 
(Table 2.2).  At the same visit, in those who were tested, the prevalence of chlamydia was 8.54% 
(21/246), gonorrhoea was 2.61% (8/307), BV was 17.14% (42/245), trichomoniasis was 2.82% 
(7/248) and candida was 8.87% (22/248).  At follow-up visits where tests were performed, the 
incidence of chlamydia was 3.79% (43/1134), gonorrhoea was 1.87% (31/1660), BV was 17.36% 
(204/1175), trichomoniasis was 1.37% (16/1172) and candida was 11.91% (140/1175).  In total, fifty 
women (16.29%) were diagnosed with chlamydia during the study and twenty-nine (9.45%) were 
diagnosed with gonorrhoea.  PID was diagnosed in forty eight (15.64%) women during follow-up.  At 
the time of a first PID diagnosis eight women had a recent exposure to chlamydia, 4 to gonorrhoea 
and 1 to both infections.   
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Table 2.2: Description of cohort overall and by outcome   
 
Overall Diagnosed with PID 
Not diagnosed with 
PID 
Comparison by PID 
status 
(p value*) 
Participants (%) 307 48 (15.64) 259 (84.36) N/A 
Clinic visits (%) 1973 314 (15.91) 1659 (84.09) N/A 
Mean (median; sd) 6.43 (4; 6.64) 6.54 (4; 6.84) 6.41 (4; 6.62) 0.622** 
Mean age at enrolment (sd) 26.18 (6.43) 24.52 (5.38) 26.48 (6.57) 0.053** 
Mean age at end of follow-up 
(sd) 
27.55 (6.81) 25.81 (5.75) 27.87 (6.95) 0.062** 
Person years (%)  401.22 53.62 (13.36) 347.60 (86.64) N/A 
Median follow-up in days (range) 301 (7 – 2423) 224 (16 – 1911) 309 (7 - 2423) N/A 
Chlamydia     
Past history (%) 83/214 (38.79) 21/39 (53.85) 62/175 (35.43) 0.033 
Prevalence (%) 21/246 (8.54) 3/37 (8.11) 18/209 (8.61) 0.919 
Incidence (%) 43/1134 (3.79) 12/191 (6.28) 31/943 (3.29) 0.048 
N case during cohort (%): 
    
 Overall 50 (16.29) 13 (27.08) 37 (14.29) 0.027 
 Past history  14/83  (16.9) 4/21 (19.0) 10/62 (16.1) 0.758 
 No past history 24/131 (18.3) 7/18 (38.9) 17/113(15.0) 0.015 
 Missing 12/93  (12.9) 2/9 (22.2) 10/84 (11.9) 0.380 
Gonorrhoea 
    
Past history (%) 115/249 (46.18) 28/44 (63.64) 87/205 (42.44) 0.011 
Prevalence (%) 8/307 (2.61) 2/48 (4.17) 6/259 (2.32) 0.46 
Incidence (%) 31/1660 (1.87) 9/266 (3.38) 22/1394 (1.58) 0.046 
N case during cohort (%): 
    
 Overall 29 (9.45) 7 (14.58) 22 (8.49) 0.185 
 Past history 19/115 (16.5) 6/28 (21.4) 13/87 (14.9) 0.422 
 No past history 7/134 (5.2) 0/16 (0) 7/118 (5.9) 0.317 
 Missing 3/58 (5.2) 1/4 (25.0) 2/54 (3.7) 0.064 
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Trichomoniasis     
Prevalence (%) 7/248 (2.82) 0/38 (0) 7/210 (3.33) 0.254 
Incidence (%) 16/1172 (1.37) 6/202 (2.97) 10/970 (1.03) 0.031 
N case during cohort (%) 19 (6.19) 5 (10.42) 14 (5.41) 0.186 
BV 
    
Prevalence (%) 42/245 (17.14) 4/38 (10.53) 38/207 (18.36) 0.239 
Incidence (%) 204/1175 (17.36) 53/202 (26.24) 151/973 (15.52) <0.001 
N case during cohort (%) 124 (40.39) 23 (47.92) 101 (39.00) 0.247 
Candida 
    
Prevalence (%) 22/248 (8.87) 5/38 (13.16) 17/210 (8.10) 0.313 
Incident cases (%) 140/1175 (11.91) 23/201 (11.44) 117/974 (12.01) 0.821 
N case during cohort (%) 101 (32.90) 17 (35.42) 84 (32.43) 0.686 
 
 
sd = standard deviation; 
*Difference between two proportions;  
** Wilcoxon rank sum test 
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Table 2.3: Crude rate of STIs  
 
 
 
 
 
There were no significant differences in mean age at recruitment (p=0.053), the mean age at 
the end of follow-up (p=0.062) or the mean number of clinic visits (p=0.622) between women who 
were and were not diagnosed with PID (Table 2.2).  Women who were diagnosed with PID had a 
higher incidence of all infections except candida (chlamydia 6.3% and 3.3%, (p=0.048); gonorrhoea 
3.4% and 1.6%, (p=0.046); BV 26.2% and 15.5%, (p<0.001), trichomoniasis 3.0% and 1.0%, (p=0.031) 
and candida 11.44% and 12.01%, (p=0.281)).  For each infection, all women have a recorded 
diagnostic test result by the end of follow-up but cases that occurred at the last visit to clinic were 
not included in the survival analysis30.   
The crude incidence rate of STIs (multiple episodes per woman) is shown in Table 2.3.  The 
crude incidence rate of PID was 11.96 per 100 py (95% CI 9.02-15.88) (Table 2.4).  There were too 
few cases of PID to compare the rate following the first known infection (chlamydia n=3; gonorrhoea 
n=0) to the rate following a recurrent infection (chlamydia n=2; gonorrhoea n=3).  The rate of PID 
was approximately twice as high in women with a recent or previous case of chlamydia or 
gonorrhoea compared to women without the exposure.   
A formal test of the assumption of proportional hazards in the univariate models suggests 
that the assumption holds for all the variables (non-significant log rank test statistics, p=0.418 to 
p=0.955).  The crude HR of PID was significantly higher in women who had a recent case of 
chlamydia (HR 2.33 (95% CI 1.03-5.25)) or a previous case of chlamydia (HR 2.11 (95% CI 1.10-4.04)) 
                                                          
30
 First recorded test at last clinic visit: chlamydia n=14, trichomoniasis n=14, candida n=14, BV n= 15; Diagnosis at last 
clinic visit:  chlamydia n=4, gonorrhoea n=7, trichomoniasis n=2, candida n=28, BV n= 30; First ever diagnosis in study at 
last clinic visit: chlamydia n=2, gonorrhoea n=5, trichomoniasis n=1, candida n=14, BV n= 10. 
 Number of 
infections 
Rate per 100 py 95% CI 
Chlamydia 60 14.95 11.61 - 19.26 
Gonorrhoea 32 7.98 5.64 - 11.28 
BV  216 53.84 47.12 – 61.52 
Trichomoniasis 21 5.23 3.41 – 8.03 
Candida  134 33.40 28.20 – 39.56 
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or gonorrhoea (HR 1.87 (95% CI 1.01-3.48)) and it was inversely associated with age (HR 0.94 (95% CI 
0.89-0.99)) (Table 2.4).  The relationship between the other infections (trichomoniasis, BV and 
candida) and PID was not significant. 
I chose to include age as a continuous variable in the multivariable model because 
categorising a continuous variable can lead to a loss of information and it seemed to fit the data 
equally well in the univariate models compared to when it was a categorical variable31.  The final 
multivariable model was adjusted for age, previous chlamydia, recent gonorrhoea and previous 
gonorrhoea.  BV, trichomoniasis and candida were not included as these variables were not 
significant in the univariate analysis.  A sensitivity analysis demonstrated that this larger model did 
not provide a better explanation of the data32  (Appendix 6). 
In the adjusted model, there was a significant interaction between age and recent chlamydia 
exposure and the extended model with the interaction term provided a better fit for the data33 .  
However it was felt that including the interaction term made the results difficult to understand.  The 
model with the interaction term is included in Appendix 7.  The assumption of proportional hazards 
was met in the final model (without the interaction term) as there was no evidence of an interaction 
between time and the included variables (non-significant HR for time-varying covariates (p=0.085 to 
p=0.033) and a non-significant association between Schoenfeld residuals and time (p=0.960)).  In this 
final adjusted model, the hazard of PID was increased approximately two-fold by a recent case of 
chlamydia (AHR 2.03 (95% CI 0.75-5.49)) or a previous case of chlamydia (AHR 1.84 (95% CI 0.96-
3.54)) or gonorrhoea (AHR 2.28 (95% CI 1.14-4.56)).  Age decreased the hazard of PID by 6% per year 
(95% CI 0.88-1.00; p=0.047) and women with a recent case of gonorrhoea also had a lower hazard of 
PID (AHR 0.53 (95% CI 0.12-2.38)).   
                                                          
31
 Log likelihood for the continuous model was -230.26 compared to -229.46 for 4 categories and -230.01 for 2 categories. 
32
  Likelihood ratio comparing the larger model to the final model chi squared test statistic 2.61, p= 0.456. 
33
 Likelihood ratio chi squared statistic = 4.80 and p=0.028. 
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Table 2.4: Crude incidence rate and crude and adjusted hazard ratio of PID by age and infection status (reproduced from (Davies et al., 2013)) 
  
No. of 
women 
No. 
with 
PID 
Person 
years 
(py) 
Crude rate of PID 
(per 100 py)(95% CI ) 
Crude hazard 
ratio (95% CI) 
p 
value 
Adjusted 
hazard ratio 
(95% CI) 
p 
value 
Overall   307 48 401.22 11.96 (9.02-15.88) - - - - 
Age   - - - - 0.94 (0.89-0.99) 0.019 0.94 (0.88-1.00) 0.047 
Recent chlamydia No 278 40 355.58 11.25 (8.25-15.34) reference - reference - 
Yes 48 7 25.55 27.40 (13.06-57.47) 2.33 (1.03-5.25) 0.042 2.03 (0.75-5.49) 0.166 
Previous chlamydia No 131 15 187.21 8.01 (4.83-13.29) reference - reference - 
Yes 99 24 149.77 16.02 (10.74-23.91) 2.11 (1.10-4.04) 0.025 1.84 (0.96-3.54) 0.066 
Recent gonorrhoea No 304 44 382.73 11.50 (8.56-15.45) reference - reference - 
Yes 24 4 18.49 21.64 (8.12-57.65) 1.96 (0.70-5.47) 0.201 0.53 (0.12-2.38) 0.405 
Previous gonorrhoea No 134 16 182.24 8.78 (5.38-14.33) reference - reference - 
Yes 120 28 182.68 15.33 (10.58-22.20) 1.87 (1.01-3.48) 0.047 2.28 (1.14-4.56) 0.019 
Trichomoniasis during 
cohort 
No 285 43 365.19 11.77 (8.73-15.88) reference - - - 
Yes 18 4 17.06 23.45 (8.80-62.47) 1.95 (0.70-5.47) 0.204 - - 
Bacterial Vaginosis during 
cohort 
No 242 28 202.19 13.85 (9.56-20.06) reference - - - 
Yes 114 19 178.53 10.64 (6.79-16.68) 0.97 (0.52-1.83) 0.931 - - 
Candida during cohort 
No 266 31 241.2 12.85 (9.04-18.28) reference - - - 
Yes 87 16 141.33 11.32 (6.94-18.48) 1.17 (0.60-2.27) 0.647 - - 
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2.5 Discussion  
2.5.1 Main findings 
A recent chlamydia infection non-significantly increased the risk of PID in this cohort.  The 
risk was also increased by a previous diagnosis of chlamydia or gonorrhoea while age reduced the 
risk.  BV, trichomoniasis and candida were not independent risk factors for PID.  These findings 
should be interpreted with caution given the small size of the cohort.  The remainder of this 
discussion section is a critical appraisal of the study design and methods used in this chapter and a 
comparison of the findings to the literature.  An interpretation of the findings of the study and 
consideration of their implications will be presented in chapter 6 in combination with the findings 
from chapters 4 and 5.   
 
2.5.2 Study design  
In this chapter I described the analysis of a prospective clinical cohort.  This is the highest 
quality observational study design for looking at the association between an exposure and an 
outcome.  Its strength comes from the fact that both the exposure and the outcome are measured 
during the study using standardised procedures which can minimise bias.  However the main 
limitation is the presence of unmeasured confounders.  In the cohort used in this chapter, women 
were repeatedly assessed at a high median number of follow-up visits.  This generated a dataset 
with rich cross-sectional data on STI and PID diagnoses which allowed us to explore the relationship 
between repeat chlamydia, gonorrhoea and PID.  I performed a secondary analysis of the dataset 
and the cohort was not specifically designed to explore the association between chlamydia and PID, 
but chlamydia and PID were observed for other reasons within the study.  
  
2.5.3 Bias 
The major limitation of this observational study is the potential for misclassification bias in 
the assignment of chlamydia and PID status.  PID is predominantly a clinical diagnosis that has a low 
validity which means there is uncertainty in the proportion of women with a diagnosis who actually 
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have endometrial inflammation (see section 1.4.4) (Morris et al., 2014, Simms et al., 2003).  This 
occurs because there is no gold-standard non-invasive diagnostic test for PID and the clinical 
diagnostic criteria are non-specific, particularly for mild cases (Simms et al., 2003).  In addition to this 
there is likely to be an appropriate systematic diagnostic bias that acts to increase the likelihood of a 
diagnosis of PID in a woman with a current, recent or previous history of STIs, including chlamydia, 
compared to a woman with an equivalent clinical presentation but no past history of infection 
(Haggerty et al., 2010, Gottlieb et al., 2010b).  The effect of this bias would be to increase the 
association between chlamydia and PID.  However in this cohort, the women presenting at the study 
clinic were sex workers and it is possible that an occupational bias could have been a more 
influential driver of a diagnostic bias towards PID than recorded STI episodes.  If over-diagnosis of 
PID was related to an occupational bias and equally distributed with respect to chlamydia history it 
will not have influenced the observed association between chlamydia and PID.  
A second potential cause of misclassification bias in PID status is from under-ascertainment 
of cases because the dataset was limited to episodes of PID that were diagnosed in the study clinic.  
However this clinic was a dedicated service for a vulnerable group of users so it is feasible that this 
would have been the preferred location for healthcare for a high proportion of women.  This is 
supported by the high median number of clinic visits.  This ascertainment bias may apply 
independently of STI status in which case it would lower the PID diagnosis rate but would not 
influence the measure of association.  
The most important source of misclassification bias in chlamydia status comes from using 
information about chlamydia tests performed during periodic clinical consultations to define 
exposure.  Chlamydia tests define exposure at the instant they are performed but they provide no 
information about the date of infection onset or clearance.  Published cohorts have defined women 
as exposed to chlamydia following the date of a positive test until the end of follow-up (Bakken and 
Ghaderi, 2009, Low et al., 2006).  We attempted to improve this definition to capture the fact that 
ascension of chlamydial organisms into the upper genital tract before clearance of the infection is 
necessary to cause PID.  We did this by limiting a recent exposure to 6 months after the date of 
diagnosis.  However this time period is fairly arbitrarily defined with respect to the natural history of 
infection.  There is uncertainty about the duration of an untreated infection, but women can present 
at any point along this continuum which means that they will have been infected for a period before 
their diagnosis.  In addition, a diagnosis in this setting was followed by appropriate antibiotic 
treatment which will have ended the duration of an active infection.  This misclassification bias in 
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chlamydia exposure status is exacerbated by healthcare seeking behaviour as the more frequently a 
woman attended for testing the more likely her exposure status, as defined in the dataset, was to 
represent the true situation.    
Misclassification in chlamydia status may also have been caused by an under-ascertainment 
of chlamydia cases because, as with PID, the dataset only contained information about tests 
performed at the study clinic.  In addition there are two potential sources of undiagnosed infections:  
asymptomatic women who declined a test (a chlamydia test was not performed at 30.06% of visits) 
and false negative test results.  The diagnostic tests used during the study have a low sensitivity 
compared to NAATs (around 70% (Chernesky, 2005) and culture (DIF 74.5% (95% CI 67.6-80.5) and 
EIA 61.9% (95% CI 55.6-68.7))) (Newhall et al., 1999).  Imperfect tests randomly assign a proportion 
of exposure statuses to the incorrect class with respect to the true situation (false positive and false 
negative results, see Appendix 1).  Although the proportion of false positive and negative tests can 
be estimated it is not possible to identify the women or tests that were affected. The effect of this is 
to cause any measured association to tend towards the null hypothesis.   
Selection bias in the original dataset has been considered by previous publications about the 
cohort (Ward et al., 1999).  The cohort was biased towards women from a vulnerable population 
who could be identified by the researchers and were willing to participate with healthcare and a 
clinical study.  There may have been a bias towards healthier women participating with the cohort 
akin to the well-documented healthy worker effect seen in occupational epidemiology (Li and Sung, 
1999).  Alternatively, as the cohort was conducted in a clinical setting it may have been biased 
towards women with symptoms or those who knew they were at risk of STIs.  It is not possible to 
determine the direction of the selection bias.  We applied additional inclusion criteria to this study 
dataset which are likely to have introduced further selection bias: the requirement for at least one 
chlamydia test during follow-up will have biased the cohort towards women who were willing to 
participate with healthcare which may include those who were symptomatic.  If symptomatic 
infections may have a higher organism load and a higher probability of progression to PID than 
asymptomatic infections then this bias would increase the observed association between chlamydia 
and PID.  
 To avoid attrition bias from loss to follow-up we censored women at their last visit to the 
study clinic.  However there are likely to be systematic differences between the women who 
remained in contact with the study clinic and those who were lost to follow-up.  For example, 
  Chapter 2 
84 
 
symptomatic women may have been more likely to re-present to the clinic for treatment compared 
to asymptomatic women.  A published follow-up study of this cohort demonstrated that the women 
who could be contacted five years after the cohort ended were systematically different from those 
lost to follow-up (Ward and Day, 2006).  
 
2.5.4 Validity 
The internal validity of this study is likely to be robust because the data was collected using 
standardised procedures.  The tests used for chlamydia diagnosis were consistent although there 
were several instances where women were only tested with an EIA and the performance of this test 
is poorer that a DFA with respect to culture (Newhall et al., 1999).  It is plausible that this may result 
in a difference to the measured association between chlamydia and PID at the time these tests were 
used.  PID is a soft end-point, but the internal validity of this study is improved by the fact that the 
diagnoses in the cohort were made by one of three clinicians using consistent clinical criteria.  This is 
likely to have resulted in less variation in the application of this diagnosis that would be expected 
with a broader or less experienced study team (Morris et al., 2014).  One weakness of the internal 
validity was the high proportion of missing data that occurred because the study was conducted in a 
service setting.   
The external validity of this study is likely to be limited.  The population had an occupational 
risk factor for chlamydia and PID and the study was performed before the introduction of NAATs and 
widespread chlamydia control in the UK.  If it had been possible to observe the risk of PID following a 
true positive test in this cohort, it is likely that this risk would be an overestimate of the risk of PID 
following a true positive NAAT as it has been postulated that the infections detected by DIF or EIA 
have higher organism loads than those detected by NAAT and therefore may have an increased risk 
of progression to PID (Haggerty et al., 2010).  However adjusting estimates of the risk of PID 
following chlamydia for test performance and chlamydia prevalence adds additional uncertainty.     
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2.5.5 Confounding 
We performed a secondary analysis of an existing dataset therefore our choice of 
confounders was limited to the available data.  However the dataset contained repeat cross-
sectional information about chlamydia and gonorrhoea exposure and captured past history of STIs.  
This enabled us to explore the impact of repeat chlamydia infection and co-infection with 
gonorrhoea.  The limitations of using gonorrhoea test information as a measure of gonorrhoea 
exposure are the same as those described for chlamydia (see section 2.5.3) but in this cohort data on 
gonorrhoea testing was virtually complete (0.3% of clinic visits had missing data).  I chose not to 
include calendar period as a confounding factor because the study period was short (7 years) and 
there were no major changes to clinical practice during this period.  Gonorrhoea rates were in 
decline in the 1980s but this was included as an independent covariate in the analysis.  
The dataset contained information on some confounding variables that we did not include in 
the analysis, for example sexual behaviour.  It has been shown that this cohort reported high use of 
condoms with clients but low use with non-paying partners and that use increased over time (Ward 
et al., 1999).  The behavioural data was not included in the analysis because the dataset was small, 
and further sub-division into exposure categories would potentially have made the analysis non-
informative.   
 
2.5.6 Comparison with other studies 
The prevalence of chlamydia in this cohort was lower than that reported by two 
contemporary cohorts from the same location (London, UK) that used the same diagnostic test (DIF).  
The prevalence in this cohort was 8.54% (95% CI 5.04-12.03); women attending general practices in 
1987 had a prevalence of 10.7% and women attending a GUM clinic in 1994 had a 29% prevalence 
(Simms et al., 1997, Longhurst et al., 1987, Hay et al., 1994).  The PSP cohort reported consistent 
condom use with clients and an increase in condom use over time (Ward et al., 1999). This uptake of 
safe sex practice may have contributed to the lower prevalence of chlamydia observed in the cohort.  
Alternatively the high reported past history may mean that prevalence was reduced by testing.  But 
this prevalence reported in this study was higher than that observed in the recent  POPI study: 5.6% 
at baseline (Oakeshott et al., 2010).  
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 Of the fifty women who were diagnosed with chlamydia in this cohort, 26.0% (n=13) (95% CI 
13.8-38.2%) were subsequently diagnosed with PID.  This is similar to the proportion seen in a 
contemporary cohort of sex workers in Nairobi, Kenya with a similar mean duration of follow-up 
(15.7 months in PSP compared to 17.1 months in Kenya) 30.1% (95% CI 22.7-38.6%) (Kimani et al., 
1996).  The rate of PID in the PSP cohort following a recent chlamydia exposure, 27.40 per 100 py 
(95% CI 13.06-57.47) was considerably higher than the rate reported in recent general population 
settings: 1.6 per 100 py in women in the intervention arm of the POPI trial (censored at 12 months) 
(Oakeshott et al., 2010); 0.15 per 100 py (95% CI 0.11-0.20) in Sør-Trøndelag over 15 years, although 
this study only includes hospital presentations for PID (Bakken and Ghaderi, 2009).   
Despite differences in the absolute rate of PID, the adjusted hazard of PID following a 
previous chlamydia infection in this cohort (AHR 1.84 (95% CI 0.96-3.54)) is similar to estimates from 
Sør-Trøndelag (AHR 1.69 (95% CI 1.21-2.36)) and Uppsala (AHR 1.27 (95% CI 1.04 to 1.55)) (Bakken 
and Ghaderi, 2009, Low et al., 2006).  This is despite marked differences in sample size, 
ascertainment of PID and adjustment for covariates.  The adjusted hazard is also similar to the 
unadjusted risk of PID following a repeat infection in the cohort of sex workers in Nairobi, Kenya (OR 
1.8 (95% CI 1.3-2.4)) (Kimani et al., 1996).    
 
2.5.7 Further research 
The behavioural data that were collected during this cohort study could be used to gain 
insights into whether sexual behaviour is an independent risk factor for a diagnosis of PID.   
 
2.6 Conclusion  
In this cohort, women who had a positive chlamydia test within the last six months had a 
non-significantly increased risk of being diagnosed with PID at a later visit to the same clinic.  This 
risk of PID was further increased by a previous chlamydia infection or a previous gonorrhoea 
infection and reduced with age.  This study suggests that not all chlamydia infections have the same 
risk of progression to PID.  However the study was small and few of the analyses performed reached 
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statistical significance therefore the hypotheses suggested by these findings should be explored in a 
larger study:  
 previous infection with chlamydia is an independent risk factor for PID;  
 gonorrhoea exposure increases the risk of PID in women with chlamydia; 
 age is protective for PID. 
The utility of the findings from this study to the current policy making process are limited as 
this cohort was conducted at a time when chlamydia test performance was poorer and gonorrhoea 
rates were higher.  Therefore further research is needed in modern settings where NAATs are the 
main diagnostic method.   
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3.1 Overview 
Chapter 1 outlined the importance of improving estimates of the risk of complications 
following chlamydia infection to improve the utility of estimates from cost-effectiveness analyses for 
policy makers.  Chapter 2 demonstrated heterogeneity in the risk of PID following chlamydia 
infection and highlighted the need to adjust estimates for the presence of co-infection with other 
STIs, previous chlamydia infections and age.  In the conclusion to chapter 2, I described how the 
most informative estimates for policy makers will be those obtained from populations and settings 
that are comparable to the policy making context.  The estimates used to inform policy should also 
be robust.  These aims can be achieved by using contemporary, representative populations with 
large study sizes.   
In this chapter, I describe the rationale for using a retrospective population-based cohort 
constructed using administrative healthcare records to explore the association between chlamydia 
and adverse reproductive outcomes.  I outline why the Province of Manitoba, Canada provides a 
suitable setting for such a study and I describe its administrative healthcare datasets and the 
epidemiology of chlamydia. 
I then describe the process of designing a suitable cohort, the “Manitoba Woman’s 
Reproductive and Sexual Health” cohort, including the rationale for the sampling frame, the study 
population and the definitions for chlamydia exposure and adverse reproductive outcomes.  Finally, I 
outline the approval processes, ethical permissions and institutional approvals that were necessary 
to initiate and conduct the study and conclude with a description of the cohort.  The analysis of this 
cohort is presented in chapter 4.  
This project was a collaboration between Imperial College London (Bethan Davies, Helen 
Ward and Geoffrey Garnett) and the University of Manitoba (James Blanchard, Nancy Yu, Marissa 
Becker and Stella Leung).  It was funded by a Wellcome Trust programme grant looking at theoretical 
frameworks for HIV and STI control.  The initial concept of this cohort came from Geoffrey Garnett 
and James Blanchard.  I worked on the design and development of the cohort with Marissa Becker, 
Nancy Yu and Helen Ward.  I was responsible for developing the final design of the cohort, the 
methodology for analysing the cohort and applying for and maintaining the necessary ethical and 
institutional approvals.  Stella Leung was responsible for combining the many individual datasets 
that made up the final cohort and for performing the statistical analysis.  Additional input on study 
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design and data analysis was received from Dr Zoann Nugent, Dr Sourdet Shaw, Dr Katy Turner and 
Dr Joy Wei.  Administrative support for the cohort and for visits to the University of Manitoba, 
Canada was received from Doris Kuzma and Carol Sigurdson.    
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3.2 Introduction 
In chapter 2 I described the analysis of a small prospective clinical cohort of sex workers.  
This analysis has added to the literature by suggesting that not all chlamydia infections have an 
equal risk of progression to PID.  The analysis highlighted an increased risk following a previous  
chlamydia infection and the importance of controlling for gonorrhoea infection.  However the small 
size of the cohort may have contributed to the lack of statistical significance in these associations.  
There were also important differences between this cohort and a contemporary general population 
setting including the use of low sensitivity diagnostic tests for chlamydia and the high rate of 
gonorrhoea.  It is important to explore the associations demonstrated in chapter 2 in more detail as 
they have implications for the validity of the estimates of the risk of progression to PID following 
chlamydia used in mathematical models.  This research should use data from a large contemporary 
population that includes information about repeat infection and gonorrhoea.   
 
3.2.1 Retrospective population-based administrative healthcare cohorts 
In chapter 1 I outlined the suitable study designs for obtaining a measure of the relative risk 
of PID in women with and without chlamydia infection.  This estimate is needed to parameterise 
transmission dynamic models and to calculate a PAF of chlamydia on PID.  Given the current context 
of equipoise around chlamydia screening and the urgent need for information to inform chlamydia 
control policy, the use of a retrospective design is more appealing than introducing a time delay 
inherent with a prospective study.  Although a retrospective design has limitations, the most 
important of which is that the data available for analysis is predetermined.   
The choice between a cohort and a case-control study is guided by the research question 
and the rarity of the exposure or outcome and the size of the available population.  Neither 
chlamydia nor PID are rare34 events, during a woman’s lifetime, therefore a cohort is the more 
appropriate design for measuring the association between chlamydia and PID.  However ectopic 
pregnancy is a rare outcome.  The rate of hospitalisation with ectopic pregnancy in Manitoba was 
                                                          
34
 Defined as a lifetime prevalence of <1%. 
  Chapter 3 
92 
 
123 per 100,000 in 1990 (Orr et al., 1994). If the population size is large enough, a cohort study can 
be used to generate a nested case-control study so that rare outcomes can be explored.   
The most efficient source of the individual-level data that is needed to measure the 
association between chlamydia and adverse reproductive complications are routine administrative 
healthcare records.  These are computerised and record all activity that takes place within a 
healthcare system, often for reimbursement or other payment purposes.  Despite the widespread 
existence of administrative healthcare datasets, there are few settings where this data can be used 
to link individual-level activity across different providers (e.g. laboratory information on chlamydia 
testing with hospital admissions for PID) to obtain a complete record of an individual’s relevant 
interaction with healthcare.  
There have been two previously published cohorts that have used administrative healthcare 
datasets to measure the association between chlamydia and PID (Bakken and Ghaderi, 2009, Low et 
al., 2007).  A full description of these cohorts is provided in Appendix 2.  These studies have 
demonstrated the validity of using retrospective administrative healthcare datasets in chlamydia 
research, but they had some limitations that resulted from the available data.  Specifically they were 
not able to adjust for the presence of gonorrhoea co-infection, they did not include data on 
community managed episodes of PID and they were not able to report robust estimates of the risk 
following a repeat chlamydia infection.  The findings from both of these studies could be 
strengthened by research in a setting with more complete ascertainment of outcome episodes, data 
on gonorrhoea infections and with sufficient participation with chlamydia testing to explore the 
associations with repeat infection.  There are no examples in the published literature of large, 
detailed datasets that fit this description.   
   
3.2.2 The Province of Manitoba, Canada 
Canada is the second largest country in the world (The World Bank, 2013d).  The population 
was 34,487,000 in 2011 (World Health Organisation, 2013).  In 2006, 3.75% of the population 
reported that they had an aboriginal identity (Statistics Canada, 2009).  Canada was the eleventh 
richest country in the World in 2012, and it spent 11.18% of its gross domestic product (GDP) on 
healthcare in 2011 (The World Bank, 2013a, The World Bank, 2013c).  Just over two-thirds (70.42%) 
of healthcare expenditure is from public sources (The World Bank, 2013b).  The average life 
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expectancy at birth is 81.1 years, 17th highest in the world (The World Bank, 2013e). Canada is a 
democracy with a constitutional monarchy.  The country has a federal government and is divided 
into ten provinces35 and three territories36 with autonomous governments that are responsible for 
providing healthcare to their populations (Government of Canada, 2013).  
Manitoba is a central province of Canada.  Its population was 1,148,401 in 2006 and 15.47% 
of the population reported that they had an Aboriginal identity (Statistics Canada, 2009). The 
majority of the population (71.48%) live in an urban area (defined as “an area with a population of at 
least 1,000 and no fewer than 400 persons per square kilometre” (Statistics Canada, 2010)) and the 
remaining 28.52% live in a rural area (all other areas) (Statistics Canada, 2011).  There is a 
pronounced north to south gradient in geography and climate which is reflected by the considerably 
higher population density in the south which includes Winnipeg, Manitoba’s capital and only city.  
Winnipeg had a population of 694,668 in 2006. The next largest settlement is Brandon (population 
48,256) located in the south of the province (Statistics Canada, 2010, Statistics Canada, 2013) and 
the main settlement in the rural north of Manitoba is Churchill (population 923) (Statistics Canada, 
2007).   
 
3.2.3 Healthcare and health inequalities in Manitoba 
The health department of the provincial government, Manitoba Health (MH), has a legal 
responsibility to provide and deliver healthcare.  In practice, most healthcare services are 
administered and delivered by the regional health authorities (RHAs)37 that report to MH.  A 
minority of additional services are also provided by Cadham Provincial Laboratory (CPL), Selkirk 
Mental Health Centre and provincial nursing stations which all report directly to MH.   
Manitoba provides free healthcare to its residents through a centrally funded healthcare 
system, the Manitoba Health (MH) Services Insurance Plan38 (Manitoba Health, 2013a).  Individuals 
eligible for coverage under the insurance plan are permanent residents of Manitoba with either 
                                                          
35
 Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Prince Edward 
Island, Quebec, and Saskatchewan. 
36
 Northwest Territories, Nunavut, and Yukon. 
37
 Northern RHA, Prairie Mountain Health, Southern Health-Santé, Interlake-Eastern RHA and Winnipeg RH 
38
 Further details of this insurance plan can be found in the Health Services Insurance Act (Manitoba Health, 2013a).   
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Canadian citizenship or immigration status, who reside in Manitoba for at least 6 months a year.  
Coverage starts either at birth (for individuals born in Manitoba), or on the first day of the third 
month of residence in Manitoba (for individuals who immigrate). The healthcare covered under this 
insurance plan includes physician visits, X-ray and laboratory services (ordered by a Physician), 
surgery, anaesthesia and inpatient hospital services (Manitoba Health, 2013a).   
There are geographic inequalities in the distribution of healthcare resources in the province 
as they are clustered in areas with higher population density.  However most general practitioner 
visits and hospital admissions occur within the RHA of residence but specialist visits are more often 
held in Winnipeg (Fransoo, 2013).  There are also marked inequalities in health and socio-economic 
status across Manitoba.  In 2006, Winnipeg RHA had a better than average socio-economic status, 
the Southern RHA was at the average for the province, Prairie-Mountain and Interlake-Eastern were 
slightly worse than average and Northern RHA was much worse than average  (Fransoo, 2013). 
Following this (2007-2011) there was an improvement in the health status of the province, with the 
exception of residents in the north and those in the inner city area of Winnipeg (Fransoo, 2013).  It 
has been shown that the healthcare system is responding to the needs of the population as those in 
the poorest health access healthcare the most (Fransoo, 2013). 
 
3.2.4 Description of administrative healthcare datasets in Manitoba  
In the 1970s, MH introduced a comprehensive electronic register of all individuals registered 
with the MH Services Insurance Plan (the Manitoba Health Insurance Registry), a dataset containing 
administrative records of all discharges from public hospitals (MH Hospital Separations Abstracts) 
and a dataset containing all medical services provided by MH (MH Medical Claims (Physician 
Billings)).  This data collection is on-going and has expanded to include dispensed drug prescriptions 
(MH Drug Program Information Network (DPIN)) and laboratory services at CPL.  A summary of these 
datasets is provided in Table 3.1 and a more detailed description is provided in Appendix 8. 
The Manitoba Centre for Health Policy (MCHP) based in the Faculty of Medicine, University of 
Manitoba, through their Population Health Research Data Repository, acts as the steward for these 
administrative health datasets (in addition to a comprehensive collection of other administrative 
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datasets39).  The information in these health datasets describes “virtually all contact with the 
provincial health care system” by registered individuals (Manitoba Centre for Health Policy, 2009). It 
is possible, by linking the information held across these different datasets using an individual’s 
unique nine-digit Personal Health Information Number (PHIN)40, to generate a longitudinal record 
that describes when an individual was resident in Manitoba, when they were tested for chlamydia or 
diagnosed with gonorrhoea, what healthcare they received (within and outside a hospital), the 
diagnostic reason(s) for this care (Bernstein et al., 1999, Bernstein et al., 2001) and which drug 
prescriptions they had dispensed.   
 
3.2.5 Chlamydia in Manitoba  
Manitoba was an early adopter of chlamydia control.  It introduced a chlamydia control 
programme in 1987; the same year that chlamydia became a statutory notifiable infectious disease 
(Orr et al., 1994). Chlamydia’s importance on the policy agenda, together with the province’s high 
quality administrative health datasets has meant that Manitoba has been at the forefront of 
chlamydia epidemiology research for decades.  This body of research highlights a complex and 
changing epidemiology of chlamydia with marked health inequalities and high-risk population 
groups localised to geographical areas.   
By convention, the geographical areas used in STI research are slightly different to the areas 
defined by the RHAs.  The RHAs are administration districts that can change over time, but for 
research the following areas are used: Rural North; Rural South; Rural-Mid; Urban Non-core; Urban 
core.  The relationship between RHAs and the regions used in this research is described in the 
Appendix 9. 
  
                                                          
39
 As of 12
th
 November 2013, The Population Health Data Repository at MCHP housed 20 administrative health datasets; 1 
survey health dataset; 7 clinical health datasets; 10 social databases; 5 educational databases; 1 justice database; 4 
registries and 9 special data files (Manitoba Centre for Health Policy, 2009). 
40
 PHINs are assigned on registration and retained for the duration of coverage under the plan.  The PHIN is contained 
within every record held in every administrative health dataset.   
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Table 3.1: Description of Administrative Healthcare datasets held by MCHP (Manitoba Centre for Health Policy, 2009) 
i  
(Manitoba Centre for Health Policy, 2012b); 
ii
 (Manitoba Centre for Health Policy, 2012a); 
iii
  (Manitoba Centre for Health Policy, 2011b); 
iv
 (Manitoba Centre for Health Policy, 2011a); 
v
 
(Manitoba Health, 2013b); 
vi
 (Manitoba Health, 2010c); 
vii
 (Manitoba Health, 2010b) 
Data Source Description  Date  Approximate Size Coding 
MH Insurance Registry 
i
  Individuals eligible for healthcare 
through the MH Insurance Plan 
1970/71 - present  1.2 million individuals with 
active coverage 
Internal system 
MH Hospital Separations 
abstracts 
 ii
  
 In-patient admissions and surgical or 
diagnostic procedures performed 
without admission 
1970/71 - present  8-12 million records  ICD-9 and ICD-9 CM;  ICD-10 
CA and ICD-10 CA/CCI;  MH 
Tariff codes 
vi
  
MH Medical Claims 
 
(Physician Billings) 
 iii
  
 Physician delivered services (visits in 
offices and hospitals (in and out 
patient), laboratory and X-ray 
services) 
1970/71 - present  12-17 million records/year   First 3 digits ICD-9; MH Tariff 
codes 
 vi
   
MH Drug Programme 
Information Network 
iv
 
Prescriptions dispensed by retail 
pharmacies 
1970/71 - present 15 million claims/year  Drug Identification Number 
(DIN) 
vii
  
Cadham Provincial 
Laboratory 
v
  
 Tests performed at the Public Health 
Laboratory in Manitoba 
1992 to 2010 
 
120,000 microbiology 
records/year 
Internal system 
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3.2.5.1 Notification of chlamydia 
Chlamydia is a notifiable infection in Manitoba.  This means that all cases diagnosed by 
laboratories must be reported to the Chief Public Health Officer within the Manitoba Communicable 
Disease Unit of Manitoba Health within 24 hours.  The information about reported cases is 
maintained in the Communicable Disease and Surveillance dataset (Appendix 8) (Wylie and Jolly, 
2001). In addition to this, chlamydia is subject to compulsory partner notification under the 
Manitoba Public Health Act, 2009 (Manitoba Health, 2010a). The healthcare provider is responsible 
for contacting people after a positive test and obtaining information about their partners.  The form 
that accompanies a notification contains demographic, clinical (including details about treatment 
provided) and behavioural (including partners) information.    
 
3.2.5.2 Indications for testing 
Manitoba does not have any specialised sexual health clinics and therefore the management 
of chlamydia is performed in general medical clinics or hospitals (Jolly and Wylie, 2002).  When the 
chlamydia control programme was introduced, testing was recommended for the following groups 
(Jolly et al., 1995, Orr et al., 1994):  
 Sexually active people under 25 years of age;  
 Individuals who have had an STI in the previous year; 
 Individuals with a new sexual partner in last months or more than two in previous year; 
 Women undergoing therapeutic abortion or intrauterine device insertion;  
 Individuals who report injecting drug use; 
 Symptomatic people with “chlamydial syndrome” (defined as mucopurulent cervicitis, 
urethritis, epididymitis or PID); 
 Victims of sexual assault or abuse; 
 Sexual contacts/partners of people with chlamydia;  
 Individuals who have had unprotected sex with a person in any category outlined above. 
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Tests of cure were routinely recommended for pregnant women, people with continuing 
behavioural risk factors and those with PID (Jolly et al., 1995). The guidelines for testing 
asymptomatic people have been expanded and in 2008 they included (Manitoba Health, 2008):  
 
 Specific recommendation that sexually active people under 25 years of age have at least one 
test per year; 
 Sexually active individuals with more than one partner in the last year;  
 Pregnant women (at least one test during the pregnancy); 
 Women when they have a trans-cervical procedure (intrauterine device fitted; D&C) or 
termination of pregnancy; 
 Sexually active individuals with a partner who has other partners; 
 Street-involved individuals; 
 Individuals who use substances; 
 Individuals who work in or use commercial sex. 
 
A test of cure was recommended for pregnant women, those with unresolved symptoms, 
suspected non-compliance with treatment or if an alternative treatment has been used (e.g. 
amoxicillin) (Manitoba Health, 2008).  
 
3.2.5.3 Diagnostic test 
The type of chlamydia test in use in Manitoba between 1983 and 2008 is described in Table 
3.2 and a summary of their performance is provided in Table 3.3.  In 1990, 98.3% of tests performed 
in Manitoba were ELISAs, 1.5% were DIFs and 0.2% were culture (Orr et al., 1994).    
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Table 3.2: Chlamydia diagnostic tests in use in Manitoba, 1983-2008 (Orr et al., 1994, Elliott et al., 
2002)   
Date Urine Urethral and Cervical 
Before 1983  Culture 
 
1983-1984  Microtrak DIF test 
(Syva Co., San Jose, CA) 
 
1985-1989  Chlamydiazyme (ELISA) test  
(Abbott Laboratories, Chicago, IL) 
 
1990-1997 Chlamydiazyme (ELISA) test  
(Abbott Laboratory, Chicago IL) 
with confirmatory testing of positivesi 
Chlamydiazyme (ELISA) test  
(Abbott Laboratory, Chicago IL) 
with confirmatory testing of positivesi 
 
1998-2006 AMP-CT NAAT  
(GenProbe, San Diego CA) 
PACE 2 nucleic acid probe test  
(GenProbe, San Diego CA) 
 
2007-2008 Aptima COMBO 2 NAAT  
(GenProbe, San Diego CA) with 
confirmatory test if positive 
Aptima COMBO 2 NAAT  
(GenProbe, San Diego CA) with 
confirmatory test if positive 
i Using DIF or blocking antibodies (Orr et al., 1994) 
 
 
Table 3.3: Comparative performance of chlamydia tests used in Manitoba between 1992 and 2008 
 
 Test Sensitivity (%) Specificity (%) PPV (%) NPV (%) 
a) Endocervical specimens compared to culture (Crotchfelt et al., 1998, Newhall et al., 1999) 
 MicroTrak DIF 74.5 (67.6-80.5) 99.8 (99.6-99.9) 94.0 - 
 Chlamydiazyme 61.9 (55.6-68.7) 99.6 (99.3-99.7) 85.1 - 
 PACE 2 75.3 (68.6-81.2) 99.6 (99.4-99.8) 89.0 - 
 AMP-CT 100 99.5 97.0 100.0 
b) Endocervical specimens compared to AMP-CT (Wylie et al., 1998) 
 Chlamydiazyme 63.4 100 100 95.9 
 PACE 2 79.3 100 100 97.6 
c) Urine compared to patient infection status (Gaydos et al., 2003) 
 COMBO 2 96.8 (88.8-99.6) 99.0 (97.7-99.7) 92.3 99.6 
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3.2.5.4 Epidemiology of Chlamydia in Manitoba  
The introduction of the control programme in Manitoba saw a large increase in the volume 
of chlamydia testing.  The number of tests increased from 1,197 in 1981 to 83,304 in 1990 (Orr et al., 
1994) and by 1998 it was estimated41 that 26.6% of women and 3.4% of men aged 20-24 years and 
17.7% of women and 2.0% of men aged 15-19 were tested for chlamydia annually (Moses and Elliott, 
2002).  However the proportion of tests that were positive fell from 7.8% in 1981 to 5.3% in 1990 
and 3.6% in 1994 (Jolly et al., 2005, Orr et al., 1994).  The rate of diagnosis also fell from 780 per 
100,000 in 1988 (male and female) to plateau between 1992 and 1997 followed by a slight rise to 
362 per 100,000 in 1999 (Elliott et al., 2002). During a similar period (1987 compared to 1995), the 
number of reported cases of chlamydia fell by 61% in Winnipeg (Blanchard et al., 1998).   
A fall in positivity would occur if there was a change in the prevalence of chlamydia in the 
people being tested.  The large increase in the number of people tested suggests that there must 
have been a widening in the pool of people tested from the high-risk groups to the general 
population.   
Within Manitoba there are social and geographical inequalities in the distribution of 
chlamydia diagnoses (Elliott et al., 2002, Jolly et al., 1995).  At an individual level, women with 
chlamydia in 1988, when compared to women who tested negative for chlamydia and gonorrhoea, 
were more likely to be younger and have a First Nation status (Jolly et al., 1995). While there were 
no differences in the risk of diagnosis based on income at the individual-level, an ecological analysis 
of postal areas in Winnipeg found that the areas with the highest rates of chlamydia all had low 
socioeconomic status42 (Blanchard et al., 1998).   
Geographic patterns in the distribution of chlamydia have been documented at the 
province-level and within Winnipeg.  In 1999, the north of the province had the highest incidence 
rates and the rural south had the lowest rates (Elliott et al., 2002). Within Winnipeg in 1991-1995, 
                                                          
41
 These estimates were based on the number of chlamydia tests performed and therefore may overestimate of the true 
proportion of the population tested.  
42
 The areas with the highest rates of chlamydia (over 800 per 100,000 compared to between 100-550 per 100,000 in the 
rest of the city) had higher: population density; proportion of men; proportion of non-English/French speakers; population 
mobility; unemployment; incidence of infectious disease and lower mean household income.  
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cases were clustered in four postal areas that had rates of diagnosis five times higher than those in 
the 23 low risk areas (986 per 100,000 py compared to 186 per 100,000 py) (Blanchard et al., 1998).  
These existing geographic inequalities may have been widened by the introduction of the control 
programme.  The incidence of diagnosed chlamydia fell in all regions between 1991 and 1998 except 
for the north where number of cases as a proportion of the total cases in the province increased 
from 21% to 31%, while it declined in the urban core (14% to 11%) and urban non-core (46% to 40%) 
(Elliott et al., 2002). This shift in the distribution of chlamydia led to the suggestion that chlamydia 
was becoming geographically concentrated and entering the decline phase of its epidemic 
(Blanchard et al., 1998, Wasserheit and Aral, 1996) and this was supported by evidence that the 
sexual networks of people with chlamydia in Manitoba “resembled the theoretical structure of STD 
[STI] core groups” (Wylie and Jolly, 2001).  
At the time the control programme was introduced (1988-1990), repeated chlamydia 
infection43 was relatively common as 13.4% of people went on to have a second infection  (Orr et al., 
1994).  The risk factors for the repeat infection were being female, aged 15-24 years, having First 
Nation status and a gonorrhoea co-infection (Orr et al., 1994). A similar study in 1990-1992 found 
that women with more than one repeat chlamydia infection were more likely to be younger, have 
First Nation status and have a higher income than women with a single infection during the time 
period (Jolly et al., 2005). 
 
3.2.6 Gonorrhoea in Manitoba 
Gonorrhoea has been a notifiable infection in Manitoba since 1924 and information about 
reported cases is stored in the Communicable Disease Surveillance dataset (Lix, 2012).     
Gonorrhoea testing has been performed in a range of laboratories across the province.  In 1995, 
approximately half of the samples sent to CPL were tested using culture (if they arrived at the 
laboratory within 24 hours) and the rest were tested using Gonozyme ELISA (Abbott Laboratories, 
Chicago, IL) (Jolly et al., 1995).  By 1997, most laboratories used NAAT (Jolly et al., 2005) and in 2007 
                                                          
43
 Defined as a positive test ≥6 weeks after a previous positive with evidence that treatment was provided and taken. 
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CPL began testing all chlamydia samples for gonorrhoea using the APTIMA COMBO 2 NAAT 
(GenProbe, San Diego, CA).   
Gonorrhoea incidence has declined since the 1980s in Manitoba (from 397 per 100,000 in 
1980 to 46 per 100,000 by 1997) (Jolly et al., 2005).  This decline plateaued in 1997, the same time 
that NAATs replaced culture as the main method of diagnosis (Jolly et al., 2005). The province-wide 
geographical inequalities in diagnosis rates are more pronounced than those seen for chlamydia: the 
proportion of cases diagnosed in the north rose from 27% in 1991 to 41% by 1998 (Elliott et al., 
2002) and a small number (<5) of postal areas, had very high rates (over 400 cases per 100,000 in 
1998) while the majority had low rates (<100 per 100,000) (Blanchard et al., 1998).  In 1988 the risk 
factors for gonorrhoea, compared to women who tested negative for chlamydia and gonorrhoea 
were young age, urban residence, First Nation status and low mean income (Jolly et al., 1995). 
 
3.2.7 PID in Manitoba 
In Manitoba, women with acute symptoms compatible with a diagnosis of PID have several 
options for where to present for healthcare: their primary health care physician in the community; 
an urgent care department at a hospital or a hospital emergency department.  After women have 
had an initial assessment in one of these setting, they may be referred to the hospital for treatment 
as an in-patient or to the out-patient department for routine follow-up.  In Manitoba, there was a 
decline in hospitalisations for PID (defined as ICD-9 614 and 633) between 1981 and 1990 (from 139 
per 100,000 to 71 per 100,000) and in out-patient presentations (695 per 100,000 to 463 per 
100,000) (Orr et al., 1994).  
 
3.2.8 Research Question  
The association between chlamydia and adverse reproductive outcomes (PID, ectopic 
pregnancy and tubal factor infertility) are confounded by many factors, including age, co-infection 
with other STIs, treatment with antibiotics, use of contraceptive agents, pregnancy and healthcare 
seeking behaviour.  Furthermore, there have been secular changes in the epidemiology of STIs, 
sexual risk behaviour, chlamydia testing policy and diagnostic tests which may have impacted on the 
temporal trends in the association between chlamydia and adverse reproductive complications.   
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We wish to determine whether it is feasible to create a research database that is suitable for 
robust exploration of the association between chlamydia, PID, ectopic pregnancy and tubal factor 
infertility at the individual-level and that can take into account the presence of confounding 
variables.   
 
3.2.9 Aims and objectives 
To describe and create an appropriate population-based retrospective cohort using 
administrative data from the province of Manitoba, Canada that can be used to address the research 
questions of this thesis and further questions about the relationship between chlamydia and 
women’s reproductive and sexual health.  The specific aims of this chapter are to:  
 Define the study population; exposure to chlamydia; adverse reproductive outcomes and 
appropriate confounders; 
 Obtain the necessary approvals for the study; 
 Generate a study dataset using administrative health records 
 
 
 
3.3 Methods  
3.3.1 Cohort definition 
3.3.1.1 Population  
The sampling frame for the population-based cohort was the MH Insurance Registry because 
it is considered to be an almost complete representation of the resident population of Manitoba.  An 
individual was defined as a person registered for health insurance through the MH Insurance 
Registry with a unique 9-digit PHIN and the scrambled version of the PHIN was used to link the 
healthcare records of an individual across the datasets.  The cohort was defined as all women aged 
12-24 years in 1992 to 1996 (Figure 3.1).  Women entered the cohort on the first date that they 
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were registered with MH after they became eligible for the cohort44.  We chose to use a birth cohort 
design that spanned 12 years rather than including the entire population.  In line with the ethical use 
of healthcare data this would restrict the dataset to information directly relevant to our research 
questions.    
 
Figure 3.1: Illustration of the cohort: definition of cohort, run-in period, follow-up period and 
description of women’s age by year of birth and calendar year  
 
 
 
This age range was chosen to focus on women who are targeted by specific chlamydia 
control interventions, 16-24 years (Manitoba Health, 2008). Furthermore by including a cohort of 
girls who were 12-15 years in 1992-1996 we aim to capture the first chlamydia test for a proportion 
of the cohort.  It was not possible to start the cohort before 1992 as this is when electronic records 
                                                          
44
 It is possible for women to enter the cohort over the age of 24 but between 1992 and 1996 if they would 
have fit the cohort definition if they were resident in Manitoba but they moved into the Province part way 
through the defining time period.       
1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
1968 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
1969 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39
1970 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38
1971 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37
1972 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
1973 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35
1974 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
1975 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
1976 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
1977 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
1978 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
1979 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
1980 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
1981 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
1982 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
1983 12 13 14 15 16 17 18 19 20 21 22 23 24 25
1984 12 13 14 15 16 17 18 19 20 21 22 23 24
Run-in period Cohort definition Follow-up period No information collected
Calendar year 
Y
e
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 o
f 
B
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of chlamydia testing became available.  At the time we applied for access to the MH data, complete 
information about healthcare presentations for adverse reproductive outcomes was available until 
the end of 2008.  This date range was also chosen to allow sufficient time for outcomes to occur 
during the follow up period.  No formal sample size calculation was performed as this was a birth 
cohort. 
 
3.3.1.2 Exposure to Chlamydia 
The source of data on chlamydia was the CPL dataset.  This resource was selected because it 
contains data on most of the chlamydia tests performed in Manitoba since 1996.  We defined a test 
as:  
 any chlamydia test recorded in the CPL database between 01/01/1992 and 31/12/2008; 
 with a valid date (specimen date or date received by laboratory) and PHIN; 
 that occurred >60 days after an earlier test45; 
 that was not a duplicate (defined as tests with the same PHIN, date and result); 
 that had a valid result recorded.  
The cohort included a record of all chlamydia tests a woman had between 1992 and 2008.  
This information will be used to determine cumulative exposure to chlamydia testing and chlamydia 
infections during follow up.  
 
3.3.1.3 Outcomes  
Information about outcome events (PID, ectopic pregnancy, infertility (including tubal 
factor), pregnancy and abortion) was obtained from the Medical Claims (Physician Billings) and the 
Hospital Separations Abstracts datasets.  The cohort has permission to include all records of an 
individual’s interactions with healthcare between 1/1/1987 (or age 12) and 31/12/2008.  The five 
year run-in period before entry to the cohort (or from age 12) will allow us to identify individuals 
                                                          
45
 This is in keeping with earlier studies and aims to reduce the possibility of false positive tests from residual genetic 
material post-treatment (Bakken and Ghaderi, 2009, Bakken et al., 2007). 
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with a diagnosis of interest during this period (Figure 3.1).  Outcomes were defined using ICD codes 
and a description of commonly used ICD-9 and ICD-10 diagnostic codes and ICD-9-CM and ICD-10-
CCI procedure codes is provided in Appendix 10.  Of note, the hospital records include 4 digit ICD-9 
or 10 codes, while the Medical claims dataset is limited to the first 3 digits of ICD-9.  To ensure as 
much consistency as possible, we restricted the ICD-9 codes in the medical dataset to those that 
would also be obtained from the Hospital Separations abstract dataset.   
 
3.3.1.3.1 PID 
In chapter 1 I outlined the lack of a consensus ICD definition for PID and suggested that this 
was because the ICD codes refer to anatomical locations and/or causes of inflammation rather than 
the clinical diagnosis of PID.  A summary of the ICD-10 codes used in similar epidemiological studies 
is presented below (Andersen et al., 2010, Bakken and Ghaderi, 2009, Low et al., 2006):  
 
 Bakken et al. 2009 N70  
 Low et al. 2006  N70-74  
 Andersen et al. 2010 N70.0;70.9;71.0;71.9;73.0;73.3;73.5;73.8 & O03.0; 03.5; 04.0; 04.5;  
07.0  
 
I also discussed the poor performance of ICD codes in administrative healthcare datasets at 
representing a case of PID in the medical notes.  Given the broad use of non-specific diagnostic 
codes with a low PPV for PID, we used a broad range of relevant ICD codes presented in Table 3.4 
and a case is defined as a relevant code in the medical or hospital datasets.   
 
3.3.1.3.2 Ectopic pregnancy  
There is little variation in the ICD codes used for ectopic pregnancy in the literature.  
Andersen et al. used ICD-10 O00 (all sub-codes) and Bakken et al. use the same code (or ICD-9 633) 
with the additional requirement of an ultrasound scan or relevant histology in the medical case 
notes (Andersen et al., 2005, Bakken et al., 2007). Hoover et al. used the ICD diagnosis code plus a 
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treatment code within the following 14 days (methotrexate; laparoscopy; laparotomy)  (Hoover et 
al., 2010).  In this cohort, we do not have access to the medical notes but we do have access to drug 
prescriptions and surgical procedures (in-patient and out-patient).  We defined ICD codes (Table 3.4) 
and relevant procedure codes in the medical or hospital datasets46 and used these to formulate 
three definitions for ectopic pregnancy:  
 ICD code in either the Medical Claims of Hospital dataset;  
 ICD code in either the Medical Claims or Hospital dataset plus a relevant procedure code in 
either dataset within 14 days;  
 ICD code in either the Medical Claims or Hospital dataset plus a relevant procedure code in 
either dataset or prescription for methotrexate in the DPIN dataset within 14 days.  
 
 
3.3.1.3.3 Infertility  
Low et al. and Andersen et al. defined infertility as ICD-10 N97 (all sub-codes) and we 
identified appropriate ICD-9 codes (Endres, 2009, Low et al., 2006). Tubal factor infertility has a 
specific ICD-9 and ICD-10 code (628.2 and N97.1 respectively) however it does not appear in the MH 
medical dataset.  It is our opinion that women may receive a diagnosis of infertility in their notes 
while they are undergoing investigation for the presence of this condition.  Therefore, to improve 
the potential sensitivity of the definition we considered including the presence of a relevant 
procedure code in the medical or hospital datasets. We defined ICD codes (Table 3.4) and relevant 
procedure codes47 in the medical or hospital datasets and used these to formulate two definitions 
for infertility: 
 
 
                                                          
46
 Relevant procedure codes for ectopic pregnancy defined as: laparoscopic surgery; laparotomy surgery; 
surgical removal of extra-uterine pregnancy (including salpingectomy for removal of EP); removal of extra-
tubal ectopic pregnancy; salpingectomy with removal of tubal pregnancy; methotrexate injection. 
47
 Relevant procedure codes for infertility defined as: functional study fallopian tube;  hysterosalpingogram (HSG) (inc. 
uterosalpingogram); X-ray of female genital organs  (includes HSG); diagnostic procedure on fallopian tube ; other specified 
procreative management; hysteroscopy; open/closed biopsy of uterus; laparoscopy; endometrial biopsy; uterine 
inspection; uterine ultrasound.  
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 ICD code in either the Medical Claims of Hospital dataset;  
 ICD code in either the Medical Claims or Hospital dataset plus a relevant procedure code in 
the Medical claims or Hospital datasets within 14 days.  
 
3.3.1.3.4 Pregnancy 
We defined a healthcare event for pregnancy in order to identify the sub-set of the cohort 
that experienced a pregnancy during their membership to explore the association between 
chlamydia and ectopic pregnancy.  This assumption that only women who experience a pregnancy 
are at risk of an ectopic pregnancy has been used by previous studies (Andersen et al., 2005, Bakken 
et al., 2007). We defined a pregnancy as a diagnosis of abortion (any type), delivery or any other 
diagnostic code that indicated healthcare was received for or at the same time as a co-existing 
pregnancy diagnosis (Canadian Institute for Health Information, 2006, Manitoba Centre for Health 
Policy, 2013) (Table 3.4).  We did not include procedure codes in the definition as pregnancy is a 
likely to be a confirmed, rather than suspected diagnosis.  
 
3.3.1.4 Covariates  
3.3.1.4.1 Age 
The cohort contained women aged 12-40 years.  Age categories have been defined a priori 
as 12-15; 16-19; 20-24; 25-29; 30-34; 35-39 years.  This is in keeping with the target age range for 
chlamydia screening.  A woman’s age will obviously change over time; therefore it is necessary to 
specify the time point at which age will be applied.  The choice will depend on the specific analysis, 
but the options are age at entry to the cohort; age at the index chlamydia test; age at outcome; 
current age at the event. 
 
3.3.1.4.2 Year 
The cohort runs from 1992 to 2008.  Year groups have been defined a priori as 1992-1996; 
1997-2002; 2003-2008.  There is a degree of co-linearity between age and time in this cohort as new 
women stop entering the cohort in 1996 and all women age uniformly until 2008.  However there 
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are 12 different ages in any given calendar year.  There is an a priori assumption that the year in 
which a chlamydia test was performed may affect the relationship between the test result and 
future adverse reproductive outcomes.  This is because over time tests have become more sensitive 
and have changed from detecting viable organisms to detecting the presence of genetic material.  
Analyses that adjust for both age and calendar year will be kept to a minimum.   
 
3.3.1.4.3 Geography 
The MH insurance registry updates an individual’s self-reported place of residence, using the 
first 3 digits of their postcode, known as the Forward Sortation Area (FSA), every six months.  FSAs 
contain small numbers of residents and are unlikely to contain enough outcome events for a robust 
analysis.  Therefore we used FSA to allocate individuals to one of the five regions; Rural North; Rural 
South; Rural-Mid; Urban Non-core; Urban core (section 3.2.2).  There are well-described differences 
between the regions of Manitoba in terms of the distribution of the population, socioeconomic 
status and patterns of healthcare availability and access.  RHA is used as a broad proxy for sexual 
network; chlamydia screening availability and access to healthcare. 
There are several possible options for allocating women to an RHA, including her location at 
time she enters the cohort; at the most recent chlamydia test; at the most recent health event; or at 
the end of follow-up.  Given that we know adequate treatment of a chlamydia infection is able to 
prevent the occurrence of PID (Oakeshott et al., 2010), it seems reasonable to assume that the 
factors we are most interested in occur at or around the time of a chlamydia exposure.  However if 
we allowed a time varying location for women who are tested for chlamydia this would create a bias 
when compared to women who are never tested (and therefore would not have a changing location 
in the cohort, even if they move residence).  Therefore we assigned women a single location at the 
time they entered the cohort.   If this information was not available, we used her recorded residence 
within 5 years of this date.  
 
  Chapter 3 
110 
 
3.3.1.4.4 Gonorrhoea 
We requested permission to use the CPL and Communicable Disease Surveillance datasets48 
as a source of information on cases of gonorrhoea.   
3.3.1.4.5 Antibiotic treatment 
The DPIN dataset will be used to identify all dispensed appropriate antibiotic prescriptions 
for chlamydia in the immediate period following a positive test, starting in 1995/6.  Antibiotic 
therapy guidelines have changed over time as novel therapeutic agents have been developed and as 
the organism’s sensitivity to therapeutic agents evolved.  Clinical guidelines (from CDC and PHAC) 
were used to identify appropriate antibiotic prescribing for chlamydia between 1992 and 2008 (see 
Appendix 11).  These drug names and dosing schedules can then be converted into Drug 
Identification Numbers (DINs) to identify appropriate prescription from the DPIN.   The 
Communicable Disease Surveillance Dataset can also be used to identify any additional women who 
are reported to have received treatment for chlamydia.   
3.3.1.4.6 Contraception  
The DPIN dataset will be used to identify all prescriptions for hormonal contraceptives 
starting in 1995/6.  This includes COC, progesterone-only pill or contraception 
implant/injection/patch that can be identified from their DINs.  Information on the use of intra-
uterine devices or sterilisation will be obtained from the Hospital Separations Abstract dataset as 
these methods of contraception require a medical procedure.   Identification of women who are 
using methods of contraception can be used to refine the definition of the cohort at risk of 
pregnancy.  
                                                          
48
 Before 2007, gonorrhoea infections were diagnosed using culture.  This technique was widely available and therefore 
samples collected in Manitoba were processed in a variety of laboratories across the province.  When the Aptima COMBO 
2 NAAT (GenProbe, San Diego CA) was introduced for chlamydia tests in 2007, all chlamydia specimens were automatically 
tested for both chlamydia and gonorrhoea using this dual-platform test.  Therefore after 2007 CPL became a 
comprehensive source of gonorrhoea testing information.  However gonorrhoea has been a notifiable infection in 
Manitoba since 1924 therefore as the electronic records in the Communicable Disease Surveillance dataset predate the 
start of the cohort, it will contain all cases of gonorrhoea in the province during the cohort (Lix, 2012). 
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Table 3.4 Summary of definitions of variables used in Manitoba cohort 
Variable Definition Dataset  Diagnosis Codes Procedure codes  
Chlamydia  A chlamydia trachomatis test in the CPL 
database between 01/01/1992 and 
31/12/2008 with a valid date of specimen or 
valid received date and complete 
demographic information (specify which 
variables) ≥60 days after an earlier test 
CPL CHLT, excluding those for non 
trachomatis species C.psittaci and 
C.pneumoniae; The field 
“results_cmb” was used to identify 
positive, negative and other results 
Positive results: CHD; LCCRD; 
Negative results: CHND; CTNI; CTPN; 
LCRRN 
N/A 
PID A healthcare presentation (inpatient, 
outpatient or community) with an ICD code 
for PID in the MH Hospital separations 
abstracts or MH Physicians claims dataset 
Hospital 
separations 
abstracts  
ICD-9 614-616.0; 098.10; 098.15; 
098.16; 098.17; 098.30; 098.35-7; 
099.56; 098.86; 016.6  
ICD-10 N70-74.8; A56.1; A18.1; A51.4; 
A54.2; A52.7 
N/A 
Medical claims  614-615; 098; 099; 016 N/A 
EP A healthcare presentation (inpatient, 
outpatient or community) with an ICD code 
for ectopic pregnancy in  the MH Hospital 
separations abstracts or MH Physicians 
claims dataset 
Hospital 
separations 
abstracts 
ICD-9 633.0-633.9  
ICD-10 O00.00-O00.9 
ICD-9-CM: 54.21; 54.1; 99.25; 74.3; 66.62 
ICD-10-CCI: 2.OT.70.DA; 2.OT.70.LA; 
5.CA.88.AL-M2; 5.CA.88.DA-M2; 5.CA.88.CA-
M2; 5.CA.88.HA-M2; 5.CA.93.^^.^^ 
Medical claims 633 N/A 
Infertility A healthcare presentation (inpatient, 
outpatient or community) with an ICD code 
for infertility in the MH Hospital separations 
abstracts or MH Physicians claims dataset 
Hospital 
separations 
abstracts 
ICD-9 628 – 628.9  
ICD-10 N97  
 
ICD-9-CM: V26.21; 87.8; 66.1; V26.8; 68.12; 
68.16; 68.13; 54.21 
ICD-10-CCI: 2.RF.58^^; 3.RK.^^.^^; 
3.RK.10.^^; 2.RM.70.^^; 2.OT.70.DA; 
2.RM.71.^^; 2.KT.70.^^; 3.RZ.30.^^; 
5.AB.04.^^ 
Medical claims 628 N/A 
 
  Chapter 3 
112 
 
TFI A healthcare presentation (inpatient, 
outpatient) with an ICD code for TFI in the 
MH Hospital separations abstracts dataset 
Hospital 
separations 
abstracts 
ICD-9 628.1 
ICD-10 N97.1 
As for infertility 
Abortion  A healthcare presentation (inpatient, 
outpatient or community) with an ICD code 
for abortion in the MH Hospital separations 
abstracts or MH Physicians claims dataset 
Hospital 
separations 
abstracts 
ICD-9 632; 634-637  
ICD-10 O02.1; O03-06 
N/A 
Medical claims 632; 634-637 N/A 
Delivery A healthcare presentation (inpatient, 
outpatient or community) with an ICD code 
for delivery in the MH Hospital separations 
abstracts or MH Physicians claims dataset 
Hospital 
separations 
abstracts 
ICD-9  V27  
ICD-10  Z37-38  
N/A 
Medical claims V27 N/A 
Pregnancy  Any code for abortion, delivery or additional 
pregnancy events during membership to the 
cohort  
  N/A 
Additional 
pregnancy 
events 
A healthcare presentation (inpatient, 
outpatient) with an ICD code for a pregnancy 
related event or diagnosis in the MH Hospital 
separations abstracts dataset 
Hospital 
separations 
abstracts 
ICD-9 630; 631; 640-649;670-677; 
V22; V23; V28 
ICD-10 O01; O02.0; O02.8; O02.9; 
O10-16; O20-29;  O85-92; O94-99; 
Z32.1; Z33-36 
N/A 
Age Time varying covariate MH Insurance 
Registry 
  
Year Time varying covariate Relevant 
event record 
  
Geography RHA of residence on the date of entry to the 
study cohort 
MH Insurance 
Registry 
FSA converted to RHA using MCHP 
SAS programme  
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3.3.2 Sub-cohorts 
3.3.2.1 Cohort A 
This is the whole Manitoba Women’s Reproductive and Sexual Health Cohort.  It contains all 
women who were resident in Manitoba and aged 12 to 24 in 1992-1996. This cohort contains 
information about women who are known to have had a chlamydia test, to have tested negative for 
chlamydia and never to have had a chlamydia test.   
 
3.3.2.2 Cohort B 
We used the information from the run-in period (1987 or from age 12) to identify and 
remove all women in cohort A who had an outcome of interest (PID, pregnancy or infertility) in the 
five-year period before they entered the cohort (or from age 12).  The aim was to generate a cohort 
that captures a woman’s first known adverse reproductive outcome.   
 
3.3.2.3 Cohort C 
We further restricted cohort B to women who had a chlamydia test during their membership 
in cohort B and removed any women who had an outcome of interest before their first chlamydia 
test.  Women enter cohort C on the date of their first chlamydia test which removed the potential 
bias in the duration of follow-up if women entered at the start of the cohort and were classified 
according to the results of their chlamydia tests.  This sub-cohort is no longer representative of 
overall population because it does not contain information about women who are not tested for 
chlamydia however it was designed to explore the association between chlamydia and complications 
in a population of women who participated with testing.   
 
 
  Chapter 3 
114 
 
3.3.3 Ethical and institutional approvals 
There are two important ethical issues that affect this secondary analysis of administrative 
healthcare data: consent from participants and the potential identification of data participants.  The 
relevant approval bodies have determined that it is not necessary or appropriate to obtain consent 
from the individual data participants.   
 
3.3.3.1 Health Information Privacy Committee   
Applications to conduct research using personal health information must be approved by the 
Health Information Privacy Committee (HIPC) of MH.  This process is designed to ensure that 
confidentiality of data participants is maintained and that the intrusion to privacy can be justified by 
the outcomes from the research, as described in the Personal Health Information Act of Manitoba.  
We submitted an initial application to HIPC on 16th November 2010.  After clarification with 
MH about the data requirements and processes for accessing the data a re-application was 
submitted on 18th January 2011 and approved (study approval number: HIPC 2010/2011-48).  Two 
subsequent amendments were made to change the process of accessing the data and to add an 
additional researcher to the project team.  
  
3.3.3.2 University of Manitoba Health Research Ethics Board  
We applied for ethical approval for the study from the University of Manitoba Health 
Research Ethics Board (HREB) on 5th November 2010 (Reference H2010-373).  Two subsequent 
amendments were made to change the process of accessing the data and to add an additional 
researcher to the project team.  We have submitted annual progress reports during the study to 
maintain this approval. 
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3.3.3.3 Data security and access restrictions 
Individual-level data are required for this research and must contain an identifier so that the 
information across datasets can be linked.  Every effort has and will be taken to ensure that the 
identity of the data participants remains unknown to the researchers.  This was achieved by 
removing or encrypting the direct identifiers (e.g. name, address, PHIN) and limiting the number of 
indirect identifiers (e.g. date of birth).  Indirect identifiers were required to perform the data linkage.  
To safeguard this dataset it was housed in the MCHP offices at the University of Manitoba 
and access was restricted to a single computer terminal located in the Centre for Global Public 
Health (CGPH) at the University of Manitoba, connected through a Virtual Private Network.  All data 
users had a unique password and all access to the data was logged.  It was not possible to connect to 
the internet from this terminal in the CGPH.  Furthermore, all hardcopy outputs from the dataset 
had to go through an approval process within MCHP to ensure that no identifiable information (cells 
with <5 individuals) was released. 
 
3.3.4 Construction of the study cohort from constituent datasets 
The construction of the study cohorts from the datasets provided by MHCP was performed 
by Stella Leung, CGPH, University of Manitoba in collaboration with Bethan Davies.  
 
 
3.4 Results 
3.4.1 Description of the study cohort 
3.4.1.1 Cohort A 
There were 147,258 women who were eligible for the Manitoba Women’s Reproductive and 
Sexual Health cohort, of whom 2,158 entered the cohort after their 24th birthday as they moved 
into Manitoba after this age, but between 1992 and 1996.   
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3.4.1.2 Cohort B  
Cohort B contains 88.61% of cohort A (n=130,485).  These women did not have a healthcare 
event for PID, pregnancy or infertility before they entered the overall cohort.   
3.4.1.3 Cohort C 
Cohort C contains 49.49% of cohort A and 55.86% of cohort B (n=72,883).  These women 
were tested for chlamydia during their membership in the cohort and did not have a healthcare 
event before their first chlamydia test in this cohort.  
  
Figure 3.2: Description of Cohort A, B and C. Adapted from Davies et al. (2014). Heterogeneity in risk 
of pelvic inflammatory diseases after Chlamydia infection: a population-based study in Manitoba, 
Canada. J Infect Dis, 210 Suppl 2, S549-55. With permission. 
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Figure 3.3 illustrates the number of women in each birth cohort (1968-1972; 1973-1976; 
1977-1980; 1981-1984) that contribute to cohort A, B and C respectively between 1992 and 2008.  In 
Cohort A women born between 1968 and 1972 form the largest birth cohort and the remaining 3 
cohorts are of roughly equal size once women born 1981-1984 had all entered the cohort.  In Cohort 
B, the 1968-1972 and 1973-1976 birth cohorts are similar in size but smaller than in Cohort A.  The 
largest birth cohort is 1977-1980 until it is equalled by the 1981-1984 cohort when all members have 
entered, this birth cohort then becomes the largest.  Cohort C shows a similar pattern to Cohort B 
except that the 1967-1972 birth cohort is smaller than the 1973-1976 cohort.  This decline in the size 
of the 1968-1971 birth cohort and the increase in the relative contribution from the younger cohorts 
can be seen in Figure 3.4.
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Figure 3.3: Line charts of number of women 
in study cohort by calendar year (1992-2008) 
and birth cohort (1968-1972; 1973-1976; 
1977-1980; 1981-1984) for (a) Cohort A; (b) 
Cohort B; (c) Cohort C 
 
a) Cohort A 
 
 
b) Cohort B 
 
 
c) Cohort C 
 
Figure 3.4: Stacked line charts illustrating the 
contribution of each birth cohort (1968-1972; 
1973-1976; 1977-1980; 1981-1984) to the 
overall cohort by calendar year (1992-2008) 
for (a) Cohort A; (b) Cohort B; (c) Cohort C 
 
a) Cohort A
 
 
b) Cohort B 
 
 
c) Cohort C 
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3.5 Discussion 
In this chapter I have described the design, development and construction of a population-
based retrospective cohort, the Manitoba Women’s Reproductive and Sexual Health cohort, using 
administrative healthcare data from the province of Manitoba, Canada.  This cohort will be used in 
chapter 4 and future research to explore the association between chlamydia and adverse 
reproductive health.  It has several major advantages over the similar cohorts that have been 
described in the published literature: it is much larger; it includes outcomes diagnosed in both 
community and hospital settings; it allows us to explore the role of repeat chlamydia infection, 
gonorrhoea co-infection, hormonal contraception and antibiotic treatment on the relationship 
between chlamydia and adverse reproductive outcomes.  Its large size and long period of follow-up 
mean that rare outcomes that occur in the future (e.g. tubal factor infertility) can be studied.  
The main limitation is that it was created from administrative data that were collected for 
another purpose and it is not possible to identify or correct for errors in the initial datasets. This has 
the potential to introduce bias and validity concerns.  However previous studies have demonstrated 
the potential high quality of the MH administrative datasets (Lix, 2006, Lix, 2008).  Key data that 
were not available for this study include information about sexual behaviour (including sexual 
networks), healthcare seeking behaviour and reproductive intentions.  
The remainder of this discussion follows the format of a critical appraisal as this is a rigorous 
and systematic method for exploring the strengths, limitations and alternatives to our study design.  
This discussion provides a detailed review of the methodological concerns affecting this cohort as 
background to the interpretation of the analytic findings presented in the next chapter.   
 
3.5.1 Study design: intervention versus observation 
We used a retrospective cohort design.  The gold-standard would have been an RCT because 
they can be used to test for the presence of a cause-effect relationship between a chlamydia test 
and adverse reproductive outcomes.  In comparison, a cohort is able to demonstrate the presence of 
a temporally appropriate association between these factors.  The unique strength of an RCT comes 
from the random allocation of women into chlamydia test (intervention) groups. This results in an 
equal distribution of both known and unknown confounders between the tested and untested 
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women so that any difference in the magnitude of the association between chlamydia and the 
outcome across the groups can be attributed to the intervention or chance.  In a cohort there are 
likely to be any number of factors that differ between groups defined by their exposure status (e.g. 
age; healthcare seeking behaviour; risk of chlamydia; method of PID diagnosis) and these differences 
could contribute to or be the underlying explanation for any observed associations.   In addition an 
RCT uses standard procedures for relevant events (e.g. chlamydia testing or outcome assessment) 
that are applied equally to all women which reduces the potential for misclassification or 
ascertainment bias.   
A major limitation of RCTs is their enormous resource requirement.  They demand a large 
number of staff, repeat contact with participants and a follow-up period that is appropriate to the 
timing of the outcome of interests (e.g. for tubal factor infertility, follow-up would need to last the 
complete duration of a woman’s reproductive lifetime given the trend towards delayed 
parenthood).  Retrospective cohort studies have considerably fewer resource requirements as they 
involve a smaller research team and use routinely collected data that is immediately available with 
few additional costs involved in extracting and maintaining it.  This use of routinely collected data 
also has an important ethical advantage because it does not involve direct participation by research 
subjects and therefore creates a lower risk of harm that RCTs which alter an individual’s interaction 
with healthcare.  
There are clear pragmatic advantages to using a retrospective cohort study to explore our 
research question but there are a number of limitations inherent to this study design.  I discuss the 
methodological concerns that arise from this, including bias, confounding and validity, consider their 
potential impact on the subsequent research findings and describe steps we have taken in the 
design stages to minimise this.   
 
3.5.2 Bias 
Misclassification bias in the assignment of chlamydia and PID status is the most important 
methodological concern for this and all retrospective observational cohorts because the information 
used to assign exposure and outcome status has been collected before the onset of the study.  There 
is also the potential for systematic differences in how the exposed and unexposed women were 
treated.   
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The main source of this misclassification bias in PID status is from the diagnostic bias that is 
discussed in chapter 2.  Briefly, a past medical history of chlamydia is likely to influence the 
probability that the doctor will assign a diagnosis of PID rather than give an alternative explanation 
for mild to moderate non-specific abdominal pain.  This misclassification bias may be exacerbated by 
under-ascertainment of PID cases because the dataset does not contain presentations to hospital 
urgent care or emergency departments.  If the women who present to these settings and are 
discharged without admission or referral for follow-up (i.e. the event does not appear in the hospital 
or medical claims datasets) have a differential risk of chlamydial-PID then this may bias the 
association between chlamydia and PID.  For example, women who fit this description may have a 
mild to moderate presentation where the causative agents differ from those of mild PID or severe 
PID.  However the impact of this is likely to be small because women who were referred back to 
primary care, admitted to hospital or seen as an out-patient after discharge will have been detected 
at this point.  
As discussed in chapter 2, the principal source of misclassification bias in chlamydia status is 
the use of chlamydia laboratory test records to define exposure.  Therefore exposure assessment is 
only accurate at the time the test is performed, and this cannot be altered in a retrospective study.  
In a prospective study it would be theoretically possible to collect information on chlamydia status 
through systematic repeat testing; however it is unlikely that the benefit of this in a large (and 
therefore representative) study would outweigh the expense or intrusion.   
In this cohort, women were able to freely access testing therefore there is a potential bias 
towards accurate exposure assessment (i.e. testing) in women who are symptomatic compared to 
those who are asymptomatic.  The direct of this bias on the association between chlamydia and PID 
will depend on the relative contribution of chlamydia to their symptoms and symptomatic chlamydia 
to PID.  In most studies, chlamydia exposure is defined as the presence of a past history of chlamydia 
(Bakken and Ghaderi, 2009, Low et al., 2006) therefore women are defined as exposed for much 
longer than the likely duration of infection (Geisler, 2010, Price et al., 2013). This method of 
classification may dilute and therefore underestimate the association between an acute chlamydia 
infection and PID.  
A further source of misclassification bias is that the accuracy of the exposure assessment 
depends on the performance of the diagnostic test.  As discussed in chapter 2 the imperfect 
performance of chlamydia tests cause false positive and false negative results and misclassification 
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of exposure status.  This will only amount to a bias if it differentially affects groups of women or 
infections on the basis of characteristics that affect their risk of progression to adverse reproductive 
complications.  
The imperfect sensitivity of chlamydia diagnostic tests means that a proportion of infected 
women have a negative test result and go untreated.  Therefore one would expect to see a rate of 
chlamydia-associated PID in “negative” women related to the proportion of women who are 
infected (false negative) and to the risk of progression to PID.   This would weaken the measured 
association between chlamydia and PID.  However during the study, the sensitivity of diagnostic 
tests has increased therefore the proportion of infected women with a negative result will have 
declined and the proportion with a positive test result will have increased.  The likely effect of this is 
an isolated decline in the rate of PID in “negative” women and an increase in the measured 
association between chlamydia and PID because women with a positive result will have been 
treated.  
However the relationship might not be quite so straightforward.  The specificity of diagnostic 
tests is reported to have remained relatively unchanged during the study period (Crotchfelt et al., 
1998, Newhall et al., 1999) so the proportion of all uninfected women who have a positive result (i.e. 
women without a risk for chlamydia-associated PID) would be constant.  However if all other factors 
remain equal (true incidence, testing patterns etc.) as the proportion of women in the “positive” 
group increases with the increase in sensitivity the contribution of false positive women to the 
“positive” category will decline.  Therefore there may be a slight increase in the observed association 
between chlamydia and PID. A caveat to this discussion is that it requires an assumption that the 
pathogenicity of a diagnosed chlamydia infection has remained constant over the time period.  If this 
is not the case, then this is a threat to the internal validity of the study and is addressed in section 
3.5.3.   
The final important source of misclassification bias in chlamydia status is that the CPL 
dataset was not a complete record of chlamydia tests performed in female residents of Manitoba 
because historically tests were processed by other laboratories.  Allocated chlamydia exposure 
status will not take into account the results of missing tests and this introduces a bias because the 
CPL disproportionately under represents chlamydia tests performed in the north of the province.  
The risks of misclassification bias for gonorrhoea status are broadly the same as those stated for 
chlamydia.   
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A major strength of this cohort is the absence of selection bias in the identification of the 
study population.  This will strengthen the accuracy of comparisons between the exposure groups. 
The cohort was generated from a high quality registry that is an almost complete record of the 
resident population of Manitoba and the inclusion criteria that we applied (date of birth and 
calendar year of residence) were independent of exposure and outcome measures.  This means that 
women in the cohort who were tested for chlamydia would have been included in the never tested 
group if they had not had a recorded chlamydia test, and vice versa.  There are unlikely to be 
differences in insurance system registration based on age, year, region of residence, or exposure and 
outcome status.  However it is important to consider the role of selection bias in the sub-cohorts 
(cohorts B and C) because the additional inclusion and exclusion criteria we applied were related to 
exposure and outcome status and therefore may affect the comparability of the exposure groups. 
 Cohort B was created from the overall cohort by excluding women who had a healthcare 
event for an adverse reproductive outcome in the five years before the cohort started when women 
were aged somewhere between 12 and 23.  Reproductive events occur after sexual debut therefore 
there is likely to be an age-related difference in the likelihood that women had an outcome before 
data collection started and were therefore not excluded from cohort B.  It is difficult to suggest what 
the impact of this would have on the results.  If some individuals have an increased susceptibility to 
PID then we may see more cases in the cohort in older women as we were not completely able to 
identify and remove all with a previous history.   
There is the greatest potential for selection bias within cohort C because it was generated by 
restricting cohort B to women who had a chlamydia test during the cohort.  The older a woman was 
in 1992, the more likely she is to have had a previous chlamydia test and the less likely she is to have 
had a chlamydia test during the study as she entered at the maximum age targeted by asymptomatic 
testing (although there are several non-age related indications for a test).  This may systematically 
bias the association between age, chlamydia exposure and PID, if there is a differential risk between 
first and recurrent chlamydia infections. In addition, cohort C is likely to be less representative of 
women from the north of the province as CPL was not a robust source of information on testing in 
this area until recently.   
The overall cohort is likely to be robust to attrition bias as loss to follow-up is unlikely to be 
related to chlamydia or reproductive outcomes.  The only potential exception to this is with ectopic 
pregnancy but this is a very rare cause of mortality (overall mortality rate in women aged 15-60 in 
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Canada between 1994 and 1998 was 55 per 1,000 (or 0.5%) (The World Bank, 2014a)).  The 
measurement of the duration of follow-up is very accurate (to the nearest day) and it is independent 
of healthcare seeking as it obtained from the population registry.  Women who present for 
chlamydia testing at a younger age will have their chlamydia status assigned sooner and therefore a 
longer duration of follow-up to accrue outcomes.  However the appropriate use of survival analysis 
techniques can remove the potential bias from differences in the duration of follow-up.  
 
3.5.3 Validity 
The internal validity of this study is dependent on whether the underlying association 
between a positive and a negative chlamydia test as recorded in the CPL dataset and a healthcare 
event for PID recorded in the Manitoba Health datasets remained constant during the study.  There 
were several important changes over the period of the cohort that may threaten the internal validity 
of this dataset.  The one that has received the most attention in the published literature is the 
change to the chlamydia diagnostic method.   
Chlamydia tests have changed from detecting the presence of viable organisms (culture) to 
antigens (DIF/EIA) to potentially miniscule quantities of genetic material (NAATs).  There are two 
possible mechanisms through which this process could affect the internal validity of the study.  
Firstly the pathogenicity of diagnosed infections may have changed and secondly the ratio of false 
positive to false negative tests may have changed (see section 3.5.2).  A positive NAAT can occur in 
the presence of genetic material rather than an organism that is able to ascend and infect the upper 
genital tract therefore the pathogenicity of diagnosed cases, on average, may have declined.  This in 
turn would reduce the association between a positive chlamydia test and PID.  In the absence of 
research addressing this question it is not possible to speculate on the size of this effect on the 
relationship between chlamydia and PID.  We plan to adjust the forthcoming analysis for year of the 
chlamydia test to partially control for the effect of changing diagnostic methods.  There is no 
evidence to suggest that strains of chlamydia differ with respect to their pathogenic potential 
(Byrne, 2010) but this is an important area of research.  A new variant of chlamydia that recently 
emerged was phenotypically identical to the original strain and genes linked to virulence were 
unchanged (Unemo and Clarke, 2011).  
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The validity of the CPL dataset, as a record of all chlamydia tests performed in Manitoba, 
increased during the study period as peripheral laboratories stopped performing chlamydia tests.  
Given the biases involved with using chlamydia test history to measure exposure, it is not possible to 
predict the direction or magnitude of this effect on the relationship between chlamydia and PID.  I 
discussed the contribution of other laboratories to missing data in the section on bias (section 3.5.2) 
but women may also have been tested in other jurisdictions (e.g. other Canadian provinces or 
overseas) whilst retaining their registration with MH (e.g. through travel).  I anticipate this will only 
have a small impact because receiving care in a different province/country is likely to be a rare event 
as healthcare is free in Manitoba.  We have attempted to reduce the impact of missing data on 
validity by removing women from the cohort at the time their coverage in the insurance plan ended, 
even if they subsequently returned to Manitoba.  We will adjust the analysis for the region of 
residence to control for the effect of location on recorded tests.  
The validity of our ICD definition for PID depends on the clinical assessment, recording of 
clinical data and the transformation of this into an ICD code.  We did not access clinical notes to 
assess the validity of the case definition.  The lack of a gold-standard diagnostic test for PID means 
that there is always some uncertainty in whether people with the diagnosis truly have the condition 
but this is unlikely to affect the internal validity of the study as there is no reason to suspect that this 
uncertainty will change over time (Morris et al., 2014).  The same can be said of the ICD-definition: 
its validity has been questioned but there is no reason to suspect that this will have changed over 
time (Bohm et al., 2010, Ratelle et al., 2003, Satterwhite et al., 2011).  We used a conservative 
approach to the ICD definition to ensure that any diagnoses from the medical claims dataset would 
also have been extracted from the hospital dataset (for example, we excluded code 616 because 
only the first sub-classification of this code met our definition of PID) but a proportion of cases of PID 
treated in the community may have been excluded.   
Studies that have only included hospital presentations for PID have been open to the 
criticism that the decline in the rate of PID with time was due to under ascertainment of cases seen 
in the community (Bender et al., 2011, Owusu-Edusei et al., 2010, Rekart et al., 2013, Scholes et al., 
2012).  We have been able to include PID diagnoses from community and hospital settings to ensure 
that we have a consistent high ascertainment of all cases in the province independent of healthcare 
policy or clinical severity.  This will strengthen the internal validity compared to studies limited to 
hospital presentations.  We did not have access to information about the clinical severity of a PID 
diagnosis but this would be interesting to explore.  
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Antibiotic prescribing practices have changed over time and if the different therapies had a 
different success rate for clearing chlamydia infection then this may affect the internal validity of the 
study, as the rate of progression of treated infections may have changed.  Finally, in an attempt to 
improve the internal validity of the cohort we have used consistent definitions of chlamydia, PID and 
covariates, generated using contemporaneous coding systems and obtained data from sources that 
are likely to have been consistent in the methods used to code and store the data.  The notable 
exception to this is the change from ICD-9 to ICD-10 coding in the MH Hospitals Separations 
Abstracts dataset in 2004.  Although it is likely that MH went to lengths to ensure consistency across 
this coding change and we developed our ICD definitions using references that had used ICD-9, ICD-
10 or both and mapped the codes from the two systems onto each other (Appendix 10)49.  
External validity or generalisability is a measure of how applicable the results of a study are 
to other settings.  It is not possible to appropriately assess generalisability without knowledge of the 
target population but I will highlight the specific issues with this cohort that should be considered 
during this assessment.  Firstly, the overall cohort is representative of women covered by the MH 
insurance scheme but this does not include a small sub-set of women: women in the military or 
Royal Canadian Mounted Police and the first three months of residence for women who moved to 
Manitoba.  Inclusion in one of these groups is unlikely to be associated with chlamydia exposure 
status.  We assume that the remainder of the resident population will be registered with the 
insurance scheme as free healthcare is a significant incentive.  Cohort B and C have a reduced 
generalisability because they are not representative of the population.   
The final consideration is whether our study is applicable to women from other birth 
cohorts.  Birth cohort effects arise because the population under study all experience certain 
external events at the same time and age (Reither et al., 2009).  This is separate from the effect of 
age (which measures physiological changes over time) that can be controlled for in multivariable 
analysis.  Secular, or period, effects e.g. chlamydia screening guidelines, testing practices and STI 
prevalence are likely to be generally comparable to other developed settings with chlamydia control 
interventions and can be adjusted for by including calendar time in the survival analysis.   
                                                          
49
Although there are examples of codes with a lack of consistency, for example ICD-10 does not uniquely specify 
gonococcal cervicitis (unlike ICD-9).  A54.0 is defined as “Gonococcal infection of lower genitourinary tract without 
periurethral or accessory gland abscess” and can include cervicitis; cystitis; urethritis; vulvovaginitis.  
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3.5.4 Confounding and covariates 
I conducted a literature review, summarised in chapter 1, to identify potential factors that 
would confound the relationship between chlamydia infection and adverse reproductive outcomes.  
We have permission to include data about the following potential confounders in the cohort: age; 
year of chlamydia test; gonorrhoea infection; use of hormonal contraceptives.  However we will not 
be able to adjust for the effect of unmeasured confounders including sexual behaviour; healthcare 
seeking behaviour; non-chlamydia and non-gonorrhoea sexually transmitted causes of PID; access to 
healthcare.  This is a major reason why this study will not be able to demonstrate a causal 
relationship between outcome and exposure (assuming one is present).  Other factors which may 
modify the association between chlamydia and PID, but are not confounders, include region of 
residence and antibiotic prescriptions (including compliance with treatment).   
Gonorrhoea exposure status will be classified using test history in the CPL dataset and the 
limitations are broadly the same as those outlined for chlamydia, with the notable difference that 
the CPL did not become a robust source of gonorrhoea tests until 2007.  One of the assumptions 
that will be used in the subsequent analysis is that any cases of PID in chlamydia (or gonorrhoea) 
exposed women that are in excess of those seen in unexposed women were due to their exposure.  
This is unlikely to be true, but it is not possible to quantify the magnitude of this over-estimation 
without data on the incidence of other STIs and their risk of progression to PID.   
Data on dispensed prescriptions of hormonal contraceptives and antibiotics with therapeutic 
efficacy against chlamydia or PID is available from 1995 onwards.  The main limitation of these data 
are that a dispensed prescription is not equivalent to compliance with treatment.  In addition, these 
types of medicines are more likely to go unreported than average because they can be dispensed 
directly to patients because of their immediate health benefits (e.g. at nursing stations).  It is 
possible that undiagnosed infections could be inadvertently treated, but this is unlikely to change 
the measured association between chlamydia and PID because it is likely to occur evenly in both 
exposure groups.      
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3.5.5 Further research 
There are several areas of research that are needed to improve the internal validity of this 
cohort:  
 Research into the pathogenicity of chlamydia detected via NAAT compared to via non-NAAT 
techniques; 
 Measurement of the validity or positive predictive value of ICD codes for cases of adverse 
reproductive outcomes in the medical notes within Manitoba as these data are likely to be 
setting specific due to practices with clinical coding; 
 Exploration of the aetiology of cases of PID diagnosed and treated in Manitoba, specifically 
what proportion of cases are caused by chlamydia.  
 
 
3.6 Conclusion  
We have demonstrated that it was feasible to create a large population-based cohort of 
women using administrative healthcare data from Manitoba that can be used to explore the 
association between chlamydia and PID.  The following chapter will describe the use of this dataset 
to explore the association between chlamydia and PID in women who were tested for chlamydia.  
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Analysis of the Manitoba Women’s 
Reproductive and Sexual Health cohort: the risk 
of pelvic inflammatory disease in women tested 
for chlamydia 
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4.1 Overview 
In chapter 3 I described the rationale, design and development of the Manitoba Women’s 
Reproductive and Sexual Health cohort.  In this chapter I describe how we have used this cohort to 
measure the risk of PID following chlamydia infection in women in Manitoba, including an 
exploration of the association between PID and previous (or repeat) infection that was identified in 
chapter 2.  I outline the rationale for performing the analysis in women who participated with the 
province’s chlamydia control programme and report the findings. 
This chapter is the result of a collaboration between Imperial College London and the 
University of Manitoba.  I designed the statistical analysis presented here with input from Dr Nancy 
Yu, Professor Helen Ward, Dr James Blanchard, Dr Katy Turner and Professor Geoffrey Garnett.  
Stella Leung performed the statistical analysis using an analysis plan I drafted and provided the 
original figures that are included in the chapter.  I was responsible for interpreting the results with 
input from Helen Ward, James Blanchard, Katy Turner and Nancy Yu.  The work has been presented 
at a closed meeting, the Wellcome Trust Theoretical Frameworks for STI Epidemiology Workshop in 
January 2014 in Paddington, London and accepted for publication in the Journal of Infectious 
Diseases supplement accompanying the meeting.  The analysis, interpretation and conclusions 
presented in this thesis are mine and those of the acknowledged collaborators.  These views do not 
necessarily represent those of the Manitoba Centre for Health Policy, Manitoba Health, or other 
data providers and no official endorsement should be inferred.    
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4.2 Introduction  
In chapter 3 I described how we designed and constructed a large retrospective population-
based cohort of women of reproductive age in Manitoba, Canada.  The design of this cohort is very 
similar to those of Low et al., Bakken et al. and Andersen et al. (Andersen et al., 2005, Bakken and 
Ghaderi, 2009, Bakken et al., 2007, Low et al., 2006).  The novel feature of our cohort is that the data 
routinely collected in Manitoba made it possible for us to include episodes of PID diagnosed in the 
community and therefore address a limitation of the published analyses (Bakken and Ghaderi, 2009, 
Low et al., 2006).  Our research question and approach to the analysis presented in this chapter has 
been informed by the work undertaken during chapter 2.  In chapter 2 we demonstrated 
heterogeneity in the risk of PID following a chlamydia infection.  Specifically, we found that age was 
protective for PID (AHR 0.94 (95% CI 0.88-1.00)) and a past history of gonorrhoea was a risk factor 
(AHR 2.28 (95% CI 1.14-4.56)).  We also identified a non-significantly higher risk of PID in women 
with a chlamydia infection in the previous 6 months (AHR 2.03 (95% CI 0.75-5.49)) or a chlamydia 
infection more than six months ago or before the cohort (AHR 1.84 (95% CI 0.96-3.54)).  However 
there were too few cases of chlamydia to explore the risk following a first infection compared to a 
second infection.   
 
4.2.1 Repeat infection  
In chapter 1 I highlighted the importance of designing chlamydia control interventions using 
knowledge of the natural history of infection to ensure that they have the highest possible impact on 
health (Gottlieb et al., 2010a).  One of the key issues I explored was uncertainty about how to 
prioritise chlamydia testing because it is not known whether there is a difference in the risk of PID 
following a first or repeat chlamydia infection.  In chapter 2 we observed an increased risk of PID in 
women with recent and previous chlamydia infection, but the small sample size meant that we could 
not assess the direct risk following repeat infection.  The representative cohorts by Low et al. and 
Bakken and Ghaderi did not present estimates of the risk of PID following repeat infection (Bakken 
and Ghaderi, 2009, Low et al., 2006).  Low et al. explained that rate of repeat infection in their 
cohort was low, this was likely to be a consequence of the contemporary (1985-1995) chlamydia 
tests that required a sample obtained from the cervix, rather than non-invasive urine specimens.  
The Manitoba cohort provides the first opportunity to explore in detail whether there is a 
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differential risk following repeat infection because it is a large contemporary dataset with high 
ascertainment of PID cases from a population with high participation with chlamydia testing.    
 
4.2.2 Chlamydia exposure  
Low et al. compared the association between chlamydia and PID across three exposure 
groups that collectively contained the entire cohort: chlamydia positive, chlamydia negative and 
never tested women.  Women were assigned to these exposure groups using chlamydia test 
participation data that started on the date they entered the cohort (defined using age criteria).  
Therefore virtually all women would have been “never tested” on their date of entry.  Exposure 
status then changed to negative or positive on the date of their first chlamydia test, depending on 
the result, and from negative to positive on the date of their first positive test.  Exposure status 
could not return from positive to negative.  It’s important to stress that as the time axis for the 
analysis was age it was not possible for women to appear in more than one exposure group at any 
one time.   
The strength of this approach is that the study cohort is representative of the population 
from which it was drawn and the rate of PID in the overall population can be determined.  However 
the external validity is compromised because the “never tested” group is likely to be composed of 
sub-groups of women with different risk profiles: women in the interval before their first test and 
women who do not have a test during the cohort.  Furthermore, the never tested group is unlikely to 
be representative of the contemporary never tested population because the study was conducted at 
a time when endocervical swabs were used and widespread testing had not yet become the norm.   
Bakken and Ghaderi chose to exclude the never tested group and look at women from the 
date of their first chlamydia test and allow movement from the negative to positive group at the 
time of a positive test.  This approach could potentially make the exposure groups more comparable 
by standardising the risk of misclassification bias and reducing the difference in the distribution of 
unmeasured confounders (as all women met the criteria for testing, were offered and accepted a 
test) and improve external validity as the eligibility criteria for each group are clear.  However by 
limiting the cohort to tested women it is not possible to make statements about risk in the overall 
population.    
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4.2.3 Population, baseline and cohort attributable fraction 
Policy makers are keen to know the proportion of cases of PID in their population that are 
caused by chlamydia (the PAF), so that they may appropriately target resources based on need.  
However it is very difficult to get an accurate estimate of this statistic: 
𝑃𝐴𝐹 =
𝑝𝑒(𝑅𝑅−1)
1+𝑝𝑒(𝑅𝑅−1)
 
A systematic review has identified very few unbiased estimates of the population prevalence 
(pe) of chlamydia (European Centre for Disease Control and Prevention, 2014).  They included two 
studies that were performed in Canada but neither can be considered generalisable to the 
population of a province as they were both conducted in remote Northern communities (Steenbeek 
et al., 2009, Hodgins et al., 2002).  
Authors have questioned whether the relative risk (RR) can be appropriately estimated using 
a Cox model because as time progresses the closed cohort will diverge from the underlying 
population (Sjolander, 2014) and complex statistical techniques have been proposed to convert the 
time-varying risk obtained from survival techniques into an attributable risk function (Chen et al., 
2006).  Authors suggest that estimates obtained from a cohort should be called a “cohort 
attributable fraction” or that a more appropriate approximation of the PAF could be obtained from 
using data from the baseline in the cohort, a “baseline attributable fraction” (Sjolander, 2014).   
We propose to use data from the first year of our cohort to determine a cohort attributable 
fraction (CAF) of chlamydia on PID.  We will use the proportion of women who test positive at their 
first test episode as a proxy for the prevalence of chlamydia and estimate the RR from the 
cumulative incidence of PID at one year.  This cohort attributable fraction estimate would not be 
generalisable to the population of Manitoba, but it should theoretically, describe the association 
seen within the study population.  A Manitoba-wide PAF is not likely to be transferrable to other 
settings because PID has multiple aetiologies and diagnostic challenges that may differ between 
settings.   
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4.2.4 Research questions  
What is the association between chlamydia and PID in women in Manitoba who participated 
with a well-established chlamydia control programme?  Is there evidence to suggest that this 
association differs following repeat positive tests?  What is the population attributable fraction of 
chlamydia on PID at 12 months in this cohort?  
 
4.2.5 Aims and objectives 
The aims of this chapter are to:  
 
 describe the study cohort; 
 determine the cohort attributable fraction of chlamydia on PID at 12 months; 
 measure the rate of PID following a chlamydia test by test result; 
 construct Kaplan-Meier plots of time to PID following a chlamydia test by test result; 
 use Cox proportional hazards regression to measure the association between a positive 
chlamydia test and PID over the reproductive lifetime; 
 repeat 3-5 for cohorts that start on the date of the second and third chlamydia test 
respectively. 
 
4.3 Methods 
We used a sub-group of women who participated with chlamydia testing from the Manitoba 
Women’s Reproductive and Sexual Health Cohort for this analysis: cohort C.  We were only able to 
allocate women to a single exposure category for the duration of follow-up as we did not have the 
necessary resource to classify chlamydia as a time-varying covariate with the level of detail achieved 
in chapter 250.  Therefore we chose to follow the method of Bakken and Ghaderi and limit the cohort 
                                                          
50
 The data manipulation and analysis of the Manitoba Women’s Reproductive and Sexual Health cohort was performed on 
a single computer terminal at the University of Manitoba, Winnipeg, Canada by a member of the research team based at 
this Centre.   
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to women with a chlamydia test (Bakken and Ghaderi, 2009).  The rationale for the overall cohort 
and the definitions used for the population, exposure, outcome and covariates are explained in 
detail in chapter 3.  Briefly, the cohort was generated from multiple administrative healthcare 
datasets51 maintained by Manitoba Health and provided by the Manitoba Centre for Health Policy, 
University of Manitoba.   Data linkage was performed using a scrambled version of the unique 9-digit 
PHIN.  Cohort C is defined as women resident in Manitoba and aged 12-24 between 1992 and 1996 
and followed-up to their 41st birthday; leaving Manitoba (death/emigration) or the end of the study 
(31/12/2008) who had at least one chlamydia test during their membership in the cohort and were 
not diagnosed with an adverse reproductive event (PID, pregnancy, infertility) before their first 
recorded chlamydia test.   
Women entered cohort C on the date of their first chlamydia test (the “baseline test”) 
recorded in the CPL dataset (after they met the eligibility criteria for the cohort) and they were 
assigned a chlamydia exposure status (positive or negative) based on the result of this test (Table 
4.1).  This exposure status did not vary during follow-up.  PID was defined as a healthcare 
presentation with an ICD code for PID in either a community or hospital setting (excluding urgent or 
emergency care departments).  The date of the first chlamydia test was moved backwards by one 
day if women were diagnosed with PID on the date they entered the cohort (this was to ensure that 
women were retained in the survival analysis).   
We describe the baseline characteristics of cohort C: the number of women, age, region of 
residence and year of entry.  We then describe the number of chlamydia tests and number of 
positive tests per woman during the cohort.  For the first chlamydia test (the test that marks entry to 
the cohort) we calculated the proportion of women who were diagnosed with chlamydia and the 
number of women who had a PID diagnosis on the same date.  We then determined the cumulative 
incidence52 of PID at 1 year.  The cohort attributable fraction of chlamydia on PID at 1 year was 
estimated from the cumulative incidence of PID at 12 months and the proportion of women who 
had a positive first test.  This required the assumption that follow-up was complete and women only 
left the cohort within 12 months because of PID (i.e. no death, emigration or aging out of cohort and 
                                                          
51
 Manitoba Health Insurance Registry; Manitoba Health Medical Claims (Physician Billings) dataset; Manitoba Health 
Hospital Separations Abstracts dataset; Cadham Provincial Laboratory dataset.  
52
 Cumulative incidence is synonymous with risk.  It is the probability that an event will occur within a given time period 
and is equal to [the number of new cases in time period]/[number of people disease free at start of time period]. 
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no entry within 12 months of the end of the study) and that the incidence of chlamydia at the first 
test was an appropriate approximation of prevalence.  
The dataset was then converted to survival analysis format with follow-up was censored at 
the first episode of PID.  Women were divided into categories based on their baseline test result, 
age, year and region of residence.  The rate of PID in each sub-group was calculated and Kaplan-
Meier plots were created to illustrate the time to PID by the chlamydia test result.  Cox proportional 
hazards regression53 was used to estimate the association between a positive chlamydia test and PID 
adjusted for result of age, year and region of residence with time axis as time since the first test.  
Women who had a second chlamydia test before censoring or the end of follow-up were 
identified and extracted into a second dataset.  They entered this cohort on the date of their second 
test and their chlamydia exposure status was defined as the result of this test and their previous 
chlamydia exposure status was defined as the result of their first test.  Their rate of PID was 
calculated and Cox proportional hazards regression was performed with women divided into 
categories based on their second test result, first test result (as a proxy for recurrent infection 
status), age at second test, year of second test and region of residence at first test.  The same 
procedure was followed for women with a third test during the cohort.   
This study received ethical approval from the Health Research Ethics Board at the University 
of Manitoba and institutional approval from the Manitoba Centre for Health Policy (Chapter 3 
Section3.3.3).  The statistical analysis presented here was performed by Stella Leung on a secure 
terminal at the University of Manitoba, Winnipeg, Canada using SAS 9.2 (SAS Institute Inc, Cary, NC). 
  
                                                          
53
 A discussion of the rationale for using cox proportional hazards regression rather than poisons regression is outlined in 
chapter 1. 
  Chapter 4 
137 
 
Table 4.1:  Definition of exposure, outcome and covariates 
 
Variable Definition  Categories/coding 
Chlamydia test 
(baseline) 
A non-serological test for chlamydia 
recorded in the CPL dataset and 
performed ≥60 days after a previous test 
 
Positive or negative 
PID An episode of healthcare with an ICD 
code for PID in either the MH Medical 
claims (Physicians billings) dataset or the 
MH Hospital Separations abstracts 
dataset 
 
Medical claims: ICD-9 614; 615 
Hospital Separations Abstracts 
ICD-9: 614-616.0; 016.6; 098.10; 
098.15; 098.16; 098.17; 098.30; 
098.35-7; 099.56; 098.86 
ICD-10: N70-74.8; A56.1; A18.1; 
A51.4; A54.2; A52.7 
 
Age  Age at time of baseline test  12-15; 16-19; 20-24; 25-29; 30-40 
 
Region  Location of residence at entry to cohort54 
 
Rural North; Rural Mid; Rural South; 
Urban Core; Urban Non-core 
 
Year  Calendar year of baseline test 1992-1996; 1997-2000; 2001-2004; 
2005-2008 
 
 
  
                                                          
54
 If information was not available on the date of entry, information from within 5 years of this date was used. 
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4.4 Results 
There were 72,883 women in cohort C (Figure 3.3).  The age at cohort entry (which is 
equivalent to the age at first chlamydia test) ranged from 12 to 40 years with a mean of 20.47 years 
(sd 4.05) (Figure 4.1).  The most common age at first test was 18 years (11.46%) and over half of the 
cohort had been tested by age 20 (56.59%).  When we considered all chlamydia tests performed 
during women’s membership in cohort C, the median number of tests per woman was 4 (mean 4.74) 
(Figure 4.2) and 14.93% (n=10,880) had at least one positive chlamydia test at some point during 
follow-up (Figure 4.3).  Almost a third of these women went on to have at least one repeat positive 
test (n= 3,310, 30.42%) and 240 women (0.33%) had five or more positive tests.   
Women entered cohort C on the date of their first chlamydia test and 5.48% (n=3,991) had a 
positive result at their first test.  PID was diagnosed on the same date55 as the first test in 0.62% 
(n=448) of women.  The cumulative incidence of PID56 after one year was 2.09% (95% CI 1.98-2.19) 
overall; 1.90% (95% CI 1.80-2.00) in negative women and 5.27% (95% CI 4.57-5.95) in positive 
women. Therefore the relative risk of PID at one year in women with a positive chlamydia test 
compared to women with a negative test at baseline was 2.77 (95% CI 2.41-3.20) and the 
attributable risk percentage of chlamydia on PID was 63.95% (Table 4.2).  If the underlying 
prevalence of chlamydia is assumed to equal the proportion of women who had a positive result at 
their first test, then the cohort attributable fraction of chlamydia on PID at one year was 8.86%.  If 
we use the proportion of women who were diagnosed with PID by the end of follow-up rather than 
12 months (14.81% (95% CI 13.71-15.91) in positive women and 7.87% (95% CI 7.67-8.07) in 
negative women) with the same prevalence of 5.48%, the cohort attributable fraction of chlamydia 
on PID is 4.61%.  
 
 
  
                                                          
55
 These events were retained in the analysis as the date of chlamydia infection was backdated by one day.  
56
 This figure includes the cases diagnosed on the date of the baseline test.  
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Figure 4.1:  Age at first chlamydia test in cohort C by number of women and cumulative proportion 
            
Figure 4.2: Number of chlamydia tests by number of women and cumulative proportion  
 
Figure 4.3: Number of positive tests by number of women and cumulative proportion 
  
Number of women  
Cumulative proportion  
Number of women  
Cumulative proportion  
Number of women  
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Table 4.2: Summary of risk estimates 
 
Parameter Estimate 
12 months  
Estimate  
End of follow up* 
Incidence in chlamydia positive (Ie) 5.27% 14.81% 
Incidence in chlamydia negative (Iu) 1.90% 7.87% 
Relative risk  (RR = Ie/Iu)   2.77 (95% CI 2.41-3.20) 1.88 (95%CI 1.74-2.04) 
Attributable risk per 100 women 
(AR = Ie - Iu ) 
3.37 6.94 
Attributable risk percentage   
(AR% = [(Ie - Iu)/ Ie ) ]*100 
63.95% 46.85% 
Cohort attributable fraction (CAF = 
pe (RR-1) / [1 + pe (RR-1)] ) 
8.86% 4.61% 
*Total person years of follow-up in cohort = 625,621; Mean follow-up time per woman = 8.58 years 
 
 
The 72,338 women in cohort C contributed 625,621 person years (py) of follow-up and the 
overall rate of PID was 0.96 per 100 py (95% CI 0.77-1.15) (Appendix 12).  The rate of PID was 
significantly higher in women with a positive test at entry to the cohort compared to women with a 
negative test (1.68 per 100 py (95% CI 1.43-1.94) and 0.92 per 100 py (95% CI 0.73-1.11).  The rate of 
PID was also significantly higher in women in the rural north compared to women in the urban non-
core; women under 16 compared to all other age groups and women tested pre-1997 compared to 
women tested post-2001.  Kaplan-Meier survival plots of time to PID by chlamydia test result on 
entry to the cohort are shown in Figure 4.4 illustrates the risk of PID following the first test and 
shows an immediate divergence in risk between women who test positive and those who test 
negative followed by a less marked, but nevertheless continuous divergence of the curves until the 
end of follow-up.   
The final Cox model was adjusted for baseline chlamydia test result, age at test, year of test 
and region of residence (summary presented in Table 4.3 and full results presented in Appendix 12).  
We found that the adjusted hazard of PID at any point during follow-up was significantly higher in   
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Figure 4.4: Kaplan-Meier survival curves of time to PID following a chlamydia test by test result.  
(a) following the first chlamydia test; (b) following the second chlamydia test;  (c) following the 
third chlamydia test.               Negative women;                Positive women.   
Reproduced from Davies et al. (2014). Heterogeneity in risk of pelvic inflammatory diseases after 
Chlamydia infection: a population-based study in Manitoba, Canada. J Infect Dis, 210 Suppl 2, 
S549-55. With permission. 
(a) First test 
 
 
 
 
 
 
 
 
(b) Second test 
 
 
 
 
 
 
 
 
(c)  Third test 
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women who had a positive chlamydia test at entry to cohort C compared to women who had a 
negative test (AHR 1.55 (95% CI 1.43-1.70)).  The risk of PID was also significantly higher in women 
under the age of 15 compared to women aged over 30 (AHR 1.55 (95% CI 1.22-1.98)) and higher in 
women living in all regions compared to the urban non-core.  The risk of PID was significantly lower 
in women 20-29 years compared to women over 30 years (AHR 0.72 (95% CI 0.57-0.91) in 20-24 year 
olds and AHR 0.74 (95% CI 0.58-0.95) in 25-29 year olds) and lower if the first test was performed 
post-1997 compared to pre-1997.     
The cohorts that started on the date of the second and third chlamydia test respectively 
were designed to explore the relationship between previous positive chlamydia tests and PID.  There 
were 58,473 (80.23% of cohort C) women in the cohort that started at the date of the second test, 
4.60% were diagnosed with chlamydia at this test and 6.05% (n=3,535) had a previous positive test 
(their first test in cohort C) (Appendix 13).  The cohort that started on the date of the third test 
contained 45,924 (63.01% of cohort C) women of whom 4.33% were diagnosed with chlamydia at 
this test, 10.37% were positive for chlamydia at one of their first two tests and 0.91% were positive 
for chlamydia at both of their first two tests (Appendix 14).  In the second and third test cohorts the 
rate of PID was significantly higher in women who had a positive chlamydia test compared to 
women with a negative test (2nd test: 1.59 per 100 py (95% CI 1.34-1.83) in positive women and 
0.77 per 100 py in negative women (95% CI 0.59-0.94); 3rd test: 1.28 per 100 py (95% CI 1.06-1.50) 
and 0.68 per 100 py (95% CI 0.52-0.84) respectively).  The rate of PID was also significantly higher in 
women who had one or more previous positive test results compared to women who were negative 
at their first and/or second tests (Appendices 13 and 14).   
In the final adjusted Cox models (adjusted for age at test; year of test; region of residence; 
previous test result(s)), women who had a previous positive test had an increased hazard of PID 
regardless of the result of their baseline test result.  Women with a positive first test had a 17% 
increased risk of PID following their second test (AHR 1.17 (95% CI 1.06-1.30)) (Table 4.3) and 
women who has a positive first and second test had a 35% increased risk of PID following their third 
test (AHR 1.35 (95% CI 1.04-1.75)).  The women with the highest risk of PID following any of the first 
three chlamydia tests in cohort C were those aged under 16 at the time of their third chlamydia test 
(AHR 4.55 (95%CI 3.59-5.78)).    
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Table 4.3: Summary of crude and adjusted hazard ratio of PID after the first, second and third chlamydia test. Adapted from Davies et al. (2014). 
Heterogeneity in risk of pelvic inflammatory diseases after Chlamydia infection: a population-based study in Manitoba, Canada. J Infect Dis, 210 Suppl 2, 
S549-55. With permission. 
   
  
1st test 2nd test 3rd test 
  
Crude HR Adjusted HR* Crude HR Adjusted HR* Crude HR Adjusted HR* 
Current test  i                                                + 1.85 (1.70-2.01) 1.55 (1.43-1.70) 2.07 (1.86-2.29) 1.55 (1.39-1.72) 1.89 (1.66-2.14) 1.29 (1.13-1.47) 
One previous test ii                                + - - 1.68 (1.52-1.86) 1.17 (1.06-1.30) - - 
Two previous tests ii             - / + - - - - 1.81 (1.58-2.07) 1.23 (1.08-1.42) 
 + / - - - - - 1.66 (1.47-1.87) 1.13 (1.00-1.28) 
 + / + - - - - 2.19 (1.70-2.85) 1.35 (1.04-1.75) 
Age at test iii  25-29 0.96 (0.76-1.23) 0.74 (0.58-0.95) 1.45 (1.19-1.77) 1.04 (0.85-1.27) 1.69 (1.40-2.05) 1.19 (0.98-1.45) 
 
20-24 1.07 (0.85-1.35) 0.72 (0.57-0.91) 2.02 (1.68-2.42) 1.22 (1.01-1.48) 2.57 (2.15-3.08) 1.52 (1.26-1.83) 
 
16-19 1.48 (1.18-1.86) 0.96 (0.76-1.22) 3.61 (3.01-4.32) 1.95 (1.60-2.36) 5.31 (4.44-6.34) 2.65 (2.18-3.21) 
 
12-15 2.63 (2.08-3.32) 1.55 (1.22-1.98) 7.06 (5.78-8.63) 3.25 (2.62-4.03) 10.79 (8.66-13.43) 4.55 (3.59-5.78) 
i Baseline is risk following a negative test; ii Baseline risk is only previous negative test(s); iii Baseline risk is aged 30-40 
“+”= positive; “-” = negative  
*Adjusted for age at test; year of test; region of residence; previous test result(s) 
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4.5 Discussion  
4.5.1 Main findings 
In women who were tested for chlamydia, a single positive test increased their risk of PID by 
50% (AHR 1.55 (95% CI 1.43-1.70)) across their reproductive lifetime.  Regardless of the result of the 
current test, each previous positive test increased the risk of PID by around 20% (AHRs 1.17 (95% CI 
1.06-1.30), 1.23 (95% CI 1.08-1.42) and 1.13 (95% CI 1.00-1.28)) and young women had the highest 
risk of PID (AHR 4.55 (95% CI 3.59-5.78) compared to women over 30 years at the time of the third 
test).  This heterogeneity in risk could be used to inform the design of chlamydia control 
interventions. 
In addition, women with a positive test at baseline were three times more likely to develop 
PID by one year (RR 2.77 (95% CI 2.41-3.20)).  Only two-thirds (63.95%) of these episodes of PID 
could be attributed to the positive chlamydia test and in the cohort as a whole, less than 10% 
(8.86%) of cases of PID that developed within the first year could be attributed to a positive result at 
baseline.  
 The strengths and limitations of the Manitoba Women’s Reproductive and Sexual Health 
cohort design are considered in detail in the discussion section of chapter 3.  This discussion will 
focus on the additional factors that are pertinent to the analysis presented in this chapter and a 
discussion of the meanings of our findings is the subject of chapter 6.   
 
4.5.2 Strengths and limitations 
The major strength of this study is that we were able to explore the impact of repeat 
positive tests on the risk of PID because of the high level of repeat testing that was achieved through 
Manitoba’s well-established chlamydia control programme.  This is also the first time that the overall 
burden of PID in the studied population (diagnosed in a community or hospital setting) has been 
represented in the hazard of PID following a positive chlamydia test in a population-based sample  
(Bakken and Ghaderi, 2009, Low et al., 2006).  We limited the analysis to women who were tested 
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for chlamydia in an attempt to reduce differences in the distribution of unmeasured confounders 
between the two exposure groups and to reduce bias in the duration of follow-up.  We suggest that 
women who have been offered, and accept, a chlamydia test may be more similar to each other in 
terms of healthcare usage and perhaps sexual health risk, than women who are not offered or 
decline chlamydia testing.  Exclusion of the never tested group will allow robust conclusions to be 
draw about the effect of the chlamydia test result that are not complicated by unknown differences 
between the women who participated with testing compared to those that did not.  However we are 
not able to generalise our findings to the entire population and there are likely to be unmeasured 
confounders that differ in their distribution between women who test positive and those who test 
negative for chlamydia.  This exposure definition also provided an unbiased time point for entry to 
the cohort: the date of the first chlamydia test and we assume that women are at risk of chlamydia 
and therefore PID from the start of follow-up.  
To our knowledge, this is the first time that a cohort attributable fraction of chlamydia on 
PID has been estimated.  The major limitation to our calculation is that we have used the proportion 
of women diagnosed with chlamydia at their first test as a proxy for cohort prevalence.  As women 
were able to enter the cohort at any point between 1992 and 2008 this prevalence estimate is likely 
to be influenced by the distribution of risk factors across age groups and time.  We do not suggest 
that this estimate may apply to the overall population of women in Manitoba.  
The most important limitation to the analysis is that chlamydia exposure status was only 
measured once at the start of each cohort and kept constant throughout follow-up.  Fifteen percent 
of cohort C had at least one positive chlamydia test during the cohort, but only 5% of women were 
classified as positive in our cohort using the result of their first test and we were not able to move 
women from the negative to the positive group on the date of their first positive test as described by 
Low et al. and Bakken and Ghaderi (Bakken and Ghaderi, 2009, Low et al., 2006).  Neither could we 
achieve the ideal situation with a constantly varying description of chlamydia exposure based on 
number of tests and number of previous infections at each instant in the cohort.  This was due to 
resource limitations but this is a potential source of misclassification bias in chlamydia exposure 
status (further to those considered in the discussion of chapter 3).  We are not able to comment on 
the magnitude of the effect of this bias because it is likely to act in both directions: positive women 
go on to have negative tests and negative women go on to have positive tests.   
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Due to this limitation with classifying exposure as time-varying we used a static approach to 
explore the association of repeat positive tests on PID and generated three separate study cohorts 
that allowed us to measure the risk of PID following the first, second and third test taking into 
account the results of any earlier tests.  This meant that we lost the ability to explore the effect of 
time since the previous exposure on future risk of PID.  At the time this study was conducted we 
were not able to include information about all of the measured confounders that we had data on, 
specifically gonorrhoea infection and antibiotic use were omitted.  This will have limited the 
accuracy and external validity of the associations that we have presented. 
 
4.5.3 Comparison with other studies  
The adjusted hazard of PID following a positive chlamydia test was similar in our cohort to 
the comparable cohorts by Low et al. and Bakken and Ghaderi  (Manitoba, AHR 1.55 (95% CI 1.43-
1.70); Sør-Trøndelag, AHR 1.69 (95% CI 1.21-2.37); Uppsala, AHR 1.27 (95% CI 1.04-1.55)) (Bakken 
and Ghaderi, 2009, Low et al., 2006).  All three studies found that a single positive chlamydia test 
increased the risk of PID across the reproductive lifetime.  It is difficult to comment on this similarity 
in the magnitude of the AHR because there were important differences in the study designs 
(including chlamydia diagnostic test and PID ascertainment) and in the factors that were adjusted for 
in the analyses.  However the cumulative incidence of PID by the end of follow-up was much higher 
in our cohort than Uppsala or Sør-Trøndelag (Manitoba, 14.81% (95% CI 13.71-15.91) positive 
women and 7.87% (95% CI 7.67-8.07) negative women; Sør-Trøndelag, 1.09% (95% CI 0.82-1.14) 
positive and 0.70% (95% CI 0.59-0.82) negative; Uppsala, 5.6% (95% CI 4.7-6.7) positive and 4.0% 
(95%CI 3.7-4.4) negative).  This is likely to reflect the increased case ascertainment in our cohort: we 
were able to include episodes of PID from a community setting, we used a broader definition of PID 
and there are no private hospitals in Manitoba.  Other factors that may also have contributed to this 
observed difference include variations in the rates of other STIs leading to PID or variations in the 
clinical definitions used for PID.   
We demonstrated an increased risk of PID in women with more than one positive chlamydia 
test that was similar in magnitude to the risk following a repeat infection demonstrated by Hillis et 
al. in a large cohort from Wisconsin (risk in women with two previous infections: Manitoba,  
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unadjusted HR 2.20 (95% CI 1.70-2.85) and Wisconsin, OR 4.0 (95% CI 1.6-9.9) (Hillis et al., 1997).  
Although there were underlying differences between the studies, for example we used consecutive 
positive tests while the Wisconsin study used cumulative positive tests, it is interesting that the 
findings are similar.   
4.6 Conclusions 
For the women in this cohort, a single positive chlamydia test increased their lifetime risk of 
PID.  However the low cohort attributable fraction of chlamydia on PID at one year suggests that the 
baseline chlamydia test is not the only explanation for the increased risk.  We have demonstrated 
heterogeneity in the risk of PID in women in Manitoba with young women and those with previous 
positive tests most at risk.  Further research is needed to determine the factors that are contributing 
to the observed increases in risk, but in the short term chlamydia control interventions should be 
aimed at young women and those with a previous infection to reduce health inequalities.  Finally, 
our findings suggest that an event around 1997 led to a decline in the risk of PID and it is important 
to identify the cause of this so that the results of historic studies can be appropriately interpreted in 
a modern context.    
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5  
Chapter 5 
Danish Chlamydia Study: the risk of pelvic 
inflammatory disease following chlamydia in 
Denmark 
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5.1 Overview 
The analysis presented in chapter 4 provided additional evidence that a single positive 
chlamydia test is associated with an increase in the lifetime risk of PID and it demonstrated 
heterogeneity in this risk by age and repeat infection status.  The magnitude of the increased risk in 
Manitoba was similar to those reported from Norway and Sweden despite underlying differences in 
the study designs and populations (Bakken and Ghaderi, 2009, Low et al., 2006).  These findings have 
raised interesting questions about the generalisability of estimates of the association between 
chlamydia and PID across different settings.  This chapter describes a similar exploration of the 
association between chlamydia, repeat infection and PID in a national retrospective population-
based study from Denmark.  I describe and compare the risk in women who participated with 
chlamydia testing and the risk in the overall population, including never tested women.   
The data used in this chapter is from a wider programme of research, the “Epidemiology of 
chlamydia and its complications in Denmark: a national study” established by Professor Henrik 
Westh, Hvidovre Hospital, Hvidovre, Denmark.  The study is overseen by a steering group whose 
members are Professor Henrik Westh, Dr Steen Rasmussen, Dr Thomas Benfield, Dr Maria Frølund 
and Dr Katy Turner.  The steering group was responsible for the institutional approvals, design and 
construction of the Denmark Chlamydia study.  I was responsible for planning and performing the 
analysis of the association between chlamydia and PID in women, in collaboration with the steering 
group.  I was provided with a sub-set of the Denmark Chlamydia study that I used to generate a 
study dataset.  I performed the statistical analysis of this dataset.   Additional advice on the 
statistical analysis was received from Dr Margaret May, University of Bristol.  Dr Katy Turner, 
Professor Helen Ward and Professor Henrik Westh contributed to the interpretation of the analysis 
presented in this chapter. 
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5.2 Introduction 
In chapter 4 I presented estimates of the association between chlamydia and PID in women 
from the province of Manitoba, Canada who participated with a well-established chlamydia control 
programme.  Like the earlier retrospective cohort studies from Norway and Sweden (Bakken and 
Ghaderi, 2009, Low et al., 2007), this analysis demonstrated that women who have a single positive 
chlamydia test have an elevated risk of PID throughout their reproductive lifetime.  The analysis also 
demonstrated a clear heterogeneity in risk of PID that had not been reported in the earlier studies, 
with the highest risk in younger women and following repeat positive chlamydia tests.  If these 
patterns are present in other settings then using individual-based risk of progression to PID may 
improve the representativeness of mathematical models.   
The estimates from Manitoba, Norway and Sweden were obtained from cohorts drawn from 
a region of the respective country.  Manitoba is a unique setting with a characteristic division of the 
population between the rural north and urban south.  As such, there may be limitations to the 
generalisability of the findings to other settings where chlamydia control policy is being considered.  
Furthermore the analysis in chapter 4 excluded women who were not tested for chlamydia in an 
attempt to reduce unmeasured confounding between the exposure arms in the study.  But this 
excluded the never tested women and limited our ability to draw conclusions about the overall 
population.  It would be interesting to compare estimates from the tested population to estimates 
from the overall population within the same setting to consider the impact on generalizability.  This 
comparison may also generate additional insights into the observed differences between the 
Norwegian and Swedish cohorts.    
 
5.2.1 Denmark 
Denmark is a small Northern European country that consists of a peninsula and 391 islands 
(Statistics Denmark, 2013, The Official Website of Denmark, 2014).  The national language is Danish 
and its population was 5,575,000 in 2011 of which 10% were from an ethnic minority group (The 
Official Website of Denmark, 2014) (World Health Organisation, 2013).  The country is a democracy 
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with a constitutional monarchy.  It is divided into five regions57 and 96 municipalities for 
administrative purposes.  
Denmark was the 33rd richest country in the World in 2012, with a GDP of US $ 315,242 
million.  (The World Bank, 2013a) It spends a high proportion of its GDP on healthcare, 11.15%, and 
85.16% of this is from public sources which is the 11th highest globally  (The World Bank, 2013c, The 
World Bank, 2013b).  Denmark has the world’s lowest income inequality (The World Bank, 2014b) 
and average life expectancy at birth is 79.8 years (The World Bank, 2013e).  The legal age of consent 
for sexual activity is 15 years.   
 
5.2.2 Healthcare in Denmark  
The Danish healthcare system adheres to the principal of equal access for equal need.  
Healthcare is free at the point of use and funded through central taxation, with a contribution from 
municipal funds.  The five regions of the country are responsible for providing healthcare, under 
regulation issued by central government while population-based health promotion activities are 
funded by the municipalities.  Primary care physicians act as the gatekeeper to secondary care which 
is mostly provided by hospitals (Nguyen-Nielsen et al., 2013). The Danish Health and Medicines 
Authority is responsible for the planning and approval of healthcare (Danish Health and Medicines 
Authority, 2013).  The Statens Serum Institut (State Serum Institute, (SSI)), funded by the Danish 
Ministry of Health, is Denmark’s public health agency with responsibility for the prevention and 
control of infectious diseases, biological threats and congenital disorders.  It provides reference 
laboratory facilities (including for chlamydia) and performs research-based health surveillance (State 
Serum Institute, 2013).  
In 2011, almost the entire (94%) population had some interaction with the National Health 
Service and the average number of visits was 11.4 per year (Statistics Denmark, 2013). There were 
1.3 million hospital admissions, 7.7 million out-patient appointments and 1 million emergency 
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 Greater Copenhagen, Zealand, North Jutland, Southern Denmark, and Central Jutland 
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department visits (Statistics Denmark, 2013).  People can receive healthcare for STIs at specialist 
sexual health clinics, gynaecologists or their primary care practitioner and the cost is covered by the 
health system (Lind et al., 2009).  Antibiotic treatment is free if it is provided by a hospital or GUM 
clinic; otherwise the patient must contribute to the cost (Lind et al., 2009).   
Denmark is committed to reducing social inequalities.  It supports the World Health 
Organisation (WHO), 2005 initiative to explore the social determinants and social inequalities in 
health.  In the 1990s the country identified an increased mortality in unemployed people and it has 
current initiatives for adolescents and for lifestyle change (Diderichsen et al., 2012).    
 
5.2.3 Description of administrative health datasets in Denmark 
Denmark has maintained an accurate electronic population register (Danish Civil Registration 
System (CRS)) since 1968 and electronic records of general hospital admissions (Danish National 
Patient Register (LPR)) dating from 1977 (Nguyen-Nielsen et al., 2013).  This hospital dataset was 
expanded to include psychiatric hospital admissions, out-patient and emergency department care in 
1995 and data from private hospitals in 2003 (Lynge et al., 2011).  These administrative datasets are 
maintained by Statistics Denmark.  The primary purpose of these datasets it to improve the 
efficiency of the planning, delivery and monitoring of public services but they also provide a useful 
source of secondary data for epidemiological research (Pedersen, 2011).  The information about an 
individual that is held across the different administrative datasets can be linked using their unique 
10-digit civil register (CPR) number58 to generate a longitudinal record of their healthcare.  
Each laboratory in Denmark maintains electronic records of their activity.  These data 
contribute to the national surveillance of infectious disease.  The chlamydia test data that are part of 
the “Epidemiology of chlamydia and its complications in Denmark” study have been purposively 
collated from all the public laboratories in Denmark that process chlamydia tests by the SSI.  A 
                                                          
58
 It is a legal requirement for residents of Denmark to have a CPR number 
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description of Denmark’s administrative datasets is provided in Table 5.1 and a more detailed 
description is provided in Appendix 15.  
 
Table 5.1: Description of key Danish administrative health datasets 
i 
(Nguyen-Nielsen et al., 2013); 
ii
(Lynge et al., 2011)   
 
5.2.4 Research using retrospective population-based administrative 
healthcare datasets from Denmark 
The administrative healthcare datasets held by Statistics Denmark have been used to 
conduct two regional retrospective studies looking at the association between chlamydia and 
adverse reproductive complications that are described Appendix 2 (Andersen et al., 2005, Andersen 
et al., 2010).  There are many further examples in the published literature of the Statistics Denmark 
datasets being used to generate case-control studies to explore the epidemiology of disease 
(Baastrup Nordsborg et al., 2013, Bang et al., 2014, Egerup et al., 2014, Frederiksen et al., 2014). 
 
Data Source Description Date Coding 
Danish Civil 
Registration Systemi 
Individuals resident in 
Denmark or Greenland 
1968-present Internal system 
Danish National 
Patient Register  ii 
General and psychiatric in-
patient admissions, out-
patient and Emergency 
department presentations 
1977-present ICD-8; ICD-10 
Laboratory data Held by individual 
laboratories 
Unknown Internal system 
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5.2.5 Chlamydia in Denmark  
Chlamydia has been a public health and research priority in Denmark for over thirty years.  
Akin to the situation in Manitoba, the country’s high quality laboratory and administrative datasets 
have contributed to the world-leading clinical microbiological and epidemiological research that is 
described in the forthcoming sections.  This epidemiological research has described a population 
with high participation with well-established control interventions aimed at asymptomatic people.  
In summary, published data on early chlamydia trends was sparse until compulsory notification was 
introduced in 1994.  Since this time, there has been a documented steady increase in the volume of 
testing.  The diagnosed incidence and test positivity were relatively stable until the time that NAATs 
became the predominant test method when both measures increased.  Despite this increase in 
chlamydia, the rates of PID and ectopic pregnancy have been significantly falling over time.  As in 
most other settings, there is a marked health inequality as young women experience the highest 
burden of chlamydia.   
Clinical studies performed in Denmark have had a central role in establishing the efficacy, 
clinical and cost effectiveness of chlamydia screening strategies.  Two of the four RCTs of chlamydia 
screening were conducted in Aarhus County, Denmark in 1997: a cluster randomised trial of 
screening performance in 15-19 year olds in 17 high schools (Ostergaard et al., 2000) and a 
population-based RCT in 21-23 year olds to explore the efficacy of postal screening, accompanied by 
a detailed cost-effectiveness analysis (Andersen et al., 2002, Andersen et al., 2006).  These two RCTs 
are summarised in Table 1.4 and the follow-up study is describe in Appendix 2.  There has also been 
an RCT of partner notification methods (Ostergaard et al., 2003).   
 
5.2.5.1 Notification of chlamydia in Denmark 
Denmark has had legislation governing the treatment of STIs since 1773 (Lind et al., 2009).  
In 1988, voluntary reporting of laboratory diagnosed cases of chlamydia was introduced and this 
reporting became compulsory in 1994 when chlamydia was added to the statutory infectious disease 
notification system (Lind et al., 2009).  
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5.2.5.2 Indications for testing in Denmark 
 A Europe-wide survey commissioned by the European Centre for Disease Prevention and 
Control (ECDC) in 2007 found that Denmark has case management guidelines for chlamydia and that 
opportunistic chlamydia testing is recommended in primary care for the following groups of 
asymptomatic people (Bender et al., 2011, European Centre for Disease Control and Prevention, 
2009):  
 people with frequent sex partner change; 
 women under 26 before trans-cervical procedure (e.g. intrauterine device insertion;  
hysterosalpingogram; termination of pregnancy); 
 partners of a case of chlamydia; 
 people with other STIs. 
 
In 1999/2000 in the Aarhus County region of Denmark the majority of tests (56.5%) in 
women were performed as opportunistic testing, 14.5% were in symptomatic women, 5.8% were in 
women with a chlamydia positive partner and 13.9% preceded a trans-cervical procedure (Moller et 
al., 2003).  This study was performed at a time when samples were obtained from the cervix; 
therefore the majority of those tested opportunistically are likely to have been undergoing a pelvic 
examination for another reason (Moller et al., 2003).  Between 1988 and 2007, 85-90% of patients 
who were tested for chlamydia were seen by their general practitioner (Lind et al., 2009).  
 
5.2.5.3 Diagnostic tests used in Denmark 
In 1984 there were seven laboratories providing chlamydia testing in Denmark and by 2006 
there were fourteen (Lind et al., 2009, Westh and Jensen, 2008).  These laboratories operate 
independently, therefore the specific tests used differed both by time and location.  In 1988, almost 
half (48%) of the reported chlamydia cases were diagnosed using culture, by 1994 the majority (88%) 
were diagnosed using EIA and by 2004 virtually all (>99%) were diagnosed using NAATs (Lind et al., 
2009).  
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Westh and Kolmos estimated the impact on chlamydia case detection rates of changing from 
the MicroTrack II EIA59 (Dade-Behring, Trinity Biotec Plc, Bray, Ireland; used at Hvidovre Hospital, 
Copenhagen from 1995 to 1999) to a hypothetical NAAT60 (Westh and Kolmos, 2003).  They 
predicted that overall the new test would identify 15 extra positive samples per 100 tests processed 
(an increase of 18.75%).  However when age-specific testing rates and prevalence were used the 
predicted increase in case detection was 4%.  The authors also demonstrated that diagnostic tests 
perform differently in different age groups, which is to be expected if the prevalence of infections 
differs by age (Appendix 1).  The highest positive predictive value (PPV) was seen in 17 year olds 
(94% EIA and 98% NAAT) and lowest negative predictive value (NPV) was in 16-22 year olds (96% EIA 
and 99% NAAT).   
 
5.2.5.4 Epidemiology of chlamydia and gonorrhoea in Denmark 
There was evidence of an early steady increase in the volume of chlamydia testing in 
Denmark.  Between 1984 and 1988 the proportion of women seen in GUM who reported a past 
history of chlamydia – a potential proxy for the availability of diagnostic tests - significantly increased 
(8% in 1984 to 23% in 1988 (p<0.01)).  By the late 1990s there was high participation with chlamydia 
testing reported in Copenhagen, 19.3% of women were tested at least once every year (on average) 
with the highest participation rate seen in 23 year olds where 29% had an annual test (Westh and 
Kolmos, 2003).  The volume of tests in men and women has continued to increase: there were an 
average of 270,323 tests per year in 1994-2003 and 320,000 tests per year from 2005-2007, 
although this may reflect an increase in male participation (Lind et al., 2009).  The overall rate of 
chlamydia testing in Denmark was 6,175 tests per 100,000 population in 2008 (Bender et al., 2011).  
Between 1988 and 1994 laboratory reporting of chlamydia was voluntary therefore the 
earliest robust estimates of the national annual diagnosed incidence rate of chlamydia in women 
start in 1994.  The diagnosed incidence rate in Denmark was stable from 1994 until 2002 at 350 to 
                                                          
59
 MicroTrak II EIA performance compared to culture: sensitivity 80% and specificity 99% (with confirmatory 
testing from MicroTrak Direct Specimen Test (Dade-Behring (Syva), Trinity Biotec Plc, Bray, Ireland) on grey-
zone sample) (Westh and Kolmos, 2003)   
60
 Defined as sensitivity 95% and specificity 99.5% 
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400 cases per 100,000 women and the number of cases diagnosed per test performed (a proxy for 
positivity) was steady at around 5% (Lind et al., 2009). There were marked inequalities by age and 
geography with young women and residents of Copenhagen most affected.  The average diagnosed 
incidence rates in Copenhagen were 834 per 100,000 in women overall but almost 3,000 per 
100,000 in women aged 17-20, and test positivity61 was 4.3% overall and 16.8% in women aged 17 
(Westh and Kolmos, 2003).  Diagnosed incidence rate and test positivity sharply increased in 
Denmark around the time that testing changed from EIA to NAAT.  In 2007, the diagnosed incidence 
rate was 586 per 100,000 women and positivity was 8.1% (Lind et al., 2009).  In 2012 the absolute 
number of diagnosed cases of chlamydia was 16,043 in women and 10,257 in men (Statistics 
Denmark, 2013). 
During the early documentation of the chlamydia epidemic in the mid to late 1980s the 
prevalence of chlamydia in attendees at Copenhagen’s GUM clinic was very high, but stable at 
around 25% despite an increase in the volume of testing (Olivarius Fde et al., 1992).  In the same 
population, the diagnosed prevalence of gonorrhoea decreased significantly over the time period 
(22% to 6%, p<0.01).  Inequalities with age were observed in Aarhus Country where the highest 
overall prevalence of chlamydia was seen in women aged 16-20 years (7.2% (95% CI 5.4-9.3)) (Moller 
et al., 2003).  The prevalence of chlamydia in tested women may also vary according to the 
indication for their test (Moller et al., 2003).  In 16-20 year olds with an overall prevalence of 7.2%, 
women tested because of an infected partner had a prevalence of 14.9% (95% CI 8.6-23.3) and those 
tested before a trans-cervical procedure had a prevalence of 5.5% (95% CI 1.8-12.4).   
There have been three population-based studies to estimate the prevalence of chlamydia in 
women in Denmark (Andersen et al., 2002,  European Centre for Disease Control and Prevention, 
2014, Munk et al., 1999, Ostergaard et al., 1998).  Estimates from these three studies were different, 
but this may reflect the different populations studied.  In sexually active 15-19 years old women 
from high schools the prevalence was 5.16% (95% CI 3.74-6.58), (Ostergaard et al., 1998), it was 
6.70% (95% CI 4.56-8.85) in a small cohort of women aged 20-29 years (Munk et al., 1999) and 
10.20% (95% CI 9.06-11.35) in a large population of sexually active 21-23 year olds (Andersen et al., 
2002).  
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 Positivity defined as [number of women with a positive test/ total number of women tested]. 
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There is less published data on the incidence or prevalence of other STIs.  But gonorrhoea is 
rare in Denmark with only 339 cases nationwide in 2011 (Statistics Denmark, 2012).  A study of 
women presenting for termination of pregnancy found that chlamydia and Mycoplasma hominis 
infection were common (15.69% (n=16) and 18.63% (n=19) respectively) but Mycoplasma genitalium 
was rare (0.98%, n=1) (Baczynska et al., 2008).    
 
5.2.5.5 Pelvic inflammatory disease, ectopic pregnancy and tubal factor infertility in 
Denmark 
An ecological time trend analysis of women aged 15-39 in Denmark reported a rate of PID62 
hospitalisations of 106.0 per 100,000 in 2004 (Bender et al., 2011).  They compared the association 
between chlamydia and adverse complications at the national level and found the same patterns 
universally reported by settings with chlamydia control: an increase in chlamydia test positivity63 
associated with a significant decline in the rate of PID (RR 0.79 (95% CI 0.75-0.84)) and no change in 
ectopic pregnancy (RR 1.09 (95% CI 0.95-1.25)) (Bender et al., 2011).  
The RCT of chlamydia screening in women aged 21-23 (Andersen et al., 2002) was extended 
to include a study of the impact of screening on adverse reproductive outcomes using Danish 
administrative healthcare datasets (Andersen et al., 2010).  The cumulative incidence of PID in the 
15,459 women in the original RCT was 0.63% by 12 months, it was 0.66% for ectopic pregnancy and 
2.9% for infertility at nine years, with no difference in incidence between the intervention and 
control arms (Andersen et al., 2010).  Denmark has also been the location of an individual-based 
epidemiological study reporting the risk of ectopic pregnancy following chlamydia using a 
retrospective population-based administrative healthcare data cohort (described in Appendix 2) 
(Andersen et al., 2005). In this cohort women with a previous chlamydia infection had a lower risk of 
an ectopic pregnancy compared to women who tested negative for chlamydia (AHR 0.55 (95% CI 
0.31-0.96)).     
                                                          
62
 PID defined as ICD-10 N70-N74.4 and A56.1 
63
 Positivity defined as number of cases in women 15-39 as a proportion of all tests performed in population (no age or sex 
stratification) 
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5.2.6 Denmark Chlamydia Study 
To inform chlamydia control policy in Denmark a programme of research is being 
undertaken to explore the impact of chlamydia in Denmark, covering its epidemiology, testing 
patterns, the epidemiology of its long-term complications and the association between chlamydia 
and adverse health in men and women.  This programme is titled the “Epidemiology of chlamydia 
and its complications in Denmark: a national study”.  The study is overseen by a steering group 
whose members include Henrik Westh (Hvidovre Hospital, Hvidovre, Denmark), Steen Rasmussen, 
Thomas Benfield, Maria Frøland and Katy Turner (University of Bristol, Bristol, UK).  This research 
involved the development of a retrospective study, the “Denmark Chlamydia Study” which has a 
case-control design based on chlamydia infection as the outcome and was constructed using 
administrative health data from the Danish National Board of Health, by a research team at Hvidovre 
Hospital led by Professor Henrik Westh.   
The Denmark Chlamydia Study dataset contained all individuals who were resident in 
Denmark (including Greenland) and had a positive chlamydia test recorded by public health 
laboratories between 1st January 1991 and 2nd November 2011.  The sampling frame for these 
chlamydia positive individuals was a purpose-generated SSI chlamydia test dataset (see Appendix 
15).  These “positive” individuals entered the study on the date of their first positive chlamydia test 
during the study period; this is called their “index date”.  To ensure that the positive people 
identified from the SSI dataset were true residents of Denmark, a list of their unique 10-digit 
personal identification numbers (Danish Civil Registration System (CPR) identification numbers) was 
provided to the Denmark Research Service (Forskerservice).  The Forskerservice then excluded the 
CPR numbers that did not have a valid date of birth in the population register (Danish Civil 
Registration System (CRS register)), or had an index date before their date of birth or had an index 
date after their date of death.   
The residents with a positive chlamydia test were then removed from a copy of the CRS 
dataset so that it only contained people without a positive chlamydia test between 1991 and 2011.  
This reduced CRS dataset was used as the sampling frame for chlamydia negative or never tested 
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individuals64.  For each chlamydia positive person, up to four individuals (of the same sex and with a 
date of birth within 7 days of the chlamydia positive person) were randomly selected from all 
individuals present in the reduced dataset on their index date.  This generated a representative 
sample of chlamydia negative or never tested people, who entered the dataset on the same date as 
their associated chlamydia positive person (i.e. the date of the positive person’s first positive test).  
This process describes matching each positive individual to four age- and sex- matched individuals 
without exposure to chlamydia (either never tested or only negative tests).   
The CPR numbers for everyone in the Danish Chlamydia Study were used to generate a 
complete set of demographic information from the CRS register and information from three 
administrative health datasets: (1) Danish National Patient Registry; (2) Danish Birth Registry; (3) 
Danish IVF register and the purpose-generated SSI chlamydia test dataset.  The CPR numbers were 
then removed from the datasets and replaced by an anonymised study identification number (IDNR).  
The key for linking the CPR number with the IDNR is held securely at SSI and is not available to the 
researchers working with the data.  A summary of the variables in the Denmark Chlamydia Study 
dataset is provided in Table 5.2. 
 
Table 5.2: Summary of variables in the Denmark case-control dataset 
Demographic Study definitions Chlamydia Hospital healthcare 
 ID number  Case/Control status  Date of test  Start date 
 Case ID number   Date of entering   Test result  End date 
 Gender Study  Type of chlamydia   Type of presentation 
(e.g. out-patient; in-
patient; ambulatory) 
 Date of birth  test 
 Residency    Site of sample 
status   Microbiology   Supplemental ICD code 
 Date of status   department  ICD diagnosis code 
change   Administrative  Administrative 
 Municipality 
code 
 identification number identification number 
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 Negative or never tested individuals did not have a positive chlamydia test in the SSI dataset (i.e. they did not meet the 
definition of a person with a positive chlamydia test), had a valid CPR number and had a known area of residence.  
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The advantage of a case-control design is that it can reduce the size of the required study 
population as you can specifically include people based on whether they experience the event of 
interest65.  Matching can reduce or control for confounding at the level of the study design (Breslow, 
1980) which can improve the efficiency of the study because, as Rose and Laan explain, when the 
distribution of confounders is similar between exposure groups the variance of the parameters is 
reduced which narrows the confidence interval around estimates of association (Rose and Laan, 
2009). However as it is an observational study design it is not possible to make any assumptions 
about the distribution of unmeasured confounders.  
 
5.2.7 Research Question 
What is the association between chlamydia and PID in women in Denmark who participated 
with a well-established chlamydia control programme?  What is the population attributable fraction 
of chlamydia on PID?  Is there a difference in the association between chlamydia and PID in the 
overall population (including never tested people)?  Does the risk of PID change following a repeat 
episode of chlamydia? 
 
5.2.8 Aims and objectives 
1. To generate a dataset of women aged 15-44 from the “Denmark Chlamydia Study”; 
 
2. To limit this dataset to women who were tested for chlamydia and:  
a. construct Kaplan-Meier plots of time to PID following a woman’s first chlamydia test by 
test result; 
b. measure the rate of PID following a woman’s first chlamydia test by test result; 
c. use Cox proportional hazards regression to measure the association between a positive 
chlamydia test and PID; 
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 The event of interest is typically the outcome of the study. The analysis presented in this chapter is a secondary analysis 
of the Danish Chlamydia Study dataset and the event of interest in the original dataset (chlamydia status) is the exposure 
of interest in this chapter.   
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3. To determine the cohort attributable fraction of chlamydia on PID in women tested for 
chlamydia:  
a. at 12 months after their first chlamydia test; 
b. at the end of the total period of follow-up. 
 
4. To use data from the complete dataset and repeat step 2 to compare women who test positive, 
test negative and are not tested for chlamydia;   
 
5. To limit the dataset to women with a positive test and:  
a. construct Kaplan-Meier plots of time to PID by number of previous positive tests;  
b. use Cox proportional hazards regression to measure the association between a repeat 
positive test and PID. 
 
5.2.9 Ethical permissions 
Ethical permissions for this dataset were not required as it is an anonymous register-based 
study.  The dataset has been approved by the Danish Data Protection Agency (J.nr. 2010-41-4866 
and J.nr. 2012-331-0228). These approvals cover the storage and analysis of a blinded dataset, at 
settings outside of Denmark. The dataset was created by electronic submission of data on chlamydia 
testing from all Departments of Clinical Microbiology and medical records and demographics for 
patients and controls from the National Danish Patient Registry at Research Services, Statens Serum 
Institut (FSEID-00000256). 
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5.3 Methods 
5.3.1 Study design 
The Danish Chlamydia Study is a case-control study that was generated by matching66 each 
individual with a positive chlamydia test to four individuals of the same age and sex who were a 
random sample of people resident in Denmark on the date of the positive chlamydia test, and either 
never tested for chlamydia or only had negative tests.  We consider this dataset to be representative 
of the Danish population because all residents who had a positive chlamydia test during the study 
period were included and the high number of negative and never tested individuals were randomly 
selected from the remaining population based on the age and sex distribution of positive individuals.   
I have used the Danish Chlamydia Study to generate a retrospective population-based 
cohort where the exposure of interest is chlamydia status (positive; negative; never tested) and the 
outcome of interest is a hospital healthcare event for PID.  This study cohort is fully described below.  
 
5.3.2 Cohort definition  
5.3.2.1 Population  
To be eligible for this study, women in the original dataset had to:  
 
 
 
 
                                                          
66
 Matching is a technique that selects people without the event of interest on the basis of pre-defined similarities (usually 
a priori confounders) to people who do experience the event of interest.  The variables used in the matching process 
should be related to both the exposure and the outcome but should not be on the causal pathway.  After matching, the 
distribution of the characteristics used in the matching process should be more similar between those with and those 
without the event of interest than they would have been if matching had not been used. 
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 be resident in Denmark (excluding Greenland);  
 be between 15 - 44 years on the date they entered the study dataset;  
 meet the chlamydia exposure definitions set out in the original study;  
 be part of a 5-person set (with one positive woman and four negative or never tested 
women)67.  
 
5.3.2.2 Study period 
We defined the start of this study as 1st January 1995 to improve ascertainment of chlamydia 
tests and internal validity in the definition of the adverse reproductive outcomes.  Chlamydia 
notification became compulsory in 1994 and in 1994/95 the LPR dataset changed from using ICD-9 
to ICD-10 coding and out-patient and emergency department presentations were added.    The study 
ended on 31st October 2012 as this one year after the last date that chlamydia test information was 
collected (latest chlamydia test 2nd November 2011) and allows a time window for subsequent PID 
events to occur.  Outcome information was collected until 31st March 2013 but we are using the 
earlier date to address a limitation of a previous study where exposure and outcome data were not 
collected over the same time period (Low et al., 2006).  
 
5.3.2.3 Follow up  
Women entered the study on the date of their first positive test in the original dataset or the 
date of the first positive test of the chlamydia positive woman that they were matched to.  For 
certain analyses, women who are chlamydia negative entered the study on the date of their first 
chlamydia test in the dataset68.  Follow up ended at the earliest of the following events: 
                                                          
67
 It was a criterion of the matching process that each negative or never tested woman could only be matched to a single 
woman with a positive test.  However in certain age groups with high rates of chlamydia testing, there were insufficient 
negative or never tested women to identify four individuals for each positive woman.  I have included this criterion to 
avoid introducing selection bias. 
68
 The first chlamydia test recorded for a negative woman can occur at any point from the date she entered the dataset to 
the end of the study.  But it cannot precede the date she entered the original dataset.  
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 cease to be a resident of Denmark (emigration or death)69; 
 45th birthday70; 
 first episode of PID; 
 end of the study on 31/10/2012.  
 
5.3.2.4 Exposure to chlamydia 
We defined a chlamydia test as:  
 a test recorded in the SSI chlamydia test dataset;  
 with a valid date and result; 
 that was performed on a specimen collected from a genital or rectal site or a urine 
sample; 
 that occurred ≥30 days after the previous test. 
 
This time criteria was used to reduce the risk of a false positive test following treatment and 
we have reduced the interval from the 60 day period used in the previous analysis (chapter 3 and 4) 
based on consensus opinion of the study team and following evidence that found that 79% (48/61) 
of women who were treated with azithromycin following a positive APTIMA Combo 2 test (Gen-
Probe, Inc., San Diego, CA, USA) did not have detectable ribosomal RNA at 14 days (Renault et al., 
2011).  We kept the interval longer than 21 days because some guidelines recommend a test of cure 
2-3 weeks after a positive test.  Women were assigned to exposure categories based on their 
chlamydia status in this study dataset, defined in Table 5.3.  For chlamydia positive women, any 
subsequent positive tests after the index test were identified and used to divide follow-up into time 
following one positive test and time following two or more positive tests.   
 
                                                          
69
 The Danish National Patient register contained information about when women ceased to be a resident of Denmark.  
70
 The date of a woman’s 45
th
 birthday was calculated using her date of birth. 
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Table 5.3: Description of positive, negative and never tested women in the original and study 
datasets 
 Original dataset Study dataset 
Positive at least one positive test 
between 1991 and 2011 
chlamydia positive in the original 
dataset and a positive test on their 
date of entering the study dataset 
Negative  no positive chlamydia test and 
at least one negative test 
between 1991 and 2011 
chlamydia negative in the original 
dataset and at least one negative 
test and no positive tests during the 
study dataset71 
Never tested  no recorded chlamydia tests 
between 1991 and 2011 
not chlamydia positive in the 
original dataset and no chlamydia 
tests in the study dataset 
 
5.3.2.5 PID, pregnancy, tubal factor infertility 
To improve the comparability of the findings from this analysis to the work presented in 
chapter 4 we used the same ICD-10 definitions as chapters 3 and 4 to identify the healthcare 
presentations for adverse reproductive outcomes contained in the LPR datasets (summarised in 
Table 5.4).  The evidence base for these definitions is provided in chapter 3, section 3.3.1.3).   
 
  
                                                          
71
 A small number of women who were initially identified as chlamydia positive in the SSI dataset during formation of the 
original dataset were discarded because their first positive chlamydia test record was invalid.  These women remained in 
the CRS dataset in the pool of women eligible for the negative and never tested groups but some had later positive 
chlamydia tests.  
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Table 5.4:  Summary of ICD codes used to define outcomes  
 
Outcome72 Code in dataset ICD-10 code 
PID DA181; DA514; DA527; DA542; 
DA561; DN70-DN748 
A18.1; A51.4; A52.7; A54.2;  
A56.1; N70-74.8 
 
EP DO00-DO009 O00.00-O00.9 
Infertility DN97 N97 
 
Tubal Factor Infertility DN971 N97.1 
 
Abortion DO021; DO003-DO006 O02.1; O03-06 
 
Additional pregnancy 
events 
DO01; DO021; DO028-DO029; 
DO10-16; DO20-29; DO85-
DO99.8; DZ321; DZ33-DZ36 
O01; O02.0; O02.8; O02.9; 
O10-16; O20-29;  O85-92; 
O94-99; Z32.1; Z33-36 
 
Delivery DZ37-DZ38 Z37-38 
 
Pregnancy Combination of abortion; 
additional pregnancy events; 
delivery 
 
 
5.3.2.6 Age 
To obtain the most detailed information, age would need to be included as a continuous 
variable.  However the overarching aim of this thesis is to provide information that may be useful for 
parameterising mathematical models and informing policy.  As policy decisions are taken for age 
groups, age was included as a categorical variable using a priori defined categories based on 
standard convention in the literature: 15-19 years; 20-24 years; 25-59 years; 30-34 years; 35-39 
                                                          
72
 However, due to the data available from Denmark, it was not possible to use procedural or treatment 
information to refine the diagnosis of ectopic pregnancy or tubal factor infertility.     
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years and 40-44 years.  Age was classified in one of two ways depending on the analysis performed 
and the value was kept constant:  
 age at entry to the study dataset; 
 age at first test in the study dataset.  
 
 
5.3.2.7 Year  
We assumed that there was no co-linearity between age and year in the study dataset 
because women could enter the study at any age and in any calendar year.  We divided time into 
three equal periods to roughly correspond with the change in test method: 1995-2000; 2001-2006; 
2007-2012.  We defined year in two different ways and kept the value constant: 
 year of entry to the study dataset; 
 year of the first chlamydia test in the study dataset. 
 
 
5.3.3 Formation of study dataset 
I was provided with a subset of the Danish Chlamydia Study generated using C++ code from 
the original Microsoft Excel spreadsheets by Dr Katy Turner.  This dataset contained all women born 
between 1965 and 1997 (i.e. aged 15 to 44 between 1995 and 2012).  Within this dataset women 
could have multiple rows of data including:  
 
 a record that described her date of entry to the study (index date);  
 separate records for each chlamydia test;  
 separate records for each hospital healthcare event for PID, ectopic pregnancy or tubal 
factor infertility that occurred after she entered the study.   
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It was also possible for multiple events (records) to occur on the same date (e.g. two 
chlamydia tests on different samples or a chlamydia test and a healthcare event).  The dataset was 
provided as a text file and I imported it into STATA SE 11.2 (StataCorp LP, TX, USA).  Details of the 
manipulation of the variables contained within this dataset (including how I recoded, regenerated 
existing variables and created new variables) are included in Appendix 16.  Dates were converted to 
STATA date format.  
I generated an additional row for each woman to record the date of her exit from the study.  
To do this, I made a copy of the original dataset, and limited it to the first row as this row did not 
contain any chlamydia test results or hospital healthcare events.  I created a variable to label this as 
an exit row and generated a woman’s “exit date”.  These exit rows were then merged back into the 
original dataset.  The following records were then removed:  
 invalid chlamydia tests;  
 date outside a woman’s membership period in the study; 
 
Then all records for the following groups of women were removed:  
 exit date before their entry date;  
 entry date before 1995;  
 not resident in Denmark (i.e. residents of Greenland);  
 under 15 years or over 45 years on the date they entered the study;  
 not in a five person set where all women met the study chlamydia exposure definitions.  
 
A single chlamydia test was then selected for each woman for each date (positive over 
negative73) then reduced to a single event per 30-day period.  Finally, duplicate records with the 
same outcome event on the same date were removed and the dataset was condensed to create a 
maximum of one row (containing information about all events that occurred) per date per woman.  
                                                          
73
 This was designed to mirror clinical practice, where a patient would be considered to be positive, and treated, if at least 
one test was positive. 
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Finally, the snapspan command in STATA was used to generate a dataset suitable for use with the 
survival analysis commands.  PID and chlamydia tests were included as event variables.    
 
5.3.4 Statistical analysis 
I have analysed the study cohort in this chapter with standard longitudinal analytic 
techniques for cohort studies74 (survival analysis), as described in section 2.3.7.2.  The matching in 
the original Danish Chlamydia Study was performed on the variable used to define exposure in this 
study dataset (chlamydia), rather than the outcome (PID) and this matching has not been accounted 
for in the analysis presented in this chapter.  The design of the original study meant that individuals 
were effectively matched on age and year of entry to the study.  Both of these variables are 
considered to confound the relationship between chlamydia and PID and will be adjusted for in the 
multivariable analysis75.  All statistical analysis was performed in STATA SE 11.2 (StataCorp LP, TX, 
USA).  
I described the study dataset including: distribution of age, chlamydia tests and PID overall 
and by chlamydia exposure status (positive compared to negative and never tested separately and 
as a combined non-positive group).  I tested for a difference in the age at entry and exit between 
positive and negative women using t-tests with equal variance; a difference in the mean number of 
chlamydia tests (between positive and negative tested women) using t-tests with unequal variance;  
and a difference between the proportion of women with PID by chlamydia status using the 
difference between two proportions.  
 
                                                          
74
 The potential consequence of not using matched analysis technique with matched data is that the hazard ratios may be 
biased towards the null. 
75
 This is similar to the situation with frequency matched case-control studies where analysis is performed using an 
unconditional technique that includes the variables used in the matching process.   
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5.3.4.1 Women tested for chlamydia  
The main analysis in this chapter attempts to recreate the analysis that was presented in 
chapter 4.  The study dataset was restricted to women who were tested for chlamydia (i.e. 
chlamydia positive and chlamydia negative women).  Both groups of women entered the study on 
the date of their first chlamydia test in the dataset and exited at censoring or the end of the study.  I 
constructed Kaplan-Meier plots of time to PID by chlamydia status, age at first test and year of first 
test and used the log rank test to test the hypothesis that there was no difference in the survival 
curves.  I determined the rate of PID for chlamydia positive women and chlamydia negative women 
separately, following their first test and used Cox proportional hazards regression to explore the 
association between an episode of PID and a positive chlamydia test adjusted for age at first test and 
year of first test.   
The assumption of proportional hazards was visually explored by looking at the shapes of 
the Kaplan-Meier curves and formally tested in the univariate Cox proportional hazards models using 
Schoenfeld residuals (Institute for Digital Research and Education, 2014).  I considered alternative 
options for addressing the occurrence of non-proportional hazards including:  
 time-varying covariates;  
 stratifying for levels of the covariates (age; year);  
 dividing follow-up time into periods with proportional hazards; 
 using a parametric model.   
 
We chose to divide follow-up time into discrete time intervals that met the assumption of 
proportional hazards.  Where it was not possible to identify an appropriate time interval with 
proportional hazards, the data were described using rates and rate ratios.  Data from categories with 
fewer than 5 women were excluded from the analysis.  All available a priori confounders were 
included in the multivariable model.  We explored the impact of interaction between the three 
variables in the model (chlamydia status*age at test; chlamydia status*year of test; age at test*year 
of test).  However, we did not consider there to be an underlying mechanism that would act to cause 
an interaction between the variables therefore it was decided not to include interaction terms in the 
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final model.  The assumption of proportional hazards in the final multivariable model was tested 
using Schoenfeld residuals and by including time-varying covariates in the model.      
I determined the cumulative incidence of PID by 12 months after the date of the first 
chlamydia test in chlamydia positive and negative women separately and at the end of follow-up 
(this analysis included women who were diagnosed with PID on the date of their first chlamydia 
test).  Due to the case-control design of the original dataset it was not possible to obtain an estimate 
of the prevalence of chlamydia from the dataset therefore I made an assumption that the 
prevalence of chlamydia was 3% in the underlying population the cohort was drawn from (based on 
the findings of a systematic review of chlamydia prevalence (European Centre for Disease Control 
and Prevention, 2014)) and calculated the cohort attributable fraction of chlamydia on PID in the 12 
months following a chlamydia test and at the end of follow-up in women tested for chlamydia using 
the following formula:  
𝑃𝐴𝐹 =
𝑝𝑒(𝑅𝑅−1)
1+𝑝𝑒(𝑅𝑅−1)
 
 
5.3.4.2 Positive, negative and never tested women  
I repeated the survival analysis as described in section 5.3.4.1 using the complete dataset.  
Women entered the analysis on the date they entered the study dataset and exited at censoring or 
the end of follow-up.  
 
5.3.4.3 Repeat infection  
I then limited the dataset to women with a positive chlamydia test and divided follow-up 
time into periods based on the number of positive tests a women had up to that point in the study 
(one (i.e. entry to the study to repeat positive test) and 2 or more (i.e. repeat positive test to end of 
follow-up or censoring).  I then repeated the survival analysis as described in section 5.3.4.1.  Except 
that the survival analysis was stratified by age group at the time of the first chlamydia test to meet 
the assumption of proportional hazards.  
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5.4 Results 
5.4.1 Formation of study dataset 
There were 580,495 women (116,099 positive and 464,396 negative or never tested) and 
1,881,544 rows of data in the subset of women from the Danish Chlamydia Study who were aged 15-
44 in 1995-2012.  The final study dataset used in this chapter contained 516,720 women (89.01% of 
the original dataset; 103,344 positive women; 182,879 negative women; 230,497 never tested 
women) and 1,737,804 rows of data that described 784,488 chlamydia tests; 12,697 healthcare 
events for PID; 11,092 healthcare events for ectopic pregnancy and 2,684 healthcare events for tubal 
factor infertility (Figure 5.1).  
 
5.4.2 Description of the dataset 
The mean age at entry to the study was 22.36 years and the mean age at exit was 30.32 
years (Table 5.5).  There was a significant difference in these ages between positive and negative 
women (entry: 22.36 years compared to 22.00 years, p<0.0001; exit: 30.32 years compared to 31.48 
years, p<0.0001).  Women in this dataset underwent repeat testing for chlamydia: the maximum 
number of tests per woman was 43 for the positive women and 27 for the negative women.  Positive 
women had a significantly higher mean number of chlamydia tests than negative women (3.84 
compared to 2.12, p<0.0001) and they had a mean of 1.29 chlamydia diagnoses during the study.  
Overall, 1.86% of women had at least one healthcare event for PID and this proportion was 
significantly different between positive women and negative women (3.55% compared to 2.48%, 
p<0.0001) and positive women and never tested women (3.55% compared to 0.6%, p<0.0001).  
There were 459 women who had a healthcare event for PID on their date of entry to the study (457 
positive; 1 negative and 1 never tested).  
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Figure 5.1: Generating the study cohort from the original dataset 
Original dataset generated from 
Danish Chlamydia study containing 
all events for women born between 
1965-1997 
 
N= 580,495 women  
N= 1,881,544 rows 
  
 
 
 
 
  
Limit to events that occur between 
a woman’s entry and exit date and 
to valid chlamydia tests 
 Removed:   
Women who exit the study before their entry date = 83 
Invalid chlamydia test records = 58,285 
Events before a woman’s entry date = 0 
Events after a woman’s exit date = 219 
 
 
 
 
 
  
Limit to women resident in 
Denmark, aged 15-44 between 
1995-2012  
 Removed:  
Enter study before 1995 = 20,124   
Resident of Greenland  = 382 
Under 15 years at study entry = 5,640 
Over 45 years at study entry = 0 
 
 
 
 
  
Limit to women who all meet the 
appropriate chlamydia exposure 
definitions 
 
 
 
 Removed: 
Positive women without a positive test on date of entry = 
7,121                                                                                             
Negative women with a positive test during study =  60 
Relabelled:  
Negative women without a test during the study as never 
tested =  69,847 
 
 
 
 
  
Limit to women in a five person set  
 
Removed:  
Not in a 5-person set = 30,365                                       
 
 
 
 
 
 
  
Dataset limited to a single 
chlamydia test per 30 day period 
and a single record containing all 
events on the same date 
 
 
N= 516,720 women 
N= 1,737,804 rows 
 Removed: 
Duplicate chlamydia records = 230,352 
Chlamydia tests less than 30 days apart = 30,906 
Duplicate entry row = 103,569 
Duplicate PID records = 3,156 
Duplicate EP records = 10,788 
Duplicate TFI records = 761 
Combined rows with events on same date = 3,028 
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Table 5.5: Description of the study cohort 
  
Overall Positive women Negative and 
never tested 
Never tested Negative Difference between 
positive and negative 
women 
Number of women  516,720 103,344 413,376 230,497 182,879 
 Age at entry       
 
mean  22.36 22.36 22.36 22.64 22.00 <0.0001 
 
sd 4.98 4.98 4.98 5.51 4.19 
 
 
range 15.00-44.97 15.01-44.97 15.00-44.97 15.00-44.97 15.00-44.66 
 Age at exit 
      
 
mean  30.32 30.32 30.32 29.4 31.48 <0.0001 
 
sd 6.61 6.61 6.61 6.99 5.89 
 
 
range 15.60-45.00 16.44-45.00 15.60-45.00 15.60-45.00 17.67-45.00 
 Chlamydia tests 
      
 
mean  1.52 3.84 0.94 - 2.12 <0.0001 
 
range  0 to 43 1 to 43 0 to 27 - 1 to 27 
 
 
total 784,488 396,377 388,111 - 388,111 
 Chlamydia diagnoses 
     
 
mean  - 1.29 - - - 
 
 
range  - 1 to 12 - - - 
 
 
total - 133,574 - - - 
 PID diagnoses       
 
women with 
≥1  9,591 (1.86%) 3,671 (3.55%) 5,920 (1.43%) 1,381 (0.60%) 4,539 (2.48%) <0.0001 
 
range 1-10 1-10 1-10 1-8 1-10 
 
 
total  12,697 4,958 7,739 1,739 6,000 
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5.4.3 Women who were tested for chlamydia  
The 457 positive women and 391 negative women who had PID on the date of their first 
chlamydia test and the 881 negative women who had a diagnosis of PID before their first test in the 
dataset were excluded from the survival analysis.  Therefore there were 284,494 women (102,887 
positive; 181,607 negative) who contributed 1,987,840 py of follow up (mean 6.99 years; range 1 
day to 17.83 years).  Overall there were 6481 cases of PID (50.4% (n=3267) in negative women and 
49.6% (n=3214) in positive women).  Kaplan-Meier plots showed that women had a significantly 
different survival curve by chlamydia status, age group and year of first test (p<0.005) (Figure 5.2). 
The assumption of proportional hazards, determined using Schoenfeld residuals, was 
violated for all variables in the univariate analysis (chlamydia status (p<0.001); age at test (p<0.001); 
year of test (p<0.001)), and stratification by age or year did not result in proportional hazards.  The 
earliest period 0-30 days did not have proportional hazards therefore rates are presented.  The 
remainder of the analysis is presented with follow-up time divided into periods with proportional 
hazards (31 to 60 days; 61 days to 4 years; 4 to 5 years; 5 to 10 years and 10 to 17 years).  For each 
time period the full analysis results (description of the data, the rate of PID and where performed 
the unadjusted and adjusted hazard ratios for PID) are presented in Appendix 17. 
In the initial 30 days following a chlamydia test, the rate of PID was three times higher in 
women with a positive test compared to women with a negative test (RR 3.03 (95% CI 2.54-3.63)) 
(Table 5.6).  The rate of PID was the same in positive and negative women between 31 to 60 days 
then returned to be higher in positive women until 10 years after the initial test when the difference 
between the groups was lost.  The rate of PID fell in successive time intervals for positive women 
and negative women until 5 years after their first test in the cohort after which time they were 
stable until the end of follow-up.  Positive women had a significantly higher adjusted hazard of PID 
from 61 days after the date of the test until the end of follow-up, when compared to negative 
women (Table 5.7).   
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Figure 5.2: Kaplan-Meier curves of time to PID from first chlamydia test  in positive and negative 
women by (a) exposure status; (b) age at entry; (c) year of entry 
 
a) 
 
 
 
 
 
b) 
 
 
 
 
 
c) 
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Table 5.6: Summary of rate of PID (95% CI) per 1000 person years in positive and negative women from first chlamydia test, over time intervals with 
proportional hazards 
  
0-30 days 31-60 days 61d-4 years 4-5 years 5-10 years 10- 17 years 
Chlamydia status 
      
 
negative 13.22 (11.49-15.20) 6.04 (4.91-7.43) 2.83 (2.70-2.96) 2.30 (2.04-2.59) 2.29 (2.13-2.46) 2.03 (1.73-2.37) 
 
positive 40.08 (36.03-44.59) 7.60 (5.95-9.71) 4.31 (4.10-4.52) 3.34 (2.95-3.78) 3.04 (2.83-3.27) 2.52 (2.22-2.85) 
 
Table 5.7: Summary of multivariable Cox models of risk of PID following first chlamydia test in positive women and negative women, over time intervals 
with proportional hazards 
 
 
31-60 days 61days-4 years 4-5 years 5-10 years 10 – 17 years 
 
 
HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
Chlamydia 
status 
          
 
negative baseline - - - - - - - - - 
 
positive 1.18 0.84-1.66 1.42 1.32-1.53 1.34 1.12-1.61 1.26 1.13-1.40 1.29 1.05-1.59 
Age at entry 
          
 
15-19 baseline - - - - - - - - - 
 
20-24 1.04 0.66-1.64 0.84 0.77-0.91 0.69 0.55-0.85 0.89 0.78-1.01 0.83 0.67-1.04 
 
25-29 1.24 0.75-2.05 0.99 0.89-1.09 0.80 0.62-1.02 0.76 0.65-0.89 0.54 0.39-0.75 
 
30-44 2.32 1.40-3.84 1.06 0.94-1.19 0.59 0.42-0.83 0.70 0.56-0.86 0.60 0.32-1.14 
Year of entry 
          
 
1995-2000 baseline - - - - - - - - - 
 
2001-2007 0.67 0.44-1.01 0.69 0.63-0.75 0.97 0.78-1.21 0.94 0.84-1.05 1.12 0.77-1.64 
 
2008-2012 0.43 0.27-0.67 0.58 0.53-0.64 0.98 0.75-1.28 0.92 0.62-1.37 No data 
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During the process of model fitting, all univariate and multivariable models conformed to 
the assumption of proportional hazards using Schoenfeld residuals and all multivariable models had 
non-significant time-varying covariates except for the 61 day to 4 year multivariable model that had 
a significant time-varying covariate for age group (p=0.008).  Given the number of statistical tests 
performed during the process of model fitting it was possible that a significant result could have 
occurred by chance.  We identified several significant interaction terms between the categorical 
exposure variables and in many cases they improved the fit of the final model.  However as a priori 
we did not identify a possible mechanism for this interaction, the significant interaction terms were 
not included in the final models. 
Including women who were diagnosed with PID on the date of their first chlamydia test, the 
cumulative incidence of PID in tested women was 3.55% (3671/103,344 (95% CI 3.44-3.67)) in 
positive women and 2.01% (3658/181,998 (95% CI 1.95-2.07)) in negative76 women by the end of 
follow-up.  The same figures for the 12 month period following the index test were 1.28% 
(1326/103,344 (95% CI 1.21-1.35)) and 0.67% (1214/181,998 (95% CI 0.63-0.70%)) respectively.  The 
cohort attributable risk77 of chlamydia on PID in women tested for chlamydia in the 12 months 
following a test is 2.70% and 2.25% at the end of follow-up (Table 5.8) 
 
 
                                                          
76
 The 881 negative women who had an episode of PID before their first test in the dataset have been excluded.  
77
 These calculations include women who were diagnosed with PID on the date of their index chlamydia test.  
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Table 5.8: Summary of parameter estimates for tested women (a) at 12 months after their first test 
and (b) at the end of follow-up assuming a 3% prevalence of chlamydia 
Parameter a)12 months 
 (95% CI) 
b)End of follow-up 
 (95% CI) 
Incidence in chlamydia positive (Ie) 1.28% (1.21-1.35) 3.55% (3.44-3.67) 
Incidence in chlamydia negative (Iu) 0.67% (0.63-0.70) 2.01% (1.95-2.07) 
Relative risk  (RR = Ie/Iu)   1.92 (1.78-2.08) 1.77 (1.69-1.85) 
Attributable risk per 100 women 
(AR = Ie - Iu ) 
0.62 1.54 
Attributable risk percentage   
(AR% = [(Ie - Iu)/ Ie ) ]*100 
48.01% 43.42% 
Cohort attributable fraction  
(CAF = pe (RR-1) / [1 + pe (RR-1)] ) 
2.70% (2.29-3.13) 2.25% (2.03-2.48) 
 
 
5.4.4 Positive, negative and never tested women  
There were 459 women in the overall cohort who had an episode of PID on their date of 
entering the study who are excluded from the survival analysis.  The 516,261 women in this analysis 
contributed 4,056,463.4 person years (mean 7.86, range 1 day to 17.83 years) before the end of the 
study or censoring.  Kaplan-Meier plots of time to PID by chlamydia status, age at entry and year of 
entry are shown in Figure 5.3.  There was a significant difference between the survival curves 
described within each plot (log rank tests p<0.0001).  
The assumption of proportional hazards, determined using Schoenfeld residuals, was 
violated for all variables (chlamydia status (p<0.001); age at entry (p<0.001); year of entry (p<0.001)) 
in the univariate analysis and stratifying the analysis by age or year at entry did not address this 
issue.  The hazards were proportional for the first 14 days, but not for 15-30 days, therefore the data 
for the first 30 days was combined and analysed with rates and rate ratios.  For the remainder of 
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follow-up survival analysis was performed separately for time intervals that conformed to the 
assumption of proportional hazards (31-60 days; 61 days – 1.5 years; 1.5-2.5 years; 2.5-5 years; 5-7 
years; 7-10 years, 10-15 years and 15 – 17 years78).  For each time period the full analysis results 
(description of the data, the rate of PID and where performed the unadjusted and adjusted hazard 
ratios for PID) are presented in Appendix 18. 
The highest rate of PID was observed in the first 30 days of follow-up in positive women: 
40.08 per 1000 py (95% CI 36.03-44.59) this rate was over ten times higher than that seen in 
negative women (rate ratio 14.68 (95% CI 10.60-20.83)) and seventy times higher than in never 
tested women (rate ratio 75.88 (95% CI 40.76-159.69)) (Table 5.9).  In positive women, the rate of 
PID fell significantly at each successive time period spanning the first 2.5 years of follow up (from 
40.05 to 3.95 per 1000 py) then continued with a more gradual decline, as consecutive time intervals 
had overlapping confidence intervals, until 15 years (from 3.53 to 2.64 per 1000 py) when there was 
a significant decline to 1.42 per 1000 py.  The rate of PID in negative women was constant over the 
first 5 years of follow-up (2.53 to 3.02 per 1000 py) and across the interval between 1.5-15 years 
(2.99 to 2.25 per 1000 py) but fell significantly in the final interval.  The rate in never tested women 
was constant throughout follow-up (0.42 to 1.08 per 1000 py) except for a significant difference 
between the 31-60 days and 5-7 years intervals.   
With the exception of the final time interval, the rate of PID in women who were tested for 
chlamydia (positive women and negative women) was significantly higher than the rate in untested 
women.  During the first seven years of follow-up the rate in positive women was significantly higher 
than that of negative women, for the remainder of the study there was no difference between the 
rates of PID between positive and negative women.  
 The adjusted hazard ratio of PID was significantly higher in positive women and negative 
women compared to never tested women for the first 15 years of follow-up (range AHR 17.12 to 
2.78 in positive women and AHR 5.81 to 2.34 in negative women) (Table 5.10).  The relationship 
between the hazards in negative and positive women was variable.  The hazard was higher in 
                                                          
78
 The 30-44 age group was excluded from the analysis of the “15 years –end” time interval because there were fewer than 
5 women in the category.    
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positive women in the 61 days to 1.5 years and 2.5-5 years intervals, but otherwise they were 
comparable.     
During the process of model fitting, all univariate and multivariable models conformed to 
the assumption of proportional hazards using Schoenfeld residuals and all multivariable models had 
non-significant time-varying covariates except for the 10-15 year multivariable model that had a 
significant time-varying covariate for chlamydia status (p=0.025).  Given the number of statistical 
tests performed during the process of model fitting it was possible that a significant result could 
have occurred by chance.  We identified several significant interaction terms between the 
categorical exposure variables and in many cases they improved the fit of the final model.  However 
as a priori we did not identify a possible mechanism for this interaction, the significant interaction 
terms were not included in the final models. 
A comparison of the rate of PID in negative women following their first chlamydia test (Table 
5.6) compared to following entry to the cohort (Table 5.9) shows a significant difference in the first 
60 days of follow-up with the highest rates seen following a test.  
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Figure 5.3: Kaplan-Meier curves of time to PID from entry to the study by (a) chlamydia exposure; 
(b) age at entry; (c) year of entry 
 
a) 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
c) 
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Table 5.9: Summary of rate of PID (95% CI) per 1,000 person years by chlamydia status over time intervals with proportional hazards 
    0-30 days 31-60 days 61d-1.5 y 1.5-2.5 y 2.5-5 y 5-7 y 7-10 y 10-15 y 15-17 y 
Chlamydia status 
         
 
never tested 0.53 (0.28-0.98) 0.42 (0.21-0.85) 0.76 (0.67-0.87) 0.79 (0.68-0.92)  0.92 (0.83-1.01) 1.05 (0.92-1.19) 0.99 (0.86-1.14) 0.93 (0.78-1.11) 1.08 (0.66-1.76) 
 
negative  2.73 (2.01-3.71) 2.53 (1.84-3.48) 3.02 (2.81-3.24) 2.99 (2.75-3.26) 2.76 (2.61-2.92) 2.54 (2.36-2.73) 2.54 (2.37-2.73) 2.25 (2.07-2.46) 1.63 (1.21-2.20) 
 
positive 40.08 (36.03-44.59) 7.60 (5.95-9.71) 5.22 (4.85-5.62) 3.95 (3.58-4.36) 3.53 (3.28-3.79) 3.23 (2.92-3.56) 2.85 (2.56-3.17) 2.64 (2.32-3.00) 1.42 (0.84-2.40) 
 
Table 5.10: Summary of multivariable Cox models of risk of PID following entry to the study in positive women, negative women and never tested 
women, over time intervals with proportional hazards  
 
  31-60 days 61days-1.5 years 1.5 2.5 years 2.5-5 years 5-7 years 7-10 years 10-15 years 15 - 17 years 
    HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
Chlamydia status 
                
 
never tested baseline - - - - - - - - - - - - - - - 
 
negative  5.81 2.68-12.61 3.75 3.22-4.36 3.68 3.09-4.39 3.01 2.68-3.38 2.45 2.10-2.84 2.48 2.12-2.91 2.34 1.93-2.85 1.51 0.85-2.69 
 
positive 17.12 8.17-35.85 6.68 5.76-7.75 4.94 4.13-5.92 3.85 3.40-4.35 3.09 2.63-3.64 2.82 2.36-3.36 2.78 2.24-3.46 1.32 0.65-2.71 
Age at entry 
      
  
        
 
15-19 baseline - - - - -   - - - - - - - - 
 
20-24 1.44 0.89-2.33 1.14 1.01-1.28 1.01 0.88-1.16 1.07 0.97-1.18 1.14 1.00-1.30 1.12 0.99-1.27 0.89 0.76-1.03 0.64 0.38-1.07 
 
25-29 2.02 1.16-3.50 1.46 1.27-1.67 1.36 1.15-1.61 1.26 1.12-1.42 1.29 1.10-1.51 0.86 0.73-1.02 0.63 0.51-0.78 0.86 0.45-1.66 
 
30-44 2.47 1.30-4.71 1.66 1.39-1.97 1.38 1.11-1.72 1.25 1.06-1.47 1.27 1.02-1.58 0.64 0.47-0.86 0.75 0.51-1.10 no data 
Year of entry 
      
  
        
 
1995-2000 baseline - - - - -   - - - - - - - - 
 
2001-2007 0.66 0.42-1.04 0.71 0.63-0.79 0.75 0.65-0.87 0.78 0.71-0.86 0.96 0.86-1.08 1.02 0.91-1.14 0.89 0.70-1.13 no data 
 
2008-2012 0.70 0.43-1.15 0.66 0.58-0.75 0.73 0.62-0.86 0.89 0.79-1.00 0.83 0.56-1.23 no data no data    no data 
  Chapter 5 
185 
 
5.4.5 Repeat infections 
The 457 women who had PID on the date of their first positive test have been censored at 
entry and are not included in the analysis.  Kaplan-Meier plot of time to PID by number of infections 
demonstrates the lack of proportional hazards in the overall study dataset (Figure 5.4).  The 
assumption of proportional hazards was met by stratifying the data by age group.  Log rank tests of 
the Kaplan-Meier curves (not presented) by number of infections within each age group were 
significant for women aged 15-19 (p=0.0158) and 20-24 (p=0.0034) but non-significant for women 
aged 24-25 (p=0.1226) and 30-44 (p=0.3035).  The unadjusted risk of PID following a repeat positive 
test was around 20% higher than the risk following the first test in all age groups, but it only reached 
statistical significance in women under the age of 25 (HR 1.16 (95% CI 1.03-1.31) in women 15-19 
years and HR 1.23 (95% CI 1.07-1.42) in women 20-24 years) (Table 5.11).  The test for proportional 
hazards in the final model was marginally below the 95% level of significance, p=0.047.   
 
Figure 5.4: Kaplan-Meier plots of time to PID by number of previous infections, overall  
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Table 5.11: Unadjusted hazard ratio of PID following a repeat infection compared to a first 
infection by age group 
 
Age group at 
first test 
Number of 
positive tests 
Number of 
women 
Number 
with PID py HR 95% CI  
       15-19 1 33123 872 189587.1 baseline 
 
2 or more  12160 408 86950.26 1.16 1.03-1.31 
       20-24 1 34821 941 264341 baseline 
 
2 or more  7781 254 63154.98 1.23 1.07-1.42 
       25-29 1 14556 411 118713.9 baseline 
 
2 or more  1983 63 16305.21 1.23 0.94-1.61 
       30-44 1 8389 242 54479.14 baseline 
 
2 or more  685 23 4662.29 1.23 0.80-1.89 
 
 
5.5 Discussion 
5.5.1 Summary of main findings 
This study has identified heterogeneity in the risk of PID.  Chlamydia test participation, 
chlamydia test result, previous history of chlamydia and time since testing all affect the individual 
risk of PID.  We found that a chlamydia test, regardless of the result, increased the risk of PID 
throughout the reproductive lifetime by at least two-fold.  But the absolute risk of a hospital episode 
of healthcare for PID in this cohort was low, less than 2% of positive women had PID by one year and 
less than 4% by the end of follow-up.  The highest rate of PID was seen in the first 30 days following 
a positive test, this rate then declined significantly for next two and a half years, yet remained higher 
than the rates seen in never tested women across fifteen years of follow-up.  When the analysis was 
restricted to women who were tested for chlamydia, the risk of PID at any time was over 20% higher 
in positive women compared to negative women except for the 30-60 day interval after the baseline 
test.  Negative women had at least a two-fold higher rate of PID in the first 60 days following a test 
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compared to following entry to the cohort.  The risk of PID was also 20% higher following a repeat 
positive test.  Further exploration of the low rate of PID in never tested women is warranted.  
The contribution of diagnosed chlamydia to PID is low.  Less than half of PID at 12 months 
can be attributed to the baseline positive chlamydia test in women with a positive test, and in the 
overall cohort of tested women, less than 3% of cases of PID that developed within the first year of 
the baseline test could be attributed to a positive result.   
This discussion section will include a critical appraisal of the study design and methods used 
in this chapter which will build on the appraisals presented in chapter 2, 3 and 4 and focus on the 
specific design features of the Denmark Chlamydia Study to avoid repetition.  It will then include a 
comparison of the findings in relation to other studies.  However a discussion of the potential 
interpretation of these findings will be presented in the concluding chapter along with an 
interpretation of the findings of chapter 2 and chapter 4. 
 
5.5.2 Study design  
This study was a secondary analysis of a sub-set of a large, retrospective, observational 
population-based dataset that was constructed from timely and complete administrative health 
data.  These factors confer many of the same limitations and strengths that were outlined in the 
discussion of chapter 3 for the Manitoba Women’s Reproductive and Sexual Health cohort.  Briefly 
these include an unequal distribution of unmeasured confounders between the exposure groups 
which means that a causal relationship between exposure and outcome cannot be determined; 
misclassification bias in exposure and outcome assessment; limited resource requirements and a low 
risk of potential harm to data participants.  The decision to use a case-control design for the 
Denmark Chlamydia Study rather than a cohort was a pragmatic choice taken by the steering group 
for this programme of research to limit the size of the study population whilst retaining the ability to 
produce generalisable findings.   
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5.5.3 Bias 
The potential for misclassification bias from the use of administrative health data to define 
exposure to chlamydia and PID has been discussed in section 3.5.2.  A strength of the Denmark 
Chlamydia Study is that it had complete ascertainment of all chlamydia tests performed in Denmark 
during the study period, therefore any misclassification bias in the original dataset comes from the 
use of test history to define a woman’s status.  I recoded chlamydia exposure status during the 
formation of this study cohort to reflect exposure during the study dataset rather than lifetime 
exposure.  This meant that a proportion of “negative” women were reclassified as never tested.  
These women could have had their chlamydia test before or after their period in the study cohort 
therefore there is uncertainty about whether they had a risk factor for chlamydia before entry to the 
study cohort.  The effect of this bias would be to reduce the observed difference in the risk of PID 
between negative women and never tested women.  Notification of chlamydia changed from 
voluntary to compulsory in Denmark in 1994.  Therefore starting the study in 1995 may have 
reduced ascertainment bias in test data based on the location of the testing laboratory.   
PID outcomes in this dataset were limited to hospital presentations (in-patient, out-patient 
and emergency department presentations).  If under ascertainment of PID cases managed in the 
community occurred equally across chlamydia exposure groups then this non-differential 
misclassification bias will have reduced the observed rate of PID compared to actual rate but will not 
have changed the rate ratio between the exposure groups.  However it is possible that the severity 
of an episode of PID (which will be directly related to the location of treatment) may be related to 
chlamydia exposure.  Authors have suggested that PID that follows chlamydia may be less severe 
than that following other infectious agents and therefore chlamydia negative women with PID may 
be more likely to appear in the hospital dataset (Reekie et al., 2014, Short et al., 2009).  This would 
reduce our estimates of the association between chlamydia and PID but we cannot explore this 
effect without additional data on the distribution of other causes of PID.  On balance, this is more 
likely to be a theoretical than an actual concern in this setting because a major agent of severe PID is 
gonorrhoea and the number of cases in women in Denmark is very small (Statistics Denmark, 2012).  
The Danish Chlamydia Study was generated with minimal selection bias.  All women who 
had a positive test were eligible to be included and the selection criteria were unrelated to 
chlamydia and PID status (residency status and data completeness).  There was no bias in the 
selection of negative and never tested women as people who met the matching criteria were 
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selected at random from the dataset.  The additional inclusion criteria used to generate the dataset 
used in this chapter may have introduced a bias.  To reduce the potential for this, any women that 
were excluded were excluded with all the members of their 5-person set and every 5-person set had 
to include five women.   
The structure of the original dataset has introduced a bias in the duration of follow-up.  
Positive, negative and never tested women did not enter the dataset at a time that was based on 
their individual circumstance e.g. age or chlamydia risk.  Instead, negative and never tested women 
entered the dataset on the date of the first positive chlamydia test in the woman they were linked to 
and positive women entered at a time when they were considered at risk for chlamydia.  The impact 
of this design feature is especially pertinent because we performed the analysis over discrete time 
periods with proportional hazards rather than generating an overall hazard.  The likely effect of this 
bias is to inflate the risk of PID in positive women compared to negative women, particularly in the 
early time intervals.  In an attempt to mitigate this bias and explore the magnitude of its effect, the 
analysis was also performed with positive and negative women entering on the date of their first 
chlamydia test.  
 
5.5.4 Validity 
The internal validity of this study depends on the consistency of the relationship between a 
positive chlamydia test and a diagnosis of PID.  I discussed the implications of a change in the 
sensitivity of the diagnostic test in section 3.5.3.  In this dataset the cross-over period from the 
majority of tests being non-NAAT to the majority being NAAT was in 1999/2000.  We adjusted the 
analysis for either year of entry to the study or year of first test, partially to control for this effect.  
Future work could improve on this by adjusting the analysis for the type of chlamydia test that was 
performed, e.g. culture, EIA, DIF or NAAT, as this has been shown to alter case detection rates 
(Westh and Kolmos, 2003).  
As we did not have complete ascertainment of PID cases, the validity of the study may be 
affected by changes in clinical practice that altered the location of healthcare (independent of 
clinical severity).  There is debate over whether the decline in PID hospitalisations reported in 
virtually all studied populations can be attributed to a change in healthcare policy, but if this was the 
case, we would observe a weakening of any relationship between chlamydia and PID over time.  We 
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started the study in 1995, to improve the internal validity of our definition of PID as this was the year 
that coding changed from ICD-9 to ICD-10 and out-patient and emergency department data was 
added to the hospital dataset.  As discussed in chapter 3, there are concerns over the validity of ICD 
definitions of PID but we used a broad definition to improve ascertainment.  There is only one 
published study evaluating the validity of the LPR dataset that did not demonstrate validity for 
diagnoses of multiple sclerosis (Mason et al., 2012). However this is a very different clinical condition 
to PID and the authors caution against applying this conclusion to other diagnoses in the absence of 
direct evidence.   
The major strength of this study is that it was drawn from the complete population of 
Denmark which means that it is representative of the country and it is considerably larger than all 
previous studies.  These factors will increase the strength of statistical associations and improve the 
generalisability of the findings to other settings.  One caveat is that the overall study population is 
not representative of the underlying Danish population because the proportion of positive and 
negative/never tested women was specified by the study design rather than their distribution in the 
population.  Therefore this study cannot be used to make statements about the prevalence of 
chlamydia or overall rate of PID in the population but provides detailed information on the rate of 
PID within chlamydia exposure groups.   
This dataset is also the first study of this type that is not a birth cohort.  This will further 
enhance generalizability provided other settings experienced secular trends at comparable times.  
There is a question about how generalisable the findings are from the time intervals towards the end 
of the study, for example post 15 years as these analyses include a specific group of women (under 
30 at the start of the study and were not censored or lost to follow-up) but this data may provide 
insights relevant to this particular population group.  
 
5.5.5 Confounding  
We adjusted the analysis for year of entry (or test) and age at entry (or test) but we did not 
interpret these findings as the distribution of these variables across the exposure groups will be 
more similar than expected by chance due to the design of the original study.  We did not adjust for 
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gonorrhoea79 because this is rare in women in Denmark and we did not adjust the analysis for region 
of residence because of the relative absence of income, social and geographic inequalities in health 
in Denmark.  However this may have meant that the analysis was not adjusted for the unmeasured 
effects of sexual networks and widespread effects of control interventions. 
 
5.5.6 Strengths and limitations of statistical analysis 
The Cox proportional hazards model is a non-parametric approach for modelling time to 
event data.  In this analysis, the assumption of proportional hazards was violated by all the variables 
explored in the univariate analysis.  This event is not unexpected given the nature of the dataset: as 
positive women enter the dataset on the date of a positive chlamydia test it is reasonable to 
hypothesis that their highest risk of PID (related to this testing episode) will occur in the immediate 
time interval after diagnosis (either in the interval between testing and treatment or from 
reinfection within the same sexual partnership) and that this risk of PID will decline, on average, over 
time from diagnosis as infections are cleared.  It is plausible that the average risk profile of a positive 
woman will tend towards that of a negative woman as time from the index test increases as they 
both undergo testing and treatment.  The hazard in never tested controls could be expected to show 
less fluctuation with time as they may not have a risk factor for chlamydia testing (and therefore 
sexually transmitted causes of PID).   
We considered several options for addressing the violation of proportional hazards.  
Stratifying the analysis was rejected because stratifying by age or year did not correct the lack of 
proportional hazards in the two main analyses.  The use of time-varying covariates was rejected 
because they impair the interpretability of the hazard ratios.  The use of a parametric survival 
analysis model was rejected, for this analysis, as this technique requires the correct identification of 
the appropriate probability distribution for the PID events to avoid biasing the results and there 
were time constraints for completing the analysis.  Future work should explore the difference in the 
findings from an appropriate parametric model and the non-parametric approach.  The decision to 
divide follow-up time into discrete periods seemed like an appropriate method given the nature of 
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 The exposure was not included in the original dataset, most likely because of its rarity.  
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the accepted association between chlamydia and PID: it is plausible that the relationship is only 
causal during the interval of an acute infection which has an estimated duration in the absence of 
treatment of 12 to 18 months (Geisler, 2010, Price et al., 2013). 
It was not possible to stratify the analysis of repeat testing by year of first test because the 
univariate analysis did not conform to proportional hazards.  This approach was attractive because 
the of the altered immunity hypothesis that suggest the risk of PID goes down as prevalent cases are 
treated because their shorter duration means that women do not develop the immune mechanisms 
that contribute to later PID episodes.  If we assume that the earlier the year of the first test, the 
more likely a woman is to have had a previous undetected positive tests, stratifying by year of test 
may have provided insights into the association between chlamydia and PID.    
We compared risk across three chlamydia exposure groups and adjusted all analysis for the 
age and year.  An alternative approach would have been to perform the analysis with a single 
comparator group (negative and never tested combined) but we hypothesised that there were 
interesting differences between negative (i.e. tested) and never tested controls.  In addition, it is 
challenging to interpret the findings from an earlier population-based cohort because the never 
tested comparator group was a composite of women before their first chlamydia test and women 
who had a lifetime without a test (Low et al., 2006).  Ideally, we would have performed a sensitivity 
analysis with one negative woman and one never tested woman per positive women.  However due 
to the distribution of women without a positive test in the Danish population and therefore the 
resulting composition of the 5-person sets, this would have reduced the size of the dataset by 25% 
and may have excluded certain population groups (e.g. age groups with high participation with 
testing).   
In the Cox regression analysis presented in this Chapter, follow-up time was divided into 
multiple time intervals (up to 9 per analysis) to satisfy the assumption of proportional hazards.  
Therefore we constructed up to 9 multivariable regression models to describe the risk of progression 
from chlamydia to PID in each cohort of women defined by their chlamydia test status.  In contrast, 
if the assumption of proportional hazards been met by the overall cohorts we would have 
performed a single regression analysis for each dataset.  This necessary increase in the number of 
statistical analyses performed provides an illustration for the common problem of interpreting the 
statistical significance of analyses performed in the context of multiple testing.   
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In this thesis we have used the 95% level of significance for hypothesis testing.  This means 
that there is a 5% chance of incorrectly rejecting the null hypothesis when it is true.  As the number 
of hypotheses that are tested in an analysis (or the number of statistical comparisons that are made) 
increases, the probability of encountering a type 1 error will increase.  Therefore as the number of 
hypotheses that are tested increases, the probability of incorrectly rejecting a null hypothesis also 
increases,       
In this Chapter, we did not use any formal methods to adjust for the problem of multiple 
comparisons80, instead we accepted the assumption of proportional hazards for each multivariable 
model presented, despite a single significant hazard ratio for a time varying covariates amongst the 
15 and 27 hazard ratios calculated for the time varying covariates for each respective cohort.   
 
5.5.7 Comparison with other studies 
The rate of PID in the first thirty days following a positive chlamydia test was 4.01% per year 
(95% CI 3.60-4.46) in women who tested positive for chlamydia and the cumulative incidence of PID 
at 12 months following a test was 1.28% (95% CI 1.21-1.35) in women who tested positive (and we 
assume were treated).  This is clear evidence that the risk of PID is higher in the immediate interval 
following a test as seen in a recent study in the Australian general population (Reekie et al., 2014).  
However the incidence of PID in Denmark at 12 months was lower than observed in the POPI RCT, 
1.6% (95% CI 1.1-2.1) and the Manitoba cohort 5.27% (95% CI 4.57-5.95)(Oakeshott et al., 2010). The 
comparative figures for cumulative incidence at 12 months following a negative test were 0.67% 
(95% CI 0.63-0.70) in Denmark and 1.90% (95% CI 1.80-2.00) in Manitoba.  The lower risk in Denmark 
may reflect the absence of community cases, but the lower RR at 12 months compared to Manitoba 
(Denmark: RR 1.92 (95% CI 1.78-2.08)) and Manitoba: RR 2.77 (95% CI 2.41-3.20)) suggested than 
there may be an additional explanation, possibly the fact that negative women in the Manitoba and 
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 A simple method for addressing the problem of multiple comparisons in the Bonferroni Correction.  In this 
technique, the chosen level of significance is divided by the number of hypotheses to be tested in an analysis 
and the p value for each test statistic is then compared to this lower value.  For example, if 5 tests are to be 
performed at the 95% level of significance, the probability the p values of the test statistics will be compared 
to is equal to 0.05 divided by 5 or 0.01. 
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POPI studies could go on to have a positive test within the time period which was not possible in 
Denmark.  
The cumulative incidence of PID in Denmark by the end of follow up in women with a 
positive chlamydia test was intermediate between the estimates from Uppsala and Sør-Trøndelag 
but much lower than the estimate from Manitoba (Denmark: 3.55%  (95% CI 3.44-3.67); Uppsala: 
5.6% (95% CI 4.7 to 6.7%);  in Uppsala; Sør-Trøndelag:  1.09% (95% CI 0.82-1.44); Manitoba 14.81% 
(95% CI 13.71-15.91)) (Bakken and Ghaderi, 2009, Low et al., 2006). The same pattern was seen for 
women who tested negative (Denmark: 2.01% (95% CI 1.95-2.07); Uppsala: 4.0% (95% CI 3.7-4.4); 
Sør-Trøndelag: 0.70% (95% CI 0.59-0.82); Manitoba: 7.87% (95% CI 7.67-8.07)).  And the incidence in 
never tested women was also lower in Denmark than Uppsala (Denmark: 0.60% (95% CI 0.57-0.63); 
Uppsala: 2.9% (95% CI 2.7-3.2)).  As discussed in chapter 4, the higher incidence in Manitoba is likely 
to reflect the inclusion of community diagnosed cases.  The remaining three studies were limited to 
hospital presentations and differences may reflect population factors including the prevalence of 
STIs or features of the study design.  
It is challenging to compare the absolute values of the adjusted hazard ratios from the 
analysis presented in this chapter to estimates from chapter 4 or other published cohort studies 
because the hazards cover discrete time intervals.  However the same overall patterns are seen: a 
single positive test can increase the risk of PID by at least 20% across the reproductive lifetime 
compared to women with a negative test (apart from the interval 30-60 days following a test).  Given 
the design of the original study it was not possible to explore for the heterogeneity in risk by age and 
year of test that was demonstrated in Manitoba.    
This study builds on the evidence from Manitoba that a repeat positive test can increase the 
risk of subsequent PID by 20%, particularly in young women.  We used the same methodology to 
estimate the cohort attributable fraction of chlamydia on PID in the 12 months following a test in 
Denmark and Manitoba and the risk in both settings was very low.  However it was lower in 
Denmark (2.70%) compared to Manitoba (8.86%).  There are several differences between the 
datasets that may contribute to this difference: the Manitoba analysis includes PID diagnosed in the 
community and cases of PID diagnosed on the date of the index chlamydia test.  The estimate of 
chlamydia prevalence may have been more accurate for Manitoba as it was estimated from the 
dataset compared to in Denmark where we used the literature.  But it is interesting despite these, 
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and other differences between the populations (e.g. gonorrhoea rates; age distribution) the cohort 
attributable fraction estimates were broadly comparable.   
   
5.5.8  Further analysis 
It would be interesting to perform additional analyses to explore the source of the variation 
between the estimates from Manitoba and Denmark.  This dataset also provides an opportunity to 
perform a sensitivity analysis of the different methods used by Low et al. and Bakken et al..  
However it was not possible to do this with a semi-parametric analysis as multiple hazard ratios 
were generated for each analysis.  Further analysis should include:  
 Determine the validity of our PID definition for a case of PID in the hospital medical record; 
 
 Move date of the chlamydia test backwards if a woman had an outcome around the time 
of entering the study (as seen in the Manitoba cohort and (Reekie et al., 2014)).  The aim of 
this is to quantify the risk of PID over the lifetime that includes immediate progression 
before treatment;    
 
 Limit outcomes in Manitoba to hospital presentations and compare to the cumulative 
incidence of PID at 12 months and 15 years in Denmark; 
 
 Compare Cox proportional hazards regression to results from an appropriate parametric 
model.  
 
 
5.6 Conclusion  
We have used a cohort constructed from a population-based case-control study to 
demonstrate that women in Denmark have an elevated risk of PID following a chlamydia test that 
lasts for fifteen years.  This risk of PID is significantly higher in women with a single positive test 
compared to women who test negative.  A subsequent positive test also elevated the risk of PID in 
young women.  The proportion of PID in tested women by 12 months that could be attributed to an 
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initial positive test was very small, which suggests as we saw in Manitoba, the baseline chlamydia 
infection is not the main cause of PID.  The cause of the majority of PID seen within 12 months is not 
yet known.  There was a low background rate of PID in women who were never tested for 
chlamydia, it may be appropriate to perform a clinical audit to determine why women with PID were 
not tested for chlamydia.  
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6 6 
Chapter 6  
Conclusion: the association between chlamydia 
and pelvic inflammatory disease  
  Chapter 6 
198 
 
6.1 Overview 
In this thesis I have described three observational studies that have been used to advance 
the evidence base for chlamydia testing interventions by improving estimates of the risk of PID 
following chlamydia that can be used to parameterise mathematical models.  In combination with 
other research, these findings can be used to improve the accuracy and therefore utility of estimates 
of the population-level impact and cost-effectiveness of chlamydia testing interventions for policy 
makers.  
In this chapter I draw together the findings from chapters 2, 4 and 5 on the relationship 
between chlamydia and PID.  The main observations I explore are the increased lifetime risk of PID 
following any chlamydia test and the higher risk following a positive test; heterogeneity in the risk of 
PID based on age, co-infection, year of test, time since test and repeat infection; and the low cohort 
attributable fraction of diagnosed chlamydia on PID.  I consider the potential mechanisms that may 
underlie or drive these observations and consider their implications for chlamydia control policy.   
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6.2 Observed association between chlamydia and PID 
6.2.1 Overview 
In each of the analytic chapters in this thesis an observational study was used to explore the 
association between chlamydia81 and PID82.  Even though there were marked variations in the 
individual study designs, populations, chlamydia test method and PID case ascertainment, we have 
observed strikingly consistent associations between chlamydia and PID.   
 
6.2.2 Comparison of the studies  
There are interesting and relevant differences between the populations studied in this thesis 
that need to be considered in order to appropriately compare the findings.  Chapter 2 described a 
historic cohort of high risk women in a clinical setting who had a high burden of genital infection, PID 
and other morbidities (Ward and Day, 2006, Ward et al., 2004, Ward et al., 1993, Ward et al., 1999).  
Chapter 4 analysed a novel birth cohort of women who participated with chlamydia testing in a 
setting with geographic inequalities in STIs (Blanchard et al., 1998, Elliott et al., 2002).  Chapter 5 
considered a representative sample from a national population in a setting with widespread 
population-based chlamydia testing and limited evidence of inequality (Diderichsen et al., 2012, 
Westh and Kolmos, 2003).  
A critical appraisal of each study has been presented at the end the relevant chapter and is 
summarised in Table 6.1.  Briefly, the findings from all three studies are limited by misclassification 
bias in chlamydia status and PID diagnosis.  Chlamydia tests are an incomplete source of information 
about the occurrence of infection, biased by healthcare seeking behaviour, test performance and the 
inability to discriminate between persistence and repeat infection.  Clinical diagnoses of PID suffer 
from low validity and diagnostic bias.  We were able to explore the impact of a variety of 
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 Chlamydia was defined based on the presence of a positive test in chapters 2, 4 and 5.   
82
 PID was defined as healthcare presentations with an appropriate ICD code in administrative datasets in chapters 4 and 5 
and a clinical diagnosis from the medical notes in chapter 2.  In the remainder of this chapter both of these definitions are 
referred to as “a diagnosis of PID”.  
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Table 6.1: Summary of the methods and findings from the analytic work presented in this thesis 
Methods Praed Street Cohort Manitoba Cohort Denmark Cohort 
Population Sex workers, over 16 years in London  Manitoba residents, 12-24 years in 1992-1996, 
tested for chlamydia  
Denmark residents, 15-44 years in 1995-
2012 
Design  Prospective clinical cohort Retrospective cohort of administrative data  Retrospective cohort of administrative data 
Date 1986-1993 1992-2008 1995-2012 
Size 300  70,000 500,000 
Chlamydia  Lower sensitivity tests (DFA and EIA);  
potential incomplete ascertainment  
Lower sensitivity EIA, replaced by high 
sensitivity NAAT; high ascertainment   
Lower sensitivity antigen methods, replaced 
by high sensitivity NAAT; complete 
ascertainment  
PID  Likely to be most accurate; obtained from 
clinical records from specialist clinic; risk of 
incomplete ascertainment 
Uncertain validity of definition; complete 
ascertainment of community and hospital 
cases 
Uncertain validity of definition; complete 
ascertainment of hospital cases; no 
community cases 
Main limitations Small size; historic; potential selection bias; 
under ascertainment of exposure and 
outcome  
Excludes never tested women Under ascertainment of PID 
Main strengths Prospective design; incidence of other 
genital infections; repeat infections  
High ascertainment of PID; first three repeat 
tests 
Size; complete ascertainment of chlamydia 
tests   
Adjustment Age at diagnosis; repeat infection;  
gonorrhoea 
Age at test; year of test; region of residence; 
repeat infection   
Age and year at entry to study or test; repeat 
infection  
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Main findings Praed Street Cohort Manitoba Cohort Denmark Cohort 
Chlamydia   Prevalence at baseline test 8.54% Prevalence at baseline test 5.48% - 
Cumulative 
incidence of PID  
 At 12 months: 5.27% in positive and 1.90% in 
negative; RR 2.77 (95% CI 2.41-3.20) 
At 12 months*: 1.28% in positive; 0.67% in 
negative; RR 1.92 (95% CI 1.78-2.08) 
 At 7 years: 26.00% in women with 
chlamydia and 13.62% in women without;  
RR 1.91 (95% CI 1.09-3.34) 
At 15 years: 14.81% in positive and 7.87% in 
negative; RR 1.88 (95% CI 1.74-2.04) 
At 15 years*: 3.55% in positive; 2.01% in 
negative; 0.60% in never tested; RR 1.77 
(95% CI 1.69-1.85) positive to negative 
Adjusted hazard 
ratio for PID  
Two-fold increased risk from a recent 
chlamydia exposure  
50% increase in lifetime risk following single 
positive test compared to negative test 
Increase in lifetime risk following single 
positive test compared to negative test and 
never tested that declines with time (42% to 
26% and 17-fold to 3-fold respectivelyø) 
Age Protective (6% per year) Highest risk in 12-15 year olds - 
Repeat infection  84% increase in risk  13-23% increase after 1 infection; 35% after 2 
infections 
16-23% increase risk  
Year  - Highest risk if tested pre-1997 - 
Attributable risk 
percent 
End of study: 47.62% 12 months: 63.95% 12 months: 48.01% 
Cohort 
attributable 
fraction  
 12 months: 8.86% 12 months: 2.67% 
End of study: 7.20%  End of study: 4.61% End of study: 2.25% 
*Estimates report analysis of positive and negative women entering on date of first test, except for ø that is comparison of positive and never tested (excluding period 15 years-end)
  Chapter 6 
202 
 
confounding factors (repeat infection; age; year; co-infection) on the relationship between 
chlamydia and PID but no studies controlled for the effect of sexual behaviour, healthcare seeking 
behaviour or antibiotic treatment on the underlying relationship.  The effect of unmeasured 
confounders has reduced our ability to draw firm conclusions and the following discussion should be 
interpreted in this light.  We assumed that women in all of these studies who had a positive 
chlamydia test were appropriately and promptly treated.  Therefore we have not observed the 
natural history of untreated infection rather the burden of PID that remains despite participation 
with chlamydia testing.  
 
6.2.3 Synthesis of observations 
In the setting of widespread population-based chlamydia testing the risk of PID 12 months 
after a positive chlamydia test was much lower than the estimate of 22% commonly used in 
mathematical models of chlamydia interventions (cumulative incidence of PID in Manitoba 5.27% 
(95% CI 4.57-5.95) and in Denmark 1.28% (95% CI 1.21-1.35))(Herzog et al., 2012b) (Table 6.1).  A 
positive chlamydia test was associated with a two-fold increase in the risk of PID at 12 months 
compared to women who tested negative (RR 2.77 (95% CI 2.41-3.20) in Manitoba and RR 1.92 (95% 
CI 1.78-2.08) in Denmark).  This increased risk was also present across the entire duration of follow-
up (cumulative incidence of PID in positive compared to negative women: PSP 26.00% (95% CI 13.84-
38.15%) compared to 13.62% (95% CI 9.43-17.81), RR 1.91 (95% CI 1.09-3.34); Manitoba 14.81% 
(95% CI 13.71-15.91) compared to 7.87% (95% CI 7.67-8.07), RR 1.88 (95% CI 1.74-2.04); Denmark 
3.55% (95% CI 3.44-3.67) compared to 2.01% (95% CI 1.95-2.07), RR 1.77 (95% CI 1.69-1.85)) . 
It is difficult to interpret the significance of this consistent ratio as there were marked 
differences in the study designs and populations but they are unlikely to have occurred in all three 
settings through chance.  In the previously published cohorts from Sør-Trøndelag, Norway and 
Uppsala, Sweden the magnitude of the difference between the cumulative incidence of PID in 
chlamydia positive and negative women was not as pronounced (cumulative incidence of PID in 
positive compared to negative women by the end of follow-up : Sør-Trøndelag 1.09% (95% CI 0.82-
1.14) and 0.70% (95% CI 0.59-0.82); Uppsala, 5.6% (95% CI 4.7-6.7) and 4.0% (95%CI 3.7-4.4)) 
(Bakken and Ghaderi, 2009, Low et al., 2006).  But taken together these five studies provide strong 
consistent evidence that women with a positive chlamydia test, that we presume has been treated, 
remain at increased risk of a diagnosis of PID.  
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There are marked differences in the absolute risks of PID across the studies in this thesis 
(from 26.00% to 3.55% in positive women and 13.62% to 2.01% in negative women).  Possible 
explanations for these differences are likely to include PID case ascertainment (high in Manitoba, 
uncertain in PSP, low in Denmark), differences in the aetiology of PID (higher rates of gonorrhoea in 
PSP and Manitoba than Denmark) and the age-structure of the populations.  Comparing the adjusted 
hazard of PID across the studies is a potentially more meaningful comparison of the observed 
increased risk of PID in women with a positive chlamydia test.  
There is a remarkable consistency in the adjusted hazard of PID in women with a positive 
chlamydia test compared to women without a positive test.  It was 2.03 (95% CI 0.75-5.49) in PSP83, 
1.55 (95% CI 1.43-1.70) in Manitoba84 and 1.42 (95% CI 1.32-1.53) in Denmark85.  There are no 
significant differences between these values and those reported from Sør-Trøndelag (1.69 (95% CI 
1.21-2.37)) and Uppsala (1.27 (95% CI 1.04-1.55)).  Again, this similarity is challenging to interpret 
because of the considerable differences between the studies and the factors that were adjusted for 
in the analyses.  However the addition of the three studies in this thesis means that there is now 
strong evidence that women with a treated positive chlamydia test remain at significant increased 
risk of a diagnosis of PID after adjustment for confounding factors.  
We were able to explore the impact of a repeat infection on the risk of PID in each of the 
three studies reported in this thesis.  Despite a variable definition of a repeat infection86, the 
adjusted hazard of PID following a repeat infection was consistent across the studies: 1.84 (95% CI 
0.96-3.54) in PSP, 1.17 (95% CI 1.06-1.30) after one repeat infection and 1.35 (95% CI 1.04-1.75) 
after two repeat infections in Manitoba; 1.23 (95% CI 1.07-1.42) in women aged 20-24 in Denmark.  
These studies provide strong evidence that the risk of PID following a repeat positive chlamydia test 
is higher than the risk following the initial event.  The risks we observed were similar in magnitude to 
those reported in a cohort of sex workers from Kenya (OR 1.8 (95% CI 1.3-2.4)) (Kimani et al., 1996) 
                                                          
83
 Women with a positive chlamydia test in the last 6 months compared to women without a positive test (either negative 
or not tested) in the last 6 months adjusted for age, current gonorrhoea and previous chlamydia and gonorrhoea. 
84
 Women with a positive test at entry to the cohort compared to women with a negative test (women in both groups 
could go on to have further positive or negative tests) adjusted for age at test, year of test, region of residence. 
85
 Women with a positive test at baseline compared to women with a negative test at baseline and no future positive test 
adjusted for age at test and year of test. The hazard is presented for the time period 61 days to 4 years after the baseline 
test.  
86
 PSP: a past history before the cohort or an infection in the cohort more than 6 months ago; Manitoba: a repeat diagnosis 
at one of the first 3 tests during the cohort, each ≥60 days apart; Denmark: a repeat infection ≥30 days after a previous 
diagnosis at any point during follow-up.  
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and a retrospective population-based cohort in Wisconsin87 (AOR 4.0 (95% CI 1.6-9.9)) (Hillis et al., 
1997). There is debate in the literature about whether repeat infections increase the risk of PID in an 
additive or cumulative fashion (Haggerty et al., 2010).  We have been able to provide limited 
evidence from Manitoba that this risk may be additive.   
It was only possible to study the effect of gonorrhoea co-infection on the relationship 
between chlamydia and PID in the PSP cohort where we found that gonorrhoea was a risk factor for 
PID.  Women with a previous gonorrhoea infection were twice as likely to be diagnosed with PID as 
women without a previous infection (AHR 2.28 (95% CI 1.14-4.56)).  It is not possible to compare this 
estimate as the Wisconsin cohort that adjusted for the presence of gonorrhoea does not present a 
separate risk estimate for gonorrhoea (Hillis et al., 1997).  We found that age was protective against 
PID in the PSP and Manitoba cohorts which supports the well-established relationship between age 
and PID: the risk of PID declined by 6% per year in the PSP cohort (AHR 0.94 (95% CI 0.88-1.00) and 
the risk of PID was significantly lower in women who were over the age of 30 at the time of their first 
test, compared to under 16 in Manitoba (AHR86 1.55 (95% CI 1.22-1.98)).  Finally, we present novel 
estimates from Manitoba that suggest that women who had their baseline test after 1996 had a 
significantly lower risk of PID than women who had their baseline test at the start of the study: 
AHR88 0.63 (95% CI 0.59-0.67) in 1997-2000 compared to 1992-1996.   
The estimates of the cohort attributable fraction of chlamydia on PID presented in this thesis 
are the first attempts to quantify this important parameter.  We found that approximately half of 
the cases of PID that occurred in chlamydia positive women by 12 months could be attributed to 
their initial positive test (Manitoba 63.95% and Denmark 48.01%).  But in the overall population of 
women who were tested for chlamydia, fewer than 10% of cases of PID that developed within 12 
months could be attributed to a positive baseline chlamydia test (Manitoba 8.86%; Denmark 2.67%) 
and by the end of follow-up this proportion was less than 5% (Manitoba 4.61%; Denmark 2.25%).  
The difference in the magnitude of the association in the different settings could reflect the higher 
PID case ascertainment and higher assumed prevalence of chlamydia in Manitoba or other 
differences in the underlying risk of PID in positive and negative women in each setting. 
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 Risk following a second positive test adjusted for age, gonorrhoea, ethnicity, place of residence, type of healthcare 
setting and date. 
88
 This is the AHR following the first chlamydia test in the dataset.  
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In the following sections I will explore the potential mechanisms for the observed 
associations between chlamydia, chlamydia testing and PID, including the role of confounding 
factors, to provide additional insights that may inform the structure and parameterisation of 
mathematical models.  
 
6.3 Mechanism of the association between chlamydia and PID 
Chlamydia is an accepted and established cause of PID, clinical studies show that women 
with untreated chlamydia have an increased risk of PID and interventional studies have indirectly89 
demonstrated that diagnosing and treating infection can decrease this risk by 40% (European Centre 
for Disease Control and Prevention, 2014, Haggerty et al., 2010, Rahm et al., 1986, Stamm et al., 
1984).  Most of these studies have reported on the very short term risk of PID assumed to be 
mediated by the direct ascension of chlamydia through the cervix, often in the interval between 
testing and treatment.  A proportion of the association between chlamydia and PID that we have 
observed is likely to be caused by this mechanism: the rate of PID following a positive test declined 
significantly with time since the test in Denmark (4.01% per year at 0-30 days and 0.76% per year at 
31-60 days) and Kaplan-Meier plots from Manitoba illustrate an immediate divergence in risk 
following the initial chlamydia test in positive and negative women.  
However the elevated risk of PID that we observed extends beyond the interval where active 
infection, that can ascend through the cervix, is likely to remain: under 21 days in the presence of 
appropriate and effective treatment (Renault et al., 2011) and between 12 to 16 months in the 
presence of natural clearance following treatment failure or non-compliance90 (Geisler, 2010, Price 
et al., 2013).  This is demonstrated by the continual divergence of the Kaplan-Meier survival curves 
in Manitoba and the elevated risk of PID in positive women in Denmark that persisted throughout 
follow-up.  The most likely explanation is that the positive chlamydia test is acting as a marker for a 
risk (a confounder) that was not adjusted for in these analyses and does not act through direct 
ascension of chlamydia organisms present at the time of diagnosis.   
                                                          
89
 These studies report the benefit from the offer of a screening test (Andersen et al., 2010, Oakeshott et al., 2010, 
Ostergaard et al., 2000, Scholes et al., 1996).  
90
 Treatment failure may be in the order of 2% for doxycycline and 3% for azithromycin (Lau and Qureshi, 2002).  
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Diagnostic bias in relation to PID must be given serious consideration as a potential cause for 
the lifetime elevated risk of PID following a positive chlamydia test.  Studies have demonstrated the 
poor validity of a clinical diagnosis of PID to represent the presence of signs and symptoms that 
meet the local diagnostic criteria for PID (Morris et al., 2014, Peipert et al., 2001) which suggests that 
clinicians are drawing on other information in order to make their diagnosis.  It’s reasonable to 
assume that this will include a woman’s past medical history of STIs and again, it seems appropriate 
that a positive answer (i.e. a past history of chlamydia or gonorrhoea) may bias the differential 
diagnosis towards PID, particularly given the evidence that treatment delay can worsen prognosis 
(Hillis et al., 1993, Haggerty et al., 2010).  The inexplicit reasoning behind this diagnostic bias is most 
likely to be that if a woman has had one STI then she will be at more risk of another, compared to 
average, and this infection could progress to cause PID (Haggerty et al., 2010).  This is a well-founded 
assumption if you look at the epidemiology of STIs: you are only at risk of an STI if you have 
unprotected sex with someone with an STI.  So women who have their chlamydia diagnosed and 
treated but have an inadequately treated partner91 are likely to be at higher risk of reinfection than 
average.  In addition, acquiring one STI suggests that your sexual behaviour patterns may put you at 
risk of a future STI or sexually-related genital infection that is independently associated with PID.    
We were not able to adjust for the presence of other genital infections in the two large 
population-based cohorts therefore if this risk of a second STI is higher in women with a baseline 
positive test compared to women with a baseline negative test this may explain the difference in risk 
between these groups in the absence of a diagnostic bias.  PID has a broad aetiology, the PHAC 
outline 13 potential causative organisms (Public Health Agency of Canada, 2010).  I will limit my 
consideration to three STIs (chlamydia, gonorrhoea and M.genitalium) and BV although it is possible 
that the aetiologic agent for a proportion of PID cases remains unidentified.  
Chlamydia is predominantly an asymptomatic infection and cases will frequently go 
undetected.  Women who test positive are more likely to have an ongoing source of chlamydia by 
way of an infected untreated sexual partner (even if contact tracing and partner notification are 
being performed at the recommended levels, 40% of partners can go untreated) and through sexual 
behaviour choices they may be more at risk of an STI from a future sexual partner.  It has previously 
been shown that women with an initial positive test have a 3-fold higher rate of a second positive 
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 The UK performance target for chlamydia partner notification is 0.6 contacts per case (McClean et al., 2013). 
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test compared to women who test negative (5.9 per 100 py in negative women compared to 18.1 
per 100 py in positive women in Cornwall, UK) (Turner et al., 2013).  This rate of reinfection is high, 
and in Denmark we observed a cumulative incidence of diagnosed repeat infection (before PID) of 
36.71% (95% CI 36.19-37.23) in women who were under 20 at the time of their first positive test.  
Therefore it is plausible that the burden of undiagnosed chlamydia may contribute a significant 
proportion of the unexplained risk of PID.  In addition, chlamydia organisms from the initial 
infectious event may persist as aberrant RBs and trigger local chronic inflammation at some point in 
the future (Wyrick, 2010).  Such an event may be more likely in the presence of a past history of 
gonorrhoea, as penicillin, an antibiotic that was widely used to treat gonorrhoea, can induce 
transformation into abnormal RBs (Wyrick, 2010) although there is no evidence that this occurs in 
vivo.    
Gonorrhoea has historically been a major cause of PID and the decline in its incidence over 
the last 30 years is likely to have contributed to the lower rates of PID seen in contemporary 
populations (Jolly et al., 2005, Kamwendo et al., 1996, Miller and Zenilman, 2005).  But gonorrhoea 
has not disappeared and it remains an important STI in certain population groups, including areas of 
low socio-economic status (Blanchard et al., 1998) and the risk factors for infection mirror those of 
chlamydia.  A recent study from the Netherlands demonstrated that gonorrhoea could only be found 
in women who also tested positive for chlamydia, where the incidence of co-infection was 2.4% 
(95% CI 0.1-4.7)(van Bergen et al., 2006).  Although this study looked at co-infection at the time of a 
chlamydia diagnosis, this was a screening intervention with asymptomatic participants so it is 
reasonable to assume that the same distribution may occur with undiagnosed chlamydia.  Therefore 
gonorrhoea infection or co-infection may differentially affect chlamydia positive and negative 
women.  However there is further evidence from a variety of settings that the absolute incidence of 
gonorrhoea compared to chlamydia is very low (a ratio of diagnosis of 1:38 in New South Wales 
(Reekie et al., 2014); prevalence in the adult general population in the UK of gonorrhoea is <0.1% 
and chlamydia is 1·5% (95% CI 1·1-2·0) (Sonnenberg et al., 2013); 339 cases of gonorrhoea in 
Denmark in 2011 (Statistics Denmark, 2012)) but it is associated with a three-fold higher risk of a 
hospitalisation for PID (adjusted92 incidence rate ratio 3.48 (95% CI 2.51-4.82) (Reekie et al., 2014)).  
On balance, the overall contribution from gonorrhoea is likely to be low.   
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 Compared to chlamydia and adjusted for age, year, socio-economic status, region, parity.  
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M.genitalium is not routinely tested for in clinical practice but there is growing evidence that 
it may be an independent cause of PID.  In a small sample of women with clinically suspected PID, 
the presence of M.genitalium at baseline was associated with a two-fold increase risk of 
endometritis (AOR93 2.0 (95% CI 1.0-4.2)) and in women who were treated for chlamydia and 
gonorrhoea the risk of developing endometritis in the first thirty days was six times higher in women 
with baseline M.genitalium compared with women without (ARR94 6.0 (95% CI 1.4 to 27.1)) 
(Haggerty et al., 2008). The incidence of M.genitalium has been shown to be similar to that of 
chlamydia in populations of high-risk women (Haggerty and Taylor, 2011) and co-infection with 
chlamydia was also common (37.5% in symptomatic or at-risk adolescents in US (Huppert et al., 
2008)). Therefore this organism is a potentially important cause of the unexplained PID in this thesis 
although further research is needed to determine whether treating this infection will prevent PID.    
Finally, BV is a clinical syndrome associated with sexual intercourse and characterised by an 
“imbalance” in the vaginal flora (Taylor et al., 2013, Verstraelen et al., 2010).  It is a common 
condition (prevalence in the PSP study was 17.14% (Davies et al., 2013) and prevalence of up to a 
third in women in the US has been reported (Taylor et al., 2013)) and it has been associated with 
PID.  However there is no evidence to suggest that it is a causative agent.  We did not find a 
significant association between BV and PID in the PSP study (unadjusted HR of PID 0.97 (95% CI 0.52-
1.83)) and in a larger prospective cohort the women with BV at baseline did not have an increased 
risk of PID over four years (AHR 0.89 (95% CI 0.55-1.45)) (Ness et al., 2004).  Therefore it may not be 
an independent explanation for the burden of PID in this thesis.   
At the population level, we estimated that fewer than 10% of cases of PID in the 12 months 
following a test could be averted if the risk of PID in women who tested positive was reduced to the 
risk seen in women who tested negative.  This reflects the other aetiological agents of PID and the 
burden of PID that we observed in women who test negative for chlamydia.  In women who were 
tested for chlamydia, regardless of the result, the rate of PID was elevated for five years following 
the baseline test, before reaching a background level for the reminder of follow-up.  The fact that 
this relationship is independent of chlamydia status suggests that a behavioural risk is more likely 
that a biological one given the association between other genital infections and chlamydia.  It could 
be interpreted as evidence that five years may mark the average duration of high risk sexual 
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 Adjusted for age, race, chlamydia and gonorrhoea. 
94
 Adjusted for co-infection with chlamydia and gonorrhoea. 
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behaviour.  The role of sexual behaviour may also explain the finding that there was no difference in 
the risk of PID in women who were tested for chlamydia based on their test result during the first 
interval in which a repeat test could occur (30 to 60 days).  It is possible that women who tested 
positive moderated their behaviour in the immediate interval after an infection lowering their risk of 
a further acute infection when compared to women who tested negative.  
 The lifetime risk of PID in women who tested negative was higher than women who were 
never tested.  A proportion of this increased risk is likely to be mediated through false negative 
chlamydia tests and the presence of a clinical indication for performing a chlamydia test.  An 
alternative interpretation of this association is that the chlamydia test itself is the risk factor for PID.  
The only plausible method I can discern for this is that when endocervical swabs were used for 
diagnosis, they may have disrupted the cervical os and facilitated progression of micro-organisms 
(not necessarily chlamydia) into the upper tract, although this would only be relevant as a risk factor 
during a short interval after a test.  I was not able to find any literature discussing this hypothesis.  
An alternative explanation is that the majority of women tested for chlamydia with an endocervical 
swab would have been undergoing a speculum examination (Moller et al., 2003) which could 
indicate the presence of symptoms, and a risk for PID that may or may not have been chlamydia.  I 
will come back to this potential association when I consider the temporal pattern in risk associated 
with the change in test method (from antigen tests on endocervical swabs to NAATs on urine 
samples).   
In summary, research is needed to quantify the aetiology of clinical PID in settings with 
individual-based administrative data so that the relationship between chlamydia and PID can be 
more comprehensively described. 
 
6.4 Heterogeneity in risk 
The combined results of the three studies in this thesis provide strong evidence of 
heterogeneity in the risk of PID.  In the following sections I will consider the potential mechanisms 
for each observed relationship.   
  Chapter 6 
210 
 
6.4.1 Repeat chlamydia infection 
The increased risk of PID following a repeat chlamydia infection was similar in each analysis 
presented in this thesis.  Interpreting this finding is complicated by the lack of a consensus in the 
definition of a repeat infection in the literature and in this thesis 95 (Bakken et al., 2007, Turner et al., 
2013, Hillis et al., 1997) and by the high risk of misclassification bias in the assignment of the 
comparator “first infection” as women may have multiple undiagnosed infections because chlamydia 
tests are an incomplete measure of chlamydia exposure.    
The consistent magnitude of the association after adjustment for confounding in different 
populations makes an underlying biological component to this risk an attractive explanation.  But an 
increased risk of PID following a second diagnosed and treated infection is at odds with one of the 
contemporary theories to explain the ecological trend of rising chlamydia incidence rates in 
association with a declining diagnosis rate of PID.  The altered immunity hypothesis proposes that 
clearance of chlamydia through antibiotic treatment attenuates the development of an adaptive 
immune response and protects from future PID (Brunham and Rekart, 2008).   
This is based on the assumption that the immunological paradigm of chlamydia 
pathogenesis - where small amounts of antigen reaching the upper genital tract can stimulate 
primed T-cells – is true (Darville and Hiltke, 2010).  If this is the case, then our observations suggest 
that this immune response is not universally modulated by antibiotic therapy.  This could plausibly 
occur if an adaptive immune response can develop before the median duration of an untreated 
infection so that at least half of women with a previous treated infection would have the ability to 
mount an early T-cell response.  If this T-cell response shortens the time interval from infection to 
PID then a higher proportion of repeat infections compared to first infections will progress in the 
interval between infection and screening, leading to the observed association.   
However, I think our findings fit better with the cellular paradigm of chlamydia 
pathogenesis, where infected epithelial cells are the main agents of inflammation.  We found that 
the increased risk of PID following a repeat infection was only significant in women in Denmark who 
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 (PSP: either a past history or any previous test during the cohort; MB: ≥60 days since a previous test; 
Denmark: ≥30 days since a previous test).   
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were under 25 at the time of their first test.  Given the age structure of this study population, these 
women were under 15 in 1984 when chlamydia control interventions were introduced and therefore 
they are the group most likely to have had infections diagnosed and treated rather than undergoing 
natural clearance.  Therefore this suggest that natural clearance, (assumed to have occurred with 
historic infections in older women), may have contributed to the development of an immune 
response that protected from ascension of chlamydia across the cervix.   
We also observed an increased risk of PID following repeat infection that was more marked 
in young women in Manitoba.  This may be a less significant finding in terms of the relationship 
between infection and immunity as the oldest members of this birth cohort were 15 at the time 
chlamydia control was introduced in Manitoba (1987) but this is an important marker of risk that is 
considered below in the section on age (section 6.4.2).   
An alternative, non-immunological explanation for the association between repeat infection 
and PID is that the effect of chlamydia infections may be additive rather than cumulative and simply 
be explained by an increase in length of time that women are exposure to chlamydia causing an 
increased risk of PID (Haggerty et al., 2010).  In Manitoba we demonstrated a 20% increased risk 
following the first repeat infection and a 35% increased risk following the second infection which 
could provide evidence of an additive rather than cumulative effect.  
It is important to think about bias and confounding as explanations for the increased risk of 
PID following a repeat infection.  We may have observed the effect of the same unmeasured 
confounders described for a single positive test (diagnostic bias and undiagnosed STIs) where a 
repeat infection was a marker for an increased risk of PID rather than being the direct cause.  Under 
these conditions it is easier to reconcile the observed increased risk following repeat infection with 
the ecological analyses that suggest the incidence of repeat infection is rising while the diagnosis 
rate of PID is in decline.   
 
6.4.2 Age 
Younger age is an established risk factor for both chlamydia and PID that was observed in 
both cohorts that explored this association.  Young women are known to have an increased 
susceptibility to chlamydia mediated by their immature cervix (Lee et al., 2006).  However additional 
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factors are likely to be involved as we have demonstrated an elevated risk of PID throughout the 
reproductive lifetime.  These may include a diagnostic bias more pronounced in young women 
together with a higher prevalence of undiagnosed STIs.  In addition, this age-related effect may be 
enhanced by the poor validity of chlamydia screening tests: in older women, who may be more likely 
to participate with testing as a maternity intervention (rather than through contact tracing or a 
sexual health concern) the prevalence of chlamydia and therefore the PPV of a test is likely to be 
lower than in young women so a lower proportion of chlamydia positive older women may be 
infected.  Finally, age may be associated with healthcare seeking behaviour, including the prompt 
treatment of STIs, which may reduce the risk of progression to PID (Davies et al., 2013).   
The evidence that younger women are more at risk of PID following a repeat infection was 
discussed as a potential marker of immunity in section 6.4.1.  Alternatively this association may be 
an extension of the factors outlined above: immature cervix; diagnostic bias; undiagnosed STIs; 
higher PPV of a test.  Some of which may accumulate with repeat infections (e.g. diagnostic bias and 
undiagnosed STIs).    
 
6.4.3 Gonorrhoea and other genital infections  
We found that a past history of gonorrhoea was a risk factor for PID in women with 
chlamydia in the PSP cohort.  If penicillin was used to treat previous infections, it raises the potential 
for reactivation of persistent RBs as the cause of the risk (Wyrick, 2010).  The other studied 
infections (trichomoniasis, BV and candida) were not linked to PID.  In the context of this thesis, this 
finding suggests it is important to adjust the risk of PID following chlamydia for the presence of other 
organisms that can cause PID.   
 
6.4.4 Year of test 
In Manitoba, we demonstrated a lower risk of PID in women who were tested post-1997 
compared to women tested pre-1997, regardless of the result of the chlamydia test.  This 
demarcation occurs close to the introduction of NAATs in 1998 and there are several potential 
mechanisms that would link these findings.  In negative women: the increased sensitivity of NAATs 
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means that fewer women with a negative test will be infected, and therefore this cohort are likely to 
have a lower risk of subsequent PID.  In positive women: it has been argued that the infections 
detected by NAATs may have a lower pathogenic potential and therefore a lower rate of progression 
to PID however there are no direct studies of this (Hadgu and Sternberg, 2009).  Alternatively, the 
change in test method, from endocervical swabs to urine samples may have reduced the risk of the 
test leading to a decline in PID in both positive and negative women.  In addition, the introduction of 
more acceptable urine testing may have widened the potential pool of women who were tested, 
expanding from the high-risk population undergoing a pelvic examination to the low-risk population.  
This would likely be accompanied by a change in the prevalence of chlamydia and a reduction in the 
proportion of positive women who were truly infected and a lower risk of other STIs in the negative 
women.  
Also in the late 1990s azithromycin replaced doxycycline as the first line antibiotic therapy 
for chlamydia treatment.  Therefore this relationship, at least in positive women, could plausibly 
reflect an increase in treatment compliance as azithromycin has a shorter course and fewer side-
effects.  However azithromycin may have a marginally lower efficacy leading to an increase in 
treatment failure (Kong et al., 2014, Lau and Qureshi, 2002).  The exact magnitude of these effects 
(compliance and treatment failure) is needed to estimate the overall impact of this policy shift.  
Finally, this change in the late 1990s could be explained by a change to the incidence or prevalence 
of other aetiological agents of PID, e.g. circulating STIs or IUCD insertions (Kamwendo et al., 1998).   
 
6.5 Implications 
6.5.1 Public Health  
This thesis has not been able to demonstrate that widespread chlamydia control 
interventions reduced the expected burden of PID at the population-level compared to if chlamydia 
had been left undetected and untreated.  The most robust estimate of the risk of PID at 12 months 
following untreated chlamydia in a contemporary setting is 9.5% (95% CI 4.7-18.3%) from the control 
arm of the POPI trial and this estimate does not differ from the 5.27% (95% CI 4.61-6.01) risk of PID 
seen at 12 months in diagnosed and treated women in Manitoba (Oakeshott et al., 2010).  Urgent 
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research is needed to determine the aetiology96 of PID to inform the development of sexual and 
reproductive health promotion advice and services to effectively reduce PID.  From a public health 
perspective, the observed heterogeneities in the risk of PID following chlamydia testing amount to 
unacceptable health inequalities that require urgent appropriate action to reduce their impact.  
Specific public health messages have been drawn from each of the individual analyses presented in 
this thesis and generalizable recommendations were identified from the synthesis of the studies 
(Table 6.2). 
 
Table 6.2: Recommendations for chlamydia control policy 
 
Setting Recommendations 
General   Chlamydia testing should target young women and those at risk of a repeat 
infection*;  
 Chlamydia testing should be used as a health promotion opportunity because 
women who are tested (regardless of the result) have an increased risk of PID. 
  
Sex workers  Regular repeat testing for STIs.  
 
Manitoba  Review practice in the region with the lowest risk of PID (urban non-core) to 
identify good practice that could be transferred to other locations. 
 
Denmark   Clinical audit to determine why women with PID were not tested for chlamydia.   
*defined as women who have had a positive test.  
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 Potential targets include undiagnosed chlamydia, chlamydia that is not cleared (treatment failure; non-
compliance with treatment; persistence of RBs), other STIs or endogenous vaginal flora that either naturally 
ascend or ascend during trans-cervical instrumentation.  
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The goal of averting PID is partly driven by the desire to reduce morbidity from this 
condition, but its role as an intermediary in the development of ectopic pregnancy and tubal factor 
infertility has elevated its importance.  These complications can follow PID of any aetiology, or 
subclinical endometritis.  If undiagnosed chlamydia is the cause of a proportion of the unexplained 
diagnosed cases of PID97 then we can expect to see an even greater burden of subclinical 
endometritis.  Therefore the overall population-level benefit of chlamydia screening interventions in 
women can only be determined if estimates of its impact on ectopic pregnancy and tubal factor 
infertility are quantified.  
 
6.5.2 Mathematical modelling 
This thesis has described heterogeneity in the risk of PID following a chlamydia test based on 
age, time since test and past history of chlamydia that call into question the validity of using a single 
risk of progression as seen in mathematical models of chlamydia testing interventions (Herzog et al., 
2012b).  We have also demonstrated that women who test negative for chlamydia have an elevated 
risk of PID compared to never tested women; that estimates of the risk of progression obtained in 
clinical settings prior to the introduction of NAATs may over-estimate the risk seen in contemporary 
general population settings; and that the elevated risk of PID following a chlamydia test lasts beyond 
assumed duration of infection.  
This thesis provides a strong case for using sensitivity analyses within individual-based 
models to explore the impact of individualised risks of progression on the estimated impact of 
chlamydia testing interventions.  The improved precision of individual-based measures of risk may 
improve the accuracy and therefore the utility of estimates of the cost-effectiveness of chlamydia 
testing interventions for policy makers.  It is not possible to present suggested parameters from the 
work undertaken in this thesis.  However the large retrospective population-based datasets created 
or analysed in this thesis should form the basis of further research to generate generalizable 
individual-based parameters.  This future research should also quantify individual-based parameters 
for the risk of ectopic pregnancy and tubal factor infertility.  
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 The absence of chlamydia in the lower genital tract does not exclude it as the cause of inflammation in the 
upper tract (Paavonen 2008).  
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In addition, our systematic review highlighted concerning variability in the chlamydia natural 
history parameters (proportion of asymptomatic infections; duration of infection; transmission 
probability) that have been used in contemporary cost-effectiveness analyses of chlamydia control 
interventions (Davies et al., 2014).  Empirical research should be performed to reduce this 
parameter uncertainty before further modelling studies are performed, or at a minimum the effect 
of these parameters should be explored with a sensitivity analysis.  
 
6.6 Further research  
The cohort from Manitoba that was created in this thesis and the cohort from Denmark can 
be used to further the evidence base for chlamydia control interventions by exploring the following 
areas of uncertainty in the parameterisation of mathematical models:   
 
 Estimate the risk of PID following chlamydia adjusted for additional confounding factors, 
including antibiotic and hormonal contraception prescriptions; gonorrhoea; trans-cervical 
instrumentation;  
 Estimate the risk of PID in the never tested population (all healthcare settings);  
 Estimate the association between chlamydia and ectopic pregnancy and tubal factor 
infertility and compare this to the association between PID and these outcomes to gain 
insights into the burden of adverse reproductive complications that can be attributed to 
chlamydia via clinical and sub-clinical PID; 
 Explore parametric models for survival analysis  to improve the utility of estimates of the 
risk of PID following chlamydia;   
 Explore participation with healthcare in Manitoba to improve estimates of actual and 
potential population participation with screening interventions;  
 Describe the epidemiological patterns in chlamydia to provide incidence data that can be 
used to fit mathematical models.  
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This research has also identified further areas of uncertainty that should be explored to 
complement the work presented in this thesis, but require alternative data sources or study designs:   
 Evaluate the sensitivity and specificity of the ICD definitions used in this thesis; 
 Develop a consensus definition of repeat infection;   
 Develop methodology to improve the calculation of attributable fraction from 
retrospective cohorts and survival analyses; 
 Test the impact of heterogeneity in the risk of PID on the output of cost-effectiveness 
analyses linked to mathematical models using sensitivity analysis;  
 Clinical research into the aetiology of PID in settings with individual-based data on the risk 
of PID following an STI diagnosis. 
6.7 Conclusion  
In this thesis I have described three observational studies that have advanced the evidence 
base for chlamydia testing interventions by improving estimates of the risk of PID following 
chlamydia that can be used to parameterise mathematical models.  We measured the absolute risk 
of PID in these populations and demonstrated heterogeneity in the risk of PID following a chlamydia 
test, including test result, age, time since test and repeat infection.  Our findings support the 
hypothesis that contemporary estimates of the risk of progression may be lower than those from 
historical clinical studies and that this risk should continue beyond 12 months in models.  These 
findings mean that the single risk of progression to PID that is the mainstay of current mathematical 
models of chlamydia control interventions may be an inappropriate oversimplification.  Sensitivity 
analyses using individual-based risks should be used to explore estimates of the cost-effectiveness of 
chlamydia control interventions and policy makers should apply caution when interpreting the 
results from current models.   
We did not find evidence to suggest that widespread chlamydia control is able to reduce the 
incidence of PID at the population level.  But in the context of well-established chlamydia control 
interventions only a small proportion of all PID can be attributed to diagnosed cases of chlamydia.  
We suggest that urgent research is needed to understand the causes of PID at the population level 
so that public health and healthcare interventions can work to reduce morbidity.  In the meantime, 
public health interventions should focus on young women and those at risk of repeat chlamydia 
infection. 
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7 1 
Appendix 1 
1.1 Chlamydia diagnostic tests 
1.1.1 Test performance 
There are four possible results from a chlamydia diagnostic test: “true positive” if the person 
has chlamydia and the test is positive; “true negative” if the person does not have chlamydia and the 
test is negative; “false negative” if the person has chlamydia but the test is negative and “false 
positive” if the person does not have chlamydia but the test is positive.  The aim of any test or 
diagnostic strategy is to minimise the proportion of false positive and false negative tests.  False 
positive results needlessly expose people to the anxiety of a diagnosis and potential harm from 
treatment and the impact of partner notification, while false negative tests offer false reassurance 
and leave people infected and at risk of transmitting the infection to their sexual partners.  False 
positive and false negative tests affect surveillance data because they bias the observed incidence 
rate.  False positive tests over-estimate and false negatives under-estimate the true incidence rate 
and their net effect depends on test performance.  The performance of all diagnostic tests is defined 
by how well it is able to describe the true situation without incorrect classification of individuals.  
This is formally described by four parameters, sensitivity, specificity, positive predictive value (PPV) 
and negative predictive value (NPV).  These terms are defined below for chlamydia (Ward et al., 
2012):  
 
 
 
 
  Appendix 1 
237 
 
 Definition Formula 
Sensitivity probability that a person with 
chlamydia will have a positive test 
 
true positive/(true positive + false negative) 
Specificity probability that a person without 
chlamydia will have a negative test 
 
true negative /(true negative + false positive) 
PPV probability that a person who tests 
positive is infected with chlamydia 
 
true positive/ (true positive + false positive) 
NPV probability that a person who tests 
negative is not infected with chlamydia 
true negative /(true negative + false 
negative) 
 
There is a complex relationship between test performance and chlamydia prevalence which 
is illustrated in Table A1.1.  In this table two hypothetical tests, with different sensitivity and 
specificity, are applied to two populations with different chlamydia prevalence.  The key feature of 
these tables is that as prevalence declines, PPV declines and NPV increases.  The proportion of all 
positive tests that occur in truly negative people can be in excess of those seen in true positive 
people.   
 
1.1.2 Historical overview of chlamydia tests for use in asymptomatic 
women (Chlamydiae.com, 2014) 
1.1.2.1 Culture 
Chlamydia culture detects the presence of viable organisms.  It has been possible in a clinical 
setting since the early 1980s but it is technically demanding and labour intensive.  In order to 
preserve the viable organisms present in a sample there are rigorous cold chain and transport 
demands and the process of generating the cell monolayer culture medium and inoculation is 
complex.  While culture has a specificity of 100% (people without the infection cannot have a 
positive result) it has a high false negative rate (people with the infection are labelled negative).  
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Table A1.1:  Relationship between test performance and chlamydia prevalence (based on example in (Ward et al., 2012)) 
 
 
 
Sensitivity 60% & Specificity 90% 
 
 
 
 
 
 
Sensitivity 90% & Specificity 99% 
 
 
 
 
 
 
Prevalence 10% 
 
 
  True situation 
    Positive Negative Total 
Test 
Positive 6000 9000 15,000 
Negative 4000 81000 85,000 
Total 10,000 90,000 100,000 
 
 
PPV 40.0% 
 
NPV 95.3% 
 
 
  True situation 
    Positive Negative Total 
Test 
Positive 9500 900 10,400 
Negative 500 89,100 89,600 
Total 10,000 90,000 100,000 
 
 
PPV 91.3% 
 
NPV 99.4% 
 
Prevalence 3% 
 
    True situation 
    Positive Negative Total 
Test 
Positive 1800 9700 11,500 
Negative 1200 87,300 88,500 
Total 3000 97,000 100,000 
 
 
PPV 15.7% 
 
NPV 98.6% 
 
    True situation 
    Positive Negative Total 
Test 
Positive 2700 970 3670 
Negative 300 96,030 96,330 
Total 3000 97,000 100,000 
 
 
PPV 73.6% 
 
NPV 99.7% 
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1.1.2.2 Antibody and Antigen detection methods 
Diagnostic methods that do not rely on the detection of viable organisms were developed in 
response to the technical challenges posed by culture.  Antigen methods of diagnosis use specific 
monoclonal antibodies to chlamydia MOMP.  In direct immunofluorescence (DIF, also known as 
direct fluorescent antibody (DFA)) the monoclonal antibody is liked to a compound that has the 
potential to fluoresce (a flurophore).  The patient’s sample is added to the antibody/flurophore 
mixture.  If the appropriate chlamydia antigen is present, the antibody will bind resulting in a change 
in the structure of the flurophore and the antibody/flurophore/antigen complex will fluoresce.  This 
can be detected with an appropriate microscope.  DIF samples had more straightforward collection 
and transfer requirements than culture.  Their limitation was that the samples were very difficult to 
read under the microscope which meant that they were not suitable for high volume testing and this 
process was operator dependent.  DIF tests have a sensitivity of 75-85% and a specificity of 98-99% 
compared to culture and a sensitivity of 70% compared to NAATs (Chernesky, 2005).  The first 
commercially available DIF was Syva Microtrak ® (Syva Co., San Jose, CA) (Uyeda et al., 1984).  
Enzyme-linked immunosorbent assays (ELISAs or EIAs) use antibodies to detect chlamydia 
antigen.  The antigens from the patient’s sample are attached to a surface and an antibody/enzyme 
complex is added.  If the appropriate antigen is present the antibody will bind changing the structure 
of the enzyme.  Finally, a compound that is activated to change colour by the altered enzyme is 
added.  These tests were less technically demanding and operator dependent than DIF, but had a 
low sensitivity (around 65-78% compared to NAATs) and a low specificity (97%) (Chernesky, 2005).  
They were affected by inhibition and the low specificity meant that they were not suitable for use in 
low prevalence populations unless a confirmatory test was performed.  The confirmatory test 
involved adding a blocking antibody directed at the target antigen so that true positive specimens 
become negative and false positive specimens remain positive (Chernesky, 2005).  Confirmatory 
testing increased the specificity to 99.5% (Chernesky, 2005).  An example of an EIA is Chlamydiazyme 
® (Abbott Laboratories, Chicago, IL).   
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1.1.2.3 Nucleic acid amplification tests 
NAATs work by identifying a target sequence of chlamydia DNA or RNA and then amplifying 
it.  A target sequence is usually chosen because it has multiple copies within an elementary body.  
This means that is theoretically possible for a test to detect the presence of a single partial 
elementary body (Chernesky, 2005).  There are several different methods of nucleic acid 
amplification98, but polymerase chain reaction (PCR) is the most common.  In PCR the DNA is 
prepared so that when primers that bind to the target nucleic acid sequence are added in the 
presence of enzymes, new sections of the target nucleic acid are produced.  The resulting material is 
then passed through a gel using electrophoresis so that the presence of the target nucleic material 
can be identified.  First generation NAATs were difficult to process and had a problem with false 
negative results due to specimen inhibition (Gen-Probe Incorporated, 2006).  Second generation 
NAATs has a very high sensitivity and specificity and they were predominantly automated making 
them easier to perform than antigen/antibody tests.  They are the first type of chlamydia test that 
are suitable for use in low prevalence asymptomatic populations with a high volume of testing. 
A criticism of these tests is that the genetic material they target may not be specific to viable 
organisms and tests which target messenger RNA (mRNA) which is only found in the presence of 
replicating bacteria have not yet been developed.  Current tests target ribosomal RNA or DNA from 
the cryptic plasmid.  An example of a nucleic acid detection test is the PACE 2 nucleic acid probe test 
(GenProbe, San Diego CA).  It uses a labelled probe that binds to a specific section of chlamydial 
rRNA (Gen-Probe Incorporated, 2011).  Others include the AMP CT NAAT (GenProbe, San Diego CA) 
that uses TMA to detect rRNA and the Aptima COMBO 2 NAAT (GenProbe, San Diego CA) that tests 
simultaneously for the presence of chlamydia and gonorrhoea rRNA using TMA.   
 
 
 
 
                                                          
98
 LCR (ligase chain reaction); SDA (strand displacement amplification); TMA (transcription mediated 
amplification is very similar to PCR but generates an RNA sequence) 
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Appendix 2 
Comparison of the Manitoba cohort and Denmark study with retrospective population-based studies exploring the association between chlamydia and 
adverse reproductive complications and a RCT of chlamydia screening and PID in Denmark 
Study 
Northern Jutland 
Cohort Aarhus County RCT Uppsala Cohort 
Sør-Trøndelag 
Cohort 
Sør-Trøndelag 
Case-control 
Manitoba Woman’s 
Reproductive and 
Sexual Health 
Cohort 
Denmark 
Chlamydia 
Study 
References  (Andersen et al., 
2005) 
(Andersen et al., 
2010) 
(Low et al., 
2006) 
(Bakken et al., 
2007a) (Bakken 
and Ghaderi, 
2009) 
(Bakken et al., 
2007b) 
Chapter 3 and 4 Chapter 5 
Resident 
population 
County of Northern 
Jutland, Denmark 
Aarhus County, 
Denmark 
Uppsala, 
Sweden 
Sør-Trøndelag 
County, 
Norway 
Sør-Trøndelag 
County, 
Norway 
Manitoba, Canada Denmark 
Sampling 
frame 
Laboratory records 
of chlamydia 
testing 
Population register Population 
register 
Laboratory 
records of 
chlamydia 
testing 
Laboratory 
records of 
chlamydia 
testing 
Population health 
insurance registry 
Lab. records of 
chlamydia 
testing; 
Population 
register 
Population 
definition 
 
 
Women tested for 
chlamydia, 1984 
and 1993 
Women 21-23 on 
31st October 1997, 
intervention and 
control groups 
Women 15-24 
years, 1985 and 
1989 
Women tested 
for chlamydia, 
1990- 2004/5 
and > 20 years 
Women with 
EP, 1990-2004 
& previous 
chlamydia test 
Women 12-24 years, 
1992 and 1996 
Women 15-44 
years, 1995-
2012 
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continued 
Northern Jutland 
Cohort Aarhus County RCT Uppsala Cohort 
Sør-Trøndelag 
Cohort 
Sør-Trøndelag 
Case-control 
Manitoba Woman’s 
Reproductive and 
Sexual Health 
Cohort 
Denmark 
Chlamydia 
Study 
Study size 20,000 15,000 40,000 20,000 616 cases 70,000 500,000 
Entry Date of test Randomisation Residence in 
Uppsala 
Date of 1st test N/A Date of 1st test Date of 1st test 
of case 
Exit 1st outcome 
 
1st outcome or 1y 
PID; 7y infertility; 
9y EP 
End of study; 
1st outcome 
event 
End of study; 
1st outcome 
event 
Date of ectopic 
pregnancy 
End of study; 1st 
outcome event 
End of study; 
1st outcome; 
age 45 
Exclusions Pregnancy before 
1st test; no test 
before 43rd 
birthday; no 
pregnancy during 
cohort 
Nil Incomplete data 
on 
socioeconomic 
status 
No valid 
identification 
number; 
Pregnancy or 
Hospital 
admission with 
PID before 1st 
test 
Nil Invalid or 
incomplete data 
Not in a 5 
person 
case/control 
set; Error in 
exposure status; 
resident outside 
Denmark 
Chlamydia 
test 
definition 
Cervical or urethral 
specimens tested 
for genital 
chlamydia 
N/A All screening 
tests for 
chlamydia at 
laboratory 
performed at 
laboratory ≥60 
days after 
previous test 
performed at 
laboratory ≥60 
days after 
previous test 
performed at 
laboratory ≥60 days 
after previous test 
urine/rectal or 
genital samples 
≥30 days after 
previous test 
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continued 
Northern Jutland 
Cohort Aarhus County RCT Uppsala Cohort 
Sør-Trøndelag 
Cohort 
Sør-Trøndelag 
Case-control 
Manitoba Woman’s 
Reproductive and 
Sexual Health 
Cohort 
Denmark 
Chlamydia 
Study 
Chlamydia 
test 
method 
Direct 
immunofluorescen
ce (Microtrak EIA; 
Syva) and ELISA  
(Chlamydiazyme; 
Abott). 
N/A 1985-1995:  
Culture; 
1996: PCR 
(Amplicor CT 
Test, Roche 
Diagnostics, 
Switzerland) 
1990-92: IDEIA 
CT test, 
Celltech 
Diagnostics/No
vo 
BioLabs/DAKO; 
1992-98: PACE2 
GenProbe; 
1999 - Amplicor 
Roche 
Molecular 
Systems 
1990-92: IDEIA 
CT test, 
Celltech 
Diagnostics/No
vo 
BioLabs/DAKO; 
199298: PACE2 
GenProbe; 
1999 - Amplicor 
Roche 
Molecular 
Systems 
 
1992-98:  
Chlamydiazyme 
(Abbott Laboratory, 
Chicago IL); 
1999-06:  PACE 2 
(GenProbe, San 
Diego CA); AMP-CT 
(GenProbe); 2007:  
Aptima (GenProbe) 
Varied by 
laboratory;  
NAATs 
introduced 
approximately 
2000 
Chlamydia 
exposure 
definition  
At 1st test assigned 
to negative or 
positive cohort; 
move from 
negative to positive 
at 1st positive test 
N/A At entry 
negative, 
positive or 
never tested; 
move never to 
positive or 
negative at 1st 
test & negative 
to positive at 
1st positive test 
 
At 1st test 
assigned to 
negative or 
positive cohort; 
move from 
negative to 
positive at1st 
positive test 
Number of 
tests before 
ectopic 
pregnancy (or 
year of 
matched case’s 
event) since 
1990 
Result of 1st 3 
chlamydia tests 
following entry to 
study 
Based on 
case/control 
status 
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continued 
Northern Jutland 
Cohort Aarhus County RCT Uppsala Cohort 
Sør-Trøndelag 
Cohort 
Sør-Trøndelag 
Case-control 
Manitoba Woman’s 
Reproductive and 
Sexual Health 
Cohort 
Denmark 
Chlamydia 
Study 
Outcomes 
of study(s)  
EP; Time to birth PID; EP; Infertility; 
Birth 
PID; EP; 
Infertility 
PID; EP EP PID; EP; Infertility PID; EP; TFI 
Source of 
outcome 
data 
In-patient In-patient & drug 
prescriptions 
In-patient 
(1985-1992); 
out-patient 
added 1993 
In-patient or 
hospital out-
patient 
In-patient or 
hospital out-
patient 
In-patient 
admissions, out-
patient or 
community 
In-patient or 
hospital out-
patient 
PID   N/A ICD 10 N70.0; 
N70.9;N71.9;N73.0
;N73.3; 
N73.5;N73.8;O03.0
;O03.5; 
O04.0;O04.5;O07.0 
or doxycycline 
prescription 
ICD-10 N70–74 ICD-9 614 
ICD-10 N70 
N/A ICD-9  614-
616.0;098.10;098.15 
098.16;098.17;098.3
0; 098.35-7;099.56; 
098.86;016.6 
ICD-10 N70-
74.8;A56.1;A18.1; 
A51.4;A54.2;A52.7 
ICD-10 N70-
74.8; A56.1; 
A18.1; A51.4; 
A54.2; A52.7 
Infertility N/A ICD-10 N97 ICD-10 N97  N/A ICD-9 628–628.9 
ICD-10 N97 
N/A 
TFI N/A N/A N/A N/A N/A ICD-10 N97.1 ICD-10 N97.1 
EP ICD-8 631 
ICD-10 O00 
ICD-10 O00 Unclear ICD-8 631 
ICD-9 633 
ICD-10 O0.00-
0.009 & 
Histology or 
Ultrasound 
ICD-8 631 
ICD-9 633 
ICD-10 O0.00-
0.009 & 
Histology or 
Ultrasound 
ICD-9 633.0-633.9 
ICD-10 O00.00-
O00.9 
ICD-10 O00.00-
O00.9 
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continued 
Northern Jutland 
Cohort Aarhus County RCT Uppsala Cohort 
Sør-Trøndelag 
Cohort 
Sør-Trøndelag 
Case-control 
Manitoba Woman’s 
Reproductive and 
Sexual Health 
Cohort 
Denmark 
Chlamydia 
Study 
Abortion ICD-8 643.8;643.9; 
634.61;645.1;640-
642 
ICD-10 O02-O06 
N/A N/A Not specified N/A ICD9 632; 634-637 
ICD-10 O02.1; O03-
06 
ICD-10 O02.1; 
O03-06 
Births ICD-8 650-666 
ICD-10 O80 – O84 
ICD-10 O80-84 N/A Not specified N/A ICD-9 V27 
ICD-10 Z37-38 
ICD-10 Z37-38 
Analysis Cox regression Cox regression Cox regression Cox regression Logistic 
regression 
Cox regression Cox regression 
Time axis Not stated Time since 
randomisation 
Age Months from 
1st chlamydia 
test 
N/A Time since 1st test Time since entry 
or 1st test 
Time 
varying 
covariates 
Age None Not stated Chlamydia 
status;  parity 
N/A None None 
Covariates Maternal age None Age; education; 
income; housing 
age at 1st test N/A Age at entry; year of 
entry; region 
residence; previous 
test results 
Age and year at 
entry/1st test; 
previous test 
results 
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Risk of pelvic inflammatory disease after chlamydia infection in a prospective cohort of 
sex workers  
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Appendix 5 
Crude incidence rate and crude and adjusted hazard ratio of pelvic inflammatory disease (PID) by age and chlamydia and gonorrhoea infection status 
following adjustment to methodology as described in footnote to section 2.3.7.2 
 
  
No. of 
women 
No. 
with 
PID 
Person 
years 
(py) 
Crude rate of PID 
(per 100 py)(95% CI ) 
Crude hazard 
ratio (95% CI) p value 
Adjusted hazard 
ratio (95% CI) p value 
Overall   307 48 401.22 11.96 (9.02-15.88) - - - - 
Age   - - - - 0.94 (0.89-0.99) 0.026 0.94 (0.89-1.00) 0.072 
Recent chlamydia No 278 37 359.18 10.30 (7.46-14.22) reference - reference - 
Yes 50 9 19.27 46.71 (24.31-89.78) 3.77 (1.79-7.94) 0.000 2.66 (1.01-6.98) 0.047 
Previous chlamydia No 131 14 181.03 7.73 (4.58-13.06) reference - reference - 
Yes 102 25 153.80 16.26 (10.98-24.06) 2.24 (1.16-4.33) 0.017 1.80 (0.92-3.53) 0.087 
Recent gonorrhoea No 304 43 387.92 11.08 (8.22-14.95) reference - reference - 
Yes 25 5 12.98 38.52 (16.03-92.55) 3.33 (1.30-8.52) 0.012 0.95 (0.25-3.53) 0.936 
Previous gonorrhoea No 134 15 176.51 8.50 (5.12-14.10) reference - reference - 
Yes 120 28 184.77 15.15 (10.46-21.95) 1.92 (1.02-3.62) 0.043 2.21 (1.08-4.54) 0.031 
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Appendix 6 
Crude incidence rate and crude and adjusted hazard ratio of PID by age and infection status (chlamydia, gonorrhoea, trichomoniasis, BV and candida)  
  No. of 
women 
contributing 
to category 
No. of 
women 
with 
PID 
Person 
years (py) 
Crude rate of PID 
(per 100 py) 
(95% CI ) 
Crude hazard 
ratio of PID 
(95% CI) p value 
Adjusted hazard 
ratio of PID 
(95% CI) p value 
Overall   307 48 401.22 11.96 (9.02-15.88) - - - - 
Age   - - - - 0.94 (0.89-0.99) 0.019 0.94 (0.88 – 1.00) 0.052 
Recent chlamydia No 278 40 355.58 11.25 (8.25-15.34) reference - reference - 
Yes 48 7 25.55 27.40 (13.06-57.47) 2.33 (1.03-5.25) 0.042 2.05 (0.76 – 5.55) 0.159 
Previous chlamydia No 131 15 187.21 8.01 (4.83-13.29) reference - reference - 
Yes 99 24 149.77 16.02 (10.74-23.91) 2.11 (1.10-4.04) 0.025 1.85 (0.96 – 3.56) 0.066 
Recent gonorrhoea No 304 44 382.73 11.50 (8.56-15.45) reference - reference - 
Yes 24 4 18.49 21.64 (8.12-57.65) 1.96 (0.70-5.47) 0.201 0.47 (0.10 – 2.12) 0.324 
Previous gonorrhoea No 134 16 182.24 8.78 (5.38-14.33) reference - reference - 
Yes 120 28 182.68 15.33 (10.58-22.20) 1.87 (1.01-3.48) 0.047 2.15 (1.07-4.35) 0.032 
Trichomoniasis during 
cohort 
No 285 43 365.19 11.77 (8.73-15.88) reference - reference - 
Yes 18 4 17.06 23.45 (8.80-62.47) 1.95 (0.70-5.47) 0.204 2.25 (0.76 – 6.66) 0.144 
Bacterial Vaginosis during 
cohort 
No 242 28 202.19 13.85 (9.56-20.06) reference - reference - 
Yes 114 19 178.53 10.64 (6.79-16.68) 0.97 (0.52-1.83) 0.931 0.93 (0.47 – 1.87) 0.842 
Candida during cohort 
No 266 31 241.2 12.85 (9.04-18.28) reference - reference - 
Yes 87 16 141.33 11.32 (6.94-18.48) 1.17 (0.60-2.27) 0.647 1.31 (0.65 – 2.64) 0.457 
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Appendix 7 
Crude incidence rate and crude and adjusted hazard ratio of pelvic inflammatory disease (PID) by age and chlamydia and gonorrhoea infection status 
including an interaction term between age and recent chlamydia 
  No. of 
women 
contributing 
to category 
No. of 
women 
with 
PID 
Person 
years (py) 
Crude rate of PID 
(per 100 py) 
(95% CI ) 
Crude hazard 
ratio of PID 
(95% CI) p value 
Adjusted hazard 
ratio of PID 
(95% CI) p value 
Overall   307 48 401.22 11.96 (9.02-15.88) - - - - 
Age   - - - - 0.94 (0.89-0.99) 0.019 0.92 (0.86 – 0.98) 0.013 
Recent chlamydia No 278 40 355.58 11.25 (8.25-15.34) reference - Reference - 
Yes 48 7 25.55 27.40 (13.06-57.47) 2.33 (1.03-5.25) 0.042 0.02 (0.00 – 1.68) 0.082 
Previous chlamydia No 131 15 187.21 8.01 (4.83-13.29) reference - reference - 
Yes 99 24 149.77 16.02 (10.74-23.91) 2.11 (1.10-4.04) 0.025 1.75 (0.91 – 3.38) 0.095 
Recent gonorrhoea No 304 44 382.73 11.50 (8.56-15.45) reference - Reference - 
Yes 24 4 18.49 21.64 (8.12-57.65) 1.96 (0.70-5.47) 0.201 0.60 (0.13 – 2.67) 0.501 
Previous gonorrhoea No 134 16 182.24 8.78 (5.38-14.33) reference - Reference - 
Yes 120 28 182.68 15.33 (10.58-22.20) 1.87 (1.01-3.48) 0.047 2.28 (1.14 – 4.56) 0.020 
Interaction term  - - - - - - 1.21 (1.02 – 1.42) 0.025 
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8 8 
Appendix 8 
8.1 Additional information about Manitoba administrative health 
datasets 
8.1.1 Personal Health Information Number 
Individuals are assigned a unique nine-digit PHIN when they register for healthcare through 
the MH Insurance Plan (Manitoba Centre for Health Policy, 2012b).  An individual keeps the same 
PHIN until their coverage under the insurance plan comes to an end (e.g. migration/ death).  This 
PHIN is used to identify the individual that is the subject of a healthcare record, or conversely which 
healthcare records belong to an individual.  It is included in all electronic records of healthcare 
activity including claims for payment (MH Hospital Separations Abstracts dataset; MH Medical 
Claims (Physician Billings) dataset and DPIN), for laboratory services (CPL dataset) and disease 
surveillance (Communicable Disease Surveillance Dataset) (Manitoba Centre for Health Policy, 2007). 
This PHIN is scrambled before it is included in data that is used in research.  This preserved the 
anonymity of data participants.  
8.1.2 MH Insurance Registry 
The MH Insurance Registry is used to determine the eligibility of claims for payment that are 
made through the MH Insurance plan (Manitoba Centre for Health Policy, 2012c).  It was established 
in 1970/71 fiscal year and contains demographic information about every individual registered to 
receive healthcare through the MH Insurance Plan.  There are approximately 2 million individuals in 
the dataset, including 1.2 million with active coverage.  The dataset is continuously updated, which 
improves the accuracy of the data as mistakes can be identified and corrected, and an individual has 
a separate record containing contemporary information for each year that they are registered with 
the plan.   
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The information contained within this registry can be used to identify an individual’s period 
of coverage under the insurance scheme (from date of entry to date of leaving through migration 
out of the province or death) which is a proxy for their period of residence in Manitoba.  The register 
is considered to provide almost complete coverage of the residents of Manitoba because free 
healthcare is conditional on registration with the insurance plan (Manitoba Health, 2013a).  
Although there is underreporting of two groups in the resident population: members of the military 
or the Royal Canadian Mounted Police (RCMP) are federally insured and therefore not registered 
with the MH Insurance Plan and new residents are not registered until their third month in the 
province (Manitoba Centre for Health Policy, 2012c).  Therefore this registry is effectively a 
longitudinal register of the population of Manitoba.  
Each record contains the following demographic information: PHIN; date of birth; date of 
entry to the province; date of leaving the province; date of registration; sex; FSA; municipal code 
(used before postal code became available); date of death.   
 
8.1.3 MH Hospital Separations Abstracts 
In Manitoba, Hospitals receive a global operating budget from the Department of Health to 
fund their services (Manitoba Centre for Health Policy, 2012a).  As part of this process, all hospitals 
are required to provide MH with detailed information about every in-patient admission, day surgery 
case or surgical or diagnostic procedure performed without admission to hospital at the time of 
discharge from hospital.  These records are collated to form the Hospital Separations Abstract 
dataset (Manitoba Centre for Health Policy, 2012a).  This dataset was established in 1970/71 fiscal 
year and is the only source of information about in-patient and out-patient hospital-based 
healthcare received by a resident of Manitoba.  It contains approximately 200,000 to 300,000 cases 
per year and between 8-12 million records overall (Manitoba Centre for Health Policy, 2012a).  
However, the dataset does not contain any information about healthcare provided by hospital 
Emergency Departments.  As hospital abstracts are submitted as part of the payment process, this 
dataset is likely to be a complete and accurate register of in-patient and out-patient hospital activity.   
Each hospital abstract is assigned to an individual using the unique nine-digit PHIN.  It 
contains information about the relevant diagnosis(es) and any procedure(s) performed.  Prior to 
2004, up to 16 diagnoses and up to 12 procedures were recorded using the ICD-9 Clinical 
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Modification (CM) codes (Centers for Disease Control and Prevention, 2014).  This was increased on 
1st April 2004 to 25 diagnoses (ICD-10 CA99) and 20 procedures (ICD-10 CA/CCI codes100) (Manitoba 
Centre for Health Policy, 2012a).   
The validity of this data for identifying people with up to 10 separate chronic disease 
diagnoses by using a diagnostic algorithm has been reviewed in 2006 (ICD-9) and 2008 (ICD-10).  
These studies found that the validity of the dataset varied between excellent to poor according to 
the specific condition and algorithm (Lix, 2006, Lix, 2008).  There are no studies looking at the 
validity of the dataset for PID, ectopic pregnancy or infertility.   
 
8.1.4 MH Medical Claims (Physician Billings) 
In Manitoba healthcare delivered by a physician is funded using a fee-for-service model.  To 
receive payment for delivered services, individual physicians must submit claims to MH detailing 
each item of service provided (including visits in offices, hospitals (in-patient and out-patient), 
laboratory services, X-ray services) (Manitoba Centre for Health Policy, 2011b).  These claims are 
recorded in the Medical Claims (Physician Billings) dataset.  This dataset was established in 1970/71 
fiscal year and contains approximately 12-17 million records per year (Manitoba Centre for Health 
Policy, 2011b).  This dataset is linked to reimbursement therefore it is likely to be a complete and 
accurate register of the services provided by physicians.  There may be some overlap in an 
individual’s records between this dataset and the MH Hospital Separations Abstracts dataset as both 
physicians and hospitals can bill separately for healthcare.   
Each record in this dataset is assigned to an individual using the unique nine-digit PHIN.  
Records contain information about the relevant diagnosis, coded using the first three digits of ICD-9, 
and the specific activity undertaken, coded using a tariff code from the Manitoba Health Physicians 
Manual (Manitoba Centre for Health Policy, 2011b, Manitoba Health, 2010b).  
                                                          
99
 ICD-10 CA is an adaptation of ICD-10 by the Canadian Institute for Health Information designed to be used to 
classify disease in Canada (Canadian Institute for Health Information, 2001).   
100
ICD-10 CA/CCI (Canadian Classification of Health Interventions) is the Canadian system for the classification 
of healthcare procedures (Canadian Institute for Health Information, 2014).   
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8.1.5 Drug Program Information Network (DPIN) 
Information about all prescriptions dispensed by retail pharmacies in Manitoba (including 
those not covered by the Insurance Plan) is collected in real-time by the Provincial Drug Programs 
unit.  The dataset is used to ensure that the costs of all drug prescriptions covered by the MH 
Insurance Plan are reimbursed to the provider (Manitoba Centre for Health Policy, 2011a).  The 
dataset was established in 1995/96 fiscal year and it contains approximately 12 million records for 
prescriptions covered by the Insurance Plan per year.  Each record can be linked to an individual 
using the unique nine-digit PHIN.   
Medications are coded in the DPIN using a unique eight-digit Drug Identification Number 
(DIN) (Manitoba Centre for Health Policy, 2011a).  A DIN is issued to every drug that has been 
approved by Health Canada.  This DIN specifies the drug’s product name and manufacturer, active 
ingredient(s) and their strengths, pharmaceutical form and route of administration (Manitoba 
Health, 2013c).  The dataset does not contain any information about the clinical indication for the 
prescription.   
While the dataset is a complete record of all medication dispensed from retail pharmacies, 
there are some important omissions.  It does not contain a record of medications dispensed directly 
from community clinics (e.g. remote community nursing station101 or community STI clinics) without 
a prescription (e.g. when for practical or pragmatic reasons drugs are given directly to the patients 
from clinic stocks), drugs dispensed to in-patients by hospital pharmacies or from ward stock and 
drugs dispensed during out-patient visits at CancerCare Manitoba.  
 
8.1.6 Cadham Provincial Laboratory  
CPL is the Public Health laboratory in Manitoba (Manitoba Health, 2013b).  The CPL dataset 
contains a record of all requests for laboratory services and the results of the tests performed 
(including microbiology, virology, serology and parasitology) between 1992 and 2010 (Manitoba 
                                                          
101
 Estimated to have dispensed 20% of prescriptions for Registered First Nation individuals pre-2006. 
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Centre for Health Policy, 2011c).  Electronic records of chlamydia tests began in 1984 but they are 
not considered complete until 1992.  CPL has always performed the majority of Manitoba’s 
chlamydia tests.  In 1988 the CPL performed 85.4% of the chlamydia tests in Manitoba (Jolly et al., 
1995) and by 1997/1998 it performed 94% of the province’s chlamydia and gonorrhoea tests (Wylie 
and Jolly, 2001).  Currently, virtually all the chlamydia tests for Manitoba residents are processed at 
CPL (Manitoba Centre for Health Policy, 2010).  
The CPL dataset also contains a record of all gonorrhoea tests performed at this setting.  
Gonorrhoea testing in Manitoba was performed across a range of laboratories until 2007 when a 
new policy was introduced (specimens for chlamydia or gonorrhoea were to be tested for both 
organisms using the APTIMA Combo 2 assay (Gen-Probe, US)).  Therefore the CPL dataset is a 
comprehensive source of information on gonorrhoea from 2007 onwards.    
Each record contains information about the laboratory test performed and the individual’s 
PHIN.  Clinical data may also be present, but is not compulsory.  A recent review has been 
undertaken to determine the validity of this dataset for research purposes.  The authors concluded 
that the CPL records are high quality with limited invalid or missing data.  Over 80% of the records 
could be linked to other administrative health datasets (Lix, 2012).  However the reviewers issued a 
caution about using the data to look at STIs as they found that only 3.1% of positive chlamydia tests 
recorded in CPL were followed by a chlamydia diagnosis in the hospital or physician claims datasets 
within 30 days, increasing to 4.9% within 180 days.  Understanding the cause of this finding is 
important from a public health perspective.  However, it is unlikely to impact on this study as the CPL 
is being used as the source of chlamydia diagnoses, rather than the Hospital Separations Abstracts or 
Physician Billings datasets.  
 
8.1.7 Manitoba Health Communicable Disease Surveillance Dataset  
Chlamydia and gonorrhoea are notifiable (reportable) infectious diseases under the 
Manitoba Public Health Act, 2009 (Manitoba Health, 2010a).  Notification of chlamydia was 
established in 1987 (Wylie and Jolly, 2001).  Chlamydia and gonorrhoea are also subject to 
compulsory contact or partner notification under The Public Health Act.  Information about cases of 
chlamydia and gonorrhoea are contained within the Communicable Disease Surveillance Dataset.   
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For chlamydia and gonorrhoea, laboratories are required to submit a report to the Chief 
Public Health Officer, Manitoba Communicable Disease Control Unit of Manitoba Health within a day 
of every positive test.  Physicians also have an obligation to report any individuals that have had 
chlamydia or gonorrhoea if they have a reasonable suspicion that the laboratory test will be negative 
(Manitoba Health, 2010a).  This initial report contains the case’s name, address, date of birth, PHIN, 
treating physician and test result and date.  On receipt of a positive test result, the treating 
Practitioner is contacted and asked to complete a detailed notification form covering clinical 
(symptoms; treatment given; date of treatment) and behavioural (contacts or partners) data.  This 
often requires a practitioner to contact the cases to ask for details of their sexual contact(s) and the 
case is required to provide this information.  The information in this form is added to the dataset.    
As notification is a legal obligation, this dataset is an electronic record of all infectious 
disease notifications within Manitoba and it is considered to be representative of infections within 
the Province (Jolly et al., 2005).  It contains every positive test episode recorded in CPL dataset, with 
additional demographic, epidemiological and clinical information.  The dataset also has an additional 
use: it can be used to identify women who received treatment for an STI that does not appear in the 
DPIN database, for example women attending nursing stations that dispense appropriate 
medications directly and without a prescription.   
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Appendix 9 
Comparison of Regional Health Authorities in Manitoba and the geographic areas used in this research from 1992-2008 (Manitoba Centre for Health 
Policy, 2013) 
Health Authority Regional Health Authority Regions used in this research 
1992-1996 1997-1999 2000-2001 2002-2012 2012-present 1997-2008 
Manitoba Health  Winnipeg Community and 
Long term Care 
Winnipeg Winnipeg Winnipeg Urban Core  
Winnipeg Hospital 
Authority 
Urban Non-core 
Churchill Churchill Churchill Rural North  
South Westman  South 
Westman  
Assiniboine Prairie Mountain  Rural South  
Marquette Marquette Rural South 
Brandon Brandon Brandon Rural South 
Parkland Parkland Parkland Mid Rural 
Central  Central  Central Southern  Rural South 
South Eastman South Eastman South Eastman Rural South 
North Eastman North Eastman  Interlake-Eastern Mid Rural  
Interlake Interlake  Mid Rural 
Burntwood Burntwood Burntwood Northern  Rural North 
NOR-MAN NOR-MAN NOR-MAN Rural North 
MANITOBA CENTRE FOR HEALTH POLICY. 2013. Concept: Regional Health Authorities (RHA) in Manitoba [Online]. University of Manitoba. Available: 
http://mchp-appserv.cpe.umanitoba.ca/viewConcept.php?conceptID=1218 [Accessed 9 December 2013 2013].  
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Appendix 10 
Summary of ICD-9 and ICD-10 diagnostic codes and definitions for the outcomes defined in the 
Manitoba Women’s Reproductive and Sexual Health cohort (World Health Organisation, 2014, 
Endres, 2009) 
 
PID   
ICD-9 ICD-10 Definition 
098.1 N74.3 Gonococcal infection (acute) of upper genitourinary tract, site 
unspecified 
098.15  Gonococcal cervicitis (acute)  
098.16  Gonococcal endometritis (acute)  
098.17  Gonococcal salpingitis, specified as acute 
098.30  Chronic gonococcal infection of upper genitourinary tract, site 
unspecified 
098.35   Gonococcal cervicitis, chronic 
098.36   Gonococcal endometritis, chronic 
098.37   Gonococcal salpingitis (chronic)  
098.15  Gonococcal cervicitis, acute 
098.86  Acute gonococcal peritonitis 
099.56  Chlamydial perihepatitis 
 A54.2 Female gonococcal pelvic inflammatory disease 
016.6-7  Tuberculous oophoritis and salpingitis/ TB cervicitis and 
endometritis 
614-
616.0 
 Inflammatory disease of female pelvic organs 
614.0 N70.0 Acute salpingitis and oophoritis 
614.1 N70.1 Chronic salpingitis and oophoritis 
614.2 N70.9 Salpingitis and oophoritis not specified as acute, subacute, or 
chronic/ unspecified 
614.3 N73.0 Acute parametritis and pelvic cellulitis 
614.4  Chronic or unspecified parametritis and pelvic cellulitis 
 N73.1 Chronic parametritis and pelvic cellulitis 
 N73.2 Unspecified parametritis and pelvic cellulitis 
614.5  Acute or unspecified pelvic peritonitis, female 
 N73.3 Female acute pelvic peritonitis 
 N73.5 Female pelvic peritonitis, unspecified 
614.6  Pelvic peritoneal adhesions, female (postoperative) (post-infection) 
 N73.6 Female pelvic peritoneal adhesions (excludes post-procedural) 
614.7 N73.4 Other chronic pelvic peritonitis, female 
614.8 N73.8  Other specified inflammatory disease of female pelvic organs and 
tissues/ Other specified female pelvic inflammatory diseases 
614.9 N73.9 Unspecified inflammatory disease of female pelvic organs and 
tissues 
615  Inflammatory diseases of uterus, except cervix 
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615.0 N71.0 Acute or subacute/ Acute inflammatory disease of uterus 
615.1 N71.1 Chronic/ Chronic inflammatory disease of uterus 
615.9 N71.9 Unspecified inflammatory disease of uterus 
616.0  Cervicitis and endocervicitis 
 N72 Inflammatory disease of cervix uteri 
 N74.0; 
A18.1 
Tuberculous infection of cervix uteri 
 N74.1; 
A18.1 
Female tuberculous pelvic inflammatory disease 
 N74.2; 
A51.4; 
A52.7 
Female syphilitic pelvic inflammatory disease 
 N74.4; 
A56.1 
Female chlamydial pelvic inflammatory disease 
 N74.8 Female pelvic inflammatory disorders in other diseases classified 
elsewhere 
 
Ectopic pregnancy  
ICD-9 ICD-10 Definition 
633 O00 Ectopic pregnancy 
633.0 O00.0 Abdominal pregnancy 
633.1 O00.1 Tubal pregnancy 
633.2 O00.2 Ovarian pregnancy 
633.8 O00.8 Other ectopic pregnancy 
633.9 O00.9 Unspecified ectopic pregnancy 
   
 
Infertility   
ICD-9 ICD-10 Definition 
628 N97 Infertility, female 
628.0 N97.0 Associated with anovulation 
628.1  Of pituitary-hypothalamic origin 
628.2 N97.1 Of tubal origin 
628.3  N97.2 Of uterine origin 
628.4 N97.3 Of cervical or vaginal origin/ Of cervical origin 
628.8 N97.8 Of other specified origin 
628.9 N97.9 Of unspecified origin 
 N97.4 Female infertility associated with male factors 
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Abortion    
ICD-9 ICD-10 Definition 
632  O02.1 Missed abortion 
634-637  Other pregnancy with abortive outcome 
634 O03 Spontaneous abortion 
635  O04 Legally induced abortion/ Medical abortion  
636   Illegally induced abortion 
637  O06 Unspecified abortion 
 O05 Other abortion  
 
 
Delivery   
ICD-9 ICD-10 Definition 
650-659  Normal delivery, and other indications for care in pregnancy, labor 
and delivery 
 O80-84 Delivery 
660-669 O60-O75 Complications of labour and delivery/complications mainly of labor 
and delivery  
V27  Z37 Outcome of delivery 
 Z38 Live born infants according to place of birth 
 
Other pregnancy   
ICD-9 ICD-10 Definition 
640-649 020-29 Complications/maternal disorders mainly related to pregnancy   
 O10-16 Odema, proteinuria and hypertensive disorders in pregnancy, 
childbirth and the puerperium 
630  O01 Hydatidiform mole 
 O02.0 Blighted ovum and nonhydatiform mole 
631  O02.8; 
O02.9  
Other abnormal product of conception 
 Z32.1 Pregnancy confirmed 
V22  Z34 Normal pregnancy/ Supervision of normal pregnancy  
V23  Z35 Supervision of high-risk pregnancy 
V28 Z36 Encounter for antenatal screening of mother  
 Z33 Pregnancy state incidental  
670-677 O85-92 Complications of the puerperium 
 O94-99 Other obstetric conditions 
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Summary of ICD-9 and ICD-10 procedure codes and definitions for the outcomes defined in the 
Manitoba Women’s Reproductive and Sexual Health cohort (Centers for Disease Control and 
Prevention, 2014, Manitoba Centre for Health Policy, 2012a, Canadian Institute for Health 
Information, 2014).   
 
Ectopic Pregnancy  
ICD-9-CM ICD-10-CCI Definition 
54.21 2.OT.70.DA laparoscopic surgery 
54.1 2.OT.70.LA laparotomy surgery 
99.25 5.CA.88.AL-M2; 
5.CA.88.DA-M2; 
5.CA.88.CA-M2; 
5.CA.88.HA-M2 
Includes Methotrexate injection (Injection or infusion of 
cancer chemotherapeutic substance)(icd9) and any use of 
methotrexate for termination of pregnancy (any route 
ICD-10)  
 5.CA.93.^^.^^ Surgical removal of extra-uterine pregnancy (including 
salpingectomy for removal of EP) 
74.3  Removal of extra-tubal ectopic pregnancy 
66.62  Salpingectomy with removal of tubal pregnancy  
 
 
Infertility  
ICD-9-CM ICD-10-CCI Definition 
 2.RF.58^^ Functional study fallopian tube 
 3.RK.^^.^^ HSG (inc. uterosalpingogram) 
V26.21   fertility testing  
87.8 3.RK.10.^^ X-ray of female genital organs  (includes HSG) 
66.1   diagnostic procedure on fallopian tube 
V26.8   Other specified procreative management 
68.12  2.RM.70.^^ Hysteroscopy 
68.16   Closed biopsy of uterus 
68.13   Open biopsy of uterus 
54.21  2.OT.70.DA Laparoscopy 
 2.RM.71.^^ Endometrial biopsy 
 2.KT.70.^^ Uterine Inspection  
 3.RZ.30.^^; 
5.AB.04.^^ 
Uterine USS 
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Appendix 11 
Summary of PHAC and CDC chlamydia antibiotic guidelines 1992-2008 (Centers for Disease Control 
and Prevention, 2010b, Centers for Disease Control and Prevention, 2010a, Centers for Disease 
Control and Prevention, 2006b, Centers for Disease Control and Prevention, 2006a, Centers for 
Disease Control and Prevention, 2002, Centers for Disease Control and Prevention, 1998, Centers 
for Disease Control and Prevention, 1993, Public Health Agency of Canada, 1998) 
 
 
Public Health Agency of Canada US Centers for Disease Prevention and Control  
  Drug Dose Drug Dose 
2010   Azithromycin  1g po, single dose 
 
  Doxycycline  100mg po bd, 7 days 
 
  Erythromycin base 500 mg po qds, 7 days 
 
  
Erythromycin 
ethylsuccinate  800 mg po qds, 7 days 
 
  Levofloxacin 500 mg po for 7 days 
  
  Ofloxacin  300 mg po bd, 7 days 
2008 Doxycycline  100 mg po bd, 7 days    
 Azithromycin  1 g po, single dose    
 Ofloxacin   300 mg po bd, 7 days   
 Erythromycin  2 g/day po, div., 7 days    
 Erythromycin  
1g/day po, div., 14 
days   
2006 
 
  Azithromycin  1 g po, single dose 
  
  Doxycycline  100 mg po bd, 7 days 
  
  Erythromycin base 500 mg po qds, 7 days 
  
  
Erythromycin 
ethylsuccinate  800 mg po qds, 7 days 
  
  Ofloxacin  300 mg po bd, 7 days 
  
  Levofloxacin 500 mg po for 7 days 
2002 
 
  Azithromycin  1g po, single dose 
  
  Doxycycline  100 mg po bd, 7 days 
  
  Erythromycin base 500 mg po qds, 7 days 
  
  
Erythromycin 
ethylsuccinate  800 mg po qds, 7 days 
  
  Ofloxacin  300 mg po bd, 7 days 
  
  Levofloxacin 500 mg po for 7 days 
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1998 azithromycin 1g po, single dose Azithromycin  1 g po, single dose 
 
doxycycline  100 mg po bd, 7 days Doxycycline  100 mg po bd, 7 days 
 
ofloxacin  300 mg bd, 7 days Erythromycin base 500 mg po qds, 7 days 
 
erythromycin  2 g/day po, div., 7 days  
Erythromycin 
ethylsuccinate  800 mg po qds, 7 days 
 
erythromycin  
1 g/day po, div., 14 
days  Ofloxacin  300 mg po bd, 7 days 
 
Pregnancy:    
  
 
amoxicillin  500 mg po tds, 7 days 
  
 
erythromycin 2 g/day po, div., 7 days  
  
 
azithromycin 1g po, single dose 
  1993 
 
  Doxycycline  100 mg po bd, 7 days 
  
  Azithromycin  1 g po, single dose 
  
  Ofloxacin  300 mg po bd, 7 days 
  
  Erythromycin base 500 mg po qds, 7 days 
  
  
Erythromycin 
ethylsuccinate  800 mg po qds, 7 days 
  
  Sulfisoxazole  500 mg po qds 
 
Key:  
Po orally 
Od once per day 
Bd twice per day 
Tds three times per day 
Qds four times per day 
Div divided doses 
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Appendix 12 
Rate of PID and crude and adjusted hazard ratio of PID following the first chlamydia test  
    
Number of 
women 
% with 
PID 
Person 
years 
Rate of PID 
per 100 py 
95% CI 
Crude 
HR 
95% CI 
Adjusted 
HR 
95% CI 
Overall 
 
72883 8.25 625260.67 0.96 0.77-1.15 - - - - 
First test result Negative 68892 7.87 590155.82 0.92 0.73-1.11 baseline - baseline - 
 
Positive 3991 14.81 35104.85 1.68 1.43-1.94 1.85 1.70-2.01 1.55 1.43-1.70 
           Region Rural South 14210 7.38 107716.07 0.97 0.78-1.17 1.17 1.01-1.26 1.28 1.19-1.38 
 
Mid 10423 10.03 90719.66 1.15 0.94-1.36 1.42 1.32-1.52 1.39 1.29-1.49 
 
Rural North 5825 11.57 53352.50 1.26 1.04-1.48 1.57 1.44-1.71 1.30 1.19-1.41 
 
Urban Core 6914 10.53 62734.73 1.16 0.95-1.37 1.44 1.33-1.57 1.28 1.18-1.39 
 
Urban Non-
Core 
35511 7.09 310737.71 0.81 0.63-0.99 baseline - baseline - 
           Age at test 12-15 5576 18.44 57363.02 1.79 1.53-2.05 2.63 2.08-3.32 1.55 1.22-1.98 
 
16-19 28485 9.66 266458.19 1.03 0.83-1.23 1.48 1.18-1.86 0.96 0.76-1.22 
 
20-24 27833 6.21 231495.97 0.75 0.58-0.92 1.07 0.85-1.35 0.72 0.57-0.91 
 
25-29 8810 4.86 60513.99 0.71 0.54-0.87 0.96 0.76-1.23 0.74 0.58-0.95 
 
30-40 2179 3.49 9429.50 0.81 0.63-0.98 baseline - baseline - 
 
          
Year of test 1992-1996 33478 12.12 368187.44 1.10 0.90-1.31 baseline - baseline - 
 
1997-2000 19050 6.90 162154.59 0.81 0.63-0.99 0.64 0.60-0.68 0.63 0.59-0.67 
 
2001-2004 14498 3.89 81746.25 0.69 0.53-0.85 0.51 0.46-0.55 0.55 0.50-0.61 
 
2005-2008 5857 1.35 13172.40 0.60 0.45-0.75 0.37 0.30-0.46 0.45 0.35-0.56 
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Rate of PID and crude and adjusted hazard ratio of PID following the second chlamydia test 
    
Number of 
women 
Proportion 
with PID 
Person 
years 
Rate of 
PID per 
100 py 
95% CI 
Crude 
HR 
95% CI 
Adjusted 
HR 
95% CI 
Overall 
 
58473 7.68 559755.69 0.80 0.63-0.98 - - - - 
Second test result Negative 55781 7.34 534674.98 0.77 0.59-0.94 baseline - baseline - 
 
Positive 2692 14.78 25080.71 1.59 1.34-1.83 2.07 1.86-2.29 1.55 1.39-1.72 
First test result Negative 54938 7.39 526147.61 0.77 0.60-0.94 baseline - baseline - 
 
Positive 3535 12.22 33608.08 1.29 1.06-1.51 1.68 1.52-1.86 1.17 1.06-1.30 
Region  Rural South 10826 6.51 92051.14 0.77 0.59-0.94 1.10 1.01-1.20 1.29 1.18-1.41 
 
Mid 8561 9.03 82567.77 0.94 0.75-1.13 1.37 1.26-1.49 1.35 1.24-1.47 
 
Rural North 5057 10.97 50371.66 1.10 0.90-1.31 1.62 1.48-1.79 1.22 1.11-1.34 
 
Urban Core 5761 9.98 57508.74 1.00 0.80-1.20 1.48 1.35-1.62 1.21 1.10-1.33 
 
Urban Non-
Core 
28268 
6.66 
277256.39 0.68 
0.52-0.84 
baseline - baseline - 
Age at test 12-15 1803 23.02 18425.79 2.25 1.96-2.55 7.06 5.78-8.63 3.25 2.62-4.03 
 
16-19 16825 11.63 167990.23 1.16 0.95-1.38 3.61 3.01-4.32 1.95 1.60-2.36 
 
20-24 24559 6.07 227936.73 0.65 0.50-0.81 2.02 1.68-2.42 1.22 1.01-1.48 
 
25-29 11174 4.51 107165.28 0.47 0.34-0.61 1.45 1.19-1.77 1.04 0.85-1.27 
 
30-40 4112 3.04 38237.66 0.33 0.21-0.44 baseline - baseline - 
Year of test 1992-1996 18331 13.14 215859.17 1.12 0.91-1.32 baseline - baseline - 
 
1997-2000 16597 7.94 173282.59 0.76 0.59-0.93 0.63 0.59-0.68 0.67 0.63-0.72 
 
2001-2004 14838 4.11 119926.96 0.51 0.37-0.65 0.39 0.36-0.43 0.48 0.44-0.53 
 
2005-2008 8707 1.80 50686.98 0.31 0.20-0.42 0.23 0.20-0.27 0.34 0.29-0.41 
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Rate of PID and crude and adjusted hazard ratio of PID following the third chlamydia test 
    
Number 
of 
women 
% 
with 
PID 
Person 
years 
Rate of 
PID 
per 
100 py 
95% CI 
Crude 
HR 
95% CI 
Adjusted 
HR 
95% CI 
Overall 
 
45924 7.26 474546.85 0.70 0.54-0.87 - - - - 
Third test result Negative 43936 7.02 454856.03 0.68 0.52-0.84 baseline - baseline - 
 
Positive 1988 12.68 19690.82 1.28 1.06-1.50 1.89 1.66-2.14 1.29 1.13-1.47 
First & second 
test results 
-- 40793 6.75 423242.47 0.65 0.49-0.81 baseline - baseline - 
-+ 1977 11.68 19645.97 1.18 0.96-1.39 1.81 1.58-2.07 1.23 1.08-1.42 
 
+- 2738 10.70 27540.72 1.06 0.86-1.27 1.66 1.47-1.87 1.13 1.00-1.28 
 
++ 416 14.42 4117.69 1.46 1.22-1.69 2.20 1.70-2.85 1.35 1.04-1.75 
Region   Rural South 7842 5.94 72498.22 0.64 0.49-0.80 1.06 0.96-1.18 1.27 1.15-1.42 
 
Mid 6807 8.54 70511.17 0.82 0.65-1.00 1.36 1.24-1.50 1.36 1.23-1.50 
 
Rural North 4409 10.14 46640.8 0.96 0.77-1.15 1.59 1.43-1.77 1.13 1.02-1.27 
 
Urban Core 4800 9.04 51152.27 0.85 0.67-1.03 1.41 1.27-1.57 1.10 0.98-1.22 
 
Urban Non-Core 22066 6.38 233744.38 0.60 0.45-0.75 baseline - baseline - 
Age at test 12-15 741 26.59 7576.9 2.60 2.28-2.92 10.79 8.66-13.43 4.55 3.59-5.78 
 
16-19 9844 13.39 102409.72 1.29 1.06-1.51 5.31 4.44-6.34 2.65 2.18-3.21 
 
20-24 19907 6.14 196090.65 0.62 0.47-0.78 2.57 2.15-3.08 1.52 1.26-1.83 
 
25-29 10541 4.40 113295.05 0.41 0.28-0.53 1.69 1.40-2.05 1.19 0.98-1.45 
 
30-40 4891 2.74 55174.53 0.24 0.15-0.34 baseline - baseline - 
Year of test 1992-1996 9952 14.48 121704.53 1.18 0.97-1.40 baseline - baseline - 
 
1997-2000 13216 8.56 153228.94 0.74 0.57-0.91 0.59 0.55-0.64 0.67 0.62-0.72 
 
2001-2004 12941 4.65 124557.91 0.48 0.35-0.62 0.37 0.34-0.41 0.49 0.44-0.55 
 
2005-2008 9815 1.65 75055.47 0.22 0.12-0.31 0.17 0.14-0.20 0.27 0.23-0.33 
  Appendix 15 
292 
 
Appendix 15  
15.1 Additional information about administrative health datasetsCivil 
Register Number 
Individuals are assigned a unique 10-digit personal identification number, the Civil Register 
(CPR) number at birth or when they become a resident of Denmark (Pedersen, 2011, Westh and 
Kolmos, 2003).  The first 6 digits of this are the individual’s date of birth (DD/MM/YY) and the next 4 
digits are a serial number that ends in an odd number for men and an even number for females 
(Malig, 1996).  This CPR number can be used to identify and link all the information on a particular 
individual held in any of the Danish public administration datasets, including the CRS and the LPR  
(Malig, 1996).  This number is replaced by an anonymised identification number in datasets used for 
research.  The research identification number retains the ability to link the records for an individual 
but does not provide information about a person’s identity.   
15.1.2 Danish Civil Registration System  
The Danish Civil Registration System (CRS) was established in 1968 (Nguyen-Nielsen et al., 
2013).  It is a legal requirement for all individuals who will be resident in Denmark for over 3 months 
(or 6 months is they are from a Nordic country) to register with the CRS.  This dataset forms a 
population register and contains a record of every individual who has been resident in Denmark 
since 1968 and Greenland since 1972 (Malig, 1996).  It is used by all public administrations in 
Denmark and for research purposes it is managed by the Denmark Research Service (Forskerservice). 
For each resident, the CRS contains the CPR, date of birth, gender, continuously updated 
information about place of residence and information about relatives (partners/ children/ parents).  
This dataset is considered to be complete as it is a legal requirement for individuals to be registered 
(Pedersen, 2011).  Although I was not able to identify any studies of its validity it is considered to be 
high quality as errors would be picked up and corrected by the many users of the data (Pedersen, 
2011). 
The CRS has been used in many published epidemiological studies as a source of information 
about the duration of people’s residence in Denmark, including date of death (Ostenfeld et al., 2013, 
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Schmidt et al., 2014) and for identifying controls for population-based matched case-control studies 
(Egerup et al., 2014, Baastrup Nordsborg et al., 2013, Bang et al., 2014, Frederiksen et al., 2014). 
15.1.3 Danish National Patient Register  
The Danish National Patient Register (Landspatientregistret (LPR)) was established in 1977 as 
a register of all general Hospital admissions in Denmark (Lynge et al., 2011).  In 1995, activity in 
Emergency Departments, out-patient departments and admissions to psychiatric hospitals were 
added (Lynge et al., 2011).  Compulsory reporting of activity from private providers came into force 
in 2003 although it is thought that the data from this setting remains incomplete (Lynge et al., 2011).  
The LPR was coded using ICD-8 until 1994 when ICD-10 codes were introduced (Lynge et al., 2011).  
Individuals are identified in the dataset by using their CPR number and each record contains 
information about the date and time of the start and end of the hospital event, the referral and final 
diagnosis and the treatment received.  It is reported to be a complete record of healthcare provided 
in public hospitals from 2000 when the register became the basis for reimbursement (Lynge et al., 
2011).  Between 1984 and 1993 it was reported to contain 99.4% of all hospital discharges 
(Andersen, 2005). 
The LPR has been used to generate population-based datasets to explore the aetiology or 
epidemiology of diseases, including the Danish National Birth Cohort Biobank (Olsen et al., 2001) and 
it has been used in conjunction with the CRS to generate case-control studies (Egerup et al., 2014, 
Baastrup Nordsborg et al., 2013, Bang et al., 2014, Frederiksen et al., 2014).  
 
15.1.4 State Serum Institute chlamydia test dataset 
The data about chlamydia testing that was used to identify positive women and document 
all testing events during a woman’s period of membership in the dataset was generated specifically 
for the “Epidemiology of chlamydia and its complications in Denmark” study.  Therefore there is, as 
yet, no published information on this dataset.  Briefly, all Departments of Clinical Microbiology that 
perform chlamydia testing in Denmark were contacted and asked to share electronic records of 
chlamydia testing.  Each chlamydia test record contained the individual’s CPR number, site and date 
of the specimen, type of chlamydia test performed and result of the test.  This dataset was cleaned, 
coded and formatted by Dr Maria Frøland.  
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Appendix 16 
Description of variables in the original Denmark Chlamydia study dataset, recoding and new 
variables generated  
 
Original variable  New Variable  Definition Method 
Demographic variables  
Anonymised 
identification 
number 
   
Anonymised 
identification 
number of 
matched case 
   
Date of birth Age at entry to 
study  
 (date of entry – date of 
birth)/365.25 
Date of 45th 
birthday 
 Day and month from date of 
birth combined with year of 
45th birthday. (Maximum age 
in the dataset was 45.00137 
years).  For women born on 
29th February, (day-1) was 
used.  
Gender    
Residency status   Describes whether a 
woman is resident in 
Denmark or Greenland 
or the reason for her 
residence to cease (e.g. 
emigration; death) 
 
Date of ceasing 
residence in 
Denmark  
 Missing if resident on 
31/12/2013 
 
Chlamydia Exposure 
Date of test    
Raw test result   Provides the original 
diagnosis code from SSI  
 
Test site  Anatomical site that the 
sample was obtained 
from  
Recoded into the following 
categories: Genital; urine; 
genital or urinary; rectal/anal; 
intra-abdominal; 
respiratory/oral; eye; male; 
rectal or respiratory; not 
known 
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Test type  Type of test performed 
(e.g. culture; ELISA; 
NAAT) 
 
 Total number of 
tests during study  
Number of tests in the 
study (constant 
variable) 
Generated using “count” 
command of variable “date of 
test”  
 Number of the 
most recent test 
in the sequence 
of all tests 
 Generated using “sequence” 
command of variable “date of 
test” 
 Total number of 
positive test 
records in dataset 
 Generated a variable that 
recorded if a test was positive 
(missing otherwise) and used 
“count” command for this 
variable 
 Number of the 
most recent 
positive test in 
the sequence of 
all positive tests 
 Generated using “sequence” 
command for positive value of 
“test result” variable 
 First or recurrent 
positive test  
Records whether the 
most recent positive 
test is the first during 
the study (i.e. on study 
entry) or a subsequent 
repeat infection  
Code variable as “number of 
this positive test”, values 
greater than 2 were replaced 
with 2 
Case, negative 
control or never 
tested control 
  Recoded negative controls to 
be never tested if they did not 
have a negative test during 
their membership in study 
dataset 
 
 
Outcomes – shaded PID variables are repeated for ectopic pregnancy and tubal factor infertility 
 Outcome type Records the diagnosis of 
the hospital admission 
in that row 
Used the rows where outcome 
date was not missing and 
coded PID = 1; EP = 2; TFI = 3 
Date of PID 
admission 
 Start date of hospital 
admission with PID 
 
 Total number of 
PID admissions 
during study 
 Generated using “count” 
command of variable “date of 
PID admission” 
 Number of the 
most recent PID 
admission in the 
sequence of all 
PID admissions  
 Generated using “sequence” 
command for “date of PID 
admission” 
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 Lifetime exposure 
to PID  
Constant variable that 
describes whether a 
woman has an episode 
of PID during the study  
Generated using “total 
number of PID admissions”, 
values >2 were replaced with 
2  
 
 
Dataset description variables 
 Date of event  Single variable that 
records the date of the 
event occurring in 
current row of the 
dataset 
Set as date of entering the 
study and then replaced by 
the date of the event 
described in the row of the 
dataset (entry; chlamydia test; 
PID; ectopic pregnancy; tubal 
factor infertility; exit) 
Date of entry to 
original study 
dataset 
   
 Year of entry  Extracts year from date of 
entry to study 
 Entry Flags the row where the 
event is entry to the 
study 
Date of entry to study  = date 
of event 
 Exit date Date woman leaves the 
dataset 
Set as 31/12/2012 then 
replaced by date of 45th 
birthday if this was earlier; 
then replaced by date of 
ceasing residence in Denmark 
if this was earlier 
 Exit Flags the row where the 
event is exit from the 
study 
Date of exit from the study= 
date of event 
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Appendix 17 
Additional tables: analysis of positive and negative women from first test to exit 
Rate of PID per 1000 person years during first 30 days after first chlamydia test by test result, age at first test and year of first test with rate ratio 
compared to baseline group 
 
  
Number of 
women 
Number 
with PID 
Person 
years (py) 
Rate per 
1000 py 
95% CI Rate ratio 95% CI 
Chlamydia status 
       
 
negative 181607 197 14907.0 13.22 11.49-15.20 baseline - 
 
positive 102887 338 8432.2 40.08 36.03-44.59 3.03 2.54-3.63 
Age at test      
  
 
15-19 67462 163 5531.7 29.47 25.27-34.36 baseline - 
 
20-24 117236 170 9621.2 17.67 15.20-20.54 0.60 0.48-0.75 
 
25-29 63460 104 5206.8 19.97 16.48-24.21 0.68 0.52-0.87 
 
30-44 36336 98 2979.5 32.89 26.98-40.09 1.12 0.86-1.44 
Year of test      
  
 
1995-2000 39999 123 3278.6 37.52 31.44-44.77 baseline - 
 
2001-2006 117353 226 9627.3 23.48 20.61-26.74 0.63 0.50-0.79 
 
2007-2012 127142 186 10433.3 17.83 15.44-20.58 0.48 0.38-0.60 
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Rate of PID per 1000 person years, unadjusted and adjusted hazard ratios (HR) of PID from first chlamydia test by test result, age at test and year of test 
during the following time periods: (a) 31-60 days; (b) 61 days to 4 years; (c) 4 to 5 years; (d) 5 to 10 years; (e) 10 years to end  
 
(a) 31-60 days, positive and negative women 
 
  
Number of 
women 
Number 
with PID 
Person 
years (py) 
Rate per 
1000 py 95% CI 
Unadjusted 
HR 95% CI 
Adjusted 
HR 95% CI 
Chlamydia status 
         
 
negative 181404 90 14895.5 6.04 4.91-7.43     
 
positive 102542 64 8419.4 7.60 5.95-9.71 1.19 0.86-1.64 1.18 0.84-1.66 
Age at test          
 
15-19 67298 30 5526.0 5.43 3.80-7.76     
 
20-24 117066 55 9612.8 5.72 4.39-7.45 1.07 0.69-1.68 1.04 0.66-1.64 
 
25-29 63352 35 5201.8 6.73 4.83-9.37 1.26 0.77-2.05 1.24 0.75-2.05 
 
30-44 36230 34 2974.2 11.43 8.17-16.00 2.13 1.30-3.48 2.32 1.40-3.84 
Year of test          
 
1995-2000 39874 35 3273.4 10.69 7.68-14.89     
 
2001-2006 117124 70 9616.9 7.28 5.76-9.20 0.69 0.46-1.03 0.67 0.44-1.01 
 
2007-2012 126948 49 10424.5 4.70 3.55-6.22 0.45 0.29-0.69 0.43 0.27-0.67 
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(b) 61 days to 4 years, positive and negative women  
 
 
  
Number of 
women 
Number 
with PID 
Person 
years (py) 
Rate per 
1000 py 
95% CI 
Unadjusted 
HR 
95% CI 
Adjusted 
HR 
95% CI 
Chlamydia status 
         
 
negative 181301 1803 637215.3 2.83 2.70-2.96     
 
positive 102474 1583 367653.9 4.31 4.10-4.52 1.53 1.43-1.63 1.42 1.32-1.53 
Age at test           
 
15-19 67265 907 238428.1 3.80 3.56-4.06     
 
20-24 117007 1265 415726.8 3.04 2.88-3.22 0.80 0.73-0.87 0.84 0.77-0.91 
 
25-29 63313 779 225968.3 3.45 3.21-3.70 0.91 0.82-1.00 0.99 0.89-1.09 
 
30-44 36190 435 124746.1 3.49 3.17-3.83 0.91 0.82-1.02 1.06 0.94-1.19 
Year of test           
 
1995-2000 39838 756 151118.1 5.00 4.66-5.37     
 
2001-2006 117048 1474 445579.8 3.31 3.14-3.48 0.66 0.61-0.72 0.69 0.63-0.75 
 
2007-2012 126889 1156 408717.3 2.83 2.67-3.00 0.55 0.51-0.61 0.58 0.53-0.64 
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(c) 4  to 5 years, positive and negative women  
 
 
  
Number of 
women 
Number 
with PID 
Person 
years (py) 
Rate per 
1000 py 
95% CI 
Unadjusted 
HR 
95% CI 
Adjusted 
HR 
95% CI 
Chlamydia status 
         
 
negative 130910 274 119111.0 2.3 2.04-2.59     
 
positive 80616 251 75068.7 3.34 2.95-3.78 1.45 1.23-1.73 1.34 1.12-1.61 
Age at test           
 
15-19 48759 163 43722.8 3.73 3.20-4.35     
 
20-24 88758 195 82230.1 2.37 3.06-2.73 0.64 0.52-0.78 0.69 0.55-0.85 
 
25-29 49361 123 46065.0 2.67 2.34-3.19 0.72 0.57-0.91 0.80 0.62-1.02 
 
30-44 24648 44 22161.9 1.99 1.48-2.67 0.53 0.38-0.74 0.59 0.42-0.83 
Year of test           
 
1995-2000 39038 111 38971.7 2.85 2.36-3.43     
 
2001-2006 115389 305 115152.9 2.65 2.37-2.96 0.93 0.75-1.16 0.91 0.78-1.21 
 
2007-2012 57099 109 40055.2 2.72 2.26-3.28 0.94 0.72-1.23 0.98 0.75-1.28 
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(d) 5 to 10 years, positive and negative women  
 
 
 
Number of 
women 
Number 
with PID 
Person 
years (py) 
Rate per 
1000 py 95% CI 
Unadjusted 
HR 95% CI 
Adjusted 
HR 95% CI 
Chlamydia status 
         
 
negative 108023 746 326092.3 2.29 2.13-2.46     
 
positive 69856 732 240854.4 3.04 2.83-3.27 1.34 1.21-1.48 1.26 1.13-1.40 
Age at test           
 
15-19 38977 365 113894.5 3.20 2.89-3.55     
 
20-24 76073 683 256304.5 2.66 2.47-2.87 0.84 0.74-0.95 0.89 0.78-1.01 
 
25-29 42943 318 142268.1 2.34 2.00-2.50 0.70 0.60-0.81 0.76 0.65-0.89 
 
30-44 19886 112 54479.5 2.06 1.71-2.47 0.64 0.52-0.79 0.70 0.56-0.86 
Year of test           
 
1995-2000 38914 527 192982.12 2.73 2.51-2.97     
 
2001-2006 114899 923 364291.3 2.53 2.38-2.70 0.90 0.81-1.00 0.94 0.84-1.05 
 
2007-2012 24066 28 9673.1 2.89 2.00-4.19 0.88 0.59-1.31 0.92 0.62-1.37 
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(e) 10 to 17 years, positive and negative women 
 
 
  
Number of 
women 
Number 
with PID 
Person 
years (py) 
Rate per 
1000 py 
95% CI 
Unadjusted 
HR 
95% CI 
Adjusted 
HR 
95% CI 
Chlamydia status 
         
 
negative 33029 157 77425.3 2.03 1.73-2.37     
 
positive 30169 246 97765.2 2.52 2.22-2.85 1.30 1.06-1.59 1.29 1.05-1.59 
Age at test           
 
15-19 17106 129 44966.1 2.87 2.41-3.41     
 
20-24 31437 212 39926.4 2.33 2.03-2.66 0.82 0.66-1.02 0.83 0.67-1.04 
 
25-29 11879 52 33708.7 1.54 1.18-2.02 0.54 0.39-0.74 0.54 0.39-0.75 
 
30-44 2776 10 5389.3 1.86 1.00-3.45 0.62 0.32-1.18 0.60 0.32-1.14 
Year of test           
 
1995-2000 49080 369 163924.0 2.25 2.03-2.49     
 
2001-2006 14118 34 11266.5 3.02 2.16-4.22 1.22 0.84-1.77 1.12 0.77-1.64 
 
  Appendix 18 
304 
 
Appendix 18 
Additional tables: analysis of positive, negative and never tested women 
Rate of PID per 1000 person years during first 30 days after entry to study by chlamydia status, age at entry and year of entry with rate ratio compared 
to baseline group  
 
  
Number of 
women 
Number 
with PID 
Person 
years (py)  
Rate per 
1000 py 95% CI Rate ratio  95% CI  
Chlamydia status 
       
 
never tested 230496 10 18930.6 0.53 0.28-0.98 baseline - 
 
negative  182878 41 15019.2 2.73 2.01-3.71 5.17 2.55-11.57 
 
positive 102887 338 8432.2 40.08 36.03-44.59 75.88 40.76-159.69 
Age at entry 
       
 
15-19 197712 149 16230.3 9.18 7.82-10.78 baseline - 
 
20-24 195435 121 16046.3 7.54 6.31-9.01 0.82 0.64-1.05 
 
25-29 78738 70 6463.6 10.83 8.57-13.69 1.18 0.87-1.58 
 
30-44 44376 49 3641.9 13.46 10.17-17.80 1.47 1.04-2.04 
Year of entry 
       
 
1995-2000 108373 113 8895.0 12.70 10.57-15.28 baseline - 
 
2001-2006 212492 165 17444.4 9.46 8.12-11.02 0.74 0.58-0.95 
 
2007-2012 195396 111 16042.7 6.92 5.74-8.33 0.54 0.42-0.71 
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Rate of PID per 1000 person years (py) and unadjusted and adjusted hazard ratios (HR) of chlamydia status on PID from entry to the study during the 
following time periods: (a) 31-60 days; (b) 61 days to 18 months; (c) 18 months to 2.5 years; (d) 2.5 to 5 years; (e) 5 to 7 years; (f) 7 to 10 years; (g) 10 to 
15 years; (h) 15-17 years 
 
a. 31-60 days, positive, negative and never tested women 
 
 
Number of 
women 
Number 
with PID 
Person 
years (py) 
Rate per 
1000 py 95% CI 
Unadjusted 
HR 95% CI 
Adjusted 
HR 95% CI 
Chlamydia status 
         
 
never tested 230461 8 18927.6 0.42 0.21-0.85 
    
 
negative  182837 38 15016.1 2.53 1.84-3.48 5.92 2.76-12.69 5.81 2.68-12.61 
 
positive 102542 64 8419.4 7.60 5.95-9.71 17.26 8.27-36.06 17.12 8.17-35.85 
Age at entry 
         
 
15-19 197555 28 16224.8 1.73 1.19-2.50 
    
 
20-24 195311 44 16040.1 2.74 2.04-3.69 1.58 0.98-2.54 1.44 0.89-2.33 
 
25-29 78666 21 6460.1 3.72 2.49-5.54 2.14 1.24-3.69 2.02 1.16-3.50 
 
30-44 44308 14 3638.0 3.85 2.28-6.50 2.21 1.16-4.19 2.47 1.30-4.71 
Year of entry 
         
 
1995-2000 108255 35 8890.1 3.94 2.83-5.48 
    
 
2001-2006 212320 42 17437.0 2.41 1.78-3.26 0.61 0.39-0.96 0.66 0.42-1.04 
 
2007-2012 195265 33 16036.0 2.06 1.46-2.89 0.52 0.32-0.84 0.70 0.43-1.15 
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b. 61 days to 18 months, positive, negative and never tested women  
 
 
Number of 
women 
Number 
with PID 
Person 
years (py) 
Rate per 
1000 py 95% CI 
Unadjusted 
HR 95% CI 
Adjusted 
HR 95% CI 
Chlamydia status 
         
 
never tested 230431 234 306854.6 0.76 0.67-0.87     
 
negative  182799 735 243671.3 3.02 2.81-3.24 3.96 3.41-4.58 3.75 3.22-4.36 
 
positive 102474 711 136182.4 5.22 4.85-5.62 6.85 5.91-7.94 6.68 5.76-7.75 
Age at entry           
 
15-19 197520 526 263165.7 2.00 1.84-2.18     
 
20-24 195264 657 260043.1 2.53 2.64-2.73 1.26 1.13-1.42 1.14 1.01-1.28 
 
25-29 78638 326 104693.8 3.11 2.79-3.47 1.56 1.36-1.79 1.46 1.27-1.67 
 
30-44 44282 171 58805.7 2.91 2.50-3.38 1.45 1.22-1.73 1.66 1.39-1.97 
Year of entry           
 
1995-2000 108218 528 144149.2 3.66 3.36-3.99     
 
2001-2006 212272 684 283019.7 2.42 2.24-2.60 0.66 0.59-0.74 0.71 0.63-0.79 
 
2007-2012 195214 468 259539.4 1.80 1.65-1.97 0.49 0.43-0.56 0.66 0.58-0.75 
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c. 18 months to 2.5 years, positive, negative and never tested women  
 
  
Number of 
women 
Number 
with PID 
Person 
years (py) 
Rate per 
1000 py 95% CI 
Unadjusted 
HR 95% CI 
Adjusted 
HR 95% CI 
Chlamydia status 
         
 
never tested 226539 172 218123.1 0.79 0.68-0.92     
 
negative  182019 543 181332.2 2.99 2.75-3.26 3.80 3.20-4.51 3.68 3.09-4.39 
 
positive 100845 389 98480.7 3.95 3.58-4.36 5.01 4.19-6.00 4.94 4.13-5.92 
Age at entry           
 
15-19 195490 376 191065.6 1.97 1.78-2.18     
 
20-24 192922 414 188864.2 2.19 1.99-2.41 1.11 0.97-1.28 1.01 0.88-1.16 
 
25-29 77628 215 76078.9 2.83 2.47-3.23 1.44 1.21-1.70 1.36 1.15-1.61 
 
30-44 43363 99 41927.3 2.36 1.94-2.88 1.20 0.96-1.50 1.38 1.11-1.72 
Year of entry           
 
1995-2000 107645 336 107454.5 3.13 2.81-3.48     
 
2001-2006 211495 463 211222.5 2.19 2.00-2.40 0.70 0.61-0.81 0.75 0.65-0.87 
 
2007-2012 190263 305 179259.0 1.70 1.52-1.90 0.54 0.47-0.63 0.73 0.62-0.86 
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d. 2.5 to 5 years, positive, negative and never tested women 
 
 
Number of 
women 
Number 
with PID 
Person 
years (py) 
Rate per 
1000 py 95% CI 
Unadjusted 
HR 95% CI 
Adjusted 
HR 95% CI 
Chlamydia status 
         
 
never tested 207557 388 422436.0 0.92 0.83-1.01     
 
negative 180219 1172 424666.8 2.76 2.61-2.92 3.01 2.68-3.38 3.01 2.68-3.38 
 
positive 95497 734 208059.5 3.53 3.28-3.79 3.84 3.40-4.35 3.85 3.40-4.35 
Age at entry           
 
15-19 184911 774 392910.2 1.97 1.84-2.11     
 
20-24 183899 918 409242.2 2.24 2.10-2.39 1.14 1.03-1.25 1.07 0.97-1.18 
 
25-29 74244 420 167783.3 2.5 2.27-2.75 1.27 1.13-1.43 1.26 1.12-1.42 
 
30-44 40219 182 85226.7 2.14 1.85-2.47 1.08 0.92-1.27 1.25 1.06-1.47 
Year of entry           
 
1995-2000 107281 731 267129.6 2.74 2.55-2.94     
 
2001-2006 210966 1051 525670.0 2.00 1.88-2.12 0.73 0.66-0.80 0.78 0.71-0.86 
 
2007-2012 165026 512 262362.8 1.95 1.79-2.13 0.71 0.63-0.80 0.89 0.79-1.00 
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e. 5 to 7 years, positive, negative and never tested women  
 
 
Number of 
women 
Number 
with PID 
Person 
years (py) 
Rate per 
1000 py 95% CI 
Unadjusted 
HR 95% CI 
Adjusted 
HR 95% CI 
Chlamydia status 
         
 
never tested 131015 228 217316.1 1.05 0.92-1.19     
 
negative 154240 704 277169.6 2.54 2.36-2.73 2.43 2.09-2.82 2.45 2.10-2.84 
 
positive 69856 390 120837.1 3.23 2.92-3.56 3.08 2.62-3.63 3.09 2.63-3.64 
Age at entry           
 
15-19 125476 398 207765.2 1.92 1.74-2.11     
 
20-24 142205 564 252626.1 2.23 2.06-2.42 1.17 1.03-1.33 1.14 1.00-1.30 
 
25-29 59528 259 107685.5 2.41 2.13-2.72 1.26 1.08-1.47 1.29 1.10-1.51 
 
30-44 27902 101 47246.1 2.14 1.76-2.60 1.12 0.90-1.39 1.27 1.02-1.58 
Year of entry           
 
1995-2000 106441 487 212319.2 2.29 2.10-2.51     
 
2001-2006 209368 807 387298.4 2.08 1.94-2.23 0.90 0.81-1.01 0.96 0.86-1.08 
 
2007-2012 39302 28 15705.2 1.78 1.23-2.58 0.71 0.48-1.05 0.83 0.56-1.23 
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f. 7 to 10 years, positive, negative and never tested women 
 
  
Number of 
women 
Number 
with PID 
Person 
years (py) 
Rate per 
1000 py 95% CI 
Unadjusted 
HR 95% CI 
Adjusted 
HR 95% CI 
Chlamydia status 
         
 
never tested 89171 197 198862.4 0.99 0.86-1.14     
 
negative 122806 749 294392.6 2.54 2.37-2.73 2.57 2.20-3.01 2.48 2.12-2.91 
 
positive 51703 342 120017.2 2.85 2.56-3.17 2.88 2.42-3.43 2.82 2.36-3.36 
Age at entry           
 
15-19 84676 392 184982.8 2.12 1.92-2.34     
 
20-24 111598 647 271270.4 2.39 2.21-2.58 1.13 0.99-1.28 1.12 0.99-1.27 
 
25-29 48016 201 115928.6 1.73 1.51-1.99 0.82 0.69-0.97 0.86 0.73-1.02 
 
30-44 19390 48 41090.4 1.17 0.88-1.55 0.55 0.41-0.74 0.64 0.47-0.86 
Year of entry           
 
1995-2000 105874 670 316368.9 2.12 1.96-2.28     
 
2001-2006 157806 618 296903.2 2.08 1.92-2.25 0.98 0.87-1.09 1.02 0.91-1.14 
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g. 10 to 15 years, positive, negative and never tested women 
 
 
Number of 
women 
Number 
with PID 
Person 
years (py) 
Rate per 
1000 py 95% CI 
Unadjusted 
HR 95% CI 
Adjusted 
HR 95% CI 
Chlamydia status 
         
 
never tested 48024 127 136590.2 0.93 0.78-1.11     
 
negative 76304 513 227803.1 2.25 2.07-2.46 2.43 2.00-2.95 2.34 1.93-2.85 
 
positive 30169 232 87929.8 2.64 2.32-3.00 2.84 2.29-3.53 2.78 2.24-3.46 
Age at entry           
 
15-19 44382 285 125219.8 2.28 2.03-2.56     
 
20-24 71201 437 217971.7 2.00 1.83-2.20 0.88 0.76-1.03 0.89 0.76-1.03 
 
25-29 29931 121 89853.4 1.35 1.13-1.61 0.59 0.48-0.73 0.63 0.51-0.78 
 
30-44 8983 29 19278.3 1.50 1.05-2.16 0.65 0.45-0.96 0.75 0.51-1.10 
Year of entry           
 
1995-2000 104960 789 408666.7 1.93 1.80-2.07     
 
2001-2006 49537 83 43656.5 1.9 1.53-2.36 0.88 0.69-1.13 0.89 0.70-1.13 
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h. 15 to 17 years, positive, negative and never tested women 
 
 
Number of 
women 
Number 
with PID 
Person 
years (py) 
Rate per 
1000 py 95% CI 
Unadjusted 
HR 95% CI 
Adjusted 
HR 95% CI 
Chlamydia status 
         
 
never tested 11641 16 14856.9 1.08 0.66-1.76     
 
negative 20395 43 26301.0 1.63 1.21-2.20 1.52 0.86-2.70 1.51 0.85-2.69 
 
positive 7659 14 9835.4 1.42 0.84-2.40 1.32 0.65-2.71 1.32 0.65-2.71 
Age at entry           
 
15-19 10991 27 14536.9 1.86 1.27-2.71     
 
20-24 20653 32 27317.0 1.17 0.83-1.66 0.63 0.38-1.06 0.64 0.38-1.07 
 
25-29 8051 14 9139.4 1.53 0.91-2.59 0.82 0.43-1.57 0.86 0.45-1.66 
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